

Return of Private Foundation

or Section 4947(a)(1) Trust Treated as Private Foundation

2021

Open to Public Inspection

Form **990-PF**

Department of the Treasury
Internal Revenue Service

▶ Do not enter social security numbers on this form as it may be made public.
▶ Go to www.irs.gov/Form990PF for instructions and the latest information.

For calendar year 2021 or tax year beginning **APR 1, 2021**, and ending **MAR 31, 2022**

Name of foundation
THE LEONA M. AND HARRY B. HELMSLEY CHARITABLE TRUST

Number and street (or P.O. box number if mail is not delivered to street address)
230 PARK AVENUE

Room/suite
659

City or town, state or province, country, and ZIP or foreign postal code
NEW YORK, NY 10169

A Employer identification number
13-7184401

B Telephone number
212-679-3600

C If exemption application is pending, check here

D 1. Foreign organizations, check here
2. Foreign organizations meeting the 85% test, check here and attach computation

E If private foundation status was terminated under section 507(b)(1)(A), check here

F If the foundation is in a 60-month termination under section 507(b)(1)(B), check here

G Check all that apply: Initial return Initial return of a former public charity
 Final return Amended return
 Address change Name change

H Check type of organization: Section 501(c)(3) exempt private foundation
 Section 4947(a)(1) nonexempt charitable trust Other taxable private foundation

I Fair market value of all assets at end of year (from Part II, col. (c), line 16)
\$ **8,221,675,612.**

J Accounting method: Cash Accrual
 Other (specify) _____ (Part I, column (d), must be on cash basis.)

Part I Analysis of Revenue and Expenses (The total of amounts in columns (b), (c), and (d) may not necessarily equal the amounts in column (a).)		(a) Revenue and expenses per books	(b) Net investment income	(c) Adjusted net income	(d) Disbursements for charitable purposes (cash basis only)
Revenue	1 Contributions, gifts, grants, etc., received			N/A	
	2 Check <input checked="" type="checkbox"/> if the foundation is not required to attach Sch. B				
	3 Interest on savings and temporary cash investments	17,175.	17,175.		STATEMENT 1
	4 Dividends and interest from securities	36,631,242.	129,538,579.		STATEMENT 2
	5a Gross rents				
	b Net rental income or (loss)				
	6a Net gain or (loss) from sale of assets not on line 10	761,645,902.			
	b Gross sales price for all assets on line 6a	1,837,772,977.			
	7 Capital gain net income (from Part IV, line 2)		713,350,607.		
	8 Net short-term capital gain				
	9 Income modifications				
	10a Gross sales less returns and allowances				
b Less: Cost of goods sold					
c Gross profit or (loss)					
11 Other income	41,198,822.	279,081,117.		STATEMENT 3	
12 Total. Add lines 1 through 11	839,493,141.	1,121,987,478.			
Operating and Administrative Expenses	13 Compensation of officers, directors, trustees, etc.	4,376,425.	1,691,434.		2,196,238.
	14 Other employee salaries and wages	15,931,176.	5,200,197.		10,353,131.
	15 Pension plans, employee benefits	7,356,974.	1,775,482.		5,487,497.
	16a Legal fees STMT 4	446,869.	240,534.		171,108.
	b Accounting fees STMT 5	618,474.	288,521.		280,539.
	c Other professional fees STMT 6	9,031,764.	6,537,533.		2,576,991.
	17 Interest		1,565,857.		
	18 Taxes STMT 7	16,033,503.	3,095,765.		0.
	19 Depreciation and depletion	412,792.	23,687.		
	20 Occupancy	1,118,651.	5,163.		1,067,322.
	21 Travel, conferences, and meetings	401,351.	33,206.		266,155.
	22 Printing and publications				
	23 Other expenses STMT 8	23,083,802.	52,769,729.		2,101,380.
	24 Total operating and administrative expenses. Add lines 13 through 23	78,811,781.	73,227,108.		24,500,361.
	25 Contributions, gifts, grants paid	461,305,969.			385,014,429.
26 Total expenses and disbursements. Add lines 24 and 25	540,117,750.	73,227,108.		409,514,790.	
27 Subtract line 26 from line 12:					
a Excess of revenue over expenses and disbursements	299,375,391.				
b Net investment income (if negative, enter -0-)		1,048,760,370.			
c Adjusted net income (if negative, enter -0-)			N/A		

Application for Automatic Extension of Time To File an Exempt Organization Return

Department of the Treasury
Internal Revenue Service

▶ **File a separate application for each return.**
▶ **Go to www.irs.gov/Form8868 for the latest information.**

Electronic filing (e-file). You can electronically file Form 8868 to request a 6-month automatic extension of time to file any of the forms listed below with the exception of Form 8870, Information Return for Transfers Associated With Certain Personal Benefit Contracts, for which an extension request must be sent to the IRS in paper format (see instructions). For more details on the electronic filing of this form, visit www.irs.gov/e-file-providers/e-file-for-charities-and-non-profits.

Automatic 6-Month Extension of Time. Only submit original (no copies needed).

All corporations required to file an income tax return other than Form 990-T (including 1120-C filers), partnerships, REMICs, and trusts must use Form 7004 to request an extension of time to file income tax returns.

Type or print	Name of exempt organization or other filer, see instructions. THE LEONA M. AND HARRY B. HELMSLEY CHARITABLE TRUST	Taxpayer identification number (TIN) 13-7184401
File by the due date for filing your return. See instructions.	Number, street, and room or suite no. If a P.O. box, see instructions. 230 PARK AVENUE, 659	
	City, town or post office, state, and ZIP code. For a foreign address, see instructions. NEW YORK, NY 10169	

Enter the Return Code for the return that this application is for (file a separate application for each return) 0 4

Application Is For	Return Code	Application Is For	Return Code
Form 990 or Form 990-EZ	01	Form 1041-A	08
Form 4720 (individual)	03	Form 4720 (other than individual)	09
Form 990-PF	04	Form 5227	10
Form 990-T (sec. 401(a) or 408(a) trust)	05	Form 6069	11
Form 990-T (trust other than above)	06	Form 8870	12
Form 990-T (corporation)	07		

NICHOLAS J. SCHIAVO, CFO

• The books are in the care of ▶ **230 PARK AVENUE, SUITE 659 - NEW YORK, NY 10169**

Telephone No. ▶ **212-679-3600**

Fax No. ▶ _____

- If the organization does not have an office or place of business in the United States, check this box
- If this is for a Group Return, enter the organization's four digit Group Exemption Number (GEN) _____. If this is for the whole group, check this box . If it is for part of the group, check this box and attach a list with the names and TINs of all members the extension is for.

1 I request an automatic 6-month extension of time until **FEBRUARY 15, 2023**, to file the exempt organization return for the organization named above. The extension is for the organization's return for:

- ▶ calendar year _____ or
- ▶ tax year beginning **APR 1, 2021**, and ending **MAR 31, 2022**.

2 If the tax year entered in line 1 is for less than 12 months, check reason: Initial return Final return Change in accounting period

3a If this application is for Forms 990-PF, 990-T, 4720, or 6069, enter the tentative tax, less any nonrefundable credits. See instructions.	3a	\$	19,560,988.
b If this application is for Forms 990-PF, 990-T, 4720, or 6069, enter any refundable credits and estimated tax payments made. Include any prior year overpayment allowed as a credit.	3b	\$	15,460,988.
c Balance due. Subtract line 3b from line 3a. Include your payment with this form, if required, by using EFTPS (Electronic Federal Tax Payment System). See instructions.	3c	\$	4,100,000.

Caution: If you are going to make an electronic funds withdrawal (direct debit) with this Form 8868, see Form 8453-TE and Form 8879-TE for payment instructions.

Part II Balance Sheets		Attached schedules and amounts in the description column should be for end-of-year amounts only.		
		Beginning of year	End of year	
		(a) Book Value	(b) Book Value	(c) Fair Market Value
Assets	1 Cash - non-interest-bearing	32,275,203.	27,238,568.	27,238,568.
	2 Savings and temporary cash investments	62,457,618.	53,717,402.	53,717,402.
	3 Accounts receivable	449,759.		
	Less: allowance for doubtful accounts		449,759.	449,759.
	4 Pledges receivable			
	Less: allowance for doubtful accounts			
	5 Grants receivable			
	6 Receivables due from officers, directors, trustees, and other disqualified persons			
	7 Other notes and loans receivable			
	Less: allowance for doubtful accounts			
	8 Inventories for sale or use			
	9 Prepaid expenses and deferred charges	1,132,903.	993,143.	993,143.
	10a Investments - U.S. and state government obligations			
	b Investments - corporate stock	STMT 9 736,377,294.	591,948,988.	591,948,988.
	c Investments - corporate bonds			
	11 Investments - land, buildings, and equipment: basis			
Less: accumulated depreciation				
12 Investments - mortgage loans				
13 Investments - other	STMT 10 7,438,326,657.	7,406,511,362.	7,406,511,362.	
14 Land, buildings, and equipment: basis	9,637,533.			
Less: accumulated depreciation	STMT 11 2,338,162.	2,756,942.	7,299,371.	
15 Other assets (describe)	STATEMENT 12 40,261,279.	133,517,019.	133,517,019.	
16 Total assets (to be completed by all filers - see the instructions. Also, see page 1, item I)	8,313,587,896.	8,221,675,612.	8,221,675,612.	
Liabilities	17 Accounts payable and accrued expenses	11,454,781.	12,198,129.	
	18 Grants payable	385,738,876.	462,030,416.	
	19 Deferred revenue			
	20 Loans from officers, directors, trustees, and other disqualified persons			
	21 Mortgages and other notes payable			
	22 Other liabilities (describe)	STATEMENT 13 48,968,356.	42,966,460.	
23 Total liabilities (add lines 17 through 22)	446,162,013.	517,195,005.		
Net Assets or Fund Balances	Foundations that follow FASB ASC 958, check here	<input checked="" type="checkbox"/>		
	and complete lines 24, 25, 29, and 30.			
	24 Net assets without donor restrictions	7,867,425,883.	7,704,480,607.	
	25 Net assets with donor restrictions			
	Foundations that do not follow FASB ASC 958, check here	<input type="checkbox"/>		
	and complete lines 26 through 30.			
	26 Capital stock, trust principal, or current funds			
27 Paid-in or capital surplus, or land, bldg., and equipment fund				
28 Retained earnings, accumulated income, endowment, or other funds				
29 Total net assets or fund balances	7,867,425,883.	7,704,480,607.		
30 Total liabilities and net assets/fund balances	8,313,587,896.	8,221,675,612.		

Part III Analysis of Changes in Net Assets or Fund Balances

1 Total net assets or fund balances at beginning of year - Part II, column (a), line 29 (must agree with end-of-year figure reported on prior year's return)	1	7,867,425,883.
2 Enter amount from Part I, line 27a	2	299,375,391.
3 Other increases not included in line 2 (itemize)	3	6,516,842.
4 Add lines 1, 2, and 3	4	8,173,318,116.
5 Decreases not included in line 2 (itemize)	5	468,837,509.
6 Total net assets or fund balances at end of year (line 4 minus line 5) - Part II, column (b), line 29	6	7,704,480,607.

Part IV Capital Gains and Losses for Tax on Investment Income

SEE ATTACHED STATEMENTS

(a) List and describe the kind(s) of property sold (for example, real estate, 2-story brick warehouse; or common stock, 200 shs. MLC Co.)		(b) How acquired P - Purchase D - Donation	(c) Date acquired (mo., day, yr.)	(d) Date sold (mo., day, yr.)
1a				
b				
c				
d				
e				
(e) Gross sales price	(f) Depreciation allowed (or allowable)	(g) Cost or other basis plus expense of sale	(h) Gain or (loss) ((e) plus (f) minus (g))	
a				
b				
c				
d				
e	1,837,772,977.	986,388,319.	713,350,607.	
Complete only for assets showing gain in column (h) and owned by the foundation on 12/31/69.			(i) Gains (Col. (h) gain minus col. (k), but not less than -0-) or Losses (from col. (h))	
(i) FMV as of 12/31/69	(j) Adjusted basis as of 12/31/69	(k) Excess of col. (i) over col. (j), if any		
a				
b				
c				
d				
e			713,350,607.	
2 Capital gain net income or (net capital loss)	{ If gain, also enter in Part I, line 7 If (loss), enter -0- in Part I, line 7 }		2	713,350,607.
3 Net short-term capital gain or (loss) as defined in sections 1222(5) and (6): If gain, also enter in Part I, line 8, column (c). See instructions. If (loss), enter -0- in Part I, line 8	}		3	N/A

Part V Excise Tax Based on Investment Income (Section 4940(a), 4940(b), or 4948 - see instructions)

1a Exempt operating foundations described in section 4940(d)(2), check here <input type="checkbox"/> and enter "N/A" on line 1. Date of ruling or determination letter: _____ (attach copy of letter if necessary - see instructions)	1	14,577,769.
b All other domestic foundations enter 1.39% (0.0139) of line 27b. Exempt foreign organizations, enter 4% (0.04) of Part I, line 12, col. (b)		
2 Tax under section 511 (domestic section 4947(a)(1) trusts and taxable foundations only; others, enter -0-)	2	0.
3 Add lines 1 and 2	3	14,577,769.
4 Subtitle A (income) tax (domestic section 4947(a)(1) trusts and taxable foundations only; others, enter -0-)	4	0.
5 Tax based on investment income. Subtract line 4 from line 3. If zero or less, enter -0-	5	14,577,769.
6 Credits/Payments:		
a 2021 estimated tax payments and 2020 overpayment credited to 2021	6a	15,460,988.
b Exempt foreign organizations - tax withheld at source	6b	0.
c Tax paid with application for extension of time to file (Form 8868)	6c	4,100,000.
d Backup withholding erroneously withheld	6d	0.
7 Total credits and payments. Add lines 6a through 6d	7	19,560,988.
8 Enter any penalty for underpayment of estimated tax. Check here <input checked="" type="checkbox"/> if Form 2220 is attached	8	0.
9 Tax due. If the total of lines 5 and 8 is more than 7, enter amount owed	9	
10 Overpayment. If line 7 is more than the total of lines 5 and 8, enter the amount overpaid	10	4,983,219.
11 Enter the amount of line 10 to be: Credited to 2022 estimated tax <input type="checkbox"/> 4,983,219. Refunded <input type="checkbox"/>	11	0.

Part VI-A Statements Regarding Activities

	Yes	No
1a During the tax year, did the foundation attempt to influence any national, state, or local legislation or did it participate or intervene in any political campaign?		X
b Did it spend more than \$100 during the year (either directly or indirectly) for political purposes? See the instructions for the definition If the answer is "Yes" to 1a or 1b, attach a detailed description of the activities and copies of any materials published or distributed by the foundation in connection with the activities.		X
c Did the foundation file Form 1120-POL for this year?		X
d Enter the amount (if any) of tax on political expenditures (section 4955) imposed during the year: (1) On the foundation. ▶ \$ _____ 0. (2) On foundation managers. ▶ \$ _____ 0.		
e Enter the reimbursement (if any) paid by the foundation during the year for political expenditure tax imposed on foundation managers. ▶ \$ _____ 0.		
2 Has the foundation engaged in any activities that have not previously been reported to the IRS?		X
If "Yes," attach a detailed description of the activities.		
3 Has the foundation made any changes, not previously reported to the IRS, in its governing instrument, articles of incorporation, or bylaws, or other similar instruments? If "Yes," attach a conformed copy of the changes		X
4a Did the foundation have unrelated business gross income of \$1,000 or more during the year?	X	
b If "Yes," has it filed a tax return on Form 990-T for this year?	X	
5 Was there a liquidation, termination, dissolution, or substantial contraction during the year?		X
If "Yes," attach the statement required by General Instruction T.		
6 Are the requirements of section 508(e) (relating to sections 4941 through 4945) satisfied either: • By language in the governing instrument, or • By state legislation that effectively amends the governing instrument so that no mandatory directions that conflict with the state law remain in the governing instrument?	X	
7 Did the foundation have at least \$5,000 in assets at any time during the year? If "Yes," complete Part II, col. (c), and Part XIV	X	
8a Enter the states to which the foundation reports or with which it is registered. See instructions. ▶ _____ NY		
b If the answer is "Yes" to line 7, has the foundation furnished a copy of Form 990-PF to the Attorney General (or designate) of each state as required by General Instruction G? If "No," attach explanation	X	
9 Is the foundation claiming status as a private operating foundation within the meaning of section 4942(j)(3) or 4942(j)(5) for calendar year 2021 or the tax year beginning in 2021? See the instructions for Part XIII. If "Yes," complete Part XIII		X
10 Did any persons become substantial contributors during the tax year? If "Yes," attach a schedule listing their names and addresses		X
11 At any time during the year, did the foundation, directly or indirectly, own a controlled entity within the meaning of section 512(b)(13)? If "Yes," attach schedule. See instructions STATEMENT 15 STATEMENT 16 STMT 17	X	
12 Did the foundation make a distribution to a donor advised fund over which the foundation or a disqualified person had advisory privileges? If "Yes," attach statement. See instructions		X
13 Did the foundation comply with the public inspection requirements for its annual returns and exemption application?	X	
Website address ▶ HELMSLEYTRUST.ORG		
14 The books are in care of ▶ NICHOLAS J. SCHIAVO, CFO Telephone no. ▶ 212-679-3600 Located at ▶ 230 PARK AVENUE, SUITE 659, NEW YORK, NY ZIP+4 ▶ 10169		
15 Section 4947(a)(1) nonexempt charitable trusts filing Form 990-PF in lieu of Form 1041 - check here ▶ <input type="checkbox"/> and enter the amount of tax-exempt interest received or accrued during the year ▶ 15 N/A		
16 At any time during calendar year 2021, did the foundation have an interest in or a signature or other authority over a bank, securities, or other financial account in a foreign country?	X	
See the instructions for exceptions and filing requirements for FinCEN Form 114. If "Yes," enter the name of the foreign country ▶ SEE STATEMENT 14		

Part VI-B Statements Regarding Activities for Which Form 4720 May Be Required

File Form 4720 if any item is checked in the "Yes" column, unless an exception applies.

	Yes	No
1a During the year, did the foundation (either directly or indirectly):		
(1) Engage in the sale or exchange, or leasing of property with a disqualified person?	X	
(2) Borrow money from, lend money to, or otherwise extend credit to (or accept it from) a disqualified person?		X
(3) Furnish goods, services, or facilities to (or accept them from) a disqualified person?	X	
(4) Pay compensation to, or pay or reimburse the expenses of, a disqualified person?	X	
(5) Transfer any income or assets to a disqualified person (or make any of either available for the benefit or use of a disqualified person)?		
(6) Agree to pay money or property to a government official? (Exception. Check "No" if the foundation agreed to make a grant to or to employ the official for a period after termination of government service, if terminating within 90 days.)		X
1a(5)		X
1a(6)		X
b If any answer is "Yes" to 1a(1)-(6), did any of the acts fail to qualify under the exceptions described in Regulations section 53.4941(d)-3 or in a current notice regarding disaster assistance? See instructions		X
1b		X
c Organizations relying on a current notice regarding disaster assistance, check here		
d Did the foundation engage in a prior year in any of the acts described in 1a, other than excepted acts, that were not corrected before the first day of the tax year beginning in 2021?		X
1d		X
2 Taxes on failure to distribute income (section 4942) (does not apply for years the foundation was a private operating foundation defined in section 4942(j)(3) or 4942(j)(5)):		
a At the end of tax year 2021, did the foundation have any undistributed income (Part XII, lines 6d and 6e) for tax year(s) beginning before 2021?		X
If "Yes," list the years ▶ _____, _____, _____, _____		
b Are there any years listed in 2a for which the foundation is not applying the provisions of section 4942(a)(2) (relating to incorrect valuation of assets) to the year's undistributed income? (If applying section 4942(a)(2) to all years listed, answer "No" and attach statement - see instructions.)		N/A
2b		N/A
c If the provisions of section 4942(a)(2) are being applied to any of the years listed in 2a, list the years here. ▶ _____, _____, _____, _____		
3a Did the foundation hold more than a 2% direct or indirect interest in any business enterprise at any time during the year?	X	
3a	X	
b If "Yes," did it have excess business holdings in 2021 as a result of (1) any purchase by the foundation or disqualified persons after May 26, 1969; (2) the lapse of the 5-year period (or longer period approved by the Commissioner under section 4943(c)(7)) to dispose of holdings acquired by gift or bequest; or (3) the lapse of the 10-, 15-, or 20-year first phase holding period? (Use Form 4720, Schedule C, to determine if the foundation had excess business holdings in 2021.)		X
3b		X
4a Did the foundation invest during the year any amount in a manner that would jeopardize its charitable purposes?		X
4a		X
b Did the foundation make any investment in a prior year (but after December 31, 1969) that could jeopardize its charitable purpose that had not been removed from jeopardy before the first day of the tax year beginning in 2021?		X
4b		X

Part VI-B Statements Regarding Activities for Which Form 4720 May Be Required (continued)

	Yes	No
5a During the year, did the foundation pay or incur any amount to:		
(1) Carry on propaganda, or otherwise attempt to influence legislation (section 4945(e))?		X
(2) Influence the outcome of any specific public election (see section 4955); or to carry on, directly or indirectly, any voter registration drive?		X
(3) Provide a grant to an individual for travel, study, or other similar purposes?		X
(4) Provide a grant to an organization other than a charitable, etc., organization described in section 4945(d)(4)(A)? See instructions	X	
(5) Provide for any purpose other than religious, charitable, scientific, literary, or educational purposes, or for the prevention of cruelty to children or animals?		X
b If any answer is "Yes" to 5a(1)-(5), did any of the transactions fail to qualify under the exceptions described in Regulations section 53.4945 or in a current notice regarding disaster assistance? See instructions		X
c Organizations relying on a current notice regarding disaster assistance, check here <input type="checkbox"/>		
d If the answer is "Yes" to question 5a(4), does the foundation claim exemption from the tax because it maintained expenditure responsibility for the grant? SEE STATEMENT 19	X	
If "Yes," attach the statement required by Regulations section 53.4945-5(d).		
6a Did the foundation, during the year, receive any funds, directly or indirectly, to pay premiums on a personal benefit contract?		X
b Did the foundation, during the year, pay premiums, directly or indirectly, on a personal benefit contract? If "Yes" to 6b, file Form 8870.		X
7a At any time during the tax year, was the foundation a party to a prohibited tax shelter transaction?		X
b If "Yes," did the foundation receive any proceeds or have any net income attributable to the transaction? N/A		
8 Is the foundation subject to the section 4960 tax on payment(s) of more than \$1,000,000 in remuneration or excess parachute payment(s) during the year?	X	

Part VII Information About Officers, Directors, Trustees, Foundation Managers, Highly Paid Employees, and Contractors

1 List all officers, directors, trustees, and foundation managers and their compensation.

(a) Name and address	(b) Title, and average hours per week devoted to position	(c) Compensation (If not paid, enter -0-)	(d) Contributions to employee benefit plans and deferred compensation	(e) Expense account, other allowances
SEE STATEMENT 18		4721265	614929.	0.

2 Compensation of five highest-paid employees (other than those included on line 1). If none, enter "NONE."

(a) Name and address of each employee paid more than \$50,000	(b) Title, and average hours per week devoted to position	(c) Compensation	(d) Contributions to employee benefit plans and deferred compensation	(e) Expense account, other allowances
MEENAKSHI C. LAKSHMAN - C/O TRUST, 230 PARK AVENUE, NEW YORK, NY 10169	DIR. OF STRATEGY & RESEARCH 40.00	938,579.	173,897.	0.
AL Y. KIM - C/O TRUST, 230 PARK AVENUE, NEW YORK, NY 10169	DIRECTOR OF INVESTMENTS 40.00	915,458.	171,409.	0.
JOSHUA W. FENTON - C/O TRUST, 230 PARK AVENUE, NEW YORK, NY 10169	DIRECTOR OF INVESTMENTS 40.00	914,728.	171,522.	0.
CHRISTOPHER J. RAPCEWICZ - C/O TRUST, 230 PARK AVENUE, NEW YORK, NY	DIR. OF RISK MNGMT. & OPERATIONS 40.00	910,449.	157,200.	0.
BRIAN B. CHUN - C/O TRUST, 230 PARK AVENUE, NEW YORK, NY 10169	INVESTMENT OFFICER 40.00	461,296.	88,692.	0.
Total number of other employees paid over \$50,000				84

Part VII Information About Officers, Directors, Trustees, Foundation Managers, Highly Paid Employees, and Contractors *(continued)*

3 Five highest-paid independent contractors for professional services. If none, enter "NONE."

(a) Name and address of each person paid more than \$50,000	(b) Type of service	(c) Compensation
HIG MIDDLE MARKET LBO FUND II, LP 600 5TH AVE., 24TH FL., NEW YORK, NY 10020	INVESTMENT MANAGEMENT	4,581,511.
HIG CAPITAL PARTNERS V, LP 600 5TH AVE., 24TH FL., NEW YORK, NY 10020	INVESTMENT MANAGEMENT	3,220,352.
HIGHCLERE INTERNATIONAL INVESTORS 2 MANCHESTER SQUARE, LONDON, UNITED KINGDOM	INVESTMENT MANAGEMENT	2,901,443.
IFP GLOBAL EQUITY LP - LEVEL 1, 10 PORTMAN SQUARE, LONDON, UNITED KINGDOM W1H 6AZ	INVESTMENT MANAGEMENT	1,516,005.
ACADIAN ASSET MANAGEMENT LLC PO BOX 412216, BOSTON, MA 02241	INVESTMENT MANAGEMENT	1,206,736.
Total number of others receiving over \$50,000 for professional services		47

Part VIII-A Summary of Direct Charitable Activities

List the foundation's four largest direct charitable activities during the tax year. Include relevant statistical information such as the number of organizations and other beneficiaries served, conferences convened, research papers produced, etc.	Expenses
1 FOR THE PRODUCTION OF VIDEO AND OTHER DESIGN SUPPORT TO COMMUNICATE IMPACT IN FURTHERANCE OF THE FOUNDATION'S MISSION.	1,003,948.
2 FOR TECHNICAL SUPPORT TO GRANTEES TO MEET THEIR STRATEGIC AND COMMUNICATIONS NEEDS TO DRIVE FURTHER IMPACT OF THEIR CHARITABLE WORK.	334,053.
3 FOR CONVENING EXPERTS TO EXPLORE PROGRAM PRIORITIES, SHARE RESEARCH AND IDEAS, AND BRAINSTORM NEW AREAS OF IMPACT IN SUPPORT OF THE FOUNDATION'S MISSION.	60,868.
4	

Part VIII-B Summary of Program-Related Investments

Describe the two largest program-related investments made by the foundation during the tax year on lines 1 and 2.	Amount
1 THETIS PHARMACEUTICALS, LLC - DEVELOPMENT OF NOVEL RESOLVIN E1 THERAPY FOR CROHN'S TREATMENT	3,285,274.
2 PERCUSENSE, INC. - DEVELOPMENT OF CONTINUOUS GLUCOSE AND KETONE METER FOR TREATMENT IN T1D	600,000.
All other program-related investments. See instructions.	
3 BIORASIS, INC. - EARLY FEASIBILITY STUDIES OF THE GLUCOWIZZARD	410,000.
Total. Add lines 1 through 3	4,295,274.

Part IX Minimum Investment Return (All domestic foundations must complete this part. Foreign foundations, see instructions.)

1 Fair market value of assets not used (or held for use) directly in carrying out charitable, etc., purposes:			
a	Average monthly fair market value of securities	1a	8,179,026,450.
b	Average of monthly cash balances	1b	194,222,475.
c	Fair market value of all other assets (see instructions)	1c	497,417.
d	Total (add lines 1a, b, and c)	1d	8,373,746,342.
e	Reduction claimed for blockage or other factors reported on lines 1a and 1c (attach detailed explanation)	1e	0.
2	Acquisition indebtedness applicable to line 1 assets	2	0.
3	Subtract line 2 from line 1d	3	8,373,746,342.
4	Cash deemed held for charitable activities. Enter 1.5% (0.015) of line 3 (for greater amount, see instructions)	4	125,606,195.
5	Net value of noncharitable-use assets. Subtract line 4 from line 3	5	8,248,140,147.
6	Minimum investment return. Enter 5% (0.05) of line 5	6	412,407,007.

Part X Distributable Amount (see instructions) (Section 4942(j)(3) and (j)(5) private operating foundations and certain foreign organizations, check here and do not complete this part.)

1	Minimum investment return from Part IX, line 6	1	412,407,007.
2a	Tax on investment income for 2021 from Part V, line 5	2a	14,577,769.
b	Income tax for 2021. (This does not include the tax from Part V.)	2b	
c	Add lines 2a and 2b	2c	14,577,769.
3	Distributable amount before adjustments. Subtract line 2c from line 1	3	397,829,238.
4	Recoveries of amounts treated as qualifying distributions	4	451,754.
5	Add lines 3 and 4	5	398,280,992.
6	Deduction from distributable amount (see instructions)	6	0.
7	Distributable amount as adjusted. Subtract line 6 from line 5. Enter here and on Part XII, line 1	7	398,280,992.

Part XI Qualifying Distributions (see instructions)

1 Amounts paid (including administrative expenses) to accomplish charitable, etc., purposes:			
a	Expenses, contributions, gifts, etc. - total from Part I, column (d), line 26	1a	409,514,790.
b	Program-related investments - total from Part VIII-B	1b	4,295,274.
2	Amounts paid to acquire assets used (or held for use) directly in carrying out charitable, etc., purposes	2	4,560,789.
3 Amounts set aside for specific charitable projects that satisfy the:			
a	Suitability test (prior IRS approval required)	3a	
b	Cash distribution test (attach the required schedule)	3b	
4	Qualifying distributions. Add lines 1a through 3b. Enter here and on Part XII, line 4	4	418,370,853.

Form 990-PF (2021)

Part XII Undistributed Income (see instructions)

	(a) Corpus	(b) Years prior to 2020	(c) 2020	(d) 2021
1 Distributable amount for 2021 from Part X, line 7				398,280,992.
2 Undistributed income, if any, as of the end of 2021:				
a Enter amount for 2020 only			120,476,741.	
b Total for prior years:		0.		
3 Excess distributions carryover, if any, to 2021:				
a From 2016				
b From 2017				
c From 2018				
d From 2019				
e From 2020				
f Total of lines 3a through e	0.			
4 Qualifying distributions for 2021 from Part XI, line 4: ▶ \$ 418,370,853.				
a Applied to 2020, but not more than line 2a ...			120,476,741.	
b Applied to undistributed income of prior years (Election required - see instructions) ...		0.		
c Treated as distributions out of corpus (Election required - see instructions)	0.			
d Applied to 2021 distributable amount				297,894,112.
e Remaining amount distributed out of corpus	0.			
5 Excess distributions carryover applied to 2021 (If an amount appears in column (d), the same amount must be shown in column (a).)	0.			0.
6 Enter the net total of each column as indicated below:				
a Corpus. Add lines 3f, 4c, and 4e. Subtract line 5	0.			
b Prior years' undistributed income. Subtract line 4b from line 2b		0.		
c Enter the amount of prior years' undistributed income for which a notice of deficiency has been issued, or on which the section 4942(a) tax has been previously assessed		0.		
d Subtract line 6c from line 6b. Taxable amount - see instructions		0.		
e Undistributed income for 2020. Subtract line 4a from line 2a. Taxable amount - see instr. ...			0.	
f Undistributed income for 2021. Subtract lines 4d and 5 from line 1. This amount must be distributed in 2022				100,386,880.
7 Amounts treated as distributions out of corpus to satisfy requirements imposed by section 170(b)(1)(F) or 4942(g)(3) (Election may be required - see instructions)	0.			
8 Excess distributions carryover from 2016 not applied on line 5 or line 7	0.			
9 Excess distributions carryover to 2022. Subtract lines 7 and 8 from line 6a	0.			
10 Analysis of line 9:				
a Excess from 2017 ...				
b Excess from 2018 ...				
c Excess from 2019 ...				
d Excess from 2020 ...				
e Excess from 2021 ...				

Part XIII Private Operating Foundations (see instructions and Part VI-A, question 9) N/A

1 a If the foundation has received a ruling or determination letter that it is a private operating foundation, and the ruling is effective for 2021, enter the date of the ruling ▶

b Check box to indicate whether the foundation is a private operating foundation described in section 4942(j)(3) or 4942(j)(5)

	Tax year				(e) Total
	(a) 2021	(b) 2020	(c) 2019	(d) 2018	
2 a Enter the lesser of the adjusted net income from Part I or the minimum investment return from Part IX for each year listed					
b 85% (0.85) of line 2a					
c Qualifying distributions from Part XI, line 4, for each year listed					
d Amounts included in line 2c not used directly for active conduct of exempt activities					
e Qualifying distributions made directly for active conduct of exempt activities. Subtract line 2d from line 2c					
3 Complete 3a, b, or c for the alternative test relied upon:					
a "Assets" alternative test - enter:					
(1) Value of all assets					
(2) Value of assets qualifying under section 4942(j)(3)(B)(i)					
b "Endowment" alternative test - enter 2/3 of minimum investment return shown in Part IX, line 6, for each year listed					
c "Support" alternative test - enter:					
(1) Total support other than gross investment income (interest, dividends, rents, payments on securities loans (section 512(a)(5)), or royalties)					
(2) Support from general public and 5 or more exempt organizations as provided in section 4942(j)(3)(B)(iii)					
(3) Largest amount of support from an exempt organization					
(4) Gross investment income					

Part XIV Supplementary Information (Complete this part only if the foundation had \$5,000 or more in assets at any time during the year-see instructions.)

1 Information Regarding Foundation Managers:
a List any managers of the foundation who have contributed more than 2% of the total contributions received by the foundation before the close of any tax year (but only if they have contributed more than \$5,000). (See section 507(d)(2).)
 NONE

b List any managers of the foundation who own 10% or more of the stock of a corporation (or an equally large portion of the ownership of a partnership or other entity) of which the foundation has a 10% or greater interest.
 NONE

2 Information Regarding Contribution, Grant, Gift, Loan, Scholarship, etc., Programs:
 Check here if the foundation only makes contributions to preselected charitable organizations and does not accept unsolicited requests for funds. If the foundation makes gifts, grants, etc., to individuals or organizations under other conditions, complete items 2a, b, c, and d.

a The name, address, and telephone number or email address of the person to whom applications should be addressed:

b The form in which applications should be submitted and information and materials they should include:

c Any submission deadlines:

d Any restrictions or limitations on awards, such as by geographical areas, charitable fields, kinds of institutions, or other factors:

Part XIV **Supplementary Information** (continued)

3 Grants and Contributions Paid During the Year or Approved for Future Payment				
Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
a Paid during the year				
4YOUANDME 2901 THIRD AVENUE SEATTLE, WA 98121	N/A	PC	WEARABLES TO MEASURE STRESS AND FORECAST CROHNS SYMPTOMS	84,107.
A GLIMMER OF HOPE FOUNDATION 3103 BEE CAVES ROAD, AUSTIN, TX 78746	N/A	PF	INTEGRATED COMMUNITY DEVELOPMENT IN ODA BULTUM, ETHIOPIA	1,449,415.
AGRICULTURAL RESEARCH ORGANIZATION DERECH HAMACCABIM 68, RISHON LETSIYON RISHON LETSIYON, ISRAEL	N/A	GOV	THE HELMSLEY CENTER FOR AI IN AGRICULTURE AT THE VOLCANI CENTER	1,591,900.
ALASKA NATIVE TRIBAL HEALTH CONSORTIUM 4000 AMBASSADOR DRIVE ANCHORAGE, AK 99508	N/A	PC	TULUKSAK WATER AND WASTEWATER SYSTEM	792,660.
ALBERT EINSTEIN COLLEGE OF MEDICINE 1300 MORRIS PARK AVE BRONX, NY 10461-1975	N/A	PC	PRECLINICAL WORK TO ADVANCE D-PEPTIDES AS ANTIGEN-SPECIFIC IMMUNOTHERAPY	2,381,358.
Total	SEE CONTINUATION SHEET(S)			3a 385,014,429.
b Approved for future payment				
4YOUANDME 2901 THIRD AVENUE SEATTLE, WA 98121	N/A	PC	WEARABLES TO MEASURE STRESS AND FORECAST CROHNS SYMPTOMS	110,128.
A GLIMMER OF HOPE FOUNDATION 3103 BEE CAVES ROAD, AUSTIN, TX 78746	N/A	PF	INTEGRATED COMMUNITY DEVELOPMENT IN ODA BULTUM, ETHIOPIA	1,854,222.
ALBERT EINSTEIN COLLEGE OF MEDICINE 1300 MORRIS PARK AVE BRONX, NY 10461-1975	N/A	PC	SUPPLEMENTAL SUPPORT FOR T1DTECHCHW	163,648.
Total	SEE CONTINUATION SHEET(S)			3b 462,030,416.

Part XVI Information Regarding Transfers to and Transactions and Relationships With Noncharitable Exempt Organizations

		Yes	No
1	Did the organization directly or indirectly engage in any of the following with any other organization described in section 501(c) (other than section 501(c)(3) organizations) or in section 527, relating to political organizations?		
a	Transfers from the reporting foundation to a noncharitable exempt organization of:		
	(1) Cash	X	
	(2) Other assets		X
b	Other transactions:		
	(1) Sales of assets to a noncharitable exempt organization		X
	(2) Purchases of assets from a noncharitable exempt organization		X
	(3) Rental of facilities, equipment, or other assets		X
	(4) Reimbursement arrangements		X
	(5) Loans or loan guarantees		X
	(6) Performance of services or membership or fundraising solicitations		X
c	Sharing of facilities, equipment, mailing lists, other assets, or paid employees		X
d	If the answer to any of the above is "Yes," complete the following schedule. Column (b) should always show the fair market value of the goods, other assets, or services given by the reporting foundation. If the foundation received less than fair market value in any transaction or sharing arrangement, show in column (d) the value of the goods, other assets, or services received.		

(a) Line no.	(b) Amount involved	(c) Name of noncharitable exempt organization	(d) Description of transfers, transactions, and sharing arrangements
		ASSOCIATION OF DIABETES CARE & EDUCATION	SEE STATEMENT 20
A1	616,544.	SPECIALISTS	
A1	4,000.	INSTITUTIONAL LIMITED PARTNER ASSOCIATION	

2a Is the foundation directly or indirectly affiliated with, or related to, one or more tax-exempt organizations described in section 501(c) (other than section 501(c)(3)) or in section 527? Yes No

b If "Yes," complete the following schedule.

(a) Name of organization	(b) Type of organization	(c) Description of relationship
N/A		

Sign Here	Under penalties of perjury, I declare that I have examined this return, including accompanying schedules and statements, and to the best of my knowledge and belief, it is true, correct, and complete. Declaration of preparer (other than taxpayer) is based on all information of which preparer has any knowledge.				May the IRS discuss this return with the preparer shown below? See instr. <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
	Signature of officer or trustee <i>Nicholas Schw...</i>	Date 02/01/23	Title CFO		
Paid Preparer Use Only	Print/Type preparer's name	Preparer's signature	Date	Check <input type="checkbox"/> if self-employed	PTIN
	THOMAS BLANEY	THOMAS BLANEY	02/01/23		P00234022
	Firm's name ▶ PKF O'CONNOR DAVIES ADVISORY, LLC			Firm's EIN ▶ 87-3231666	
Firm's address ▶ 245 PARK AVENUE, 12TH FLOOR					Phone no. 212-286-2600
NEW YORK, NY 10167					

123622 12-10-21

Part IV Capital Gains and Losses for Tax on Investment Income

(a) List and describe the kind(s) of property sold, e.g., real estate, 2-story brick warehouse; or common stock, 200 shs. MLC Co.	(b) How acquired P - Purchase D - Donation	(c) Date acquired (mo., day, yr.)	(d) Date sold (mo., day, yr.)
1a SALE OF PUBLICLY TRADED SECURITIES	P		
b ACADIAN FRONTIER MARKETS	P		04/12/21
c ACADIAN FRONTIER MARKETS	P		04/23/21
d ACADIAN FRONTIER MARKETS	P		05/07/21
e ACADIAN FRONTIER MARKETS	P		06/07/21
f ACADIAN FRONTIER MARKETS	P		07/02/21
g ACADIAN FRONTIER MARKETS	P		04/16/21
h ACADIAN FRONTIER MARKETS	P		11/29/21
i ACADIAN FRONTIER MARKETS	P		12/23/21
j ACADIAN FRONTIER MARKETS	P		11/12/21
k ACCEL GROWTH FD IV LP	P		05/03/21
l ACCEL GROWTH FD IV LP	P		12/30/21
m ACCEL GROWTH FD IV LP	P		09/01/21
n ACCEL GROWTH FD IV LP	P		09/27/21
o ACCEL GROWTH FD IV LP	P		10/05/21

(e) Gross sales price	(f) Depreciation allowed (or allowable)	(g) Cost or other basis plus expense of sale	(h) Gain or (loss) (e) plus (f) minus (g)
a 783,260,325.		502,142,463.	281,117,862.
b 6,043,498.			6,043,498.
c 5,256,152.			5,256,152.
d 704,849.			704,849.
e 116,909.			116,909.
f 100,187.			100,187.
g 15,765,801.			15,765,801.
h 7,271,558.			7,271,558.
i 627,403.			627,403.
j 14,718,858.			14,718,858.
k 762,599.			762,599.
l 1,371,954.			1,371,954.
m 1,927,891.			1,927,891.
n 844,748.			844,748.
o 794,475.			794,475.

Complete only for assets showing gain in column (h) and owned by the foundation on 12/31/69			(l) Losses (from col. (h)) Gains (excess of col. (h) gain over col. (k), but not less than "-0-")
(i) F.M.V. as of 12/31/69	(j) Adjusted basis as of 12/31/69	(k) Excess of col. (i) over col. (j), if any	
a			281,117,862.
b			6,043,498.
c			5,256,152.
d			704,849.
e			116,909.
f			100,187.
g			15,765,801.
h			7,271,558.
i			627,403.
j			14,718,858.
k			762,599.
l			1,371,954.
m			1,927,891.
n			844,748.
o			794,475.

2 Capital gain net income or (net capital loss) { If gain, also enter in Part I, line 7 If (loss), enter "-0-" in Part I, line 7 }	2	
3 Net short-term capital gain or (loss) as defined in sections 1222(5) and (6): If gain, also enter in Part I, line 8, column (c). If (loss), enter "-0-" in Part I, line 8	3	

Part IV Capital Gains and Losses for Tax on Investment Income

(a) List and describe the kind(s) of property sold, e.g., real estate, 2-story brick warehouse; or common stock, 200 shs. MLC Co.	(b) How acquired P - Purchase D - Donation	(c) Date acquired (mo., day, yr.)	(d) Date sold (mo., day, yr.)
1a ACCEL GROWTH FD IV LP	P		10/08/21
b ACCEL GROWTH FD IV LP	P		09/21/21
c ACCEL GROWTH FD IV LP	P		07/09/21
d ACCEL GROWTH FD IV LP	P		06/28/21
e ACCEL GROWTH FD IV LP	P		06/22/21
f ACCEL GROWTH FD IV LP	P		06/09/21
g ACCEL GROWTH FD IV LP	P		04/13/21
h ACCEL GROWTH FD IV LP	P		06/15/21
i ACCEL GROWTH FUND II LP	P		09/07/21
j ACCEL GROWTH FUND II LP	P		06/07/21
k ACCEL GROWTH FUND II LP	P		10/12/21
l ACCEL GROWTH FUND II LP	P		09/09/21
m ACCEL GROWTH FUND II LP	P		06/22/21
n ACCEL GROWTH FUND II LP	P		06/11/21
o ACCEL GROWTH FUND III LP	P		09/15/21

(e) Gross sales price	(f) Depreciation allowed (or allowable)	(g) Cost or other basis plus expense of sale	(h) Gain or (loss) (e) plus (f) minus (g)
a 795,456.			795,456.
b 827,150.			827,150.
c 898,054.			898,054.
d 935,520.			935,520.
e 916,349.			916,349.
f 922,445.			922,445.
g 1,678,310.			1,678,310.
h 918,329.			918,329.
i 3,023,197.			3,023,197.
j 1,049,551.			1,049,551.
k 651,714.			651,714.
l 1,519,324.			1,519,324.
m 892,266.			892,266.
n 805,302.			805,302.
o 1,506,581.			1,506,581.

Complete only for assets showing gain in column (h) and owned by the foundation on 12/31/69			(l) Losses (from col. (h)) Gains (excess of col. (h) gain over col. (k), but not less than "-0-")
(i) F.M.V. as of 12/31/69	(j) Adjusted basis as of 12/31/69	(k) Excess of col. (i) over col. (j), if any	
a			795,456.
b			827,150.
c			898,054.
d			935,520.
e			916,349.
f			922,445.
g			1,678,310.
h			918,329.
i			3,023,197.
j			1,049,551.
k			651,714.
l			1,519,324.
m			892,266.
n			805,302.
o			1,506,581.

2 Capital gain net income or (net capital loss) { If gain, also enter in Part I, line 7 If (loss), enter "-0-" in Part I, line 7 }	2
3 Net short-term capital gain or (loss) as defined in sections 1222(5) and (6): If gain, also enter in Part I, line 8, column (c). If (loss), enter "-0-" in Part I, line 8	3

Part IV Capital Gains and Losses for Tax on Investment Income

(a) List and describe the kind(s) of property sold, e.g., real estate, 2-story brick warehouse; or common stock, 200 shs. MLC Co.	(b) How acquired P - Purchase D - Donation	(c) Date acquired (mo., day, yr.)	(d) Date sold (mo., day, yr.)
1a ACCEL GROWTH FUND V LP	P		01/14/22
b ACCEL INDIA V LP	P		10/19/21
c ACCEL LEADERS FUND II LP	P		02/04/22
d ACCEL LEADERS FUND LP	P		09/03/21
e ACCEL LEADERS FUND LP	P		03/10/22
f ACCEL LEADERS FUND LP	P		03/22/22
g ACCEL LEADERS FUND LP	P		04/08/21
h ACCEL LEADERS FUND LP	P		06/07/21
i ACCEL XI	P		09/08/21
j ACCEL XI	P		02/01/22
k ACCEL XI	P		09/14/21
l ACCEL XI	P		09/07/21
m ACCEL XI	P		02/09/22
n ACCEL XI	P		12/08/21
o ACCEL XI	P		09/17/21

(e) Gross sales price	(f) Depreciation allowed (or allowable)	(g) Cost or other basis plus expense of sale	(h) Gain or (loss) (e) plus (f) minus (g)
a 193,482.			193,482.
b 629,258.			629,258.
c 643,613.			643,613.
d 1,294,558.			1,294,558.
e 861,407.			861,407.
f 490,375.			490,375.
g 1,836,781.			1,836,781.
h 584,066.			584,066.
i 549,774.			549,774.
j 557,760.			557,760.
k 207,655.			207,655.
l 250,682.			250,682.
m 552,167.			552,167.
n 126,456.			126,456.
o 199,073.			199,073.

Complete only for assets showing gain in column (h) and owned by the foundation on 12/31/69			(l) Losses (from col. (h)) Gains (excess of col. (h) gain over col. (k), but not less than "-0-")
(i) F.M.V. as of 12/31/69	(j) Adjusted basis as of 12/31/69	(k) Excess of col. (i) over col. (j), if any	
a			193,482.
b			629,258.
c			643,613.
d			1,294,558.
e			861,407.
f			490,375.
g			1,836,781.
h			584,066.
i			549,774.
j			557,760.
k			207,655.
l			250,682.
m			552,167.
n			126,456.
o			199,073.

2 Capital gain net income or (net capital loss) { If gain, also enter in Part I, line 7 If (loss), enter "-0-" in Part I, line 7 }	2	
3 Net short-term capital gain or (loss) as defined in sections 1222(5) and (6): If gain, also enter in Part I, line 8, column (c). If (loss), enter "-0-" in Part I, line 8	3	

Part IV Capital Gains and Losses for Tax on Investment Income

(a) List and describe the kind(s) of property sold, e.g., real estate, 2-story brick warehouse; or common stock, 200 shs. MLC Co.	(b) How acquired P - Purchase D - Donation	(c) Date acquired (mo., day, yr.)	(d) Date sold (mo., day, yr.)
1a ACCEL XI	P		09/07/21
b ACCEL XII LP	P		07/20/21
c ACCEL XII LP	P		10/14/21
d AH PARALLEL FUND III LP	P		05/05/21
e AH PARALLEL FUND III LP	P		04/14/21
f AH PARALLEL FUND III LP	P		05/14/21
g AH PARALLEL FUND III LP	P		05/21/21
h AH PARALLEL FUND III LP	P		06/23/21
i AH PARALLEL FUND III LP	P		08/06/21
j AH PARALLEL FUND III LP	P		11/19/21
k AH PARALLEL FUND III LP	P		02/25/22
l AH PARALLEL FUND IV LP	P		11/09/21
m AH PARALLEL FUND IV LP	P		10/07/21
n AH PARALLEL FUND IV LP	P		08/30/21
o AH PARALLEL FUND V LP	P		08/12/21

(e) Gross sales price	(f) Depreciation allowed (or allowable)	(g) Cost or other basis plus expense of sale	(h) Gain or (loss) (e) plus (f) minus (g)
a 978,678.			978,678.
b 1,225,001.			1,225,001.
c 2,092,646.			2,092,646.
d 755,268.			755,268.
e 1,913,779.			1,913,779.
f 96,328.			96,328.
g 1,292,278.			1,292,278.
h 905,039.			905,039.
i 838,046.			838,046.
j 2,040,811.			2,040,811.
k 931,238.			931,238.
l 858,855.			858,855.
m 855,947.			855,947.
n 1,472,731.			1,472,731.
o 141,753.			141,753.

Complete only for assets showing gain in column (h) and owned by the foundation on 12/31/69

(i) F.M.V. as of 12/31/69	(j) Adjusted basis as of 12/31/69	(k) Excess of col. (i) over col. (j), if any	(l) Losses (from col. (h)) Gains (excess of col. (h) gain over col. (k), but not less than "-0-")
a			978,678.
b			1,225,001.
c			2,092,646.
d			755,268.
e			1,913,779.
f			96,328.
g			1,292,278.
h			905,039.
i			838,046.
j			2,040,811.
k			931,238.
l			858,855.
m			855,947.
n			1,472,731.
o			141,753.

2 Capital gain net income or (net capital loss) { If gain, also enter in Part I, line 7 If (loss), enter "-0-" in Part I, line 7 }	2
3 Net short-term capital gain or (loss) as defined in sections 1222(5) and (6): If gain, also enter in Part I, line 8, column (c). If (loss), enter "-0-" in Part I, line 8	3

Part IV Capital Gains and Losses for Tax on Investment Income

(a) List and describe the kind(s) of property sold, e.g., real estate, 2-story brick warehouse; or common stock, 200 shs. MLC Co.	(b) How acquired P - Purchase D - Donation	(c) Date acquired (mo., day, yr.)	(d) Date sold (mo., day, yr.)
1a ANDREESSEN HOROWITZ FD III LP	P		02/25/22
b ANDREESSEN HOROWITZ FD III LP	P		04/14/21
c ANDREESSEN HOROWITZ FD III LP	P		11/19/21
d ANDREESSEN HOROWITZ FD III LP	P		08/06/21
e ANDREESSEN HOROWITZ FD III LP	P		06/23/21
f ANDREESSEN HOROWITZ FD III LP	P		05/21/21
g ANDREESSEN HOROWITZ FD III LP	P		05/05/21
h ANDREESSEN HOROWITZ FD IV LP	P		08/30/21
i ANDREESSEN HOROWITZ FD IV LP	P		10/07/21
j ANDREESSEN HOROWITZ FD IV LP	P		11/09/21
k ANDREESSEN HOROWITZ FUND V LP	P		08/12/21
l ANDREESSEN HOROWITZ LSV FD I	P		05/12/21
m ANDREESSEN HOROWITZ LSV FD I	P		05/11/21
n ANDREESSEN HOROWITZ LSV FD I	P		04/13/21
o ANDREESSEN HOROWITZ LSV FD I	P		04/14/21

(e) Gross sales price	(f) Depreciation allowed (or allowable)	(g) Cost or other basis plus expense of sale	(h) Gain or (loss) (e) plus (f) minus (g)
a 1,364,143.			1,364,143.
b 16,413,572.			16,413,572.
c 2,984,077.			2,984,077.
d 1,304,066.			1,304,066.
e 407,573.			407,573.
f 10,861,471.			10,861,471.
g 337,833.			337,833.
h 4,222,417.			4,222,417.
i 2,867,922.			2,867,922.
j 3,302,350.			3,302,350.
k 364,128.			364,128.
l 3,122,023.			3,122,023.
m 3,122,023.			3,122,023.
n 3,314,660.			3,314,660.
o 2,493,527.			2,493,527.

Complete only for assets showing gain in column (h) and owned by the foundation on 12/31/69			(l) Losses (from col. (h)) Gains (excess of col. (h) gain over col. (k), but not less than "-0-")
(i) F.M.V. as of 12/31/69	(j) Adjusted basis as of 12/31/69	(k) Excess of col. (i) over col. (j), if any	
a			1,364,143.
b			16,413,572.
c			2,984,077.
d			1,304,066.
e			407,573.
f			10,861,471.
g			337,833.
h			4,222,417.
i			2,867,922.
j			3,302,350.
k			364,128.
l			3,122,023.
m			3,122,023.
n			3,314,660.
o			2,493,527.

2 Capital gain net income or (net capital loss) { If gain, also enter in Part I, line 7 If (loss), enter "-0-" in Part I, line 7 }	2
3 Net short-term capital gain or (loss) as defined in sections 1222(5) and (6): If gain, also enter in Part I, line 8, column (c). If (loss), enter "-0-" in Part I, line 8	3

Part IV Capital Gains and Losses for Tax on Investment Income

(a) List and describe the kind(s) of property sold, e.g., real estate, 2-story brick warehouse; or common stock, 200 shs. MLC Co.	(b) How acquired P - Purchase D - Donation	(c) Date acquired (mo., day, yr.)	(d) Date sold (mo., day, yr.)
1a ANDREESSEN HOROWITZ LSV FD I	P		05/21/21
b ANDREESSEN HOROWITZ LSV FD I	P		11/09/21
c ANDREESSEN HOROWITZ LSV FD I	P		05/12/21
d ARBORETUM IV	P		06/22/21
e ARBORETUM IV	P		10/26/21
f ARBORETUM IV	P		12/07/21
g ARBORETUM VENTURES IV LP	P		10/26/21
h ARBORETUM VENTURES IV LP	P		06/22/21
i BAYVIEW OPPORTUNITY OFFSHORE IVA LP	P		01/14/22
j BLACKROCK US DEBT INDEX FUND B	P		03/30/22
k BLACKROCK US DEBT INDEX FUND B	P		01/26/22
l BLACKROCK US DEBT INDEX FUND B	P		03/25/22
m BLACKROCK US DEBT INDEX FUND B	P		07/28/21
n BLACKROCK US DEBT INDEX FUND B	P		10/27/21
o BLACKROCK US DEBT INDEX FUND B	P		05/10/21

(e) Gross sales price	(f) Depreciation allowed (or allowable)	(g) Cost or other basis plus expense of sale	(h) Gain or (loss) (e) plus (f) minus (g)
a 1,644,627.			1,644,627.
b 7,951,120.			7,951,120.
c		3,122,023.	-3,122,023.
d 2,970,948.			2,970,948.
e 3,604,563.			3,604,563.
f 676,144.			676,144.
g 2,309,164.			2,309,164.
h 153,564.			153,564.
i 685,417.			685,417.
j 20,000,000.		21,408,607.	-1,408,607.
k 26,435.		27,262.	-827.
l 30,000,000.		32,423,251.	-2,423,251.
m 24,999.		24,901.	98.
n 26,571.		26,726.	-155.
o 21,278.		21,637.	-359.

Complete only for assets showing gain in column (h) and owned by the foundation on 12/31/69			(l) Losses (from col. (h)) Gains (excess of col. (h) gain over col. (k), but not less than "-0-")
(i) F.M.V. as of 12/31/69	(j) Adjusted basis as of 12/31/69	(k) Excess of col. (i) over col. (j), if any	
a			1,644,627.
b			7,951,120.
c			-3,122,023.
d			2,970,948.
e			3,604,563.
f			676,144.
g			2,309,164.
h			153,564.
i			685,417.
j			-1,408,607.
k			-827.
l			-2,423,251.
m			98.
n			-155.
o			-359.

2 Capital gain net income or (net capital loss) { If gain, also enter in Part I, line 7 If (loss), enter "-0-" in Part I, line 7 }	2
3 Net short-term capital gain or (loss) as defined in sections 1222(5) and (6): If gain, also enter in Part I, line 8, column (c). If (loss), enter "-0-" in Part I, line 8	3

Part IV Capital Gains and Losses for Tax on Investment Income

(a) List and describe the kind(s) of property sold, e.g., real estate, 2-story brick warehouse; or common stock, 200 shs. MLC Co.	(b) How acquired P - Purchase D - Donation	(c) Date acquired (mo., day, yr.)	(d) Date sold (mo., day, yr.)
1a CHATHAM ASSET HIGH YIELD OFFSHORE FUND LTD	P		03/31/22
b CHATHAM ASSET PARTNERS HIGH YIELD FUND LP	P		03/31/22
c CHATHAM ASSET PARTNERS HIGH YIELD FUND LP	P		09/30/21
d CHATHAM CO INVEST	P		07/31/21
e CHATHAM CO INVEST	P		08/31/21
f CHATHAM CO INVEST	P		09/30/21
g CHATHAM CO INVEST	P		10/31/21
h CHATHAM CO INVEST	P		11/30/21
i CHATHAM CO INVEST	P		12/31/21
j CHATHAM CO INVEST	P		04/30/21
k CHATHAM CO INVEST	P		02/28/22
l CHATHAM CO INVEST	P		03/31/22
m CHATHAM CO INVEST	P		06/30/21
n CHATHAM CO INVEST	P		05/31/21
o CHATHAM CO INVEST	P		01/31/22

(e) Gross sales price	(f) Depreciation allowed (or allowable)	(g) Cost or other basis plus expense of sale	(h) Gain or (loss) (e) plus (f) minus (g)
a 5,000,000.		2,926,577.	2,073,423.
b 5,000,000.		2,902,961.	2,097,039.
c 2,931.		1,778.	1,153.
d 5,000,000.		3,256,345.	1,743,655.
e 5,000,000.		3,190,600.	1,809,400.
f 5,000,000.		3,048,481.	1,951,519.
g 5,000,000.		3,012,583.	1,987,417.
h 5,000,000.		2,943,605.	2,056,395.
i 5,000,000.		2,908,518.	2,091,482.
j 5,000,000.		3,409,031.	1,590,969.
k 5,000,000.		2,887,386.	2,112,614.
l 5,000,000.		2,865,182.	2,134,818.
m 5,000,000.		3,323,904.	1,676,096.
n 5,000,000.		3,394,787.	1,605,213.
o 5,000,000.		2,872,622.	2,127,378.

Complete only for assets showing gain in column (h) and owned by the foundation on 12/31/69			(l) Losses (from col. (h)) Gains (excess of col. (h) gain over col. (k), but not less than "-0-")
(i) F.M.V. as of 12/31/69	(j) Adjusted basis as of 12/31/69	(k) Excess of col. (i) over col. (j), if any	
a			2,073,423.
b			2,097,039.
c			1,153.
d			1,743,655.
e			1,809,400.
f			1,951,519.
g			1,987,417.
h			2,056,395.
i			2,091,482.
j			1,590,969.
k			2,112,614.
l			2,134,818.
m			1,676,096.
n			1,605,213.
o			2,127,378.

2 Capital gain net income or (net capital loss) { If gain, also enter in Part I, line 7 If (loss), enter "-0-" in Part I, line 7 }	2	
3 Net short-term capital gain or (loss) as defined in sections 1222(5) and (6): If gain, also enter in Part I, line 8, column (c). If (loss), enter "-0-" in Part I, line 8	3	

Part IV Capital Gains and Losses for Tax on Investment Income

(a) List and describe the kind(s) of property sold, e.g., real estate, 2-story brick warehouse; or common stock, 200 shs. MLC Co.	(b) How acquired P - Purchase D - Donation	(c) Date acquired (mo., day, yr.)	(d) Date sold (mo., day, yr.)
1a COLLER INTERNATIONAL PARTNERS VI	P		09/08/21
b COLLER INTERNATIONAL PARTNERS VI	P		11/12/21
c COLLER INTERNATIONAL PARTNERS VI	P		10/27/21
d COLLER INTERNATIONAL PARTNERS VI	P		01/10/22
e COLLER INTERNATIONAL PARTNERS VI	P		03/04/22
f COLLER INTERNATIONAL PARTNERS VI	P		08/13/21
g COLLER INTERNATIONAL PARTNERS VI	P		06/16/21
h COLLER INTERNATIONAL PARTNERS VI	P		04/19/21
i EIG ENERGY FD XVII LP	P		04/23/21
j EIG ENERGY FD XVII LP	P		06/04/21
k EIG ENERGY FUND XVI LP	P		04/28/21
l EIG ENERGY FUND XVI LP	P		01/25/22
m EIG ENERGY XVII	P		04/23/21
n EMERGENCE CAPITAL PARTNERS III	P		01/06/22
o EMERGENCE CAPITAL PARTNERS III	P		11/12/21

(e) Gross sales price	(f) Depreciation allowed (or allowable)	(g) Cost or other basis plus expense of sale	(h) Gain or (loss) (e) plus (f) minus (g)
a 391,304.			391,304.
b 1,190,000.			1,190,000.
c 1,400,000.			1,400,000.
d 730,034.			730,034.
e 430,500.			430,500.
f 930,723.			930,723.
g 753,100.			753,100.
h 449,037.			449,037.
i 8,143.			8,143.
j 78,764.			78,764.
k 209,157.			209,157.
l 2,576.			2,576.
m 2,908.			2,908.
n 21,425,317.			21,425,317.
o 3,595,293.			3,595,293.

Complete only for assets showing gain in column (h) and owned by the foundation on 12/31/69			(l) Losses (from col. (h)) Gains (excess of col. (h) gain over col. (k), but not less than "-0-")
(i) F.M.V. as of 12/31/69	(j) Adjusted basis as of 12/31/69	(k) Excess of col. (i) over col. (j), if any	
a			391,304.
b			1,190,000.
c			1,400,000.
d			730,034.
e			430,500.
f			930,723.
g			753,100.
h			449,037.
i			8,143.
j			78,764.
k			209,157.
l			2,576.
m			2,908.
n			21,425,317.
o			3,595,293.

2 Capital gain net income or (net capital loss) { If gain, also enter in Part I, line 7 If (loss), enter "-0-" in Part I, line 7 }	2	
3 Net short-term capital gain or (loss) as defined in sections 1222(5) and (6): If gain, also enter in Part I, line 8, column (c). If (loss), enter "-0-" in Part I, line 8	3	

Part IV Capital Gains and Losses for Tax on Investment Income

(a) List and describe the kind(s) of property sold, e.g., real estate, 2-story brick warehouse; or common stock, 200 shs. MLC Co.	(b) How acquired P - Purchase D - Donation	(c) Date acquired (mo., day, yr.)	(d) Date sold (mo., day, yr.)
1a EMERGENCE CAPITAL PARTNERS III	P		09/28/21
b EMERGENCE CAPITAL PARTNERS IV LP	P		09/02/21
c ENERGY FUND XV-A LP	P		12/01/21
d EPIRIS FUND II B LP	P		10/28/21
e EPIRIS II	P		10/18/21
f FORTISSIMO IV	P		04/08/21
g FORTISSIMO IV	P		08/26/21
h FORTISSIMO IV	P		12/29/21
i FORTISSIMO IV	P		12/29/21
j FRAZIER LIFE SCI PUBLIC FD LP	P		11/01/21
k FRAZIER LIFE SCI PUBLIC FD LP	P		12/17/21
l FRAZIER LIFE SCIENCES IX LP	P		05/25/21
m FRAZIER LIFE SCIENCES IX LP	P		06/15/21
n FRAZIER LIFE SCIENCES IX LP	P		07/08/21
o FRAZIER LIFE SCIENCES IX LP	P		12/31/21

(e) Gross sales price	(f) Depreciation allowed (or allowable)	(g) Cost or other basis plus expense of sale	(h) Gain or (loss) (e) plus (f) minus (g)
a 1,745,588.			1,745,588.
b 3,790,048.			3,790,048.
c 72,796.			72,796.
d 644,037.			644,037.
e 6,893.			6,893.
f 2,833,128.			2,833,128.
g 1,579,410.			1,579,410.
h 87,200.			87,200.
i 87,200.			87,200.
j 40,838.			40,838.
k 159,240.			159,240.
l		225,634.	-225,634.
m 254,331.			254,331.
n 326,233.			326,233.
o 2,528,006.			2,528,006.

Complete only for assets showing gain in column (h) and owned by the foundation on 12/31/69			(l) Losses (from col. (h)) Gains (excess of col. (h) gain over col. (k), but not less than "-0-")
(i) F.M.V. as of 12/31/69	(j) Adjusted basis as of 12/31/69	(k) Excess of col. (i) over col. (j), if any	
a			1,745,588.
b			3,790,048.
c			72,796.
d			644,037.
e			6,893.
f			2,833,128.
g			1,579,410.
h			87,200.
i			87,200.
j			40,838.
k			159,240.
l			-225,634.
m			254,331.
n			326,233.
o			2,528,006.

2 Capital gain net income or (net capital loss) { If gain, also enter in Part I, line 7 If (loss), enter "-0-" in Part I, line 7 }	2	
3 Net short-term capital gain or (loss) as defined in sections 1222(5) and (6): If gain, also enter in Part I, line 8, column (c). If (loss), enter "-0-" in Part I, line 8	3	

Part IV Capital Gains and Losses for Tax on Investment Income

(a) List and describe the kind(s) of property sold, e.g., real estate, 2-story brick warehouse; or common stock, 200 shs. MLC Co.	(b) How acquired P - Purchase D - Donation	(c) Date acquired (mo., day, yr.)	(d) Date sold (mo., day, yr.)
1a FRAZIER LIFE SCIENCES IX LP	P		02/09/22
b FRAZIER LIFE SCIENCES IX LP	P		08/06/21
c FRAZIER LIFE SCIENCES IX LP	P		08/09/21
d FRAZIER LIFE SCIENCES X LP	P		09/29/21
e FRAZIER LIFE SCIENCES X LP	P		11/24/21
f FRAZIER LIFE SCIENCES X LP	P		11/15/21
g FRAZIER LIFE SCIENCES X LP	P		06/24/21
h FRAZIER LIFE SCIENCES X LP	P		10/22/21
i GA MANAGED ACCOUNT PROGRAM	P		09/02/21
j GA MANAGED ACCOUNT PROGRAM	P		09/29/21
k GA MANAGED ACCOUNT PROGRAM	P		07/27/21
l GA MANAGED ACCOUNT PROGRAM	P		07/23/21
m GA MANAGED ACCOUNT PROGRAM	P		07/20/21
n GA MANAGED ACCOUNT PROGRAM	P		07/16/21
o GA MANAGED ACCOUNT PROGRAM	P		06/17/21

(e) Gross sales price	(f) Depreciation allowed (or allowable)	(g) Cost or other basis plus expense of sale	(h) Gain or (loss) (e) plus (f) minus (g)
a 4,462,880.			4,462,880.
b 43,664.			43,664.
c 1,149,177.			1,149,177.
d 201,963.			201,963.
e 341,938.			341,938.
f 312,788.			312,788.
g 71,396.			71,396.
h 269,979.			269,979.
i 111,027.			111,027.
j 25,580.			25,580.
k 228,439.			228,439.
l 575,546.			575,546.
m 279,264.			279,264.
n 227,636.			227,636.
o 372,092.			372,092.

Complete only for assets showing gain in column (h) and owned by the foundation on 12/31/69			(l) Losses (from col. (h)) Gains (excess of col. (h) gain over col. (k), but not less than "-0-")
(i) F.M.V. as of 12/31/69	(j) Adjusted basis as of 12/31/69	(k) Excess of col. (i) over col. (j), if any	
a			4,462,880.
b			43,664.
c			1,149,177.
d			201,963.
e			341,938.
f			312,788.
g			71,396.
h			269,979.
i			111,027.
j			25,580.
k			228,439.
l			575,546.
m			279,264.
n			227,636.
o			372,092.

2 Capital gain net income or (net capital loss) { If gain, also enter in Part I, line 7 If (loss), enter "-0-" in Part I, line 7 }	2	
3 Net short-term capital gain or (loss) as defined in sections 1222(5) and (6): If gain, also enter in Part I, line 8, column (c). If (loss), enter "-0-" in Part I, line 8	3	

Part IV Capital Gains and Losses for Tax on Investment Income

(a) List and describe the kind(s) of property sold, e.g., real estate, 2-story brick warehouse; or common stock, 200 shs. MLC Co.	(b) How acquired P - Purchase D - Donation	(c) Date acquired (mo., day, yr.)	(d) Date sold (mo., day, yr.)
1a GA MANAGED ACCOUNT PROGRAM	P		06/02/21
b GA MANAGED ACCOUNT PROGRAM	P		05/25/21
c GA MANAGED ACCOUNT PROGRAM	P		04/29/21
d GA MANAGED ACCOUNT PROGRAM	P		03/30/22
e GA MANAGED ACCOUNT PROGRAM	P		12/23/21
f GA MANAGED ACCOUNT PROGRAM	P		12/17/21
g GA MANAGED ACCOUNT PROGRAM	P		11/23/21
h GA MANAGED ACCOUNT PROGRAM	P		06/30/21
i GA MANAGED ACCOUNT PROGRAM	P		11/12/21
j GAVEA INVESTMENT FUND V B LP	P		05/21/21
k GAVEA INVESTMENT FUND V B LP	P		05/06/21
l GENERAL ATLANTIC SERVICE COMPANY LLC	P		12/23/21
m GENERAL ATLANTIC SERVICE COMPANY LLC	P		09/13/21
n GENERAL ATLANTIC SERVICE COMPANY LLC	P		07/21/21
o GENERAL ATLANTIC SERVICE COMPANY LLC	P		07/16/21

(e) Gross sales price	(f) Depreciation allowed (or allowable)	(g) Cost or other basis plus expense of sale	(h) Gain or (loss) (e) plus (f) minus (g)
a 877,858.			877,858.
b 92,332.			92,332.
c 4,551,767.			4,551,767.
d 1,305,759.			1,305,759.
e 465.			465.
f 160,272.			160,272.
g 319,657.			319,657.
h 49,370.			49,370.
i 764,379.			764,379.
j 334,593.			334,593.
k 740,446.			740,446.
l 10,640,404.			10,640,404.
m 1,587,956.			1,587,956.
n 1,855,989.			1,855,989.
o 464,870.			464,870.

Complete only for assets showing gain in column (h) and owned by the foundation on 12/31/69			(l) Losses (from col. (h)) Gains (excess of col. (h) gain over col. (k), but not less than "-0-")
(i) F.M.V. as of 12/31/69	(j) Adjusted basis as of 12/31/69	(k) Excess of col. (i) over col. (j), if any	
a			877,858.
b			92,332.
c			4,551,767.
d			1,305,759.
e			465.
f			160,272.
g			319,657.
h			49,370.
i			764,379.
j			334,593.
k			740,446.
l			10,640,404.
m			1,587,956.
n			1,855,989.
o			464,870.

2 Capital gain net income or (net capital loss) { If gain, also enter in Part I, line 7 If (loss), enter "-0-" in Part I, line 7 }	2	
3 Net short-term capital gain or (loss) as defined in sections 1222(5) and (6): If gain, also enter in Part I, line 8, column (c). If (loss), enter "-0-" in Part I, line 8	3	

Part IV Capital Gains and Losses for Tax on Investment Income

(a) List and describe the kind(s) of property sold, e.g., real estate, 2-story brick warehouse; or common stock, 200 shs. MLC Co.	(b) How acquired P - Purchase D - Donation	(c) Date acquired (mo., day, yr.)	(d) Date sold (mo., day, yr.)
1a GENERAL ATLANTIC SERVICE COMPANY LLC	P		06/30/21
b GENERAL ATLANTIC SERVICE COMPANY LLC	P		06/10/21
c GENERAL ATLANTIC SERVICE COMPANY LLC	P		06/09/21
d GENERAL ATLANTIC SERVICE COMPANY LLC	P		05/10/21
e GENERAL ATLANTIC SERVICE COMPANY LLC	P		08/11/21
f GENERAL ATLANTIC SERVICE COMPANY LLC	P		10/08/21
g GENERAL ATLANTIC SERVICE COMPANY LLC	P		12/02/21
h GENERAL ATLANTIC SERVICE COMPANY LLC	P		08/06/21
i GENERAL ATLANTIC SERVICE COMPANY LLC	P		12/29/21
j GENERAL ATLANTIC SERVICE COMPANY LLC	P		03/30/22
k GENERAL ATLANTIC SERVICE COMPANY LLC	P		04/09/21
l GENERAL ATLANTIC 2013	P		05/10/21
m GENERAL ATLANTIC 2013	P		03/30/22
n GENERAL ATLANTIC 2018	P		05/25/21
o GENERAL ATLANTIC 2018	P		06/17/21

(e) Gross sales price	(f) Depreciation allowed (or allowable)	(g) Cost or other basis plus expense of sale	(h) Gain or (loss) (e) plus (f) minus (g)
a 7,549,283.			7,549,283.
b 2,751,418.			2,751,418.
c 3,903,065.			3,903,065.
d 617,418.			617,418.
e 922,213.			922,213.
f		287,537.	-287,537.
g 605,568.			605,568.
h 1,832,219.			1,832,219.
i 236,159.			236,159.
j 16,981.			16,981.
k 480,225.			480,225.
l 454,688.			454,688.
m 328,868.			328,868.
n 670.			670.
o 28,185.			28,185.

Complete only for assets showing gain in column (h) and owned by the foundation on 12/31/69			(l) Losses (from col. (h)) Gains (excess of col. (h) gain over col. (k), but not less than "-0-")
(i) F.M.V. as of 12/31/69	(j) Adjusted basis as of 12/31/69	(k) Excess of col. (i) over col. (j), if any	
a			7,549,283.
b			2,751,418.
c			3,903,065.
d			617,418.
e			922,213.
f			-287,537.
g			605,568.
h			1,832,219.
i			236,159.
j			16,981.
k			480,225.
l			454,688.
m			328,868.
n			670.
o			28,185.

2 Capital gain net income or (net capital loss) { If gain, also enter in Part I, line 7 If (loss), enter "-0-" in Part I, line 7 }	2
3 Net short-term capital gain or (loss) as defined in sections 1222(5) and (6): If gain, also enter in Part I, line 8, column (c). If (loss), enter "-0-" in Part I, line 8	3

Part IV Capital Gains and Losses for Tax on Investment Income

(a) List and describe the kind(s) of property sold, e.g., real estate, 2-story brick warehouse; or common stock, 200 shs. MLC Co.	(b) How acquired P - Purchase D - Donation	(c) Date acquired (mo., day, yr.)	(d) Date sold (mo., day, yr.)
1a GENERAL ATLANTIC 2018	P		12/17/21
b GOLDEN GATE CAP OPP FUND MGT	P		09/28/21
c GOLDEN GATE CAP OPP FUND MGT	P		05/14/21
d GOLDEN GATE CAP OPP FUND MGT	P		05/14/21
e GOLDEN GATE CAP OPP FUND MGT	P		09/28/21
f GOLDEN GATE CAP OPP FUND MGT	P		12/31/21
g GOLDEN GATE CAP OPP FUND MGT	P		12/31/21
h GOLDENTREE OFFSHORE FUND SIDE POCKET 8	P		04/30/21
i GOLDENTREE OFFSHORE FUND SIDE POCKET 8	P		02/28/22
j GOLDENTREE OFFSHORE FUND SIDE POCKET 8	P		02/28/22
k GOLDENTREE OFFSHORE FUND SIDE POCKET 8	P		10/31/21
l GSO CAPITAL SOLUTION	P		07/22/21
m GSO CAPITAL SOLUTIONS FD III LP	P		06/29/21
n GSO CAPITAL SOLUTIONS FD III LP	P		02/24/22
o GSO CAPITAL SOLUTIONS FD III LP	P		10/27/21

(e) Gross sales price	(f) Depreciation allowed (or allowable)	(g) Cost or other basis plus expense of sale	(h) Gain or (loss) (e) plus (f) minus (g)
a 85,220.			85,220.
b 4,036,883.			4,036,883.
c 9,349,937.			9,349,937.
d 6,593,147.			6,593,147.
e 5,023,730.			5,023,730.
f 51,484,482.		80,344,042.	-28,859,560.
g 51,484,482.		80,344,042.	-28,859,560.
h 53,652.			53,652.
i 130,055.			130,055.
j 1,171,054.			1,171,054.
k 6,253,988.			6,253,988.
l 150,802.			150,802.
m 54,118.			54,118.
n 12,995.			12,995.
o 72,238.			72,238.

Complete only for assets showing gain in column (h) and owned by the foundation on 12/31/69			(l) Losses (from col. (h)) Gains (excess of col. (h) gain over col. (k), but not less than "-0-")
(i) F.M.V. as of 12/31/69	(j) Adjusted basis as of 12/31/69	(k) Excess of col. (i) over col. (j), if any	
a			85,220.
b			4,036,883.
c			9,349,937.
d			6,593,147.
e			5,023,730.
f			-28,859,560.
g			-28,859,560.
h			53,652.
i			130,055.
j			1,171,054.
k			6,253,988.
l			150,802.
m			54,118.
n			12,995.
o			72,238.

2 Capital gain net income or (net capital loss) { If gain, also enter in Part I, line 7 If (loss), enter "-0-" in Part I, line 7 }	2
3 Net short-term capital gain or (loss) as defined in sections 1222(5) and (6): If gain, also enter in Part I, line 8, column (c). If (loss), enter "-0-" in Part I, line 8	3

Part IV Capital Gains and Losses for Tax on Investment Income

(a) List and describe the kind(s) of property sold, e.g., real estate, 2-story brick warehouse; or common stock, 200 shs. MLC Co.	(b) How acquired P - Purchase D - Donation	(c) Date acquired (mo., day, yr.)	(d) Date sold (mo., day, yr.)
1a GSO CAPITAL SOLUTIONS FD III LP	P		09/30/21
b GSO CAPITAL SOLUTIONS FD III LP	P		12/20/21
c GSO CAPITAL SOLUTIONS FD III LP	P		11/18/21
d GSO CAPITAL SOLUTIONS FD III LP	P		09/02/21
e GSO CAPITAL SOLUTIONS FUND II LP	P		03/31/22
f GSO CAPITAL SOLUTIONS FUND II LP	P		12/22/21
g GSO CAPITAL SOLUTIONS FUND II LP	P		11/23/21
h H.I.G. GROWTH BUYOUTS & EQUITY FUND II L.P..	P		03/09/22
i HARBOUR ENERGY FUND LP	P		03/31/21
j HARBOUR ENERGY FUND LP	P		03/31/21
k HIG BAYSIDE LOAN OPPORTUNITY FEEDER FUND III (EUROPE-US\$) L	P		10/15/21
l HIG BAYSIDE LOAN OPPORTUNITY FEEDER FUND III (EUROPE-US\$) L	P		08/20/21
m HIG BAYSIDE LOAN OPPORTUNITY FEEDER FUND III (EUROPE-US\$) L	P		04/29/21
n HIG BIOVENTURES II	P		03/03/22
o HIG BRAZIL & LATIN AME PTNRS MASTER B LP	P		03/01/22

(e) Gross sales price	(f) Depreciation allowed (or allowable)	(g) Cost or other basis plus expense of sale	(h) Gain or (loss) (e) plus (f) minus (g)
a 12,235.			12,235.
b 31,275.			31,275.
c 17.			17.
d 2,884.			2,884.
e 568,666.			568,666.
f 300,933.			300,933.
g 862,970.			862,970.
h 4,547,554.			4,547,554.
i 15,541,938.			15,541,938.
j		17,409,877.	-17,409,877.
k 85,392.			85,392.
l 537,186.			537,186.
m 123,915.			123,915.
n 1,469,593.			1,469,593.
o 192,237.			192,237.

Complete only for assets showing gain in column (h) and owned by the foundation on 12/31/69			(l) Losses (from col. (h)) Gains (excess of col. (h) gain over col. (k), but not less than "-0-")
(i) F.M.V. as of 12/31/69	(j) Adjusted basis as of 12/31/69	(k) Excess of col. (i) over col. (j), if any	
a			12,235.
b			31,275.
c			17.
d			2,884.
e			568,666.
f			300,933.
g			862,970.
h			4,547,554.
i			15,541,938.
j			-17,409,877.
k			85,392.
l			537,186.
m			123,915.
n			1,469,593.
o			192,237.

2 Capital gain net income or (net capital loss) { If gain, also enter in Part I, line 7 If (loss), enter "-0-" in Part I, line 7 }	2
3 Net short-term capital gain or (loss) as defined in sections 1222(5) and (6): If gain, also enter in Part I, line 8, column (c). If (loss), enter "-0-" in Part I, line 8	3

Part IV Capital Gains and Losses for Tax on Investment Income

(a) List and describe the kind(s) of property sold, e.g., real estate, 2-story brick warehouse; or common stock, 200 shs. MLC Co.	(b) How acquired P - Purchase D - Donation	(c) Date acquired (mo., day, yr.)	(d) Date sold (mo., day, yr.)
1a HIG BRAZIL & LATIN AME PTNRS MASTER B LP	P		09/13/21
b HIG BRAZIL & LATIN AME PTNRS MASTER B LP	P		07/02/21
c HIG BRAZIL & LATIN AME PTNRS MASTER C LP	P		07/02/21
d HIG BRAZIL & LATIN AME PTNRS MASTER C LP	P		09/13/21
e HIG BRAZIL & LATIN AME PTNRS MASTER C LP	P		03/01/22
f HIG BRAZIL LATAM B	P		03/01/22
g HIG BRAZIL LATAM C	P		03/01/22
h HIG CAPITAL PARTNERS V L P	P		07/28/21
i HIG CAPITAL PARTNERS V L P	P		06/25/21
j HIG CAPITAL PARTNERS V L P	P		10/26/21
k HIG CAPITAL PARTNERS V L P	P		12/29/21
l HIG MIDDLE MKT LBO FD II LP	P		06/24/21
m HIG MIDDLE MKT LBO FD II LP	P		10/22/21
n HIG MIDDLE MKT LBO FD II LP	P		03/25/22
o HIG MIDDLE MKT LBO FD II LP	P		01/14/22

(e) Gross sales price	(f) Depreciation allowed (or allowable)	(g) Cost or other basis plus expense of sale	(h) Gain or (loss) (e) plus (f) minus (g)
a 552,452.			552,452.
b 407,271.			407,271.
c 407,271.			407,271.
d 552,452.			552,452.
e 192,237.			192,237.
f 187,669.			187,669.
g 187,669.			187,669.
h 2,457,479.			2,457,479.
i 1,414,386.			1,414,386.
j 8,549,112.			8,549,112.
k 1,393,508.			1,393,508.
l 1,621,239.			1,621,239.
m 3,718,411.			3,718,411.
n 1,068,400.			1,068,400.
o 4,989,393.			4,989,393.

Complete only for assets showing gain in column (h) and owned by the foundation on 12/31/69

(i) F.M.V. as of 12/31/69	(j) Adjusted basis as of 12/31/69	(k) Excess of col. (i) over col. (j), if any	(l) Losses (from col. (h)) Gains (excess of col. (h) gain over col. (k), but not less than "-0-")
a			552,452.
b			407,271.
c			407,271.
d			552,452.
e			192,237.
f			187,669.
g			187,669.
h			2,457,479.
i			1,414,386.
j			8,549,112.
k			1,393,508.
l			1,621,239.
m			3,718,411.
n			1,068,400.
o			4,989,393.

2 Capital gain net income or (net capital loss) { If gain, also enter in Part I, line 7 If (loss), enter "-0-" in Part I, line 7 }	2	
3 Net short-term capital gain or (loss) as defined in sections 1222(5) and (6): If gain, also enter in Part I, line 8, column (c). If (loss), enter "-0-" in Part I, line 8	3	

Part IV Capital Gains and Losses for Tax on Investment Income

(a) List and describe the kind(s) of property sold, e.g., real estate, 2-story brick warehouse; or common stock, 200 shs. MLC Co.	(b) How acquired P - Purchase D - Donation	(c) Date acquired (mo., day, yr.)	(d) Date sold (mo., day, yr.)
1a HIGH MIDDLE MKT LBO FD II LP	P		12/03/21
b HIGHCLERE INTL SMALL CAP FUND	P		05/07/21
c HIGHCLERE INTL SMALL CAP FUND	P		04/30/21
d HIGHCLERE INTL SMALL CAP FUND	P		03/31/22
e HIGHCLERE INTL SMALL CAP FUND	P		02/28/22
f HIGHCLERE INTL SMALL CAP FUND	P		01/31/22
g HIGHCLERE INTL SMALL CAP FUND	P		12/31/21
h HIGHCLERE INTL SMALL CAP FUND	P		12/07/21
i HIGHCLERE INTL SMALL CAP FUND	P		11/30/21
j HIGHCLERE INTL SMALL CAP FUND	P		11/05/21
k HIGHCLERE INTL SMALL CAP FUND	P		10/31/21
l HIGHCLERE INTL SMID CAP FUND	P		04/30/21
m HIGHCLERE INTL SMID CAP FUND	P		05/31/21
n HIGHCLERE INTL SMID CAP FUND	P		05/07/21
o HIGHCLERE INTL SMID CAP FUND	P		06/07/21

(e) Gross sales price	(f) Depreciation allowed (or allowable)	(g) Cost or other basis plus expense of sale	(h) Gain or (loss) (e) plus (f) minus (g)
a 5,998,290.			5,998,290.
b 10,000,000.		10,000,212.	-212.
c 203,549.		203,558.	-9.
d 124,456.			124,456.
e 128,012.			128,012.
f 129,759.			129,759.
g 140,321.			140,321.
h 12,500,000.			12,500,000.
i 144,929.			144,929.
j 12,500,000.		1,877,387.	10,622,613.
k 163,006.		882,733.	-719,727.
l 109,447.			109,447.
m 99,300.			99,300.
n 18,000,000.			18,000,000.
o 20,000,000.			20,000,000.

Complete only for assets showing gain in column (h) and owned by the foundation on 12/31/69			(l) Losses (from col. (h)) Gains (excess of col. (h) gain over col. (k), but not less than "-0-")
(i) F.M.V. as of 12/31/69	(j) Adjusted basis as of 12/31/69	(k) Excess of col. (i) over col. (j), if any	
a			5,998,290.
b			-212.
c			-9.
d			124,456.
e			128,012.
f			129,759.
g			140,321.
h			12,500,000.
i			144,929.
j			10,622,613.
k			-719,727.
l			109,447.
m			99,300.
n			18,000,000.
o			20,000,000.

2 Capital gain net income or (net capital loss) { If gain, also enter in Part I, line 7 If (loss), enter "-0-" in Part I, line 7 }	2	
3 Net short-term capital gain or (loss) as defined in sections 1222(5) and (6): If gain, also enter in Part I, line 8, column (c). If (loss), enter "-0-" in Part I, line 8	3	

Part IV Capital Gains and Losses for Tax on Investment Income

(a) List and describe the kind(s) of property sold, e.g., real estate, 2-story brick warehouse; or common stock, 200 shs. MLC Co.	(b) How acquired P - Purchase D - Donation	(c) Date acquired (mo., day, yr.)	(d) Date sold (mo., day, yr.)
1a HIGHCLERE INTL SMID CAP FUND	P		06/30/21
b HIGHCLERE INTL SMID CAP FUND	P		07/31/21
c HIGHCLERE INTL SMID CAP FUND	P		08/31/21
d HIGHCLERE INTL SMID CAP FUND	P		09/30/21
e HIGHCLERE INTL SMID CAP FUND	P		10/31/21
f HIGHCLERE INTL SMID CAP FUND	P		11/05/21
g HIGHCLERE INTL SMID CAP FUND	P		11/30/21
h HIGHCLERE INTL SMID CAP FUND	P		12/07/21
i HIGHCLERE INTL SMID CAP FUND	P		12/31/21
j HIGHCLERE INTL SMID CAP FUND	P		01/31/22
k HIGHCLERE INTL SMID CAP FUND	P		02/28/22
l HIGHCLERE INTL SMID CAP FUND	P		03/31/22
m IDG BREYER CAPITAL FUND LP	P		05/21/21
n IDG CHINA CAPITAL FUND III LP	P		12/28/21
o IDG CHINA VENTURE CAP FD IV LP	P		08/31/21

(e) Gross sales price	(f) Depreciation allowed (or allowable)	(g) Cost or other basis plus expense of sale	(h) Gain or (loss) (e) plus (f) minus (g)
a 84,495.			84,495.
b 85,060.			85,060.
c 87,509.			87,509.
d 85,692.			85,692.
e 78,622.			78,622.
f 12,500,000.			12,500,000.
g 68,698.			68,698.
h 12,500,000.			12,500,000.
i 63,477.			63,477.
j 59,851.			59,851.
k 58,784.			58,784.
l 57,314.			57,314.
m 125,348.			125,348.
n 263,591.			263,591.
o 2,117,895.			2,117,895.

Complete only for assets showing gain in column (h) and owned by the foundation on 12/31/69

(i) F.M.V. as of 12/31/69	(j) Adjusted basis as of 12/31/69	(k) Excess of col. (i) over col. (j), if any	(l) Losses (from col. (h)) Gains (excess of col. (h) gain over col. (k), but not less than "-0-")
a			84,495.
b			85,060.
c			87,509.
d			85,692.
e			78,622.
f			12,500,000.
g			68,698.
h			12,500,000.
i			63,477.
j			59,851.
k			58,784.
l			57,314.
m			125,348.
n			263,591.
o			2,117,895.

2 Capital gain net income or (net capital loss) { If gain, also enter in Part I, line 7 If (loss), enter "-0-" in Part I, line 7 }	2
3 Net short-term capital gain or (loss) as defined in sections 1222(5) and (6): If gain, also enter in Part I, line 8, column (c). If (loss), enter "-0-" in Part I, line 8	3

Part IV Capital Gains and Losses for Tax on Investment Income

(a) List and describe the kind(s) of property sold, e.g., real estate, 2-story brick warehouse; or common stock, 200 shs. MLC Co.	(b) How acquired P - Purchase D - Donation	(c) Date acquired (mo., day, yr.)	(d) Date sold (mo., day, yr.)
1a IDG-ACCEL CHINA CAPITAL FUND II L.P.	P		10/29/21
b IDG-ACCEL CHINA CAPITAL FUND II L.P.	P		06/18/21
c IDG-ACCEL CHINA CAPITAL FUND II L.P.	P		12/30/21
d IDG-ACCEL CHINA GROWTH FUND III L.P.	P		12/17/21
e IDG-ACCEL CHINA GROWTH FUND III L.P.	P		06/04/21
f IRON POINT IV	P		12/31/21
g IRON POINT RE PARTNERS IV LP	P		03/30/22
h IRON POINT RE PARTNERS IV LP	P		12/31/21
i LA CAPITAL GLOBAL EQUITY FUND	P		04/30/21
j LA CAPITAL GLOBAL EQUITY FUND	P		05/31/21
k LA CAPITAL GLOBAL EQUITY FUND	P		06/04/21
l LA CAPITAL GLOBAL EQUITY FUND	P		06/30/21
m LA CAPITAL GLOBAL EQUITY FUND	P		08/31/21
n LA CAPITAL GLOBAL EQUITY FUND	P		09/30/21
o LA CAPITAL GLOBAL EQUITY FUND	P		10/31/21

(e) Gross sales price	(f) Depreciation allowed (or allowable)	(g) Cost or other basis plus expense of sale	(h) Gain or (loss) (e) plus (f) minus (g)
a 1,674,729.			1,674,729.
b 833,149.			833,149.
c 1,641,417.			1,641,417.
d 849,833.			849,833.
e 436,414.			436,414.
f 321,188.			321,188.
g 487,378.			487,378.
h 483,261.			483,261.
i 25,589.			25,589.
j 25,988.			25,988.
k 14,000,000.			14,000,000.
l 23,857.			23,857.
m 22,212.			22,212.
n 21,315.			21,315.
o 22,091.			22,091.

Complete only for assets showing gain in column (h) and owned by the foundation on 12/31/69

(i) F.M.V. as of 12/31/69	(j) Adjusted basis as of 12/31/69	(k) Excess of col. (i) over col. (j), if any	(l) Losses (from col. (h)) Gains (excess of col. (h) gain over col. (k), but not less than "-0-")
a			1,674,729.
b			833,149.
c			1,641,417.
d			849,833.
e			436,414.
f			321,188.
g			487,378.
h			483,261.
i			25,589.
j			25,988.
k			14,000,000.
l			23,857.
m			22,212.
n			21,315.
o			22,091.

2 Capital gain net income or (net capital loss) { If gain, also enter in Part I, line 7 If (loss), enter "-0-" in Part I, line 7 }	2
3 Net short-term capital gain or (loss) as defined in sections 1222(5) and (6): If gain, also enter in Part I, line 8, column (c). If (loss), enter "-0-" in Part I, line 8	3

Part IV Capital Gains and Losses for Tax on Investment Income

(a) List and describe the kind(s) of property sold, e.g., real estate, 2-story brick warehouse; or common stock, 200 shs. MLC Co.	(b) How acquired P - Purchase D - Donation	(c) Date acquired (mo., day, yr.)	(d) Date sold (mo., day, yr.)
1a LA CAPITAL GLOBAL EQUITY FUND	P		11/04/21
b LA CAPITAL GLOBAL EQUITY FUND	P		11/30/21
c LA CAPITAL GLOBAL EQUITY FUND	P		12/31/21
d LA CAPITAL GLOBAL EQUITY FUND	P		01/31/22
e LA CAPITAL GLOBAL EQUITY FUND	P		02/28/22
f LA CAPITAL GLOBAL EQUITY FUND	P		03/31/22
g LA CAPITAL GLOBAL EQUITY FUND	P		07/08/21
h LA CAPITAL GLOBAL EQUITY FUND	P		07/31/21
i LACM WORLD SMALL CAP EQUITY FUND LP	P		07/08/21
j LACM WORLD SMALL CAP EQUITY FUND LP	P		10/29/21
k LACM WORLD SMALL CAP EQUITY FUND LP	P		11/04/21
l LACM WORLD SMALL CAP EQUITY FUND LP	P		05/06/21
m LACM WORLD SMALL CAP EQUITY FUND LP	P		04/30/21
n LACM WORLD SMALL CAP EQUITY FUND LP	P		03/31/22
o LACM WORLD SMALL CAP EQUITY FUND LP	P		02/28/22

(e) Gross sales price	(f) Depreciation allowed (or allowable)	(g) Cost or other basis plus expense of sale	(h) Gain or (loss) (e) plus (f) minus (g)
a 18,000,000.			18,000,000.
b 18,763.			18,763.
c 19,529.			19,529.
d 18,757.			18,757.
e 18,298.			18,298.
f 18,593.			18,593.
g 15,000,000.			15,000,000.
h 21,719.			21,719.
i 15,000,000.		15,930,051.	-930,051.
j 21,586.		85,504.	-63,918.
k 12,000,000.		15,442,890.	-3,442,890.
l 8,000,000.		24,702,789.	-16,702,789.
m 26,953.		696,465.	-669,512.
n 18,403.		686,793.	-668,390.
o 18,241.		680,748.	-662,507.

Complete only for assets showing gain in column (h) and owned by the foundation on 12/31/69

(i) F.M.V. as of 12/31/69	(j) Adjusted basis as of 12/31/69	(k) Excess of col. (i) over col. (j), if any	(l) Losses (from col. (h)) Gains (excess of col. (h) gain over col. (k), but not less than "-0-")
a			18,000,000.
b			18,763.
c			19,529.
d			18,757.
e			18,298.
f			18,593.
g			15,000,000.
h			21,719.
i			-930,051.
j			-63,918.
k			-3,442,890.
l			-16,702,789.
m			-669,512.
n			-668,390.
o			-662,507.

2 Capital gain net income or (net capital loss) { If gain, also enter in Part I, line 7 If (loss), enter "-0-" in Part I, line 7 }	2
3 Net short-term capital gain or (loss) as defined in sections 1222(5) and (6): If gain, also enter in Part I, line 8, column (c). If (loss), enter "-0-" in Part I, line 8	3

Part IV Capital Gains and Losses for Tax on Investment Income

(a) List and describe the kind(s) of property sold, e.g., real estate, 2-story brick warehouse; or common stock, 200 shs. MLC Co.	(b) How acquired P - Purchase D - Donation	(c) Date acquired (mo., day, yr.)	(d) Date sold (mo., day, yr.)
1a LACM WORLD SMALL CAP EQUITY FUND LP	P		01/31/22
b LACM WORLD SMALL CAP EQUITY FUND LP	P		12/31/21
c MHR INST PARTNERS IV	P		04/21/21
d MHR INST PARTNERS IV	P		05/25/21
e MHR INST PARTNERS IV	P		07/06/21
f MHR INST PARTNERS IV	P		08/24/21
g MHR INST PARTNERS IV	P		09/08/21
h MHR INST PARTNERS IV	P		09/29/21
i MHR INST PARTNERS IV	P		10/06/21
j MHR INST PARTNERS IV	P		12/30/21
k MHR LONGEVITY FUND LP	P		03/05/21
l MHR LONGEVITY FUND LP	P		06/30/21
m MHR LONGEVITY FUND LP	P		11/30/21
n ORBIMED ASIA PARTNERS III LP	P		12/29/21
o ORBIMED ISRAEL GP	P		09/17/21

(e) Gross sales price	(f) Depreciation allowed (or allowable)	(g) Cost or other basis plus expense of sale	(h) Gain or (loss) (e) plus (f) minus (g)
a 18,030.		1,226,912.	-1,208,882.
b 19,413.		1,321,045.	-1,301,632.
c 214,413.			214,413.
d 313,005.			313,005.
e 88,098.			88,098.
f 41,943.			41,943.
g 217,960.			217,960.
h 61,302.			61,302.
i 179,609.			179,609.
j 941,196.			941,196.
k 2,599,659.		2,272,606.	327,053.
l 2,024,796.		1,688,549.	336,247.
m 624,108.		523,402.	100,706.
n 1,008,201.			1,008,201.
o		2,494,266.	-2,494,266.

Complete only for assets showing gain in column (h) and owned by the foundation on 12/31/69

(i) F.M.V. as of 12/31/69	(j) Adjusted basis as of 12/31/69	(k) Excess of col. (i) over col. (j), if any	(l) Losses (from col. (h)) Gains (excess of col. (h) gain over col. (k), but not less than "-0-")
a			-1,208,882.
b			-1,301,632.
c			214,413.
d			313,005.
e			88,098.
f			41,943.
g			217,960.
h			61,302.
i			179,609.
j			941,196.
k			327,053.
l			336,247.
m			100,706.
n			1,008,201.
o			-2,494,266.

2 Capital gain net income or (net capital loss) { If gain, also enter in Part I, line 7 If (loss), enter "-0-" in Part I, line 7 }	2	
3 Net short-term capital gain or (loss) as defined in sections 1222(5) and (6): If gain, also enter in Part I, line 8, column (c). If (loss), enter "-0-" in Part I, line 8	3	

Part IV Capital Gains and Losses for Tax on Investment Income

(a) List and describe the kind(s) of property sold, e.g., real estate, 2-story brick warehouse; or common stock, 200 shs. MLC Co.	(b) How acquired P - Purchase D - Donation	(c) Date acquired (mo., day, yr.)	(d) Date sold (mo., day, yr.)
1a ORBIMED PRIVATE INVEST VI LP	P		12/16/21
b ORBIMED ROYALTY PTNRS II LP	P		03/16/22
c ORBIMED ROYALTY PTNRS II LP	P		06/21/21
d ORBIMED ROYALTY PTNRS II LP	P		12/13/21
e ORBIMED ROYALTY PTNRS II LP	P		08/20/21
f PEG SECONDARY PE II LP AND AIV	P		12/31/21
g PEG SECONDARY PE INVESTORS II LP	P		04/16/21
h PEG SECONDARY PE INVESTORS II LP	P		11/17/21
i PEG SECONDARY PE INVESTORS II LP	P		07/22/21
j PEG SECONDARY PE INVESTORS II LP	P		01/18/22
k PEG SECONDARY PE INVESTORS III LP	P		07/15/21
l PEG SECONDARY PE INVESTORS III LP	P		11/23/21
m PEG SECONDARY PE INVESTORS LLC	P		08/26/21
n PEG SECONDARY PE INVESTORS LLC	P		01/18/22
o PEG SECONDARY PE INVESTORS LLC AND AIV	P		12/31/21

(e) Gross sales price	(f) Depreciation allowed (or allowable)	(g) Cost or other basis plus expense of sale	(h) Gain or (loss) (e) plus (f) minus (g)
a 212,319.			212,319.
b		218,281.	-218,281.
c 43,808.			43,808.
d 32,499.			32,499.
e 76,078.			76,078.
f 5,046,213.		3,928,356.	1,117,857.
g 200,459.			200,459.
h 1,026,685.			1,026,685.
i 336,062.			336,062.
j		1,943,541.	-1,943,541.
k 280,309.			280,309.
l 826,089.			826,089.
m 154,917.			154,917.
n		1,638,552.	-1,638,552.
o 2,913,911.		1,570,771.	1,343,140.

Complete only for assets showing gain in column (h) and owned by the foundation on 12/31/69			(l) Losses (from col. (h)) Gains (excess of col. (h) gain over col. (k), but not less than "-0-")
(i) F.M.V. as of 12/31/69	(j) Adjusted basis as of 12/31/69	(k) Excess of col. (i) over col. (j), if any	
a			212,319.
b			-218,281.
c			43,808.
d			32,499.
e			76,078.
f			1,117,857.
g			200,459.
h			1,026,685.
i			336,062.
j			-1,943,541.
k			280,309.
l			826,089.
m			154,917.
n			-1,638,552.
o			1,343,140.

2 Capital gain net income or (net capital loss) { If gain, also enter in Part I, line 7 If (loss), enter "-0-" in Part I, line 7 }	2	
3 Net short-term capital gain or (loss) as defined in sections 1222(5) and (6): If gain, also enter in Part I, line 8, column (c). If (loss), enter "-0-" in Part I, line 8	3	

Part IV Capital Gains and Losses for Tax on Investment Income

(a) List and describe the kind(s) of property sold, e.g., real estate, 2-story brick warehouse; or common stock, 200 shs. MLC Co.	(b) How acquired P - Purchase D - Donation	(c) Date acquired (mo., day, yr.)	(d) Date sold (mo., day, yr.)
1a PITANGO GROWTH	P		09/30/21
b PITANGO VTR VI	P		07/28/21
c SEQUOIA CAP CHINA GR FD V LP	P		09/01/21
d SEQUOIA CAP CHINA GR FD V LP	P		09/27/21
e SEQUOIA CAP CHINA GR FD V LP	P		01/13/22
f SEQUOIA CAP CHINA GR FD V LP	P		06/25/21
g SEQUOIA CAP CHINA GR FD V LP	P		06/29/21
h SEQUOIA CAP CHINA GROWTH FD III LP	P		11/30/21
i SEQUOIA CAP CHINA GROWTH FD III LP	P		02/17/22
j SEQUOIA CAP CHINA GROWTH FD III LP	P		06/28/21
k SEQUOIA CAP CHINA GROWTH FD III LP	P		01/18/22
l SEQUOIA CAP CHINA GROWTH FD III LP	P		01/13/22
m SEQUOIA CAP CHINA GROWTH FD III LP	P		11/19/21
n SEQUOIA CAP CHINA GROWTH FD III LP	P		05/07/21
o SEQUOIA CAP CHINA GROWTH FD III LP	P		06/23/21

(e) Gross sales price	(f) Depreciation allowed (or allowable)	(g) Cost or other basis plus expense of sale	(h) Gain or (loss) (e) plus (f) minus (g)
a 1,142,909.			1,142,909.
b 1,539,801.			1,539,801.
c 196,564.			196,564.
d 86,521.			86,521.
e 78,915.			78,915.
f 48,653.			48,653.
g 51,318.			51,318.
h 1,141,750.			1,141,750.
i 1,198,782.			1,198,782.
j 443,625.			443,625.
k 1,266,981.			1,266,981.
l 43,933.			43,933.
m 34,901.			34,901.
n 108,588.			108,588.
o 134,841.			134,841.

Complete only for assets showing gain in column (h) and owned by the foundation on 12/31/69			(l) Losses (from col. (h)) Gains (excess of col. (h) gain over col. (k), but not less than "-0-")
(i) F.M.V. as of 12/31/69	(j) Adjusted basis as of 12/31/69	(k) Excess of col. (i) over col. (j), if any	
a			1,142,909.
b			1,539,801.
c			196,564.
d			86,521.
e			78,915.
f			48,653.
g			51,318.
h			1,141,750.
i			1,198,782.
j			443,625.
k			1,266,981.
l			43,933.
m			34,901.
n			108,588.
o			134,841.

2 Capital gain net income or (net capital loss) { If gain, also enter in Part I, line 7 If (loss), enter "-0-" in Part I, line 7 }	2	
3 Net short-term capital gain or (loss) as defined in sections 1222(5) and (6): If gain, also enter in Part I, line 8, column (c). If (loss), enter "-0-" in Part I, line 8	3	

Part IV Capital Gains and Losses for Tax on Investment Income

(a) List and describe the kind(s) of property sold, e.g., real estate, 2-story brick warehouse; or common stock, 200 shs. MLC Co.	(b) How acquired P - Purchase D - Donation	(c) Date acquired (mo., day, yr.)	(d) Date sold (mo., day, yr.)
1a SEQUOIA CAP CHINA GROWTH FD III LP	P		09/23/21
b SEQUOIA CAP CHINA GROWTH FD III LP	P		08/31/21
c SEQUOIA CAP CHINA GROWTH FD III LP	P		11/08/21
d SEQUOIA CAP CHINA GROWTH IV LP	P		09/02/21
e SEQUOIA CAP CHINA GROWTH IV LP	P		07/26/21
f SEQUOIA CAP CHINA GROWTH IV LP	P		09/27/21
g SEQUOIA CAP CHINA GROWTH IV LP	P		10/20/21
h SEQUOIA CAP CHINA GROWTH IV LP	P		01/20/22
i SEQUOIA CAP CHINA GROWTH IV LP	P		09/01/21
j SEQUOIA CAP CHINA GROWTH IV LP	P		06/29/21
k SEQUOIA CAP CHINA GROWTH IV LP	P		06/25/21
l SEQUOIA CAP CHINA GRWTH VI LP	P		06/22/21
m SEQUOIA CAP CHINA VENTURE FD IV LP	P		10/29/21
n SEQUOIA CAP CHINA VENTURE FD IV LP	P		10/22/21
o SEQUOIA CAP CHINA VENTURE V LP	P		12/30/21

(e) Gross sales price	(f) Depreciation allowed (or allowable)	(g) Cost or other basis plus expense of sale	(h) Gain or (loss) (e) plus (f) minus (g)
a 1,768,012.			1,768,012.
b 1,031,481.			1,031,481.
c 1,422,952.			1,422,952.
d 186,195.			186,195.
e 44,991.			44,991.
f 1,850,771.			1,850,771.
g 115,447.			115,447.
h 109,518.			109,518.
i 4,112,210.			4,112,210.
j 1,031,131.			1,031,131.
k 984,655.			984,655.
l 5,552.			5,552.
m 1,070,083.			1,070,083.
n 382,817.			382,817.
o 181,394.			181,394.

Complete only for assets showing gain in column (h) and owned by the foundation on 12/31/69			(l) Losses (from col. (h)) Gains (excess of col. (h) gain over col. (k), but not less than "-0-")
(i) F.M.V. as of 12/31/69	(j) Adjusted basis as of 12/31/69	(k) Excess of col. (i) over col. (j), if any	
a			1,768,012.
b			1,031,481.
c			1,422,952.
d			186,195.
e			44,991.
f			1,850,771.
g			115,447.
h			109,518.
i			4,112,210.
j			1,031,131.
k			984,655.
l			5,552.
m			1,070,083.
n			382,817.
o			181,394.

2 Capital gain net income or (net capital loss) { If gain, also enter in Part I, line 7 If (loss), enter "-0-" in Part I, line 7 }	2	
3 Net short-term capital gain or (loss) as defined in sections 1222(5) and (6): If gain, also enter in Part I, line 8, column (c). If (loss), enter "-0-" in Part I, line 8	3	

Part IV Capital Gains and Losses for Tax on Investment Income

(a) List and describe the kind(s) of property sold, e.g., real estate, 2-story brick warehouse; or common stock, 200 shs. MLC Co.	(b) How acquired P - Purchase D - Donation	(c) Date acquired (mo., day, yr.)	(d) Date sold (mo., day, yr.)
1a SEQUOIA CAP CHINA VENTURE V LP	P		09/10/21
b SEQUOIA CAP CHINA VENTURE VI LP	P		06/23/21
c SEQUOIA CAP CHINA VENTURE VI LP	P		01/13/22
d SEQUOIA CAP CHINA VENTURE VI LP	P		01/20/22
e SEQUOIA CAP CHINA VENTURE VI LP	P		09/02/21
f SEQUOIA CAP CHINA VENTURE VI LP	P		10/22/21
g SEQUOIA CAP CHINA VENTURE VI LP	P		05/27/21
h SEQUOIA CAP GBL GR III CHINA ANNEX LP	P		01/13/22
i SEQUOIA CAP GBL GROWTH FD II	P		12/10/21
j SEQUOIA CAP GBL GROWTH FD II	P		11/22/21
k SEQUOIA CAP GBL GROWTH FD II	P		02/24/22
l SEQUOIA CAP GBL GROWTH FD II	P		02/25/22
m SEQUOIA CAP GBL GROWTH FD II	P		02/28/22
n SEQUOIA CAP GBL GROWTH FD II	P		01/20/22
o SEQUOIA CAP GBL GROWTH FD II	P		04/26/21

(e) Gross sales price	(f) Depreciation allowed (or allowable)	(g) Cost or other basis plus expense of sale	(h) Gain or (loss) (e) plus (f) minus (g)
a 1,594,670.			1,594,670.
b 40,645.			40,645.
c 111,223.			111,223.
d 58,656.			58,656.
e 51,394.			51,394.
f 37,621.			37,621.
g 36,913.			36,913.
h		119,477.	-119,477.
i 98,211.			98,211.
j 1,782,585.			1,782,585.
k 168,321.			168,321.
l 314,656.			314,656.
m 904,634.			904,634.
n 426,463.			426,463.
o 357,784.			357,784.

Complete only for assets showing gain in column (h) and owned by the foundation on 12/31/69			(l) Losses (from col. (h)) Gains (excess of col. (h) gain over col. (k), but not less than "-0-")
(i) F.M.V. as of 12/31/69	(j) Adjusted basis as of 12/31/69	(k) Excess of col. (i) over col. (j), if any	
a			1,594,670.
b			40,645.
c			111,223.
d			58,656.
e			51,394.
f			37,621.
g			36,913.
h			-119,477.
i			98,211.
j			1,782,585.
k			168,321.
l			314,656.
m			904,634.
n			426,463.
o			357,784.

2 Capital gain net income or (net capital loss) { If gain, also enter in Part I, line 7 If (loss), enter "-0-" in Part I, line 7 }	2	
3 Net short-term capital gain or (loss) as defined in sections 1222(5) and (6): If gain, also enter in Part I, line 8, column (c). If (loss), enter "-0-" in Part I, line 8	3	

Part IV Capital Gains and Losses for Tax on Investment Income

(a) List and describe the kind(s) of property sold, e.g., real estate, 2-story brick warehouse; or common stock, 200 shs. MLC Co.	(b) How acquired P - Purchase D - Donation	(c) Date acquired (mo., day, yr.)	(d) Date sold (mo., day, yr.)
1a SEQUOIA CAP GBL GROWTH FD II	P		06/25/21
b SEQUOIA CAP GBL GROWTH FD II	P		06/29/21
c SEQUOIA CAP GBL GROWTH FD II	P		07/26/21
d SEQUOIA CAP GBL GROWTH FD II	P		08/31/21
e SEQUOIA CAP GBL GROWTH FD II	P		09/01/21
f SEQUOIA CAP GBL GROWTH FD II	P		09/02/21
g SEQUOIA CAP GBL GROWTH FD II	P		09/23/21
h SEQUOIA CAP GBL GROWTH FD II	P		09/27/21
i SEQUOIA CAP GBL GROWTH FD II	P		10/20/21
j SEQUOIA CAP GBL GROWTH FD II	P		11/08/21
k SEQUOIA CAP GBL GROWTH FD II	P		11/19/21
l SEQUOIA CAP GBL GROWTH FD II	P		01/18/22
m SEQUOIA CAP GLOBAL EQ FUND	P		07/26/21
n SEQUOIA CAP GLOBAL EQ FUND	P		07/26/21
o SEQUOIA CAP GLOBAL EQ FUND	P		07/26/21

(e) Gross sales price	(f) Depreciation allowed (or allowable)	(g) Cost or other basis plus expense of sale	(h) Gain or (loss) (e) plus (f) minus (g)
a 683,882.			683,882.
b 718,463.			718,463.
c 175,196.			175,196.
d 105,357.			105,357.
e 2,815,736.			2,815,736.
f 725,024.			725,024.
g 198,318.			198,318.
h 1,255,206.			1,255,206.
i 449,556.			449,556.
j 157,090.			157,090.
k 224,874.			224,874.
l 134,380.			134,380.
m 18,793,401.		3,403,850.	15,389,551.
n 11,137,547.		2,017,226.	9,120,321.
o 1,341,170.		242,912.	1,098,258.

Complete only for assets showing gain in column (h) and owned by the foundation on 12/31/69

(i) F.M.V. as of 12/31/69	(j) Adjusted basis as of 12/31/69	(k) Excess of col. (i) over col. (j), if any	(l) Losses (from col. (h)) Gains (excess of col. (h) gain over col. (k), but not less than "-0-")
a			683,882.
b			718,463.
c			175,196.
d			105,357.
e			2,815,736.
f			725,024.
g			198,318.
h			1,255,206.
i			449,556.
j			157,090.
k			224,874.
l			134,380.
m			15,389,551.
n			9,120,321.
o			1,098,258.

2 Capital gain net income or (net capital loss) { If gain, also enter in Part I, line 7 If (loss), enter "-0-" in Part I, line 7 }	2
3 Net short-term capital gain or (loss) as defined in sections 1222(5) and (6): If gain, also enter in Part I, line 8, column (c). If (loss), enter "-0-" in Part I, line 8	3

Part IV Capital Gains and Losses for Tax on Investment Income

(a) List and describe the kind(s) of property sold, e.g., real estate, 2-story brick warehouse; or common stock, 200 shs. MLC Co.	(b) How acquired P - Purchase D - Donation	(c) Date acquired (mo., day, yr.)	(d) Date sold (mo., day, yr.)
1a SEQUOIA CAP GLOBAL EQ FUND	P		07/26/21
b SEQUOIA CAP US GROWTH FD VI LP	P		04/26/21
c SEQUOIA CAP US GROWTH FD VI LP	P		11/12/21
d SEQUOIA CAP US GROWTH FD VI LP	P		02/18/22
e SEQUOIA CAP US GROWTH FD VI LP	P		08/24/21
f SEQUOIA CAP US GROWTH FD VI LP	P		08/24/21
g SEQUOIA CAP US GROWTH FD VI LP	P		11/18/21
h SEQUOIA CAP US GROWTH FD VI LP	P		11/22/21
i SEQUOIA CAP US GROWTH FD VI LP	P		11/23/21
j SEQUOIA CAP US GROWTH FD VI LP	P		02/11/22
k SEQUOIA CAP US GROWTH FD VI LP	P		08/24/21
l SEQUOIA CAP US GROWTH FD VI LP	P		06/16/21
m SEQUOIA CAP US GROWTH FD VI LP	P		08/13/21
n SEQUOIA CAP US GROWTH FD VI LP	P		06/02/21
o SEQUOIA CAP US GROWTH FD VII LP	P		10/28/21

(e) Gross sales price	(f) Depreciation allowed (or allowable)	(g) Cost or other basis plus expense of sale	(h) Gain or (loss) (e) plus (f) minus (g)
a 4,727,882.		856,311.	3,871,571.
b 130,388.			130,388.
c 526,670.			526,670.
d 541,871.			541,871.
e 44,678.		44,678.	-44,678.
f 420,919.			420,919.
g 561,892.			561,892.
i 61,574.			61,574.
j 227,016.			227,016.
k 44,678.			44,678.
l 19,607.			19,607.
m 136,168.			136,168.
n 20,032.			20,032.
o 435,040.			435,040.

Complete only for assets showing gain in column (h) and owned by the foundation on 12/31/69			(l) Losses (from col. (h)) Gains (excess of col. (h) gain over col. (k), but not less than "-0-")
(i) F.M.V. as of 12/31/69	(j) Adjusted basis as of 12/31/69	(k) Excess of col. (i) over col. (j), if any	
a			3,871,571.
b			130,388.
c			526,670.
d			541,871.
e			-44,678.
f			44,678.
g			420,919.
h			561,892.
i			61,574.
j			227,016.
k			44,678.
l			19,607.
m			136,168.
n			20,032.
o			435,040.

2 Capital gain net income or (net capital loss) { If gain, also enter in Part I, line 7 If (loss), enter "-0-" in Part I, line 7 }	2	
3 Net short-term capital gain or (loss) as defined in sections 1222(5) and (6): If gain, also enter in Part I, line 8, column (c). If (loss), enter "-0-" in Part I, line 8	3	

Part IV Capital Gains and Losses for Tax on Investment Income

(a) List and describe the kind(s) of property sold, e.g., real estate, 2-story brick warehouse; or common stock, 200 shs. MLC Co.	(b) How acquired P - Purchase D - Donation	(c) Date acquired (mo., day, yr.)	(d) Date sold (mo., day, yr.)
1a SEQUOIA CAP US GROWTH FD VII LP	P		02/25/22
b SEQUOIA CAP US GROWTH FD VII LP	P		02/28/22
c SEQUOIA CAP US GROWTH FD VII LP	P		07/08/21
d SEQUOIA CAP US GROWTH FD VII LP	P		06/02/21
e SEQUOIA CAP US GROWTH FD VII LP	P		06/16/21
f SEQUOIA CAP US GROWTH FD VII LP	P		06/29/21
g SEQUOIA CAP US GROWTH FD VII LP	P		08/11/21
h SEQUOIA CAP US GROWTH FD VII LP	P		08/30/21
i SEQUOIA CAP US GROWTH FD VII LP	P		11/19/21
j SEQUOIA CAP US GROWTH FD VII LP	P		11/22/21
k SEQUOIA CAP US GROWTH FD VII LP	P		02/24/22
l SEQUOIA CAP US VENTURE FD XV LP	P		09/21/21
m SEQUOIA CAP US VENTURE FD XV LP	P		04/06/21
n SEQUOIA CAP US VENTURE FD XV LP	P		08/13/21
o SEQUOIA CAP US VENTURE FD XV LP	P		11/23/21

(e) Gross sales price	(f) Depreciation allowed (or allowable)	(g) Cost or other basis plus expense of sale	(h) Gain or (loss) (e) plus (f) minus (g)
a 27,236.			27,236.
b 317,214.			317,214.
c 51,599.			51,599.
d 314,920.			314,920.
e 309,121.			309,121.
f 46,403.			46,403.
g 104,776.			104,776.
h 98,015.			98,015.
i 18,967.			18,967.
j 622,861.			622,861.
k 14,197.			14,197.
l 91,993.			91,993.
m 126,366.			126,366.
n 60,792.			60,792.
o 27,490.			27,490.

Complete only for assets showing gain in column (h) and owned by the foundation on 12/31/69			(l) Losses (from col. (h)) Gains (excess of col. (h) gain over col. (k), but not less than "-0-")
(i) F.M.V. as of 12/31/69	(j) Adjusted basis as of 12/31/69	(k) Excess of col. (i) over col. (j), if any	
a			27,236.
b			317,214.
c			51,599.
d			314,920.
e			309,121.
f			46,403.
g			104,776.
h			98,015.
i			18,967.
j			622,861.
k			14,197.
l			91,993.
m			126,366.
n			60,792.
o			27,490.

2 Capital gain net income or (net capital loss) { If gain, also enter in Part I, line 7 If (loss), enter "-0-" in Part I, line 7 }	2	
3 Net short-term capital gain or (loss) as defined in sections 1222(5) and (6): If gain, also enter in Part I, line 8, column (c). If (loss), enter "-0-" in Part I, line 8	3	

Part IV Capital Gains and Losses for Tax on Investment Income

(a) List and describe the kind(s) of property sold, e.g., real estate, 2-story brick warehouse; or common stock, 200 shs. MLC Co.	(b) How acquired P - Purchase D - Donation	(c) Date acquired (mo., day, yr.)	(d) Date sold (mo., day, yr.)
1a SEQUOIA CAPITAL GLOBAL GROWTH FD	P		11/12/21
b SEQUOIA CAPITAL GLOBAL GROWTH FD	P		02/18/22
c SEQUOIA CAPITAL GLOBAL GROWTH FD	P		04/26/21
d SEQUOIA CAPITAL GLOBAL GROWTH FD	P		07/26/21
e SEQUOIA CAPITAL GLOBAL GROWTH FD	P		09/02/21
f SEQUOIA CAPITAL GLOBAL GROWTH FD	P		10/20/21
g SEQUOIA CAPITAL GLOBAL GROWTH FD	P		11/18/21
h SEQUOIA CAPITAL GLOBAL GROWTH FD	P		02/25/22
i SEQUOIA CAPITAL GLOBAL GROWTH FD	P		02/25/22
j SEQUOIA CAPITAL GLOBAL GROWTH FD	P		02/24/22
k SEQUOIA CAPITAL GLOBAL GROWTH FD	P		02/24/22
l SEQUOIA CAPITAL GLOBAL GROWTH FD	P		02/11/22
m SEQUOIA CAPITAL GLOBAL GROWTH FD	P		01/20/22
n SEQUOIA CAPITAL GLOBAL GROWTH FD	P		11/19/21
o SEQUOIA CAPITAL GLOBAL GROWTH FD III - ENDURANCE PARTNERS LP	P		06/29/21

(e) Gross sales price	(f) Depreciation allowed (or allowable)	(g) Cost or other basis plus expense of sale	(h) Gain or (loss) (e) plus (f) minus (g)
a 1,480,355.			1,480,355.
b 1,589,407.			1,589,407.
c 583,983.			583,983.
d 292,977.			292,977.
e 1,203,240.			1,203,240.
f 736,170.			736,170.
g 3,285,313.			3,285,313.
h 209,704.			209,704.
i 1,323,352.			1,323,352.
j 677,244.			677,244.
k 107,914.			107,914.
l 1,770,304.			1,770,304.
m 712,545.			712,545.
n 1,009,425.			1,009,425.
o 150,404.			150,404.

Complete only for assets showing gain in column (h) and owned by the foundation on 12/31/69			(l) Losses (from col. (h)) Gains (excess of col. (h) gain over col. (k), but not less than "-0-")
(i) F.M.V. as of 12/31/69	(j) Adjusted basis as of 12/31/69	(k) Excess of col. (i) over col. (j), if any	
a			1,480,355.
b			1,589,407.
c			583,983.
d			292,977.
e			1,203,240.
f			736,170.
g			3,285,313.
h			209,704.
i			1,323,352.
j			677,244.
k			107,914.
l			1,770,304.
m			712,545.
n			1,009,425.
o			150,404.

2 Capital gain net income or (net capital loss) { If gain, also enter in Part I, line 7 If (loss), enter "-0-" in Part I, line 7 }	2
3 Net short-term capital gain or (loss) as defined in sections 1222(5) and (6): If gain, also enter in Part I, line 8, column (c). If (loss), enter "-0-" in Part I, line 8	3

Part IV Capital Gains and Losses for Tax on Investment Income

(a) List and describe the kind(s) of property sold, e.g., real estate, 2-story brick warehouse; or common stock, 200 shs. MLC Co.	(b) How acquired P - Purchase D - Donation	(c) Date acquired (mo., day, yr.)	(d) Date sold (mo., day, yr.)
1a SEQUOIA CAPITAL GLOBAL GROWTH FD III - ENDURANCE PARTNERS LP	P		06/16/21
b SEQUOIA CAPITAL GLOBAL GROWTH FD III - ENDURANCE PARTNERS LP	P		09/01/21
c SEQUOIA CAPITAL GLOBAL GROWTH FD III - ENDURANCE PARTNERS LP	P		09/23/21
d SEQUOIA CAPITAL GLOBAL GROWTH FD III - ENDURANCE PARTNERS LP	P		09/27/21
e SEQUOIA CAPITAL GLOBAL GROWTH FD III - ENDURANCE PARTNERS LP	P		11/08/21
f SEQUOIA CAPITAL GLOBAL GROWTH FD III - ENDURANCE PARTNERS LP	P		11/18/21
g SEQUOIA CAPITAL GLOBAL GROWTH FD III - ENDURANCE PARTNERS LP	P		01/18/22
h SEQUOIA CAPITAL GLOBAL GROWTH FD III - ENDURANCE PARTNERS LP	P		02/11/22
i SEQUOIA CAPITAL GLOBAL GROWTH FD III - ENDURANCE PARTNERS LP	P		06/02/21
j SEQUOIA CAPITAL GLOBAL GROWTH FD III - ENDURANCE PARTNERS LP	P		06/25/21
k SEQUOIA CAPITAL U.S. GROWTH FUND V L.P.	P		11/12/21
l SEQUOIA CAPITAL U.S. GROWTH FUND V L.P.	P		02/18/22
m SEQUOIA CAPITAL U.S. GROWTH FUND V L.P.	P		09/09/21
n SEQUOIA CAPITAL U.S. GROWTH FUND V L.P.	P		11/19/21
o SEQUOIA CAPITAL U.S. GROWTH FUND V L.P.	P		02/24/22

(e) Gross sales price	(f) Depreciation allowed (or allowable)	(g) Cost or other basis plus expense of sale	(h) Gain or (loss) (e) plus (f) minus (g)
a 950,365.			950,365.
b 576,780.			576,780.
c 178,167.			178,167.
d 253,919.			253,919.
e 84,314.			84,314.
f 2,198,913.			2,198,913.
g 71,074.			71,074.
h 1,154,709.			1,154,709.
i 968,788.			968,788.
j 142,592.			142,592.
k 1,462,337.			1,462,337.
l 1,468,146.			1,468,146.
m 20,227.			20,227.
n 413,904.			413,904.
o 331,097.			331,097.

Complete only for assets showing gain in column (h) and owned by the foundation on 12/31/69			(l) Losses (from col. (h)) Gains (excess of col. (h) gain over col. (k), but not less than "-0-")
(i) F.M.V. as of 12/31/69	(j) Adjusted basis as of 12/31/69	(k) Excess of col. (i) over col. (j), if any	
a			950,365.
b			576,780.
c			178,167.
d			253,919.
e			84,314.
f			2,198,913.
g			71,074.
h			1,154,709.
i			968,788.
j			142,592.
k			1,462,337.
l			1,468,146.
m			20,227.
n			413,904.
o			331,097.

2 Capital gain net income or (net capital loss) { If gain, also enter in Part I, line 7 If (loss), enter "-0-" in Part I, line 7 }	2
3 Net short-term capital gain or (loss) as defined in sections 1222(5) and (6): If gain, also enter in Part I, line 8, column (c). If (loss), enter "-0-" in Part I, line 8	3

Part IV Capital Gains and Losses for Tax on Investment Income

(a) List and describe the kind(s) of property sold, e.g., real estate, 2-story brick warehouse; or common stock, 200 shs. MLC Co.	(b) How acquired P - Purchase D - Donation	(c) Date acquired (mo., day, yr.)	(d) Date sold (mo., day, yr.)
1a SEQUOIA CAPITAL U.S. GROWTH FUND V L.P.	P		02/25/22
b SEQUOIA CAPITAL U.S. VENTURE FUND XIV L.P..	P		12/17/21
c SEQUOIA CAPITAL U.S. VENTURE FUND XIV L.P..	P		02/28/22
d SEQUOIA CAPITAL U.S. VENTURE FUND XIV L.P..	P		11/22/21
e THE MARATHON-LONDON GLOBAL SELECT INVESTMENT TRUST	P		04/30/21
f THE MARATHON-LONDON GLOBAL SELECT INVESTMENT TRUST	P		07/30/21
g THE MARATHON-LONDON GLOBAL SELECT INVESTMENT TRUST	P		06/30/21
h THE MARATHON-LONDON GLOBAL SELECT INVESTMENT TRUST	P		05/28/21
i THE MARATHON-LONDON GLOBAL SELECT INVESTMENT TRUST	P		03/31/22
j THE MARATHON-LONDON GLOBAL SELECT INVESTMENT TRUST	P		02/28/22
k THE MARATHON-LONDON GLOBAL SELECT INVESTMENT TRUST	P		08/31/21
l THE MARATHON-LONDON GLOBAL SELECT INVESTMENT TRUST	P		11/30/21
m THE MARATHON-LONDON GLOBAL SELECT INVESTMENT TRUST	P		12/31/21
n THE MARATHON-LONDON GLOBAL SELECT INVESTMENT TRUST	P		10/29/21
o THE MARATHON-LONDON GLOBAL SELECT INVESTMENT TRUST	P		10/29/21

(e) Gross sales price	(f) Depreciation allowed (or allowable)	(g) Cost or other basis plus expense of sale	(h) Gain or (loss) (e) plus (f) minus (g)
a 648,586.			648,586.
b 127,609.			127,609.
c 786,061.			786,061.
d 1,513,940.			1,513,940.
e 107,591.		87,168.	20,423.
f 110,280.		86,389.	23,891.
g 109,497.		86,617.	22,880.
h 110,494.		86,433.	24,061.
i 69,135.		55,056.	14,079.
j 68,370.		55,444.	12,926.
k 111,438.		86,080.	25,358.
l 69,964.		54,831.	15,133.
m 72,574.		53,721.	18,853.
n 113,440.		85,551.	27,889.
o 100,000,000.		75,415,391.	24,584,609.

Complete only for assets showing gain in column (h) and owned by the foundation on 12/31/69

(i) F.M.V. as of 12/31/69	(j) Adjusted basis as of 12/31/69	(k) Excess of col. (i) over col. (j), if any	(l) Losses (from col. (h)) Gains (excess of col. (h) gain over col. (k), but not less than "-0-")
a			648,586.
b			127,609.
c			786,061.
d			1,513,940.
e			20,423.
f			23,891.
g			22,880.
h			24,061.
i			14,079.
j			12,926.
k			25,358.
l			15,133.
m			18,853.
n			27,889.
o			24,584,609.

2 Capital gain net income or (net capital loss) { If gain, also enter in Part I, line 7 If (loss), enter "-0-" in Part I, line 7 }	2
3 Net short-term capital gain or (loss) as defined in sections 1222(5) and (6): If gain, also enter in Part I, line 8, column (c). If (loss), enter "-0-" in Part I, line 8	3

Part IV Capital Gains and Losses for Tax on Investment Income

(a) List and describe the kind(s) of property sold, e.g., real estate, 2-story brick warehouse; or common stock, 200 shs. MLC Co.	(b) How acquired P - Purchase D - Donation	(c) Date acquired (mo., day, yr.)	(d) Date sold (mo., day, yr.)
1a THE MARATHON-LONDON GLOBAL SELECT INVESTMENT TRUST	P		09/30/21
b THE MARATHON-LONDON GLOBAL SELECT INVESTMENT TRUST	P		01/31/22
c THE SILCHESTER INTERNATIONAL INVESTORS INTERNATIONAL VALUE	P		04/30/21
d THE SILCHESTER INTERNATIONAL INVESTORS INTERNATIONAL VALUE	P		03/31/22
e THE SILCHESTER INTERNATIONAL INVESTORS INTERNATIONAL VALUE	P		06/30/21
f THE SILCHESTER INTERNATIONAL INVESTORS INTERNATIONAL VALUE	P		07/30/21
g THE SILCHESTER INTERNATIONAL INVESTORS INTERNATIONAL VALUE	P		08/31/21
h THE SILCHESTER INTERNATIONAL INVESTORS INTERNATIONAL VALUE	P		09/07/21
i THE SILCHESTER INTERNATIONAL INVESTORS INTERNATIONAL VALUE	P		09/30/21
j THE SILCHESTER INTERNATIONAL INVESTORS INTERNATIONAL VALUE	P		10/29/21
k THE SILCHESTER INTERNATIONAL INVESTORS INTERNATIONAL VALUE	P		11/04/21
l THE SILCHESTER INTERNATIONAL INVESTORS INTERNATIONAL VALUE	P		11/30/21
m THE SILCHESTER INTERNATIONAL INVESTORS INTERNATIONAL VALUE	P		12/06/21
n THE SILCHESTER INTERNATIONAL INVESTORS INTERNATIONAL VALUE	P		12/31/21
o THE SILCHESTER INTERNATIONAL INVESTORS INTERNATIONAL VALUE	P		01/31/22

(e) Gross sales price	(f) Depreciation allowed (or allowable)	(g) Cost or other basis plus expense of sale	(h) Gain or (loss) (e) plus (f) minus (g)
a 109,896.		86,385.	23,511.
b 70,061.		54,718.	15,343.
c 87,366.		79,953.	7,413.
d 73,681.		66,120.	7,561.
e 89,074.		79,567.	9,507.
f 88,564.		79,617.	8,947.
g 89,392.		79,433.	9,959.
h 10,000,000.		8,885,907.	1,114,093.
i 84,177.		75,885.	8,292.
j 85,408.		75,618.	9,790.
k 12,500,000.		11,067,200.	1,432,800.
l 76,074.		71,835.	4,239.
m 12,500,000.		11,803,332.	696,668.
n 73,629.		66,235.	7,394.
o 74,089.		66,099.	7,990.

Complete only for assets showing gain in column (h) and owned by the foundation on 12/31/69			(l) Losses (from col. (h)) Gains (excess of col. (h) gain over col. (k), but not less than "-0-")
(i) F.M.V. as of 12/31/69	(j) Adjusted basis as of 12/31/69	(k) Excess of col. (i) over col. (j), if any	
a			23,511.
b			15,343.
c			7,413.
d			7,561.
e			9,507.
f			8,947.
g			9,959.
h			1,114,093.
i			8,292.
j			9,790.
k			1,432,800.
l			4,239.
m			696,668.
n			7,394.
o			7,990.

2 Capital gain net income or (net capital loss) { If gain, also enter in Part I, line 7 If (loss), enter "-0-" in Part I, line 7 }	2
3 Net short-term capital gain or (loss) as defined in sections 1222(5) and (6): If gain, also enter in Part I, line 8, column (c). If (loss), enter "-0-" in Part I, line 8	3

Part IV Capital Gains and Losses for Tax on Investment Income

(a) List and describe the kind(s) of property sold, e.g., real estate, 2-story brick warehouse; or common stock, 200 shs. MLC Co.	(b) How acquired P - Purchase D - Donation	(c) Date acquired (mo., day, yr.)	(d) Date sold (mo., day, yr.)
1a THE SILCHESTER INTERNATIONAL INVESTORS INTERNATIONAL VALUE	P		02/28/22
b THE SILCHESTER INTERNATIONAL INVESTORS INTERNATIONAL VALUE	P		05/28/21
c VENTURE LENDING & LEASING VII LLC	P		12/08/21
d VENTURE LENDING & LEASING VII LLC	P		08/09/21
e VENTURE LENDING & LEASING VII LLC	P		04/05/21
f VENTURE LENDING & LEASING VII LLC	P		03/10/22
g VENTURE LENDING & LEASING VII LLC	P		09/10/21
h VENTURE LENDING & LEASING VII LLC	P		07/02/21
i VENTURE LENDING & LEASING VIII LLC	P		07/02/21
j WTI VLL IX	P		11/24/21
k WTI VLL VIII	P		06/25/21
l WTI VLL VIII	P		08/10/21
m WTI VLL VIII	P		09/27/21
n WTI VLL VIII	P		12/10/21
o YORK CO INVEST 1	P		12/14/21

(e) Gross sales price	(f) Depreciation allowed (or allowable)	(g) Cost or other basis plus expense of sale	(h) Gain or (loss) (e) plus (f) minus (g)
a 74,309.		66,017.	8,292.
b 89,747.		79,490.	10,257.
c 260,000.			260,000.
d 300,000.			300,000.
e 300,000.			300,000.
f 140,000.			140,000.
g 763,849.			763,849.
h 1,151,524.			1,151,524.
i 1,059,489.			1,059,489.
j 116,357.			116,357.
k 98,000.			98,000.
l 346,430.			346,430.
m 49,000.			49,000.
n 318,500.			318,500.
o 452,173.			452,173.

Complete only for assets showing gain in column (h) and owned by the foundation on 12/31/69			(l) Losses (from col. (h)) Gains (excess of col. (h) gain over col. (k), but not less than "-0-")
(i) F.M.V. as of 12/31/69	(j) Adjusted basis as of 12/31/69	(k) Excess of col. (i) over col. (j), if any	
a			8,292.
b			10,257.
c			260,000.
d			300,000.
e			300,000.
f			140,000.
g			763,849.
h			1,151,524.
i			1,059,489.
j			116,357.
k			98,000.
l			346,430.
m			49,000.
n			318,500.
o			452,173.

2 Capital gain net income or (net capital loss) { If gain, also enter in Part I, line 7 If (loss), enter "-0-" in Part I, line 7 }	2	
3 Net short-term capital gain or (loss) as defined in sections 1222(5) and (6): If gain, also enter in Part I, line 8, column (c). If (loss), enter "-0-" in Part I, line 8	3	

Part IV Capital Gains and Losses for Tax on Investment Income

(a) List and describe the kind(s) of property sold, e.g., real estate, 2-story brick warehouse; or common stock, 200 shs. MLC Co.	(b) How acquired P - Purchase D - Donation	(c) Date acquired (mo., day, yr.)	(d) Date sold (mo., day, yr.)
1a YORK DISTRESSED ASSET FD III LP	P		02/11/22
b YORK DISTRESSED ASSET FD III LP	P		08/12/21
c YORK EUROPEAN DISTRESSED CREDIT FUND II LP	P		01/26/22
d YORK EUROPEAN DISTRESSED CREDIT FUND LP	P		04/01/21
e K-1 ADJUSTMENTS, NET OF UBI AND RELATED AMOUNTS ABOVE	P		
f			
g			
h			
i			
j			
k			
l			
m			
n			
o			

(e) Gross sales price	(f) Depreciation allowed (or allowable)	(g) Cost or other basis plus expense of sale	(h) Gain or (loss) (e) plus (f) minus (g)
a 2,763,089.			2,763,089.
b 4,019,690.			4,019,690.
c 635,222.			635,222.
d 822,574.			822,574.
e			-138,034,051.
f			
g			
h			
i			
j			
k			
l			
m			
n			
o			

Complete only for assets showing gain in column (h) and owned by the foundation on 12/31/69			(l) Losses (from col. (h)) Gains (excess of col. (h) gain over col. (k), but not less than "-0-")
(i) F.M.V. as of 12/31/69	(j) Adjusted basis as of 12/31/69	(k) Excess of col. (i) over col. (j), if any	
a			2,763,089.
b			4,019,690.
c			635,222.
d			822,574.
e			-138,034,051.
f			
g			
h			
i			
j			
k			
l			
m			
n			
o			

2 Capital gain net income or (net capital loss) { If gain, also enter in Part I, line 7 If (loss), enter "-0-" in Part I, line 7 }	2	713,350,607.
3 Net short-term capital gain or (loss) as defined in sections 1222(5) and (6): If gain, also enter in Part I, line 8, column (c). If (loss), enter "-0-" in Part I, line 8	3	N/A

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
ALIMENTIV INC. 100 DUNDAS STREET LONDON, CANADA	N/A	NC	DEVELOP AN INTESTINAL MUCOSAL AND IMAGING BIOMARKER FOR STRICTURING CD	366,257.
ALIMENTIV INC. 100 DUNDAS STREET LONDON, CANADA	N/A	NC	STENOSIS THERAPY AND ANTI-FIBROTIC RESEARCH (STAR) CONSORTIUM	116,515.
ALVIN AILEY DANCE FOUNDATION, INC. THE JOAN WEILL CENTER FOR DANCE NEW YORK, NY 10019	N/A	PC	GENERAL OPERATING SUPPORT	10,000.
ALYN HOSPITAL - REHABILITATION CENTER FOR CHILDREN AND YOUTH 84 SHMARYAHU LEVIN ST JERUSALEM, ISRAEL	N/A	PC	ALYN CENTER FOR INNOVATION IN PEDIATRIC REHABILITATION RESEARCH	777,749.
AMC MEDICAL RESEARCH BV MEIBERGDREEF 9 AMSTERDAM, NETHERLANDS	N/A	PC	IDENTIFICATION OF BIOMARKERS FOR PERIANAL FISTULIZING DISEASE	942,690.
AMC MEDICAL RESEARCH BV MEIBERGDREEF 9 AMSTERDAM, NETHERLANDS	N/A	PC	IDENTIFICATION OF BIOMARKERS FOR PERIANAL FISTULIZING DISEASE	50,570.
AMERICAN CAMPING ASSOCIATION INC 5000 STATE ROAD 67 NORTH MARTINSVILLE, IN 46151	N/A	PC	ACA PROFESSIONAL DEVELOPMENT 2022 - 2024	46,860.
Total from continuation sheets				378,714,989.

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
AMERICAN DIABETES ASSOCIATION, INC. 2451 CRYSTAL DRIVE, SUITE 900 ARLINGTON, VA 22202	N/A	PC	ADA MENTAL HEALTH EDUCATION PROGRAM 2022 - 2024	382,893.
AMERICAN DIABETES ASSOCIATION, INC. 2451 CRYSTAL DRIVE, SUITE 900 ARLINGTON, VA 22202	N/A	PC	2022-2024 TYPE 1 DIABETES CAMP INITIATIVE	331,219.
AMERICAN DIABETES ASSOCIATION, INC. 2451 CRYSTAL DRIVE, SUITE 900 ARLINGTON, VA 22202	N/A	PC	CGM SUPPORT FOR ADAS HEALTH EQUITY NOW 4TH NETWORK - COLUMBUS STUDY	150,000.
AMERICAN DIABETES ASSOCIATION, INC. 2451 CRYSTAL DRIVE, SUITE 900 ARLINGTON, VA 22202	N/A	PC	FOCUS ON FELLOWS, DIABETES IS PRIMARY, PROFESSIONAL MEMBERSHIP PROJECTS	300,000.
AMERICAN DIABETES ASSOCIATION, INC. 2451 CRYSTAL DRIVE, SUITE 900 ARLINGTON, VA 22202	N/A	PC	PATRON SUPPORT OF THE ASSOCIATION'S 79TH, 80TH, AND 81ST SESSIONS	75,000.
AMERICAN HEART ASSOCIATION, INC. 7272 GREENVILLE AVENUE DALLAS, TX 75231	N/A	PC	AMERICAN BOARD OF TELEHEALTH PROGRAM EXPANSION	1,346,286.
AMERICAN HEART ASSOCIATION, INC. 7272 GREENVILLE AVENUE DALLAS, TX 75231	N/A	PC	MISSION: LIFELINE STROKE MT AND POST-ACUTE STROKE CARE QUALITY STANDARDS	1,144,990.

Total from continuation sheets

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
AMERICAN HEART ASSOCIATION, INC. 7272 GREENVILLE AVENUE DALLAS, TX 75231	N/A	PC	MISSION: LIFELINE STROKE SYSTEM OF CARE IN NEBRASKA	1,034,941.
AMERICAN PHARMACISTS ASSOCIATION FOUNDATION 2215 CONSTITUTION AVE NW WASHINGTON, DC 20037	N/A	PC	EXPANDING ACCESS TO CGM THROUGH COMMUNITY PHARMACY	249,913.
AMERICAN TELEMEDICINE ASSOCIATION 901 N.GLEBE RD ARLINGTON, VA 22203	N/A	PC	GENERAL OPERATING SUPPORT	24,000.
AMERICARES FOUNDATION, INC. 88 HAMILTON AVE STAMFORD, CT 06840	N/A	PC	MATERNAL, NEWBORN, AND CHILD HEALTH INTERVENTIONS	930,374.
AMERICARES FOUNDATION, INC. 88 HAMILTON AVE STAMFORD, CT 06840	N/A	PC	OXYGEN FOR SUNTRESO HOSPITAL	183,200.
ASSOCIATION OF DIABETES CARE & EDUCATION SPECIALISTS 125 SOUTH WACKER DRIVE, SUITE 600 CHICAGO, IL 60606	N/A	NC	EXPANSION OF DANATECH PLATFORM	400,000.
ASSOCIATION OF DIABETES CARE & EDUCATION SPECIALISTS 125 SOUTH WACKER DRIVE, SUITE 600 CHICAGO, IL 60606	N/A	NC	AADE TECHNOLOGY INSTITUTE: DANA - DIABETES ADVANCED NETWORK ACCESS	216,544.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
AUSTRALASIAN GASTRO INTESTINAL RESEARCH FOUNDATION LTD. LEVEL 2 FITZROY, AUSTRALIA	N/A	PC	FECAL MICROBIOTA TRANSPLANTATION IN CROHNS DISEASE: THE MIRO STUDY	758,947.
AVERA MCKENNAN HOSPITAL AND UNIVERSITY HEALTH CENTER 1325 S. CLIFF AVENUE SIOUX FALLS, SD 57105	N/A	PC	AVERA BEHAVIORAL HEALTH CENTER EXPANSION	3,000,000.
AVERA MCKENNAN HOSPITAL AND UNIVERSITY HEALTH CENTER 1325 S. CLIFF AVENUE SIOUX FALLS, SD 57105	N/A	PC	AVERA BEHAVIORAL HEALTH CENTER EXPANSION	500,000.
AVERA MERRILL PIONEER HOSPITAL 1100 S 10TH AVE ROCK RAPIDS, IA 51246	N/A	PC	EEMERGENCY AND EPHARMACY AT AVERA MERRILL PIONEER HOSPITAL	19,959.
BALLAD RESEARCH INSTITUTE 10865 ROAD TO THE CURE SAN DIEGO, CA 92121	N/A	PC	CD127-HIGH T-CELL POPULATIONS AS BIOMARKERS	516,369.
BAPTIST MEDICAL CENTRE BAPTIST MEDICAL CENTRE ROAD NALERIGU, GHANA	N/A	PC	EMERGENCY CENTRE AND DOCTOR HOUSING DEVELOPMENT	1,513,500.
BAYLOR COLLEGE OF MEDICINE OFFICE OF RESEARCH HOUSTON, TX 77030	N/A	PC	EMR-BASED PREDICTIVE ANALYTICS FOR TARGETED & PROACTIVE T1D CARE	500,994.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
BAYLOR COLLEGE OF MEDICINE OFFICE OF RESEARCH HOUSTON, TX 77030	N/A	PC	PILOT STUDY TO ADDRESS DIABETES HEALTH-RELATED QUALITY OF LIFE	501,482.
BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON 1201 NINTH AVENUE SEATTLE, WA 98101-2795	N/A	PC	GUIDELINES FOR CLINICAL FOLLOW-UP OF MULTIPLE ISLET AUTOANTIBODIES	70,000.
BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON 1201 NINTH AVENUE SEATTLE, WA 98101-2795	N/A	PC	LINKING DISEASE MECHANISM AND CLINICAL TRIAL DESIGN IN T1D	581,045.
BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON 1201 NINTH AVENUE SEATTLE, WA 98101-2795	N/A	PC	GUIDELINES FOR CLINICAL PRACTICE OF AUTOANTIBODY POSITIVE INDIVIDUALS	70,000.
BETH ISRAEL DEACONESS MEDICAL CENTER, INC. 330 BROOKLINE AVENUE BOSTON, MA 02215-5491	N/A	PC	PROACTIVE OPTIMIZATION OF INFLIXIMAB USING A PHARMACOKINETIC DASHBOARD	526,637.
BEYOND TYPE 1 1001 LAUREL ST, STE B SAN CARLOS, CA 94070	N/A	PC	DIABETIC KETOACIDOSIS (DKA) CAMPAIGN PHASE 3	451,667.
BIG HORN HOSPITAL ASSOCIATION 17 N MILES AVE HARDIN, MT 59034	N/A	PC	EEMERGENCY AND EPHARMACY AT BIG HORN HOSPITAL ASSOCIATION IN HARDIN, MT	24,948.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
BILLINGS CLINIC FOUNDATION 2917 TENTH AVENUE NORTH BILLINGS, MT 59102	N/A	PC	MONTANA PSYCHIATRY RESIDENCY PROGRAM SUSTAINING SUPPORT	1,000,000.
BIPARTISAN POLICY CENTER, INC. 1225 I ST NW #1000 WASHINGTON, DC 20005	N/A	PC	STRENGTHENING HEALTH CARE DELIVERY AND SERVICES IN RURAL AMERICA	622,488.
BIPARTISAN POLICY CENTER, INC. 1225 I ST NW #1000 WASHINGTON, DC 20005	N/A	PC	RURAL HEALTH CARE TASK FORCE	149,200.
BLUE CIRCLE HEALTH, INC. THE CORPORATION TRUST CENTER, 1209 ORANGE STREET WILMINGTON, DE 19801	N/A	NC	CREATION OF BLUE CIRCLE HEALTH FOR UNDERSERVED COMMUNITIES WITH T1D	15,576,000.
BOSTON MEDICAL CENTER CORPORATION ONE BOSTON MEDICAL PLACE BOSTON, MA 02118	N/A	PC	STAGING CROHNS DISEASE USING MUCOSAL EXOSOMES	94,406.
BOSTON MEDICAL CENTER CORPORATION ONE BOSTON MEDICAL PLACE BOSTON, MA 02118	N/A	PC	STAGING CROHNS DISEASE USING MUCOSAL EXOSOMES	55,704.
BOSTON SYMPHONY ORCHESTRA, INC. 301 MASSACHUSETTS AVENUE BOSTON, MA 02115	N/A	PC	GENERAL OPERATING SUPPORT	10,000.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
BOULDER CITY HOSPITAL INC 901 ADAMS BLVD BOULDER CITY, NV 89005	N/A	PC	BOULDER CITY HOSPITAL ULTRASOUND INITIATIVE	100,838.
BOULDER CITY HOSPITAL INC 901 ADAMS BLVD BOULDER CITY, NV 89005	N/A	PC	BOULDER CITY HOSPITAL EQUIPMENT REVITALIZATION PROJECT	663,285.
BRIDGES TO PROSPERITY, INC. 1031 33RD STREET DENVER, CO 80205	N/A	PC	TRANSFORMATIVE CONNECTIVITY IN RURAL ETHIOPIA	5,262,850.
BRIGHAM AND WOMEN'S HOSPITAL 75 FRANCIS STREET BOSTON, MA 02115	N/A	PC	GLOBAL PARTNERSHIP TO ACHIEVE UNIVERSAL ACCESS FOR T1D AND NCDS	548,201.
BRIGHAM AND WOMEN'S HOSPITAL 75 FRANCIS STREET BOSTON, MA 02115	N/A	PC	PEN-PLUS EXPANSION	1,325,594.
BRIGHAM AND WOMEN'S HOSPITAL 75 FRANCIS STREET BOSTON, MA 02115	N/A	PC	INVESTIGATION OF ANTI-GM-CSF AUAB AS A DISEASE DETERMINANT IN CD	872,027.
BRIGHAM AND WOMEN'S HOSPITAL 75 FRANCIS STREET BOSTON, MA 02115	N/A	PC	GENERAL OPERATING SUPPORT	20,000.

Total from continuation sheets

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
BRIGHAM AND WOMEN'S HOSPITAL 75 FRANCIS STREET BOSTON, MA 02115	N/A	PC	GLOBAL PARTNERSHIP TO ACHIEVE UNIVERSAL ACCESS FOR T1D AND NCDS	3,031,033.
BURGESS HEALTH CENTER 1600 DIAMOND STREET ONAWA, IA 51040	N/A	PC	EEMERGENCY AND EPHARMACY AT BURGESS HEALTH CENTER	33,587.
CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST HILLS ROAD CAMBRIDGE, UNITED KINGDOM	N/A	GOV	UK IBD BIORESOURCE: TRANSLATING TODAYS SCIENCE INTO CD TREATMENTS	312,018.
CANDID 32 OLD SLIP, 24TH FLOOR NEW YORK, NY 10005	N/A	PC	GENERAL OPERATING SUPPORT	17,551.
CARE FOR THE HOMELESS 30 EAST 33RD STREET, 5TH FLOOR NEW YORK, NY 10016	N/A	PC	NEW YORK CITY COLLABORATIVE FOR HOMELESS HEALTHCARE	200,000.
CARE-FOR-RARE FOUNDATION DR. VON HAUNERSCHES KINDERSPITAL MUNICH, GERMANY	N/A	PC	VEOIBD FROM PRECISION MOLECULAR DIAGNOSES TO TARGETED THERAPIES - MUNICH	643,036.
CATHOLIC RELIEF SERVICES-USCCB 228 W. LEXINGTON ST. BALTIMORE, MD 21201	N/A	PC	BOUSSOUMA AND ZIGA, BURKINA FASO IMPROVED WASH INFRASTRUCTURE & SERVICES	2,045,026.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
CATHOLIC RELIEF SERVICES-USCCB 228 W. LEXINGTON ST. BALTIMORE, MD 21201	N/A	PC	INTEGRATED COMMUNITY WATER, SANITATION AND HYGIENE IMPROVEMENT IN GHANA	2,589,304.
CATHOLIC RELIEF SERVICES-USCCB 228 W. LEXINGTON ST. BALTIMORE, MD 21201	N/A	PC	MAYI MWANA PROJECT: HELPING ZAMBIAN MOTHERS & NEWBORNS SURVIVE & THRIVE	1,066,649.
CATHOLIC RELIEF SERVICES-USCCB 228 W. LEXINGTON ST. BALTIMORE, MD 21201	N/A	PC	RURAL EMERGENCY HEALTH SERVICE AND TRANSPORT FOR SYSTEM DEVELOPMENT	1,597,757.
CATHOLIC RELIEF SERVICES-USCCB 228 W. LEXINGTON ST. BALTIMORE, MD 21201	N/A	PC	COMMUNITY RECOVERY AND RESILIENCE IN EASTERN ETHIOPIA	2,752,636.
CEDARS-SINAI MEDICAL CENTER 8700 BEVERLY BLVD LOS ANGELES, CA 90048	N/A	PC	LONG-TERM RESPONSE TO SARS-COV-2 VACCINATION IN A DIVERSE IBD POPULATION	976,541.
CEDARS-SINAI MEDICAL CENTER 8700 BEVERLY BLVD LOS ANGELES, CA 90048	N/A	PC	VEOIBD PRECISION MOLECULAR DIAGNOSES TO TARGETED THERAPIES CEDARS-SINAI	115,500.
CEDARS-SINAI MEDICAL CENTER 8700 BEVERLY BLVD LOS ANGELES, CA 90048	N/A	PC	TARGETING MICROORGANISMS IN CREEPING FAT	375,747.

Total from continuation sheets

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
CEDARS-SINAI MEDICAL CENTER 8700 BEVERLY BLVD LOS ANGELES, CA 90048	N/A	PC	TARGETING MICROORGANISMS IN CREEPING FAT	393,039.
CENTER FOR EXCELLENCE IN HEALTH CARE JOURNALISM 10 NEFF HALL COLUMBIA, MO 65211	N/A	SOII	TRAINING AND DEVELOPMENT OF HEALTH CARE JOURNALISTS AND HEALTH REPORTING	180,005.
CENTER FOR URBAN COMMUNITY SERVICES, INC. 198 EAST 121ST STREET NEW YORK, NY 10035	N/A	PC	NEW YORK CITY COLLABORATIVE FOR HOMELESS HEALTHCARE	200,000.
CENTRAL MONTANA MEDICAL FACILITIES, INC. 408 WENDELL AVE. LEWISTOWN, MT 59457	N/A	PC	CANCER CENTER AT CENTRAL MONTANA MEDICAL CENTER	1,840,000.
CENTRE HOSPITALIER REGIONAL DE NANCY 29 AVENUE MAL DE LATRE DE TASSIGNY NANCY, FRANCE	N/A	GOV	PREVENTION OF EXTRA-INTESTINAL MANIFESTATIONS/ COMORBIDITIES IN CD CARE	173,555.
CHILDREN OF THE LIGHT INTERNATIONAL MINISTRIES, INC. 1171 E 95TH STREET BROOKLYN, NY 11236	N/A	PC	GENERAL OPERATING SUPPORT	25,000.
CHILDREN'S HOSPITAL CORPORATION ATTN: RESEARCH FINANCE BOSTON, MA 02241-4413	N/A	PC	VEOIBD PRECISION MOLECULAR DIAGNOSES TO TARGETED THERAPIES- BOSTON	1,155,528.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
CHILDREN'S HOSPITAL CORPORATION ATTN: RESEARCH FINANCE BOSTON, MA 02241-4413	N/A	PC	NOVEL GLUCOSE BINDERS FOR THE DEVELOPMENT OF GLUCOSE RESPONSIVE INSULINS	662,214.
CHILDREN'S HOSPITAL CORPORATION ATTN: RESEARCH FINANCE BOSTON, MA 02241-4413	N/A	PC	DEVELOPMENT OF NOVEL GLUCOSE RESPONSIVE GLUCAGON (GRG) DELIVERY SYSTEM	1,162,617.
CHILDREN'S HOSPITAL CORPORATION ATTN: RESEARCH FINANCE BOSTON, MA 02241-4413	N/A	PC	GLUCOSE-RESPONSIVE APPROACHES TO INSULIN AND GLUCAGON DELIVERY	567,507.
CHILDREN'S HOSPITAL LOS ANGELES SABAN RESEARCH INSTITUTE LOS ANGELES, CA 90027	N/A	PC	TEAM CLINIC: EXPANSION OF A CARE MODEL FOR ADOLESCENTS WITH T1D	360,832.
CHILDREN'S HOSPITAL LOS ANGELES SABAN RESEARCH INSTITUTE LOS ANGELES, CA 90027	N/A	PC	BEYOND COYOT1: EXPANSION OF PATIENT-CENTERED VIRTUAL CARE	527,168.
CHILDREN'S HOSPITAL MEDICAL CENTER 3333 BURNET AVENUE CINCINNATI, OH 45229	N/A	PC	DEVELOP A PROGNOSTIC AI MODEL FOR FORECASTING CD PATIENT OUTCOMES	1,242,522.
CHILDREN'S HOSPITAL MEDICAL CENTER 3333 BURNET AVENUE CINCINNATI, OH 45229	N/A	PC	DELIVERY SYSTEM REDESIGN TO IMPROVE CARE FOR LOW-INCOME YOUTH WITH T1D	833,493.

Total from continuation sheets

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
CHILDREN'S HOSPITAL MEDICAL CENTER 3333 BURNET AVENUE CINCINNATI, OH 45229	N/A	PC	PRECISION CROHNS DISEASE MANAGEMENT UTILIZING PREDICTIVE PROTEIN PANELS	613,632.
CHILDREN'S HOSPITAL MEDICAL CENTER 3333 BURNET AVENUE CINCINNATI, OH 45229	N/A	PC	BIOMARKERS OF INTESTINAL FIBROSIS IN SMALL BOWEL CROHNS DISEASE	692,740.
CHILDREN'S HOSPITAL OF PHILADELPHIA 2716 SOUTH STREET PHILADELPHIA, PA 19146-2305	N/A	PC	CROHNS DISEASE EPITHELIAL STEM CELL ATLAS: PEDIATRIC TO ADULT CONTINUUM	281,734.
CHILDREN'S HOSPITAL OF PHILADELPHIA 2716 SOUTH STREET PHILADELPHIA, PA 19146-2305	N/A	PC	CROHNS DISEASE EPITHELIAL STEM CELL ATLAS: PEDIATRIC TO ADULT CONTINUUM	424,937.
CHILDREN'S HUNGER FUND 13931 BALBOA BLVD SYLMAR, CA 91342	N/A	PC	MEDICAL AND ORPHAN CARE INITIATIVE IN ETHIOPIA	250,409.
CHILDREN'S MERCY HOSPITAL 2401 GILLHAM ROAD KANSAS CITY, MO 64108	N/A	PC	TYPE 1 DIABETES RAPID LEARNING LAB	445,112.
CHILDREN'S MERCY HOSPITAL 2401 GILLHAM ROAD KANSAS CITY, MO 64108	N/A	PC	TYPE 1 DIABETES RAPID LEARNING LAB	2,012,361.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
CITIZENS HOUSING AND PLANNING COUNCIL OF NEW YORK, INC. 42 BROADWAY STE 2010 NEW YORK, NY 10004	N/A	PC	EDUCATION FOR NYC POLICYMAKERS ON HOUSING INITIATIVES TO IMPROVE HEALTH	200,000.
CITY PARKS FOUNDATION 830 FIFTH AVENUE NEW YORK, NY 10065	N/A	PC	CATALYST: GROWING INTENSIVE PARK ENGAGEMENT IN VULNERABLE COMMUNITIES	479,444.
CITY PARKS FOUNDATION 830 FIFTH AVENUE NEW YORK, NY 10065	N/A	PC	NYC GREEN RELIEF & RECOVERY FUND	537,825.
CIVICA FOUNDATION 2912 WEST EXECUTIVE PARKWAY LEHI, UT 84043	N/A	PC	AFFORDABLE INSULIN BIOSIMILARS	5,000,000.
CLALIT HEALTH SERVICES 101 ARLOZOROV STREET TEL AVIV, ISRAEL	N/A	PC	KIRYAT SHMONA MEDICAL CLINIC	1,118,393.
CLALIT HEALTH SERVICES 101 ARLOZOROV STREET TEL AVIV, ISRAEL	N/A	PC	BIO-MDT APPROACH TO PERSONALIZED TREATMENT OF POUCHITIS	748,810.
CLALIT HEALTH SERVICES 101 ARLOZOROV STREET TEL AVIV, ISRAEL	N/A	PC	CLINICAL TRIAL TO EVALUATE A NOVEL MDI-BGM DECISION SUPPORT SYSTEM	589,062.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
CLALIT HEALTH SERVICES 101 ARLOZOROV STREET TEL AVIV, ISRAEL	N/A	PC	THE IBDMED NUTRITIONAL EDUCATION PROGRAM FOR CD CONTROL & PREVENTION	451,795.
CLALIT HEALTH SERVICES 101 ARLOZOROV STREET TEL AVIV, ISRAEL	N/A	PC	PET/CT SCANNER FOR EMEK MEDICAL CENTER IN AFULA, ISRAEL	2,075,000.
CLALIT HEALTH SERVICES 101 ARLOZOROV STREET TEL AVIV, ISRAEL	N/A	PC	MEDICAL EQUIPMENT FOR CARMEL MEDICAL CENTER IN HAIFA, ISRAEL	3,896,000.
CLALIT HEALTH SERVICES 101 ARLOZOROV STREET TEL AVIV, ISRAEL	N/A	PC	COVID-19 VACCINE RESPONSES IN PATIENTS WITH IBD	165,855.
CLALIT HEALTH SERVICES 101 ARLOZOROV STREET TEL AVIV, ISRAEL	N/A	PC	CLINICAL TRIAL TO EVALUATE A NOVEL MDI-BGM DECISION SUPPORT SYSTEM	589,062.
CLALIT HEALTH SERVICES 101 ARLOZOROV STREET TEL AVIV, ISRAEL	N/A	PC	EARLY CROHNS DISEASE: UNDERSTANDING PATHOGENESIS, BEHAVIOR, RESPONSE	112,000.
CLALIT HEALTH SERVICES 101 ARLOZOROV STREET TEL AVIV, ISRAEL	N/A	PC	ISRAELI IBD RESEARCH NUCLEUS (IIRN): CONSORTIUM MANAGEMENT	32,000.

Total from continuation sheets

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
CLALIT HEALTH SERVICES 101 ARLOZOROV STREET TEL AVIV, ISRAEL	N/A	PC	BIO-MDT APPROACH TO PERSONALIZED TREATMENT OF POUCHITIS	582,660.
CLALIT HEALTH SERVICES 101 ARLOZOROV STREET TEL AVIV, ISRAEL	N/A	PC	KIRYAT SHMONA MEDICAL CLINIC	1,405,714.
CLARINDA REGIONAL HEALTH CENTER 220 ESSIE DAVISON DRIVE CLARINDA, IA 51632	N/A	GOV	EEMERGENCY AT CLARINDA REGIONAL HEALTH CENTER	16,247.
CLINICAL DATA INTERCHANGE STANDARDS CONSORTIUM INC 401 WEST 15TH STREET, SUITE 800 AUSTIN, TX 78701	N/A	PC	CDISC STANDARDS DEVELOPMENT PROJECT FOR TYPE 1 DIABETES	14,355.
CLINTON HEALTH ACCESS INITIATIVE INC 383 DORCHESTER AVENUE, SUITE 400 BOSTON, MA 02127	N/A	PC	MARKET SHAPING TO IMPROVE ACCESS TO DIABETES CARE	845,202.
COLUMBIA UNIVERSITY 615 WEST 131ST STREET NEW YORK, NY 10027-3922	N/A	PC	POVERTY TRACKER SURVEY: HEALTHCARE NEEDS & USE OF LOW-INCOME NEW YORKERS	81,367.
COLUMBIA UNIVERSITY 615 WEST 131ST STREET NEW YORK, NY 10027-3922	N/A	PC	NOVEL SPATIALLY RESOLVED GENOMIC PROFILING OF CROHNS DISEASE TISSUE	210,228.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
COLUMBIA UNIVERSITY 615 WEST 131ST STREET NEW YORK, NY 10027-3922	N/A	PC	POVERTY TRACKER SURVEY: HEALTHCARE NEEDS & USE OF LOW-INCOME NEW YORKERS	110,040.
COLUMBIA UNIVERSITY 615 WEST 131ST STREET NEW YORK, NY 10027-3922	N/A	PC	NOVEL SPATIALLY RESOLVED GENOMIC PROFILING OF CROHNS DISEASE TISSUE	146,811.
COLUMBIA UNIVERSITY 615 WEST 131ST STREET NEW YORK, NY 10027-3922	N/A	PC	COMBINATORIAL PERTURBATION OF CELLULAR NETWORK IN CROHNS DISEASE	232,672.
COMMUNITY CENTERS INC 2 ST ROCH AVENUE GREENWICH, CT 06830	N/A	PC	GENERAL OPERATING SUPPORT	35,000.
COMMUNITY MEMORIAL HOSPITAL DISTRICT 2731 HEALTHCARE DRIVE SYRACUSE, NE 68446	N/A	GOV	ECARE EMERGENCY AT SYRACUSE AREA HEALTH	33,296.
CONSORCI INSTITUT D'INVESTIGACIONES BIOMEDICAS AUGUST ROSSELL 149 BARCELONA, SPAIN	N/A	GOV	EARLY DETECTION OF PERIANAL FISTULIZING DISEASE	270,828.
CONSORCI INSTITUT D'INVESTIGACIONES BIOMEDICAS AUGUST ROSSELL 149 BARCELONA, SPAIN	N/A	GOV	EARLY DETECTION OF PERIANAL FISTULIZING DISEASE	262,204.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
COUNCIL ON FOUNDATIONS, INC. 1255 23RD ST NW WASHINGTON, DC 20037	N/A	PC	GENERAL OPERATING SUPPORT	34,000.
COUNCIL ON THE ENVIRONMENT, INC. 100 GOLD ST. SUITE 3300 NEW YORK, NY 10038	N/A	PC	INTER-GENERATIONAL, VIABLE GREENSPACE IN NYCHA COMMUNITIES	116,600.
CROHN'S & COLITIS FOUNDATION, INC. 733 THIRD AVENUE, SUITE 510 NEW YORK, NY 10017	N/A	PC	SUPPORT FOR CCF'S CROHNS AND COLITIS CONGRESS- JANUARY, 2022	205,000.
CROHN'S & COLITIS FOUNDATION, INC. 733 THIRD AVENUE, SUITE 510 NEW YORK, NY 10017	N/A	PC	SYSTEMATIZING IMPROVEMENT INTERVENTIONS OF URGENT CARE MANAGEMENT IN CD	544,115.
CROHN'S & COLITIS FOUNDATION, INC. 733 THIRD AVENUE, SUITE 510 NEW YORK, NY 10017	N/A	PC	SUPPORT JUNIOR SCIENTISTS TO ESTABLISH CAREERS IN IBD RESEARCH.	1,067,400.
CROHN'S & COLITIS FOUNDATION, INC. 733 THIRD AVENUE, SUITE 510 NEW YORK, NY 10017	N/A	PC	SYSTEMATIZING IMPROVEMENT INTERVENTIONS OF URGENT CARE MANAGEMENT IN CD	494,615.
CROHN'S AND COLITIS CANADA 60 ST CLAIR AVE EAST, SUITE 600 TORONTO, CANADA	N/A	PC	IMPLEMENTATION OF A TELEMEDICINE NETWORK FOR CROHNS DISEASE PATIENTS	323,983.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
CROHN'S AND COLITIS CANADA 60 ST CLAIR AVE EAST, SUITE 600 TORONTO, CANADA	N/A	PC	RCT TO IMPROVE TRANSITION OF PATIENTS W CD FROM PEDIATRIC TO ADULT CARE	261,030.
CROHN'S AND COLITIS CANADA 60 ST CLAIR AVE EAST, SUITE 600 TORONTO, CANADA	N/A	PC	SUPPORT FOR CROHNS & COLITIS CANADA 2020- 21 PATIENT PROGRAMS	65,990.
CROHN'S AND COLITIS CANADA 60 ST CLAIR AVE EAST, SUITE 600 TORONTO, CANADA	N/A	PC	RCT TO IMPROVE TRANSITION OF PATIENTS W CD FROM PEDIATRIC TO ADULT CARE	315,009.
CROHN'S AND COLITIS CANADA 60 ST CLAIR AVE EAST, SUITE 600 TORONTO, CANADA	N/A	PC	IMPLEMENTATION OF A TELEMEDICINE NETWORK FOR CROHNS DISEASE PATIENTS	165,648.
CROHN'S AND COLITIS UK 1 BISHOPS SQUARE HATFIELD, UNITED KINGDOM	N/A	PC	2021 2022 OPERATING SUPPORT FOR CROHNS AND COLITIS UK	75,900.
CROHN'S COLITIS CURE 1 O'CONNELL STREET SYDNEY, AUSTRALIA	N/A	PC	DEVELOPMENT OF CCCARE-P, A PEDIATRIC CD EMR TO DRIVE CONSISTENCY IN CARE	175,233.
DARTMOUTH- HITCHCOCK CLINIC ONE MEDICAL CENTER DRIVE LEBANON, NH 03756	N/A	PC	CAPACITY BUILDING FOR VIRTUAL IBD TELEMEDICINE NETWORK PROGRAM	195,140.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
DE LA SALLE SOLIDARIETAINTE ONLUS VIA AUREALIA, 476 ROME, ITALY	N/A	PC	ESTABLISHING A ROBUST MEDICAL EDUCATION CENTER - ETHIOPIA	294,372.
DE LA SALLE SOLIDARIETAINTE ONLUS VIA AUREALIA, 476 ROME, ITALY	N/A	PC	ETHIOPIAN CATHOLIC UNIVERSITY DIAGNOSTIC LABORATORY	1,043,204.
DELAWARE COUNTY MEMORIAL HOSPITAL 709 W MAIN ST MANCHESTER, IA 52057	N/A	PC	EEMERGENCY AND EPHARMACY AT REGIONAL MEDICAL CENTER IN MANCHESTER, IA	29,195.
DUKE UNIVERSITY C/O OFFICE OF RESEARCH SUPPORT DURHAM, NC 27705-4677	N/A	PC	UTILIZATION OF INTERACTION BETWEEN AMINO ACIDS & GIP IN PANCREATIC CELLS	275,000.
ELLSWORTH MUNICIPAL HOSPITAL 920 SOUTH OAK STREET IOWA FALLS, IA 50126	N/A	GOV	EPHARMACY AT HANSEN FAMILY HOSPITAL	8,493.
ENGINEERING MINISTRIES INTERNATIONAL USA 7025 CAMPUS DRIVE COLORADO SPRINGS, CO 80920	N/A	PC	ALASKA WASH PROJECT	6,680,429.
FALL RIVER HEALTH SERVICES 1201 HIGHWAY 71 S HOT SPRINGS, SD 57747	N/A	PC	EEMERGENCY AT FALL RIVER HEALTH SERVICES	17,325.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
FEEDING SOUTH DAKOTA 4701 N. WESTPORT AVE. SIOUX FALLS, SD 57107-0123	N/A	PC	GENERAL OPERATING SUPPORT	25,000.
FIRST AFFILIATED HOSPITAL OF SUN YAT-SEN UNIVERSITY 58 ZHONGSHAN II ROAD GUANGZHOU, CHINA	N/A	GOV	INDUSTRIALIZATION RELATED ENVIRONMENTAL CHANGES & MICROBIOME ALTERATIONS	120,000.
FLORESTA USA INCORPORATED 4747 MORENA BLVD. STE 100 SAN DIEGO, CA 92117	N/A	PC	SCALING AT THE WATERSHED LEVEL TO EQUIP RURAL FAMILIES	1,048,129.
FLOYD VALLEY HOSPITAL 714 LINCOLN STREET NE LE MARS, IA 51031	N/A	GOV	EEMERGENCY AT FLOYD VALLEY HEALTHCARE	14,837.
FOR INSPIRATION AND RECOGNITION OF SCIENCE TECHNOLOGY 200 BEDFORD STREET MANCHESTER, NH 03101	N/A	PC	INSPIRE YOUNG PEOPLE TO BE SCIENCE AND TECHNOLOGY LEADERS	200,000.
FORSCHERGRUPPE DIABETES E.V. HELMHOLTZ ZENTRUM MUNCHEN, NEUHERBERG, GERMANY	N/A	PC	FR1DA-PLUS COHORT STUDY	467,844.
FRANCISCAN CARE SERVICES INC 430 N MONITOR ST WEST POINT, NE 68788	N/A	PC	TELE-EMERGENCY SERVICES AT FRANCISCAN HEALTHCARE	114,632.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
FRIENDS OF THE ISRAEL DEFENSE FORCES 60 EAST 42 STREET NEW YORK, NY 10165	N/A	PC	THE UNIFORM TO UNIVERSITY SCHOLARSHIP PROGRAM	334,400.
FUND FOR PUBLIC HEALTH IN NEW YORK, INC. 22 CORTLANDT STREET, SUITE 802 NEW YORK, NY 10007	N/A	PC	NYC VACCINE EQUITY PARTNER ENGAGEMENT PROJECT	2,249,533.
FUND FOR PUBLIC HOUSING, INC. 90 CHURCH STREET NEW YORK, NY 10007	N/A	PC	STRATEGIC PLANNING AND DEMONSTRATION PROJECT	200,000.
GALILEE MEDICAL CENTER GALILEE MEDICAL CENTER NAHARIYA, ISRAEL	N/A	GOV	PURCHASE OF TWO ECMO MACHINES FOR GALILEE MEDICAL CENTER	157,000.
GEORGIA TECH RESEARCH CORPORATION 505 10TH STREET, NW ATLANTA, GA 30332-0420	N/A	SOIII FI	TRACKING & INTERPRETATION OF SINGLE-CELL CHARACTERISTICS IN CD PATIENTS	951,960.
GIRLS WITH GUTS 6024 RIDGE AVENUE PHILADELPHIA, PA 19128	N/A	PC	2021 & 2022 OPERATING SUPPORT TO GIRLS WITH GUTS.	9,862.
GIRLS WITH GUTS 6024 RIDGE AVENUE PHILADELPHIA, PA 19128	N/A	PC	2021 2022 OPERATING SUPPORT TO GIRLS WITH GUTS.	9,862.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
GLOBAL SOLIDARITY FUND 425 LEXINGTON AVE. NEW YORK, NY 10017	N/A	PC	JOB CREATION IN ETHIOPIA	1,508,200.
GORDON MEMORIAL HOSPITAL DISTRICT 300 E 8TH ST GORDON, NE 69343	N/A	GOV	EEMERGENCY AT GORDON MEMORIAL HOSPITAL	14,384.
GRAND CANYON UNIVERSITY 3300 WEST CAMELBACK ROAD PHOENIX, AZ 85017	N/A	PC	DEVELOPMENT OF A CONTINUOUS INSULIN-GLUCOSE SENSOR	766,986.
GRANTMAKERS FOR EFFECTIVE ORGANIZATIONS 1310 L. STREET NW WASHINGTON, DC 20005	N/A	PC	GENERAL OPERATING SUPPORT	18,920.
GRANTMAKERS IN HEALTH 1100 CT AVENUE NW WASHINGTON, DC 20036	N/A	PC	GENERAL OPERATING SUPPORT	23,760.
GRANTMAKERS IN HEALTH 1100 CT AVENUE NW WASHINGTON, DC 20036	N/A	PC	GRANTMAKERS IN HEALTH EFFECTIVE PHILANTHROPY FUND	30,197.
GUARDIAN ORG FOUNDATION 900 17TH STREET NW, SUITE 250 WASHINGTON, DC 20006	N/A	PC	AN INDEPENDENT JOURNALISM SERIES ON NON-COMMUNICABLE DISEASES	875,000.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
GUTTENBERG MUNICIPAL HOSPITAL 200 MAIN ST GUTTENBERG, IA 52052	N/A	GOV	EEMERGENCY AND EPHARMACY AT GUTTENBERG MUNICIPAL HOSPITAL	26,922.
HANNOVERSCHE KINDERHEILANSTALT JANUSZ-KORCZAK-ALLEE 12 HANNOVER, GERMANY	N/A	PC	FR1DA IN NORTH GERMANY: PRE-SYMPOMATIC TYPE 1 DIABETES TESTING IN KIDS	286,700.
HARLAN COUNTY HEALTH SYSTEM 717 NORTH BROWN ALMA, NE 68920-0836	N/A	GOV	EPHARMACY AT HARLAN COUNTY HEALTH SYSTEM	9,737.
HEALTH ADVOCACY SUMMIT, INC. 1962 DOCKSIDE DRIVE GREENWOOD, ID 46143	N/A	PC	2021 OPERATING SUPPORT FOR HEALTH ADVOCACY SUMMIT AND THE CCYAN	25,000.
HEALTH ADVOCACY SUMMIT, INC. 1962 DOCKSIDE DRIVE GREENWOOD, IN 46143	N/A	PC	2021 OPERATING SUPPORT FOR HEALTH ADVOCACY SUMMIT AND THE CCYAN	25,000.
HEALTH FINANCE INSTITUTE 1690 NORTH QUINN STREET ARLINGTON, VA 22209	N/A	PC	CATALYZE FINANCE & PARTNERS TO ADDRESS GLOBAL BURDEN OF CHRONIC DISEASE	1,633,848.
HEALTHPARTNERS INSTITUTE PO BOX 1309 MINNEAPOLIS, MN 55440	N/A	PC	DIRECT INTEGRATION OF CGM DATA INTO THE EMR	284,446.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
HEALTHPARTNERS INSTITUTE PO BOX 1309 MINNEAPOLIS, MN 55440	N/A	PC	DIRECT INTEGRATION OF CGM DATA INTO THE EMR	258,500.
HEBREW UNIVERSITY OF JERUSALEM OFFICE OF THE PRESIDENT JERUSALEM, ISRAEL	N/A	PC	METHYLATION PATTERNS OF CELL-FREE DNA AS A NOVEL BIOMARKER IN CROHNS	775,164.
HEBREW UNIVERSITY OF JERUSALEM OFFICE OF THE PRESIDENT JERUSALEM, ISRAEL	N/A	PC	METHYLATION PATTERNS OF CELL-FREE DNA AS A NOVEL BIOMARKER IN CROHNS	18,350.
HEBREW UNIVERSITY OF JERUSALEM OFFICE OF THE PRESIDENT JERUSALEM, ISRAEL	N/A	PC	METHYLATION PATTERNS OF CELL-FREE DNA AS A NOVEL BIOMARKER IN CROHNS	249,301.
HELEN KELLER INTERNATIONAL ONE DAG HAMMARSKJOLD PLAZA NEW YORK, NY 10017	N/A	PC	A CONTINUED PATH TO RESILIENCE AND EMPOWERMENT	1,902,757.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) HELMHOLTZ ZENTRUM MUNCHEN (GMBH), NEUHERBERG, GERMANY	N/A	PC	GPPAD DRIED BLOOD SPOT OMICS TO PREDICT HEALTH OUTCOMES IN CHILDREN	604,654.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) HELMHOLTZ ZENTRUM MUNCHEN (GMBH), NEUHERBERG, GERMANY	N/A	PC	THE GPPAD-03 STUDY: THE PRIMARY ORAL INSULIN TRIAL	1,800,000.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) HELMHOLTZ ZENTRUM MUNCHEN (GMBH), NEUHERBERG, GERMANY	N/A	PC	CONTINUATION OF THE GPPAD-02-STUDY	2,428,367.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) HELMHOLTZ ZENTRUM MUNCHEN (GMBH), NEUHERBERG, GERMANY	N/A	PC	GPPAD COORDINATION CENTER CONTINUATION	668,907.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) HELMHOLTZ ZENTRUM MUNCHEN (GMBH), NEUHERBERG, GERMANY	N/A	PC	FR1DA ORAL INSULIN INTERVENTION TRIAL AMENDMENT	263,397.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) HELMHOLTZ ZENTRUM MUNCHEN (GMBH), NEUHERBERG, GERMANY	N/A	PC	IDENTIFICATION OF INFANTS WITH HIGH RISK OF T1D - PRIMARY PREVENTION	3,653,834.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) HELMHOLTZ ZENTRUM MUNCHEN (GMBH), NEUHERBERG, GERMANY	N/A	PC	THE GPPAD-03 STUDY: THE PRIMARY ORAL INSULIN TRIAL	2,705,330.
HENRY J. KAISER FAMILY FOUNDATION 185 BERRY STREET NO 2000 SAN FRANCISCO, CA 94107	N/A	PC	KHN RURAL HEALTH DESK	1,451,938.
HERLEV OG GENTOFTE HOSPITAL HERLEV AND GENTOFTE HOSPITAL HERLEV, DENMARK	N/A	GOV	UTILIZATION OF INTERACTION BETWEEN AMINO ACIDS & GIP IN PANCREATIC CELLS	275,000.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
HERLEV OG GENTOFTE HOSPITAL HERLEV AND GENTOFTE HOSPITAL HERLEV, DENMARK	N/A	GOV	TARGETING GIP/GLP-2 RECEPTORS TO PREVENT HYPOGLYCEMIA IN T1D	249,897.
HILLEL YAFFE MEDICAL CENTER HA-SHALOM ST. HADERA, ISRAEL	N/A	GOV	PURCHASE TWO ECMO MACHINES FOR HILLEL YAFFE MEDICAL CENTER	155,418.
HUMBOLDT COUNTY HOSPITAL DISTRICT 118 E. HASKELL STREET WINNEMUCCA, NV 89445	N/A	GOV	ULTRASOUND EQUIPMENT	209,393.
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI 1 GUSTAVE L. LEVY PL NEW YORK CITY, NY 10029	N/A	PC	VEOIBD: PRECISION DIAGNOSES TO TARGETED THERAPIES: MOUNT SINAI STUDIES	220,000.
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI 1 GUSTAVE L. LEVY PL NEW YORK CITY, NY 10029	N/A	PC	MODULATING EARLY LIFE MICROBIOME THROUGH DIETARY INTERVENTION IN CROHNS	479,190.
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI 1 GUSTAVE L. LEVY PL NEW YORK CITY, NY 10029	N/A	PC	SAFETY AND TOLERABILITY OF ORAL BFAHF-2 IN PEDIATRIC CROHNS DISEASE	267,814.
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI 1 GUSTAVE L. LEVY PL NEW YORK CITY, NY 10029	N/A	PC	EVALUATING AID TECHNOLOGY IN PREGNANT WOMEN WITH T1D	482,282.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI 1 GUSTAVE L. LEVY PL NEW YORK CITY, NY 10029	N/A	PC	NEXT PHASE OF STEM CELL TRANSPLANT FOR REFRACTORY CROHNS DISEASE	664,751.
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI 1 GUSTAVE L. LEVY PL NEW YORK CITY, NY 10029	N/A	PC	MODULATING EARLY LIFE MICROBIOME THROUGH DIETARY INTERVENTION IN CROHNS	492,812.
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI 1 GUSTAVE L. LEVY PL NEW YORK CITY, NY 10029	N/A	PC	SAFETY AND TOLERABILITY OF ORAL BFAHF-2 IN PEDIATRIC CROHNS DISEASE	375,235.
ICHUD HATZALAH ISRAEL 1221 (R.A.) 78 YIRMIYAHU ST. JERUSALEM, ISRAEL	N/A	PC	UNITED HATZALAH HUMANITARIAN MISSION FOR UKRAINE	385,000.
ICHUD HATZALAH ISRAEL 1221 (R.A.) 78 YIRMIYAHU ST. JERUSALEM, ISRAEL	N/A	PC	URGENT NEED FOR PROTECTIVE VESTS AND HELMETS	500,000.
IDA COUNTY IOWA COMMUNITY HOSPITAL 701 EAST SECOND STREET IDA GROVE, IA 51445	N/A	PC	ECARE PHARMACY AT HORN MEMORIAL HOSPITAL	24,192.
IDEO.ORG 444 SPEAR STREET SAN FRANCISCO, CA 94105	N/A	PC	HUMAN-CENTERED DESIGN STUDY OF T1D IN MEDICALLY UNDERSERVED COMMUNITIES.	200,000.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
IDEO.ORG 444 SPEAR STREET SAN FRANCISCO, CA 94105	N/A	PC	HUMAN-CENTERED DESIGN STUDY OF T1D IN MEDICALLY UNDERSERVED COMMUNITIES.	150,000.
INCLINE VILLAGE COMMUNITY HOSPITAL FOUNDATION 880 ALDER AVE INCLINE VILLAGE, NV 89451	N/A	PC	DIAGNOSTIC IMAGING EQUIPMENT RELATED FUNDING SUPPORT	1,796,260.
INDIANA UNIVERSITY (AMPATH PROJECT) 702 ROTARY CIRCLE INDIANAPOLIS, IN 46202	N/A	PC	AMPATH MODEL REPLICATION IN GHANA	2,131,500.
INDIANA UNIVERSITY 702 ROTARY CIRCLE INDIANAPOLIS, IN 46202	N/A	PC	AMPATH MODEL REPLICATION IN GHANA	3,474,440.
INSTITUT INTEGRATED BIOBANK OF LUXEMBOURG 1, RUE LOUIS RECH DUDELANGE, LUXEMBOURG	N/A	GOV	GPPAD BIOBANK - SINT1A	41,401.
INSTITUT NATIONALE DE LA SANTE DE LA RECHERCHE MEDICALE 86, RUE REGNAULT PARIS, FRANCE	N/A	GOV	BENIGN ISLET AUTOIMMUNITY TO T1D: CD8+ T-CELL BIOMARKERS OF PROGRESSION	373,431.
INSTITUT NATIONALE DE LA SANTE ET DE LA RECHERCHE MEDICALE 86, RUE REGNAULT PARIS, FRANCE	N/A	GOV	BENIGN ISLET AUTOIMMUNITY TO T1D: CD8+ T-CELL BIOMARKERS OF PROGRESSION	178,286.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
INSULIN FOR LIFE USA, INC. 2555 SW 76TH STREET GAINESVILLE, FL 32608	N/A	PC	INSULIN FOR LIFE USA STRENGTHENING ORGANIZATIONAL CAPACITY	296,175.
INTERNATIONAL BOWEL ULTRASOUND GROUP E.V. HARKORTSTR. 1 MUNSTER, GERMANY	N/A	NC	THE DEVELOPMENT OF A DISEASE ACTIVITY INDEX FOR INTESTINAL ULTRASOUND	693,935.
INTERNATIONAL WATER MANAGEMENT INSTITUTE 127 SUNIL MAWATHA BATTARAMULLA, SRI LANKA	N/A	PC	WATER SECURE AFRICA INITIATIVE: OPEN DATA CUBE EXTENSION	942,226.
IOWA DEPARTMENT OF PUBLIC HEALTH 321 EAST 12TH DES MOINES, IA 50319	N/A	GOV	IOWA FIRST RESPONDER AED INITIATIVE	5,283,804.
ISRAEL ANTIQUITIES AUTHORITY 27 SULTAN SULEIMAN STREET JERUSALEM, ISRAEL	N/A	GOV	JAY & JEANIE SCHOTTENSTEIN NATIONAL CAMPUS FOR THE ARCHAEOLOGY OF ISRAEL	2,600,000.
ISRAEL CROHN'S DISEASE AND ULCERATIVE COLITIS FOUNDATION YOKNEAM 5 TEL AVIV, ISRAEL	N/A	PC	2020 OPERATING SUPPORT FOR CCFI'S EMERGENCY TRANSPORTATION PROGRAM	57,428.
ISRAEL CROHN'S DISEASE AND ULCERATIVE COLITIS FOUNDATION YOKNEAM 5 TEL AVIV, ISRAEL	N/A	PC	2020 OPERATING SUPPORT FOR CCFI'S EMERGENCY TRANSPORTATION PROGRAM	59,407.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
JAEB CENTER FOR HEALTH RESEARCH FOUNDATION, INC. 15310 AMBERLY DRIVE, SUITE 350 TAMPA, FL 33647	N/A	PC	EVALUATION OF THE RELATIONSHIP OF GLUCOSE METRICS VIA CGM W DIABETES RETINOPATHY	56,265.
JAEB CENTER FOR HEALTH RESEARCH FOUNDATION, INC. 15310 AMBERLY DRIVE, SUITE 350 TAMPA, FL 33647	N/A	PC	EXERCISE IN DIABETES INITIATIVE: PEDIATRIC STUDY	600,000.
JAEB CENTER FOR HEALTH RESEARCH FOUNDATION, INC. 15310 AMBERLY DRIVE, SUITE 350 TAMPA, FL 33647	N/A	PC	CGM MONITORING OF MATERNAL DYSGLYCEMIA	453,159.
JDRF AUSTRALIA 80-84 CHANDOS STREET SYDNEY, AUSTRALIA	N/A	PC	ENDIA FOLLOW UP 2020-2022	1,133,601.
JDRF AUSTRALIA 80-84 CHANDOS STREET SYDNEY, AUSTRALIA	N/A	PC	ENDIA EARLY TO MID-CAREER SCIENCE ACCELERATOR AWARDS 2021	239,784.
JDRF INTERNATIONAL 200 VESEY STREET NEW YORK, NY 10281	N/A	PC	DEVELOPMENT OF NOVEL INSULIN INFUSION SET	432,631.
JDRF INTERNATIONAL 200 VESEY STREET NEW YORK, NY 10281	N/A	PC	JDRF GLOBAL DIABETES ACCESS INITIATIVE	999,800.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
JDRF INTERNATIONAL 200 VESEY STREET NEW YORK, NY 10281	N/A	PC	JDRF TRAINING PROGRAMS	1,250,000.
JDRF INTERNATIONAL 200 VESEY STREET NEW YORK, NY 10281	N/A	PC	HCP T1D EDUCATION PROGRAM (STATE OF AFFAIRS AND PEAK)	99,699.
JDRF INTERNATIONAL 200 VESEY STREET NEW YORK, NY 10281	N/A	PC	AUTOIMMUNITY SCREENING IN KIDS (ASK) RENEWAL	400,000.
JDRF T1D FUND, LLC 99 HIGH STREET BOSTON, MA 02110	N/A	PC	JDRF T1D FUND PHASE III	3,000,000.
JENNIE M. MELHAM MEMORIAL MEDICAL CENTER, INC. 145 MEMORIAL DRIVE BROKEN BOW, NE 68822	N/A	PC	EPHARMACY AT JENNIE M MELHAM MEMORIAL MEDICAL CENTER, INC.	11,360.
JERUSALEM COLLEGE OF TECHNOLOGY 21 HAVAAD HALEUMI ST. JERUSALEM, ISRAEL	N/A	PC	HELMSLEY FACULTY OF LIFE AND HEALTH SCIENCES BUILDING	2,859,000.
JOHNS HOPKINS UNIVERSITY 733 NORTH BROADWAY, MRB 117 BALTIMORE, MD 21205	N/A	PC	A MULTIDISCIPLINARY BIOENGINEERING APPROACH TO FISTULA-IN-ANO IN CROHNS	360,255.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
JOHNS HOPKINS UNIVERSITY 733 NORTH BROADWAY, MRB 117 BALTIMORE, MD 21205	N/A	PC	A MULTIDISCIPLINARY BIOENGINEERING APPROACH TO FISTULA-IN-ANO IN CROHNS	239,373.
JOSLIN DIABETES CENTER, INC. ONE JOSLIN PLACE BOSTON, MA 02215	N/A	PC	AN INTEGRATED CARE MODEL FOR OLDER ADULTS WITH INSULIN-TREATED DIABETES	1,177,265.
JUVENILE DIABETES RESEARCH FOUNDATION CANADA 235 YORKLAND BLVD., SUITE 600 TORONTO, CANADA	N/A	PC	JDRF CANADA PSYCHOSOCIAL HEALTH INITIATIVE	54,000.
KATHOLIEKE UNIVERSITEIT LEUVEN WAAISTRAAT 6 BOX 5105 LEUVEN, BELGIUM	N/A	PC	INNODIA HARVEST	481,994.
KATHOLIEKE UNIVERSITEIT LEUVEN WAAISTRAAT 6 BOX 5105 LEUVEN, BELGIUM	N/A	PC	AN ENTEROCHROMAFFIN CELL AND MACROPHAGE ATLAS OF THE HUMAN GUT	530,355.
KATHOLIEKE UNIVERSITEIT LEUVEN WAAISTRAAT 6 BOX 5105 LEUVEN, BELGIUM	N/A	PC	SUPPORT FOR INNODIA HARVEST ACTIVITIES AT ACADEMIC CONSORTIUM MEMBERS.	792,845.
KATHOLIEKE UNIVERSITEIT LEUVEN WAAISTRAAT 6 BOX 5105 LEUVEN, BELGIUM	N/A	PC	AN ENTEROCHROMAFFIN CELL AND MACROPHAGE ATLAS OF THE HUMAN GUT	497,699.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
KING'S COLLEGE LONDON 150 STAMFORD STREET LONDON, UNITED KINGDOM	N/A	PC	MULTIPEPTIDE PROOF-OF-CONCEPT STUDY: STAGE III	1,509,981.
KING'S COLLEGE LONDON 150 STAMFORD STREET LONDON, UNITED KINGDOM	N/A	PC	IDENTIFYING THE ROLE OF FOOD ADDITIVE EMULSIFIERS IN CROHNS DISEASE	740,062.
KING'S COLLEGE LONDON 150 STAMFORD STREET LONDON, UNITED KINGDOM	N/A	PC	EVALUATE THE BIOLOGICAL, SOCIAL AND ECONOMIC IMPACT OF HYPOGLYCEMIA	46,929.
KITTSON MEMORIAL HOSPITAL ASSOCIATION 1010 SOUTH BIRCH AVENUE HALLOCK, MN 56728	N/A	PC	EEMERGENCY AT KITTSON HEALTHCARE	29,321.
KLINIKUM DER LUDWIG-MAXIMILIANS-UNIVERSITT MUNCHEN FEODOR-LYNEN-STRAE 17 MUNCHEN, GERMANY	N/A	GOV	FMT FOR MAINTENANCE OF REMISSION AFTER EEN TREATMENT IN CROHNS DISEASE	639,055.
KMR ADVANCEMENT OF MEDICAL CENTERS LTD. 8 HA'ALIYAH ST. HAIFA, ISRAEL	N/A	PC	ESTABLISHMENT OF THE HEALTH DISCOVERY TOWER	2,950,750.
LAKES REGIONAL HEALTHCARE HIGHWAY 71 SOUTH SPIRIT LAKE, IA 51360	N/A	GOV	ECARE PHARMACY AT LAKES REGIONAL HEALTHCARE	27,140.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
LANDER COUNTY HOSPITAL DISTRICT 535 SOUTH HUMBOLDT STREET BATTLE MOUNTAIN, NV 89820-1988	N/A	GOV	RADIOLOGY EQUIPMENT FOR BATTLE MOUNTAIN GENERAL HOSPITAL	142,265.
LINCOLN COUNTY HOSPITAL DISTRICT 700 NORTH SPRING STREET CALIENTE, NV 89008	N/A	GOV	GROVER C. DILS MEDICAL CENTER EQUIPMENT REVITALIZATION PROJECT	666,782.
LIVING WATER INTERNATIONAL 4001 GREENBRIAR DRIVE STAFFORD, TX 77477	N/A	PC	INTEGRATED WASH PROGRAM IN CHIPATA DISTRICT, ZAMBIA	1,251,684.
LUCAS COUNTY HEALTH CENTER 1200 NORTH 7TH STREET CHARITON, IA 50049	N/A	PC	AVERA ECARE EMERGENCY VIRTUAL HEALTH AT LUCAS COUNTY HEALTH CENTER	118,418.
MACCABI HEALTHCARE SERVICES 27 HAMERED ST TEL AVIV, ISRAEL	N/A	PC	MOBILE MAMMOGRAPHY UNIT	877,000.
MACCABI HEALTHCARE SERVICES 27 HAMERED ST TEL AVIV, ISRAEL	N/A	PC	DA VINCI 4XI SYSTEM DUAL CONSOLE SURGICAL ROBOT AND STERILIZATION EQUIP.	3,505,000.
MADISON COUNTY MEMORIAL HOSPITAL 300 W. HUTCHINGS STREET WINTERSSET, IA 50273	N/A	GOV	IMPLEMENTATION OF EEMERGENCY AT MADISON COUNTY HEALTH CARE SYSTEM	111,961.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
MAINEHEALTH 22 BRAMHALL STREET PORTLAND, ME 04102	N/A	PC	TRANSFORMING RURAL DIABETES CARE IN MAINE	729,688.
MARY C. WHEELER SCHOOL, INC. 216 HOPE STREET PROVIDENCE, RI 02906	N/A	PC	GENERAL OPERATING SUPPORT	10,000.
MASSACHUSETTS GENERAL HOSPITAL 55 FRUIT STREET BOSTON, MA 02114-2696	N/A	PC	TETHERED CAPSULE ENDOMICROSCOPY VISUALIZATION OF THE CROHNS BOWEL WALL	100,000.
MASSACHUSETTS GENERAL HOSPITAL 55 FRUIT STREET BOSTON, MA 02114-2696	N/A	PC	CROHNS DISEASE IN SOUTH ASIANS: DEFINING DISEASE BIOLOGY FOR PREVENTION	350,279.
MAT-SU TRAILS & PARKS FOUNDATION PO BOX 652 PALMER, AK 99645	N/A	PC	INDEPENDENCE MINE REHABILITATION	1,339,417.
MAYO CLINIC 200 FIRST STREET SW ROCHESTER, MN 55905	N/A	PC	DEVELOP AN INTESTINAL MUCOSAL AND IMAGING BIOMARKER FOR STRICTURING CD	495,833.
MAYO CLINIC 200 FIRST STREET SW ROCHESTER, MN 55905	N/A	PC	2019-2021 MILITARY SCIENCES MEDICAL TRAINING/SUPPORT PROJECT (ARIZONA)	124,891.

Total from continuation sheets

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
MEDICAL COLLEGE OF CORNELL UNIVERSITY 1300 YORK AVENUE NEW YORK, NY 10065-4805	N/A	PC	TARGETING THE MYCOBIOME IN CROHNS DISEASE	283,903.
MEEKER MEMORIAL HOSPITAL 612 S SIBLEY AVE LITCHFIELD, MN 55355	N/A	GOV	EEMERGENCY AT MEEKER MEMORIAL HOSPITAL	18,524.
MEEKER MEMORIAL HOSPITAL 612 S SIBLEY AVE LITCHFIELD, MN 55355	N/A	GOV	EPHARMACY AT MEEKER MEMORIAL HOSPITAL	30,671.
MERCY HEALTH SERVICES IOWA CORP 308 NORTH MAPLE AVENUE NEW HAMPTON, IA 50659	N/A	PC	EEMERGENCY AT MERCYONE NEW HAMPTON MEDICAL CENTER	15,178.
MI STATE UNIVERSITY HANNAH ADMINISTRATION BUILDING EAST LANSING, MI 48824-2601	N/A	PC	A C-PEPTIDE COMPLEX FOR IMPROVED GLUCOSE METABOLISM IN PEOPLE WITH T1D	430,158.
MIDDLE EAST MEDIA AND RESEARCH INSTITUTE INC. PO BOX 27837 WASHINGTON, DC 20038	N/A	PC	IRAN STUDIES PROJECT	100,000.
MONROE COUNTY HOSPITAL 6580 165TH STREET ALBIA, IA 52531	N/A	GOV	EPHARMACY AT MONROE COUNTY HOSPITAL & CLINICS	156,759.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
MONTANA DEPARTMENT OF HEALTH AND HUMAN SERVICES PO BOX 202951 HELENA, MT 59620	N/A	GOV	MONTANA FIRST RESPONDER AED PROJECT	191,663.
MONTANA DEPARTMENT PUBLIC HEALTH AND HUMAN SERVICES PO BOX 202951 HELENA, MT 59620	N/A	GOV	MONTANA FIRST RESPONDER AED PROJECT	219,190.
MONUMENT HEALTH NETWORK, INC. 2140 JUNCTION AVE. STURGIS, SD 57785	N/A	PC	EEMERGENCY AT MONUMENT HEALTH STURGIS HOSPITAL	129,650.
NATIONAL COMMITTEE FOR QUALITY ASSURANCE 1100 13TH ST NW WASHINGTON, DC 20005	N/A	PC	TRANSFORM HEALTHCARE THROUGH MEASUREMENT, TRANSPARENCY, & ACCOUNTABILITY	1,336,294.
NATIONAL PARK FOUNDATION 1500 K ST. NW WASHINGTON, DC 20005	N/A	PC	BERING LAND BRIDGE VISITOR CENTER	848,202.
NATURAL AREAS CONSERVANCY, INC. 1234 FIFTH AVENUE NEW YORK, NY 10029	N/A	PC	FORMALIZING A NEW YORK CITY TRAIL SYSTEM	500,000.
NATURE CONSERVANCY 4245 NORTH FAIRFAX DRIVE, SUITE 100 ARLINGTON, VA 22203	N/A	PC	FUTURE FOREST NEW YORK CITY PHASE II	500,000.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
NCD ALLIANCE 31-33 AVENUE GIUSEPPE MOTTA GENEVA, SWITZERLAND	N/A	PC	PUTTING PEOPLE WITH NCDS FIRST: DRIVING ADVOCACY, CHANGE, IMPROVING CARE	1,015,450.
NCD ALLIANCE 31-33 AVENUE GIUSEPPE MOTTA GENEVA, SWITZERLAND	N/A	PC	GENERAL OPERATING SUPPORT	42,500.
NCD ALLIANCE 31-33 AVENUE GIUSEPPE MOTTA GENEVA, SWITZERLAND	N/A	PC	PUTTING PEOPLE WITH NCDS FIRST: DRIVING ADVOCACY, CHANGE, IMPROVING CARE	1,055,700.
NEBRASKA DEPARTMENT OF HEALTH & HUMAN SERVICES 301 CENTENNIAL MALL SOUTH LINCOLN, NE 68508	N/A	GOV	NEBRASKA FIRST RESPONDER AED PROJECT	5,608,814.
NEVADA COMMUNITY FOUNDATION, INC. 1980 FESTIVAL PLAZA DRIVE LAS VEGAS, NV 89135	N/A	PC	DESERT VIEW AND MESA VIEW HOSPITAL EQUIPMENT REVITALIZATION PROJECT	2,216,426.
NEW DESTINY HOUSING CORPORATION 12 W. 37TH STREET, 7TH FLOOR NEW YORK, NY 10018	N/A	PC	AFTERCARE INTERVENTION TO IMPROVE HOUSING & HEALTH STABILITY	376,970.
NEW VENTURE FUND 1201 CT AVE NW, SUITE 300 WASHINGTON, DC 20036	N/A	PC	TYPE 1 DIABETES CAMPS PROJECT (2022 - 2024)	3,302,000.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
NEW VENTURE FUND 1201 CT AVE NW, SUITE 300 WASHINGTON, DC 20036	N/A	PC	GENERAL OPERATING SUPPORT FOR THE OPEN RESEARCH FUNDERS GROUP	45,000.
NEW VENTURE FUND 1201 CT AVE NW, SUITE 300 WASHINGTON, DC 20036	N/A	PC	TYPE 1 DIABETES CAMPS PROJECT (2022 - 2024)	102,000.
NEW YORK CITY BALLET, INC. DAVID H. KOCH THEATER NEW YORK, NY 10023	N/A	PC	GENERAL OPERATING SUPPORT FOR NEW COMBINATIONS FUND	15,000.
NEW YORK CITY HEALTH AND HOSPITALS CORPORATION 125 WORTH STREET NEW YORK, NY 10013	N/A	PC	EXPRESSCARE TELE-BEHAVIORAL SERV. & STRATEGIES (NYC HIGH NEEDS PATIENTS)	1,657,500.
NEW YORK CITY HEALTH AND HOSPITALS CORPORATION 125 WORTH STREET NEW YORK, NY 10013	N/A	PC	EXPRESSCARE PLATFORM UPDATE AND SERVICE DELIVERY TO HOMELESS PATIENTS	250,000.
NEW YORK UNIVERSITY 665 BROADWAY NEW YORK, NY 10012	N/A	PC	ANALYSIS OF MEDICAID DATA TO IMPROVE CARE FOR HOMELESS PATIENTS	98,834.
NEW YORK UNIVERSITY 665 BROADWAY NEW YORK, NY 10012	N/A	PC	EVALUATION OF INTERVENTIONS FOR COLLABORATIVE FOR HOMELESS HEALTHCARE	194,404.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
NEW YORK UNIVERSITY 665 BROADWAY NEW YORK, NY 10012	N/A	PC	IDENTIFYING ENVIRONMENTAL CONTRIBUTORS TO CROHNS DISEASE	695,626.
NEW YORK-PRESBYTERIAN FUND INC 850 THIRD AVENUE NEW YORK, NY 10022	N/A	PC	IMPROVING CARE FOR UNDERSERVED CHILDREN WITH T1D	200,000.
NEWCASTLE UNIVERSITY NEWCASTLE UPON TYNE NEWCASTLE, UNITED KINGDOM	N/A	PC	GPPAD UK EXPANSION: NEWCASTLE	15,776.
NORTH DAKOTA DEPARTMENT OF HEALTH 600 E BOULEVARD AVENUE BISMARCK, ND 58505-0200	N/A	GOV	NORTH DAKOTA LAW ENFORCEMENT AED PROJECT	153,789.
NORTHERN WESTCHESTER HOSPITAL ASSOCIATION 400 EAST MAIN STREET MOUNT KISCO, NY 10549	N/A	PC	MATERNAL CHILD HEALTH UNIT FACILITIES RENOVATION	200,000.
NURU INTERNATIONAL 2020 PENNSYLVANIA AVE NW WASHINGTON, DC 20006	N/A	PC	NURU ETHIOPIA: SUSTAINING IMPACT THROUGH 2021 AND BEYOND	550,893.
OREGON HEALTH & SCIENCE UNIVERSITY 3181 SW SAM JACKSON PARK RD. PORTLAND, OR 97239-3098	N/A	GOV	DESIGN AND EVALUATION OF A MDI DECISION SUPPORT SYSTEM	515,974.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
OREGON HEALTH & SCIENCE UNIVERSITY 3181 SW SAM JACKSON PARK RD. PORTLAND, OR 97239-3098	N/A	GOV	TO EXPAND THE NICH PROGRAM IN THE CALIFORNIA BAY AREA	1,316,877.
PALO ALTO VETERANS INSTITUTE FOR RESEARCH 3801 MIRANDA AVENUE PALO ALTO, CA 94304-0038	N/A	PC	CELL ATLAS OF INTESTINAL LYMPHOID TISSUES AND CHANGES IN CROHNS DISEASE	499,175.
PALO ALTO VETERANS INSTITUTE FOR RESEARCH 3801 MIRANDA AVENUE PALO ALTO, CA 94304-0038	N/A	PC	CELL ATLAS OF INTESTINAL LYMPHOID TISSUES AND CHANGES IN CROHNS DISEASE	500,825.
PANORAMA GLOBAL 2101 FOURTH AVENUE, SUITE 2100 SEATTLE, WA 98121	N/A	PC	TYPE 1 DIABETES GLOBAL ACCESS MICRO-GRANT FUND	833,440.
PARKER INSTITUTE FOR CANCER IMMUNOTHERAPY 1 LETTERMAN DRIVE SAN FRANCISCO, CA 94129	N/A	PC	STUDYING AUTOIMMUNE DIABETES FOLLOWING CERTAIN CANCER IMMUNOTHERAPIES.	750,000.
PATH 2201 WESTLAKE AVENUE SEATTLE, WA 98121	N/A	PC	GENERAL OPERATING SUPPORT	17,750.
PATH 2201 WESTLAKE AVENUE SEATTLE, WA 98121	N/A	PC	THE DIABETES CAREPAK PROJECT: ENABLING HIGH-QUALITY DIABETES SELF-CARE	1,404,393.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
PAWNEE COUNTY MEMORIAL HOSPITAL 600 I STREET PAWNEE CITY, NE 68420	N/A	GOV	EEMERGENCY AT PAWNEE COUNTY MEMORIAL HOSPITAL	11,936.
PAWNEE COUNTY MEMORIAL HOSPITAL 600 I STREET PAWNEE CITY, NE 68420	N/A	GOV	ECARE PHARMACY AT PAWNEE COUNTY MEMORIAL HOSPITAL	150,545.
PERSHING COUNTY HOSPITAL DISTRICT 855 SIXTH STREET LOVELOCK, NV 89419	N/A	GOV	PERSHING GENERAL HOSPITAL EQUIPMENT REVITALIZATION PROJECT.	401,978.
PHILANTHROPY NEW YORK, INC. 320 EAST 43RD STREET NEW YORK, NY 10017	N/A	PC	GENERAL OPERATING SUPPORT	39,250.
PHILIP HEALTH SERVICES, INC. 503 W. PINE STREET PHILIP, SD 57567	N/A	PC	IMPLEMENTATION OF AVERA EEMERGENCY AT PHILIP HEALTH SERVICES	29,491.
PLATTE VALLEY HEALTHCARE PROJECT 203 S. 1ST ST. SARATOGA, WY 82331	N/A	PC	CT SCANNER AT NORTH PLATTE VALLEY MEDICAL CENTER	500,000.
PRESIDENT AND FELLOWS OF HARVARD COLLEGE 25 SHATTUCK STREET BOSTON, MA 02115	N/A	PC	CREATING MICRONEEDLE-BASED SENSOR TO ENHANCE AUTOMATED INSULIN DELIVERY	924,309.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
PROJECT HOSPITALITY, INC. 100 PARK AVENUE STATEN ISLAND, NY 10302	N/A	PC	GENERAL OPERATING SUPPORT	25,000.
PROJECT NYAME NSA, LTD. 33 WILLETS LANE MANHASSET, NY 11030	N/A	PC	PROJECT NYAME NSA ZAMBIA EXPANSION	277,650.
PROJECT RENEWAL, INC. 200 VARICK STREET, SUITE 900 NEW YORK, NY 10014	N/A	PC	NEW YORK CITY COLLABORATIVE FOR HOMELESS HEALTHCARE	200,000.
PROVIDENCE MEDICAL CENTER 1200 PROVIDENCE ROAD WAYNE, NE 68787	N/A	PC	EEMERGENCY AT PROVIDENCE MEDICAL CENTER	16,407.
PROVIDENCE MEDICAL CENTER 1200 PROVIDENCE ROAD WAYNE, NE 68787	N/A	PC	EPHARMACY AT PROVIDENCE MEDICAL CENTER	21,140.
PUBLIC HEALTH SOLUTIONS 40 WORTH STREET, 5TH FLOOR NEW YORK, NY 10013	N/A	PC	NEW YORK CITY COLLABORATIVE FOR HOMELESS HEALTHCARE	500,000.
PUBLIC HEALTH SOLUTIONS 40 WORTH STREET, 5TH FLOOR NEW YORK, NY 10013	N/A	PC	NEW YORK CITY FUND FOR YOUTH AND FAMILY HOMELESSNESS	550,000.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
PULITZER CENTER ON CRISIS REPORTING 1779 MASSACHUSETTS AVE NW WASHINGTON, DC 20036	N/A	PC	BUILDING RESILIENCE THROUGH JOURNALISM AND EDUCATION	223,410.
RAMBAM HEALTH CORPORATION HA'ALIA HASNIA 8 HAIFA, ISRAEL	N/A	PC	POINT OF CARE ASSAY FOR SERUM NEUTRALIZING ANTI-IFX ANTIBODIES	142,800.
RAMBAM HEALTH CORPORATION HA'ALIA HASNIA 8 HAIFA, ISRAEL	N/A	PC	POINT OF CARE ASSAY FOR SERUM NEUTRALIZING ANTI-IFX ANTIBODIES	120,355.
RAMBAM HEALTH CORPORATION HA'ALIA HASNIA 8 HAIFA, ISRAEL	N/A	PC	PREDICTING AND OPTIMIZING DRUG THERAPY IN CROHNS DISEASE	350,000.
REGENTS OF THE UNIVERSITY OF MI 3003 SOUTH STATE STREET ANN ARBOR, MI 48109	N/A	PC	HEALTH ECONOMIC ANALYSIS OF AUTOMATED INSULIN DELIVERY SYSTEMS	412,982.
REGENTS OF THE UNIVERSITY OF MI 3003 SOUTH STATE STREET ANN ARBOR, MI 48109	N/A	PC	UNDERSTANDING PERSISTENT SYMPTOMS IN QUIESCENT CROHNS DISEASE	270,158.
REGENTS OF THE UNIVERSITY OF MI 3003 SOUTH STATE STREET ANN ARBOR, MI 48109	N/A	PC	USE NLP FOR EXTRACTION OF CD RELEVANT DATA FROM CLINICAL RECORDS.	381,754.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
REGENTS OF THE UNIVERSITY OF MI 3003 SOUTH STATE STREET ANN ARBOR, MI 48109	N/A	PC	UNDERSTANDING PERSISTENT SYMPTOMS IN QUIESCENT CROHNS DISEASE	30,894.
REGENTS OF THE UNIVERSITY OF MINNESOTA 401 EAST RIVER ROAD MINNEAPOLIS, MN 55455	N/A	GOV	MINNESOTA FIRST RESPONDER AED PROJECT	12,644,876.
REGENTS OF THE UNIVERSITY OF MINNESOTA 401 EAST RIVER ROAD MINNEAPOLIS, MN 55455	N/A	GOV	PHASE 2: ENGINEERING ANTIGEN-SPECIFIC REGULATORY T CELLS FOR T1D	350,000.
REGENTS OF THE UNIVERSITY OF MINNESOTA 401 EAST RIVER ROAD MINNEAPOLIS, MN 55455	N/A	GOV	REDEFINING THE FUTURE OF EMERGENCY MEDICINE	1,752,819.
REGENTS OF THE UNIVERSITY OF MINNESOTA 401 EAST RIVER ROAD MINNEAPOLIS, MN 55455	N/A	GOV	PRECLINICAL DEVELOPMENT OF A MONOCLONAL ANTIBODY TO SERPINB13	875,045.
REGION HOVEDSTADEN KONGENS VAENGE 2 HILLERD, DENMARK	N/A	GOV	IDENTIFICATION/SCREENING OF NOVEL GLUCAGONOTROPIC ALPHA-CELL RECEPTORS	200,000.
ROCKEFELLER PHILANTHROPY ADVISORS INC. 6 WEST 48TH STREET, 10TH FLOOR NEW YORK, NY 10036	N/A	PC	FUNDING TO SUPPORT COVID COLLABORATIVE - BEREAVED CHILDREN PROJECT	175,000.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
ROCKEFELLER PHILANTHROPY ADVISORS INC. 6 WEST 48TH STREET, 10TH FLOOR NEW YORK, NY 10036	N/A	PC	COVID COLLABORATIVE - INCREASING VACCINE UPTAKE IN RURAL AMERICA	250,000.
ROSEBUD COMMUNITY HOSPITAL, INC. 383 NORTH 17TH AVENUE FORSYTH, MT 59327	N/A	PC	EPHARMACY AND ADM AT ROSEBUD HEALTH CARE CENTER IN FORSYTH, MONTANA	11,262.
ROUNABOUT THEATRE COMPANY, INC. 231 W 39TH STREET, 1200 NEW YORK, NY 10018	N/A	PC	GENERAL OPERATING SUPPORT	10,000.
SAFE WATER NETWORK 122 EAST 42ND STREET NEW YORK, NY 10168	N/A	PC	SCALING AFFORDABLE SAFELY MANAGED WATER SUPPLY	2,367,100.
SAGE BIONETWORKS 2901 THIRD AVE SEATTLE, WA 98121-3014	N/A	PC	EXTENSION OF VEOIBD DATA COORDINATION	71,204.
SAINT LOUIS UNIVERSITY 221 NORTH GRAND BOULEVARD SAINT LOUIS, MO 63103-2006	N/A	PC	NOVEL TARGET TO FIGHT ALPHA CELL DYSFUNCTION & STOP HYPOGLYCEMIA IN T1D	260,774.
SALVATION ARMY WORLD SERVICE OFFICE 615 SLATERS LANE ALEXANDRIA, VA 22314	N/A	SOI	WATER SYSTEM IMPROVEMENTS AT CHIKANKATA MISSION	1,200,000.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
SANFORD RESEARCH 2301 E 60TH STREET N SIOUX FALL, SD 57104-0569	N/A	PC	SANFORD PLEDGE: PHASES 1 AND 2	603,695.
SCHWARTZ/REISMAN SCIENCE EDUCATION CENTER, REHOVOT HERZL ST. 234 REHOVOT, ISRAEL	N/A	PC	THE HELMSLEY CAMPUS FOR SCIENCE EDUCATION IN NETIVOT	2,540,089.
SHAARE ZEDEK MEDICAL CENTER 12 SHMUEL BAIT STREET JERUSALEM, ISRAEL	N/A	PC	POPULATION-BASED ANALYSES OF IBD USING ADMINISTRATIVE DATABASE	143,000.
SHAARE ZEDEK MEDICAL CENTER 12 SHMUEL BAIT STREET JERUSALEM, ISRAEL	N/A	PC	"TASTY & HEALTHY" DIET: A RANDOMIZED CONTROLLED TRIAL FOR INDUCING AND MAINTAINING REMISSION IN CROHN'S DISEASE.	666,492.
SHAARE ZEDEK MEDICAL CENTER 12 SHMUEL BAIT STREET JERUSALEM, ISRAEL	N/A	PC	PREVENTION OF INFLAMMATORY BOWEL DISEASES IN PERSONS AT RISK	379,439.
SHAARE ZEDEK MEDICAL CENTER 12 SHMUEL BAIT STREET JERUSALEM, ISRAEL	N/A	PC	POPULATION-BASED ANALYSES OF IBD USING ADMINISTRATIVE DATABASE	137,000.
SHAARE ZEDEK MEDICAL CENTER 12 SHMUEL BAIT STREET JERUSALEM, ISRAEL	N/A	PC	"TASTY & HEALTHY" DIET: A RANDOMIZED CONTROLLED TRIAL FOR INDUCING AND MAINTAINING REMISSION IN CROHN'S DISEASE.	415,669.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
SHAARE ZEDEK MEDICAL CENTER 12 SHMUEL BAIT STREET JERUSALEM, ISRAEL	N/A	PC	PREVENTION OF INFLAMMATORY BOWEL DISEASES IN PERSONS AT RISK	413,468.
SHAARE ZEDEK MEDICAL CENTER 12 SHMUEL BAIT STREET JERUSALEM, ISRAEL	N/A	PC	THE HELMSLEY CANCER CENTER AT SHAARE ZEDEK MEDICAL CENTER JERUSALEM	9,908,264.
SHAARE ZEDEK MEDICAL CENTER 12 SHMUEL BAIT STREET JERUSALEM, ISRAEL	N/A	PC	EQUIPMENT PURCHASES FOR THE NEW RADIOTHERAPY CENTER	791,105.
SHATTERPROOF A NONPROFIT CORP 101 MERRITT 7 CORPORATE PARK NORWALK, CT 06851	N/A	PC	GENERAL OPERATING SUPPORT	200,000.
SHATTERPROOF A NONPROFIT CORP 101 MERRITT 7 CORPORATE PARK NORWALK, CT 06851	N/A	PC	GENERAL OPERATING SUPPORT	200,000.
SHENANDOAH MEDICAL CENTER 300 PERSHING AVE SHENANDOAH, IA 51601	N/A	PC	SHENANDOAH MEDICAL CENTER / AVERA EEMERGENCY IMPLEMENTATION PROJECT	38,299.
SIMULATION IN MOTION MONTANA, INC. C/O MONTANA MEDICAL ASSOCIATION HELENA, MT 59601	N/A	PC	CAPACITY BUILDING FOR A SUSTAINABLE SIMULATION IN MOTION MONTANA PROGRAM	500,000.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
SIMULATION IN MOTION MONTANA, INC. C/O MONTANA MEDICAL ASSOCIATION HELENA, MT 59601	N/A	PC	CAPACITY BUILDING TOWARD A SUSTAINABLE SIMULATION IN MOTION MONTANA	96,066.
SIOUX COUNCIL, BOY SCOUTS OF AMERICA 800 N WEST AVENUE SIOUX FALLS, SD 57104	N/A	PC	WETLAND\NATURE STUDY AREA DEVELOPMENT: LEWIS AND CLARK SCOUT CAMP	75,000.
SIOUX VALLEY MEMORIAL HOSPITAL ASSOCIATION 300 SIOUX VALLEY DRIVE CHEROKEE, IA 51012	N/A	PC	ECARE EMERGENCY AT CHEROKEE REGIONAL MEDICAL CENTER	34,691.
SNV NETHERLANDS DEVELOPMENT ORGANISATION PARKSTRAAT 83 DEN HAAG, NETHERLANDS	N/A	PC	HEALTHY FUTURE FOR ALL IMPROVING WATER, SANITATION, HYGIENE & NUTRITION	1,191,913.
SOCIETY FOR THE PRESERVATION OF NEW ENGLAND ANTIQUITIES 141 CAMBRIDGE STREET BOSTON, MA 02114	N/A	PC	GENERAL OPERATING SUPPORT	35,000.
SOS CHILDREN'S VILLAGES-USA, INC. 1620 I STREET, NW, SUITE 220 WASHINGTON, DC 20006	N/A	PC	EDUCARE 4.0: DEBRE TABOR AND GONDAR CITY, ETHIOPIA	2,401,776.
SOUTH DAKOTA HALL OF FAME 1480 S MAIN ST CHAMBERLAIN, SD 57325	N/A	PC	GENERAL OPERATING SUPPORT	20,000.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
SOUTH DAKOTA PARKS & WILDLIFE FOUNDATION 523 E. CAPITOL PIERRE, SD 57501	N/A	SOIII FI	CUSTER STATE PARK BISON CENTER	3,000,000.
SOUTH LYON HEALTH CENTER, INC. 213 S WHITACRE ST YERINGTON, NV 89447-2561	N/A	PC	SOUTH LYON MEDICAL CENTER EQUIPMENT REVITALIZATION PROJECT	518,553.
SOUTHCENTRAL FOUNDATION 4501 DIPLOMACY DR ANCHORAGE, AK 99508	N/A	PC	FWWI NU'IJU TRANSFORMATIONAL LIVING COMMUNITY PROGRAM	1,425,805.
ST LUKE HEALTH CARE FOUNDATION 28W609 HICKORY LN WEST CHICAGO, IL 60185	N/A	PC	TEACHING HOSPITAL INFRASTRUCTURE IMPROVEMENTS	210,306.
ST. ROSE DOMINICAN HEALTH FOUNDATION 102 E. LAKE MEAD PARKWAY HENDERSON, NV 89015	N/A	SOIII FI	MEDICAL SIMULATION EQUIPMENT	462,090.
STANFORD UNIVERSITY 443 VIA ORTEGA STANFORD, CA 94305	N/A	PC	EFFECTS OF AN INTERMITTENT REDUCED CALORIE DIET ON CROHNS DISEASE	331,803.
STANFORD UNIVERSITY 443 VIA ORTEGA STANFORD, CA 94305	N/A	PC	DEVELOPMENT OF A CONTINUOUS MULTIANALYTE SENSOR FOR T1D	1,366,476.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
STANFORD UNIVERSITY 443 VIA ORTEGA STANFORD, CA 94305	N/A	PC	INVESTIGATING THE ROLE OF THE HUMAN EXPOSOME IN CROHNS DISEASE	758,929.
STANFORD UNIVERSITY 443 VIA ORTEGA STANFORD, CA 94305	N/A	PC	MICROBIOME-BASED THERAPEUTICS FOR CROHNS DISEASE	990,845.
STANFORD UNIVERSITY 443 VIA ORTEGA STANFORD, CA 94305	N/A	PC	EXPANSION & EVALUATION OF ECHO FOR PEOPLE WITH DIABETES ON IIT	1,296,812.
STANFORD UNIVERSITY 443 VIA ORTEGA STANFORD, CA 94305	N/A	PC	LONGITUDINAL STUDY OF MYOELECTRIC GUTPRINT OF CROHNS PATIENTS	243,550.
STANFORD UNIVERSITY 443 VIA ORTEGA STANFORD, CA 94305	N/A	PC	EFFECTS OF AN INTERMITTENT REDUCED CALORIE DIET ON CROHNS DISEASE	334,722.
STANFORD UNIVERSITY 443 VIA ORTEGA STANFORD, CA 94305	N/A	PC	EXERCISE EDUCATION AT NEW ONSET OF T1D	249,169.
STANFORD UNIVERSITY 443 VIA ORTEGA STANFORD, CA 94305	N/A	PC	EXERCISE EDUCATION AT NEW ONSET OF T1D	183,151.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
STATE OF SOUTH DAKOTA 600 E CAPITOL AVENUE PIERRE, SD 57501	N/A	GOV	SOUTH DAKOTA FIRST RESPONDER AUTOMATED EXTERNAL DEFIBRILLATOR PROJECT	178,000.
STICHTING ACCESS TO MEDICINE FOUNDATION NARITAWEG 227 AMSTERDAM, NETHERLANDS	N/A	PC	EXPANDING ACCESS TO T1D CARE	625,000.
STICHTING HEALTH ACTION INTERNATIONAL OVERTOOM 60/II AMSTERDAM, NETHERLANDS	N/A	PC	ADDRESSING THE CHALLENGE AND CONSTRAINTS OF INSULIN SOURCES AND SUPPLY	1,246,224.
STICHTING PHARMACCESS INTERNATIONAL AHTC, TOWER C4, PAASHEUVELWEG 25 AMSTERDAM, NETHERLANDS	N/A	PC	INVESTING IN QUALITY HEALTHCARE THROUGH SAFECARE	254,457.
SYNERGOS INSTITUTE, INC. 3 EAST 54TH STREET NEW YORK, NY 10022	N/A	PC	IMPROVING LIVES AND LIVELIHOODS OF SMALLHOLDER FARMERS	998,553.
SYNERGOS INSTITUTE, INC. 3 EAST 54TH STREET NEW YORK, NY 10022	N/A	PC	IMPROVING LIVES AND LIVELIHOODS OF SMALLHOLDER FARMERS	1,485,316.
T1D EXCHANGE, INC 11 AVENUE DE LAFAYETTE BOSTON, MA 02111	N/A	PC	DATA APPROACH TO IMPROVE QUALITY AND OUTCOMES FOR INDIVIDUALS WITH T1D	513,697.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
T1D EXCHANGE, INC 11 AVENUE DE LAFAYETTE BOSTON, MA 02111	N/A	PC	DATA APPROACH TO IMPROVE QUALITY AND OUTCOMES FOR INDIVIDUALS WITH T1D	354,000.
T1D EXCHANGE, INC 11 AVENUE DE LAFAYETTE BOSTON, MA 02111	N/A	PC	DATA APPROACH TO IMPROVE QUALITY AND OUTCOMES FOR INDIVIDUALS WITH T1D	354,000.
T1D EXCHANGE, INC 11 AVENUE DE LAFAYETTE BOSTON, MA 02111	N/A	PC	DATA APPROACH TO IMPROVE QUALITY AND OUTCOMES FOR INDIVIDUALS WITH T1D	3,686,424.
T1D EXCHANGE, INC 11 AVENUE DE LAFAYETTE BOSTON, MA 02111	N/A	PC	DATA APPROACH TO IMPROVE QUALITY AND OUTCOMES FOR INDIVIDUALS WITH T1D	513,696.
T1D EXCHANGE, INC 11 AVENUE DE LAFAYETTE BOSTON, MA 02111	N/A	PC	DATA APPROACH TO IMPROVE QUALITY AND OUTCOMES FOR INDIVIDUALS WITH T1D	354,000.
TAMPERE UNIVERSITY FOUNDATION SR KALEVANTIE 4, 33100 TAMPERE, FINLAND	N/A	PC	VIRUSES AND ANTIVIRAL IMMUNE MARKERS IN TWO ENDOTYPES OF TYPE 1 DIABETES	305,030.
TAMPERE UNIVERSITY FOUNDATION SR KALEVANTIE 4, 33100 TAMPERE, FINLAND	N/A	PC	DEVELOPMENT OF MULTIPLEX MICROBIAL ANTIBODY SCREENING ARRAY FOR STUDIES	481,830.

Total from continuation sheets

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
TECHNISCHE UNIVERSITT DRESDEN HELMHOLTZSTR. 10 DRESDEN, GERMANY	N/A	GOV	GENOMIC INFLUENCE OF MATERNAL T1D - UNDERSTANDING PROTECTION AGAINST T1D	271,691.
TECHNISCHE UNIVERSITT DRESDEN HELMHOLTZSTR. 10 DRESDEN, GERMANY	N/A	GOV	SUPPORT SCREENING FOR ISLET AUTOANTIBODIES IN CHILDREN.	212,157.
THE ACADEMIC COLLEGE AT TEL-HAI TEL-HAI COLLEGE UPPER GALILEE, ISRAEL	N/A	PC	HELMSLEY SCIENCE BUILDING FOR HEALTH, ENVIRONMENT, AND BIOTECH STUDIES	634,900.
THE ASPEN INSTITUTE INC. 2300 N STREET WASHINGTON, DC 20037	N/A	PC	THE ASPEN INSTITUTE IS AN EDUCATIONAL AND POLICY STUDIES ORGANIZATION	995,988.
THE BARUCH PADEH MEDICAL CENTER, PORIYA THE BARUCH PADEH MEDICAL CENTER, PORIYA TIBERIAS, ISRAEL	N/A	GOV	THE HELMSLEY REHABILITATION CENTER OF THE NORTH	5,115,157.
THE BARUCH PADEH MEDICAL CENTER, PORIYA THE BARUCH PADEH MEDICAL CENTER, PORIYA TIBERIAS, ISRAEL	N/A	GOV	CONSTRUCTION OF THE 12-BED INTENSIVE CARE AND RESPIRATION UNIT	2,321,666.
THE BROAD INSTITUTE, INC. 415 MAIN STREET CAMBRIDGE, MA 02142	N/A	PC	HUMAN COLON AND SMALL INTESTINE CELL ATLAS IN HEALTH AND CROHNS DISEASE	476,319.

Total from continuation sheets

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
THE BROAD INSTITUTE, INC. 415 MAIN STREET CAMBRIDGE, MA 02142	N/A	PC	HUMAN COLON AND SMALL INTESTINE CELL ATLAS IN HEALTH AND CROHNS DISEASE	719,309.
THE BROAD INSTITUTE, INC. 415 MAIN STREET CAMBRIDGE, MA 02142	N/A	PC	NOVEL THERAPEUTIC APPROACHES FOR CROHNS DISEASE	3,000,000.
THE CENTER FOR EFFECTIVE PHILANTHROPY, INC. 675 MASSACHUSETTS AVENUE CAMBRIDGE, MA 02139	N/A	PC	GENERAL OPERATING SUPPORT	41,500.
THE CHINESE UNIVERSITY OF HONG KONG PI CH'IU BUILDING SHATIN, HONG KONG	N/A	PC	MATERNAL TRANSFER OF SPECIALIZED CELLS FOR TREATMENT OF BOWEL DISEASE	506,838.
THE CHINESE UNIVERSITY OF HONG KONG PI CH'IU BUILDING SHATIN, HONG KONG	N/A	PC	IBD GIVES-21: GLOBAL IBD VISUALIZATION OF EPIDEMIOLOGY STUDIES, 21ST CEN	423,667.
THE CHINESE UNIVERSITY OF HONG KONG PI CH'IU BUILDING SHATIN, HONG KONG	N/A	PC	MATERNAL TRANSFER OF SPECIALIZED CELLS FOR TREATMENT OF BOWEL DISEASE	481,225.
THE CHINESE UNIVERSITY OF HONG KONG PI CH'IU BUILDING SHATIN, HONG KONG	N/A	PC	IBD GIVES-21: GLOBAL IBD VISUALIZATION OF EPIDEMIOLOGY STUDIES, 21ST CEN	239,672.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
THE CITY OF HOPE 1500 E. DUARTE RD. DUARTE, CA 91010	N/A	PC	UNDERSTANDING GENETIC PROTECTION FROM T1D.	275,000.
THE CLEVELAND CLINIC FOUNDATION 9500 EUCLID AVENUE CLEVELAND, OH 44195	N/A	PC	DEVELOP AN INTESTINAL MUCOSAL AND IMAGING BIOMARKER FOR STRICTURING CD	808,555.
THE CLEVELAND CLINIC FOUNDATION 9500 EUCLID AVENUE CLEVELAND, OH 44195	N/A	PC	DEVELOP IUS AND HISTOPATHOLOGY INDICES FOR MONITORING STRICTURING CD	403,400.
THE CLEVELAND CLINIC FOUNDATION 9500 EUCLID AVENUE CLEVELAND, OH 44195	N/A	PC	CROHNS FISTULIZING PROGRAM INVESTIGATOR INITIATED CLINICAL TRIALS	573,271.
THE DIATRIBE FOUNDATION 804 HAIGHT ST SAN FRANCISCO, CA 94117	N/A	PC	DIATRIBE LEARN	200,000.
THE END FUND, INC. 2 PARK AVENUE, 18TH FLOOR NEW YORK, NY 10016	N/A	PC	ELIMINATION OF PARASITIC WORMS IN ETHIOPIA	1,300,001.
THE GOVERNORS OF THE UNIVERSITY OF CALGARY 2500 UNIVERSITY DRIVE NW CALGARY, CANADA	N/A	PC	VISUALIZATION OF COVID-19 VACCINE SEROLOGY IN CD	84,762.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
THE GOVERNORS OF THE UNIVERSITY OF CALGARY 2500 UNIVERSITY DRIVE NW CALGARY, CANADA	N/A	PC	DEVELOP PROTEIN PANEL TO IDENTIFY FIBROSTENOTIC CD PATIENTS	631,739.
THE GOVERNORS OF THE UNIVERSITY OF CALGARY 2500 UNIVERSITY DRIVE NW CALGARY, CANADA	N/A	PC	THE CHANGING EPIDEMIOLOGY OF CROHNS IN THE WESTERN WORLD	188,736.
THE HARDING FORD VISION, INC. 157-22 TUSKEGEE AIRMEN WAY JAMAICA, NY 11433	N/A	PC	GENERAL OPERATING SUPPORT	25,000.
THE HEALTH & HOUSING CONSORTIUM, INC. STADIUM STATION BRONX, NY 10452	N/A	PC	STRATEGY BUILDING FOR HEALTH AND HOUSING CONSORTIUM EXPANSION	290,000.
THE HOLE IN THE WALL GANG FUND, INC. 555 LONG WHARF DRIVE NEW HAVEN, CT 06511	N/A	PC	GENERAL OPERATING SUPPORT	15,000.
THE JEWISH AGENCY FOR ISRAEL 48 KING GEORGE STREET JERUSALEM, ISRAEL	N/A	PC	JEWISH REFUGEES/ALIYAH CANDIDATES FROM UKRAINE	500,000.
THE LEGATUM INSTITUTE FOUNDATION 11 CHARLES STREET LONDON, UNITED KINGDOM	N/A	NC	PHASE TWO OF THE UNITED STATES PROSPERITY INDEX	50,000.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
THE MAX STERN ACADEMIC COLLEGE OF EMEK YEZREEL YEZREEL VALLEY YEZREEL VALLEY, ISRAEL	N/A	PC	OPP. FOR SUCCESS SCHOLARSHIPS FOR ETHIOPIAN ISRAELIS SEEKING NURSING DEG	220,000.
THE MILKEN INSTITUTE 1250 FOURTH STREET SANTA MONICA, CA 90401	N/A	PC	SUPPORTS TO CREATE A STRATEGIC ROADMAP FOR T1D TO INCLUDE SCREENING	150,000.
THE MILKEN INSTITUTE 1250 FOURTH STREET SANTA MONICA, CA 90401	N/A	PC	CURES FOR LIFE: PATIENT ACCESS TO CELL AND GENE THERAPY	174,998.
THE ONE LOVE FOUNDATION IN HONOR OF YEARDLEY LOVE, INC. 44 PONDFIELD ROAD, SUITE 12 BRONXVILLE, NY 10708	N/A	PC	BUILDING FOR THE FUTURE: SUPPORT FOR DIGITAL PROGRAMS AND OPERATIONS	2,000,000.
THE RECTOR AND VISITORS OF THE UNIVERSITY OF VIRGINIA OFFICE OF SPONSORED PROGRAMS CHARLOTTESVILLE, VA 22904-4195	N/A	PC	TYPE 1 DIABETES RISK PREDICTION: INTEGRATION OF PHYSIOLOGY WITH GENETICS	241,490.
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN DIEGO 9500 GILMAN DRIVE - MAIL CODE 0934 LA JOLLA, CA 92093	N/A	PC	PERSONALIZING CROHNS DISEASE THERAPEUTICS THROUGH PHASE 0 HUMAN TRIALS	593,024.
THE REGENTS OF THE UNIVERSITY OF COLORADO, DENVER BUILDING 500 AURORA, CO 80045	N/A	PC	ASK - REMOTE SCREENING AND MONITORING	64,636.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
THE REGENTS OF THE UNIVERSITY OF COLORADO, DENVER BUILDING 500 AURORA, CO 80045	N/A	PC	CULTURALLY SENSITIVE GROUP CLINIC MODEL FOR LATINO PATIENTS W/ DIABETES	512,661.
THE REGENTS OF THE UNIVERSITY OF COLORADO, DENVER BUILDING 500 AURORA, CO 80045	N/A	PC	SEEDS PATHWAY: EMPOWERMENT FOR DIABETES TECHNOLOGY EARLY DEVICE SUCCESS	1,113,823.
THE REGENTS OF THE UNIVERSITY OF COLORADO, DENVER BUILDING 500 AURORA, CO 80045	N/A	PC	DEVELOPMENT OF A CONTINUOUS INSULIN-GLUCOSE SENSOR	313,924.
THE REGENTS OF THE UNIVERSITY OF COLORADO, DENVER BUILDING 500 AURORA, CO 80045	N/A	PC	SINGLE PERSISTENT ISLET AUTOANTIBODY PHENOTYPE: CUSTOMIZED RISK ANALYSIS	264,224.
THE REGENTS OF THE UNIVERSITY OF COLORADO, DENVER BUILDING 500 AURORA, CO 80045	N/A	PC	EXPLORING THE GENOMIC MECHANISM BEHIND THE MATERNAL PROTECTION FROM T1D	228,012.
THE REGENTS OF THE UNIVERSITY OF COLORADO, DENVER BUILDING 500 AURORA, CO 80045	N/A	PC	COMPLEMENT SYSTEM IN INITIATION AND PROGRESSION OF ISLET AUTOIMMUNITY	224,138.
THE REGENTS OF THE UNIVERSITY OF COLORADO, DENVER BUILDING 500 AURORA, CO 80045	N/A	PC	CGM IN PRIMARY CARE - REFER OR LEARN: IMPLEMENTATION AND EVALUATION	580,677.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
THE REGENTS OF THE UNIVERSITY OF COLORADO, DENVER BUILDING 500 AURORA, CO 80045	N/A	PC	FAILED GENETIC PROTECTION: T1D IN THE PRESENCE OF DQB1*06:02	268,700.
THE REGENTS OF THE UNIVERSITY OF COLORADO, DENVER BUILDING 500 AURORA, CO 80045	N/A	PC	ASK THE EXPERTS	507,558.
THE REGENTS OF THE UNIVERSITY OF COLORADO, DENVER BUILDING 500 AURORA, CO 80045	N/A	PC	DEVELOPMENT OF A CONTINUOUS INSULIN-GLUCOSE SENSOR	119,036.
THE REGENTS OF THE UNIVERSITY OF NEW MEXICO SPONSORED PROJECTS - PREAWARD ALBUQUERQUE, NM 87131-0001	N/A	GOV	THE ECHO INSTITUTE: REPLICATION OF THE ECHO MODEL	1,413,438.
THE SDEROT DEVELOPMENT FOUNDATION 6 BAR LEV STREET SDEROT, ISRAEL	N/A	PC	ESTABLISHING A WARM HOME COMPLEX FOR CHILDREN AT RISK IN SDEROT	1,422,851.
THE SHEBA FUND FOR HEALTH SERVICES AND RESEARCH (R.A.) TEL-HASHOMER RAMAT GAN, ISRAEL	N/A	PC	COMPREHENSIVE INDIVIDUALIZED PROACTIVE THERAPY OF CROHNS DISEASE	452,624.
THE SONIA NABETA FOUNDATION, INC. P.O. BOX 2222 NEW YORK, NY 10008-2222	N/A	PC	PROJECT BODA	314,814.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
THE TEL AVIV JAFFA ACADEMIC COLLEGE RABENU YERUHAM ST. 2, P.O.B 8401 TEL AVIV YAFFO, ISRAEL	N/A	PC	SCHOLARSHIP SUPPORT FOR ULTRA-ORTHODOX MEN PURSUING NURSING DEGREES	300,000.
THE UNITED NATIONS INSTITUTE FOR TRAINING AND RESEARCH UNITED NATIONS INSTITUTE FOR TRAINING AND RESEARCH GENEVA, SWITZERLAND	N/A	PC	ACCELERATING ACCESS: TREATMENT FOR NCDS IN LOW /MIDDLE-INCOME COUNTRIES.	2,000,000.
THE UNIVERSITY OF ADELAIDE THE UNIVERSITY OF ADELAIDE ADELAIDE, AUSTRALIA	N/A	PC	ENDIA EXPANDED SUPPORT	620,581.
THE UNIVERSITY OF ADELAIDE THE UNIVERSITY OF ADELAIDE ADELAIDE, AUSTRALIA	N/A	PC	ENVIRONMENTAL DETERMINANTS OF ISLET AUTOIMMUNITY (ENDIA) STUDY	710,992.
THE UNIVERSITY OF CHICAGO 5801 SOUTH ELLIS AVENUE CHICAGO, IL 60637	N/A	PC	IMMUNO PHARMACOGENOMICS TO PREDICT RESPONSE TO BIOLOGICS IN CROHNS	305,349.
THE UNIVERSITY OF CHICAGO 5801 SOUTH ELLIS AVENUE CHICAGO, IL 60637	N/A	PC	A CELL ATLAS OF THE ILEAL COLONIC CROHNS DISEASE	487,806.
THE UNIVERSITY OF CHICAGO 5801 SOUTH ELLIS AVENUE CHICAGO, IL 60637	N/A	PC	IMMUNO PHARMACOGENOMICS TO PREDICT RESPONSE TO BIOLOGICS IN CROHNS	411,939.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
THE UNIVERSITY OF CHICAGO 5801 SOUTH ELLIS AVENUE CHICAGO, IL 60637	N/A	PC	A CELL ATLAS OF THE ILEAL COLONIC CROHNS DISEASE	487,806.
THE UNIVERSITY OF EDINBURGH BHF CENTRE FOR CARDIOVASCULAR SCIENCES EDINBURGH, UNITED KINGDOM	N/A	PC	DISCERN ALPHA CELL DYSFUNCTION AND CORRECTING GLUCAGON SECRETION IN T1D	65,459.
THE UNIVERSITY OF EDINBURGH BHF CENTRE FOR CARDIOVASCULAR SCIENCES EDINBURGH, UNITED KINGDOM	N/A	PC	GCA - HUMAN GUT CELL ATLAS - NORMAL INTESTINE AND CROHNS DISEASE	100,000.
THE UNIVERSITY OF EDINBURGH BHF CENTRE FOR CARDIOVASCULAR SCIENCES EDINBURGH, UNITED KINGDOM	N/A	PC	MITOCHONDRIAL DAMPS AS MECHANISTIC BIOMARKERS OF MUCOSAL INFLAMMATION	469,844.
THE UNIVERSITY OF EDINBURGH CENTRE FOR CARDIOVASCULAR SCIENCES EDINBURGH, UNITED KINGDOM	N/A	PC	GCA - HUMAN GUT CELL ATLAS - NORMAL INTESTINE AND CROHNS DISEASE	400,400.
THE UNIVERSITY OF OXFORD UNIVERSITY OFFICES, WELLINGTON SQUARE OXFORD, UNITED KINGDOM	N/A	PC	THE CELLULAR LANDSCAPE OF MONOGENIC INFLAMMATORY BOWEL DISEASE	244,860.
THE UNIVERSITY OF OXFORD UNIVERSITY OFFICES, WELLINGTON SQUARE OXFORD, UNITED KINGDOM	N/A	PC	STUDY OF COVID-19 ANTIBODY RESPONSE UNDER SUSTAINED IMMUNE SUPPRESSION	152,072.

Total from continuation sheets

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
THE UNIVERSITY OF OXFORD UNIVERSITY OFFICES, WELLINGTON SQUARE OXFORD, UNITED KINGDOM	N/A	PC	PHARMACOLOGICAL MODULATION TO ADDRESS GLUCAGON SECRETION IN T1D	131,216.
THE UNIVERSITY OF OXFORD UNIVERSITY OFFICES, WELLINGTON SQUARE OXFORD, UNITED KINGDOM	N/A	PC	STUDY OF COVID-19 ANTIBODY RESPONSE UNDER SUSTAINED IMMUNE SUPPRESSION	627,089.
THE UNIVERSITY OF QUEENSLAND CUMBRAE STEWART BUILDING #72 BRISBANE, AUSTRALIA	N/A	PC	LIPOSOMAL ANTIGEN-SPECIFIC IMMUNOTHERAPY OF RECENT-ONSET T1D	1,231,993.
THE UNIVERSITY OF WESTERN AUSTRALIA 35 STIRLING HIGHWAY CRAWLEY, AUSTRALIA	N/A	PC	CGM ASSESSMENTS OF ENDIA CHILDREN	102,133.
THE WEIZMANN INSTITUTE OF SCIENCE 234 HERZEL ST REHOVOT, ISRAEL	N/A	PC	PERSONALIZED NUTRITIONAL, MICROBIOME AND HOST PATTERNS IN CROHNS	100,904.
THE WEIZMANN INSTITUTE OF SCIENCE 234 HERZEL ST REHOVOT, ISRAEL	N/A	PC	THE QUANTUM MATERIALS DEVICES FABRICATION LAB	165,000.
TOWNSEND HEALTH SYSTEMS, INC. 110 NORTH OAK TOWNSEND, MT 59644	N/A	PC	TELE-PHARMACY AT BILLINGS CLINIC BROADWATER	329,602.

Total from continuation sheets

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
TOWNSEND HEALTH SYSTEMS, INC. 110 NORTH OAK TOWNSEND, MT 59644	N/A	PC	EMERGENCY AT BROADWATER HEALTH CENTER	12,933.
TRICKLE UP PROGRAM, INC. 104 WEST 27TH STREET, 12TH FLOOR NEW YORK, NY 10001	N/A	PC	GENERAL OPERATING SUPPORT	25,000.
TRUSTEES OF INDIANA UNIVERSITY 509 E 3RD ST. BLOOMINGTON, IN 47401-3654	N/A	GOV	COLLABORATIVE EFFORT TO VALIDATE MICRORNAS AS BIOMARKERS OF T1D	569,823.
TRUSTEES OF INDIANA UNIVERSITY 509 E 3RD ST. BLOOMINGTON, IN 47401-3654	N/A	GOV	DEVELOPMENT OF REGULATORY ROADMAP FOR COLONOSCOPY BOWEL PREP FOR CD PTS	290,356.
TRUSTEES OF INDIANA UNIVERSITY 509 E 3RD ST. BLOOMINGTON, IN 47401-3654	N/A	GOV	MOLECULAR DESIGN AND TESTING OF GLUCOSE-RESPONSIVE THERAPIES	793,072.
TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA OFFICE OF RESEARCH SERVICES, PHILADELPHIA, PA 19104-6205	N/A	PC	ULTRA PROCESSED DIET, GUT MICROBIOME, AND XENOBIOTIC EXPOSURE IN CD	256,967.
TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA OFFICE OF RESEARCH SERVICES, PHILADELPHIA, PA 19104-6205	N/A	PC	ULTRA PROCESSED DIET, GUT MICROBIOME, AND XENOBIOTIC EXPOSURE IN CD	256,967.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
UNITED HOSPITAL FUND OF NEW YORK 1411 BROADWAY NEW YORK, NY 10018	N/A	PC	NEW YORK STATE MEDICAL RESPITE PILOT PROGRAM DESIGN	375,000.
UNITED HOSPITAL FUND OF NEW YORK 1411 BROADWAY NEW YORK, NY 10018	N/A	PC	NEW YORK STATE MEDICAL RESPITE PILOT PROGRAM DESIGN	300,000.
UNITED NATIONS DEVELOPMENT PROGRAMME 1 UNITED NATIONS PLAZA NEW YORK, NY 10017	N/A	PC	UNITED NATIONS MULTILATERAL AGENCY	257,967.
UNITED OSTOMY ASSOCIATIONS OF AMERICA P.O. BOX 525 KENNEBUNK, ME 04043-0525	N/A	PC	DEVELOPMENT OF CROHNS DISEASE CONTENT AND AWARENESS FOR THE UOAA	19,104.
UNITED OSTOMY ASSOCIATIONS OF AMERICA P.O. BOX 525 KENNEBUNK, ME 04043-0525	N/A	PC	DEVELOPMENT OF CROHNS DISEASE CONTENT AND AWARENESS FOR THE UOAA	40,350.
UNITED STATES FUND FOR UNICEF 125 MAIDEN LANE NEW YORK, NY 10038	N/A	PC	ACCELERATING GLOBAL FOCUS ON NCDS AND PEN-PLUS COUNTRY PROGRAMS	775,779.
UNIVERSITAIR MEDISCH CENTRUM UTRECHT HEIDELBERGLAAN 100 UTRECHT, NETHERLANDS	N/A	GOV	EPITHELIAL BASED DIAGNOSTICS FOR TARGETED THERAPIES OF VEOIBD	173,250.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
UNIVERSITE CATHOLIQUE DE LOUVAIN PLACE DE L'UNIVERSITE 1 LOUVAIN-LA-NEUVE, BELGIUM	N/A	PC	STUDY OF THE GLUCAGON RESPONSE TO HYPOGLYCEMIA IN CHILDREN WITH T1D	144,419.
UNIVERSITE CATHOLIQUE DE LOUVAIN PLACE DE L'UNIVERSITE 1 LOUVAIN-LA-NEUVE, BELGIUM	N/A	PC	DIRECT AND INDIRECT CAUSES FOR THE IMPAIRED GLUCAGON SECRETION IN T1D	246,186.
UNIVERSITY AT BUFFALO PEDIATRIC ASSOCIATES P. C. 1001 MAIN STREET BUFFALO, NY 14203	N/A	PC	TELEHEALTH REIMBURSEMENT STUDY FOR UNDERSERVED T1D PEDIATRIC POPULATIONS	627,429.
UNIVERSITY COLLEGE LONDON GOWER STREET LONDON, UNITED KINGDOM	N/A	PC	SPIT-C: USING SALIVA TO PREDICT CROHNS DISEASE	380,649.
UNIVERSITY OF BIRMINGHAM INSTITUTE OF IMMUNOLOGY BIRMINGHAM, UNITED KINGDOM	N/A	PC	DEFINING THE EFFICACY AND MECHANISMS OF PEPTIDE IMMUNOTHERAPY FOR T1D.	413,518.
UNIVERSITY OF BIRMINGHAM INSTITUTE OF IMMUNOLOGY BIRMINGHAM, UNITED KINGDOM	N/A	PC	ANTIGEN SPECIFIC IMMUNOTHERAPY IN TYPE 1 DIABETES	102,647.
UNIVERSITY OF CALIFORNIA, LOS ANGELES UCLA OFFICE OF CONTRACTS AND GRANTS LOS ANGELES, CA 90095-1406	N/A	PC	GLUCOSE RESPONSIVE GLUCAGON TO REDUCE HYPOGLYCEMIA IN PEOPLE WITH T1D	601,142.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO 3333 CALIFORNIA STREET, SUITE 315, BOX 0962 SAN FRANCISCO, CA 94143	N/A	PC	VALIDATING A CLASS OF DRUGS THAT MAY PROTECT BETA CELLS IN T1D	108,185.
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO 490 ILLINOIS STREET, FOURTH FLOOR SAN FRANCISCO, CA 94143	N/A	PC	ISLET AUTOIMMUNITY IN PATIENTS WITH STAT GAIN-OF-FUNCTION MUTATIONS	128,169.
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO 490 ILLINOIS STREET, FOURTH FLOOR SAN FRANCISCO, CA 94143	N/A	PC	ID ANALYSIS OF EXTREME FORMS OF T1D, ESTABLISHMENT OF PATIENT REGISTRY	433,333.
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO 490 ILLINOIS STREET, FOURTH FLOOR SAN FRANCISCO, CA 94143	N/A	PC	ENGINEERING ISLET ANTIGEN-SPECIFIC TREGS FOR T1D	500,120.
UNIVERSITY OF CAMBRIDGE THE OLD SCHOOLS CAMBRIDGE, UNITED KINGDOM	N/A	PC	CLOSED LOOP INSULIN DELIVERY IN NEWLY DIAGNOSED YOUTH WITH T1D PART 2	247,545.
UNIVERSITY OF CINCINNATI PO BOX 210641 CINCINNATI, OH 45221	N/A	GOV	UNDERSTANDING THE EFFECT OF C-PEPTIDE CO-INFUSION WITH INSULIN	363,107.
UNIVERSITY OF DUNDEE NETHERGATE DUNDEE, UNITED KINGDOM	N/A	PC	HYPO-RESOLVE - UNDERSTANDING ORGAN SPECIFIC CONSEQUENCES OF HYPOGLYCEMIA	145,758.

Total from continuation sheets

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
UNIVERSITY OF EXETER NORTHCOTE HOUSE, THE QUEEN'S DRIVE EXETER, UNITED KINGDOM	N/A	PC	UNDERSTANDING EXTREMELY EARLY-ONSET TYPE 1 DIABETES	615,166.
UNIVERSITY OF FLORIDA 219 GRINTER HALL GAINESVILLE, FL 32611-5500	N/A	GOV	T CELL RECEPTOR SEQUENCING IN T1D - BIOMARKER & TECHNOLOGY DEVELOPMENT	248,597.
UNIVERSITY OF FLORIDA 219 GRINTER HALL GAINESVILLE, FL 32611-5500	N/A	GOV	COLLABORATIVE T1D RESEARCH: NETWORK FOR PANCREATIC ORGAN DONORS WITH T1D	1,199,692.
UNIVERSITY OF FLORIDA 219 GRINTER HALL GAINESVILLE, FL 32611-5500	N/A	GOV	HUMAN ATLAS NEONATAL DEVELOPMENTAL EARLY LIFE PANCREAS/IMMUNITY CON'T	1,034,449.
UNIVERSITY OF GLASGOW COURT UNIVERSITY AVENUE GLASGOW, UNITED KINGDOM	N/A	PC	THE CLINICAL EFFECTIVENESS OF CD-TREAT IN PATIENTS WITH ACTIVE CROHNS	391,290.
UNIVERSITY OF IOWA DIVISION OF SPONSORED PROGRAMS IOWA CITY, IA 52442	N/A	GOV	SIMULATION IN MOTION IOWA (SIM-IA)	2,470,869.
UNIVERSITY OF IOWA DIVISION OF SPONSORED PROGRAMS IOWA CITY, IA 52442	N/A	GOV	RUPRI HEALTH PANEL SUPPORT	174,321.

Total from continuation sheets

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL 55 LAKE AVENUE NORTH WORCESTER, MA 01655	N/A	GOV	DAIN: A CROHNS DISEASE MANAGEMENT STRATEGY TAILORED FOR PUERTO RICANS	541,529.
UNIVERSITY OF MELBOURNE LEVEL 4, ALAN GILBERT BUILDING CARLTON, AUSTRALIA	N/A	PC	ANIMAL AND CLINICAL EVALUATION OF A NOVEL CONTINUOUS KETONE SENSOR	552,076.
UNIVERSITY OF MIAMI 1320 SOUTH DIXIE HIGHWAY, SUITE 650 CORAL GABLES, FL 33146	N/A	PC	DEVELOP A NEW METHOD OF STUDYING ALPHA CELL FUNCTION IN PANCREATIC SLICE	250,000.
UNIVERSITY OF MIAMI 1320 SOUTH DIXIE HIGHWAY, SUITE 650 CORAL GABLES, FL 33146	N/A	PC	A HOLISTIC DIET INTERVENTION FOR PEOPLE WITH CROHNS DISEASE	637,761.
UNIVERSITY OF MIAMI 1320 SOUTH DIXIE HIGHWAY, SUITE 650 CORAL GABLES, FL 33146	N/A	PC	THE GEORGE S. EISENBARTH NPOD AWARD FOR TEAM SCIENCE	323,935.
UNIVERSITY OF NEBRASKA FOUNDATION 1010 LINCOLN MALL LINCOLN, NE 68501	N/A	PC	MOBILE RURAL HEALTHCARE PROVIDER TRAINING	592,963.
UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL 104 AIRPORT DRIVE, SUITE 2200, CB 1350 CHAPEL HILL, NC 27599-1350	N/A	PC	MONITORING COVID-19 VACCINE EFFECTIVENESS IN IBD PATIENTS	236,320.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL 104 AIRPORT DRIVE, SUITE 2200, CB 1350 CHAPEL HILL, NC 27599-1350	N/A	PC	IDENTIFYING MOLECULAR PROFILES PREDICTIVE OF POST-OPERATIVE CD OUTCOMES	585,750.
UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL 104 AIRPORT DRIVE, SUITE 2200, CB 1350 CHAPEL HILL, NC 27599-1350	N/A	PC	MONITORING COVID-19 VACCINE EFFECTIVENESS IN IBD PATIENTS	93,422.
UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL 104 AIRPORT DRIVE, SUITE 2200, CB 1350 CHAPEL HILL, NC 27599-1350	N/A	PC	ANTI-TNF COMBINATION CLINICAL TRIAL IN PEDIATRIC CROHNS DISEASE	42,022.
UNIVERSITY OF NOTRE DAME DU LAC 940 GRACE HALL NOTRE DAME, IN 46556-5708	N/A	PC	GLUCOSE-BINDING MOTIFS FROM DYNAMIC COMBINATORIAL LANDSCAPES	736,645.
UNIVERSITY OF NOTRE DAME DU LAC 940 GRACE HALL NOTRE DAME, IN 46556-5708	N/A	PC	DEVELOPMENT OF A NOVEL GLUCOSE-RESPONSIVE GLUCAGON DELIVERY SYSTEM	581,100.
UNIVERSITY OF OULU P.O. BOX 8000 OULU, FINLAND	N/A	PC	MATERNAL AND PATERNAL T1D - MECHANISMS FOR RECURRENCE RISK IN OFFSPRING	452,607.
UNIVERSITY OF PITTSBURGH 3420 FORBES AVENUE PITTSBURGH, PA 15260-3203	N/A	PC	RANDOMIZED CONTROLLED TRIAL: ANALOGUE VS HUMAN INSULIN	1,184,954.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
UNIVERSITY OF TOLEDO 3000 ARLINGTON AVENUE TOLEDO, OH 43614-2595	N/A	GOV	TYPE 1 DIABETES CAR TREG THERAPEUTIC APPROACH	110,480.
UNIVERSITY OF UTAH 201 S. PRESIDENTS CIRCLE SALT LAKE CITY, UT 84112	N/A	PC	ANTI-PHAGE ANTIBODIES: CROHNS DISEASE DIAGNOSIS AND TREATMENT RESPONSE	291,996.
UNIVERSITY OF UTAH 201 S. PRESIDENTS CIRCLE SALT LAKE CITY, UT 84112	N/A	PC	ANTI-PHAGE ANTIBODIES: CROHNS DISEASE DIAGNOSIS AND TREATMENT RESPONSE	246,267.
UNIVERSITY OF VIRGINIA LAW SCHOOL FOUNDATION 580 MASSIE ROAD CHARLOTTESVILLE, VA 22903	N/A	PC	GENERAL OPERATING SUPPORT	50,000.
UNIVERSITY OF ZURICH DEPARTMENT OF IMMUNOLOGY ZURICH, SWITZERLAND	N/A	GOV	GENERATE BISPECIFIC INTERLEUKIN-2 IMMUNOTHERAPY TO TREAT T1D MELLITUS	118,250.
UPPSALA UNIVERSITET BOX 256 UPPSALA, SWEDEN	N/A	GOV	ALPHA-CELL SIGNALING FOR GLUCAGON SECRETION	121,182.
UPPSALA UNIVERSITY HOSPITAL SJUKHUSVGEN 20 UPPSALA, SWEDEN	N/A	PC	ISOLATING ISLETS TO UNDERSTAND ALPHA CELL DYSFUNCTION AND HYPOGLYCEMIA	400,000.

Total from continuation sheets

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
VAN BUREN COUNTY HOSPITAL 304 FRANKLIN STREET KEOSAUQUA, IA 52565	N/A	GOV	EEMERGENCY AT VAN BUREN COUNTY HOSPITAL	17,766.
VANDERBILT UNIVERSITY MEDICAL CENTER OFFICE OF SPONSORED PROGRAMS NASHVILLE, TN 37203	N/A	PC	DEVELOPING AN ISLET MODEL THAT MIMICS T1D	250,000.
VANDERBILT UNIVERSITY MEDICAL CENTER OFFICE OF SPONSORED PROGRAMS NASHVILLE, TN 37203	N/A	PC	USE OF MRI OF THE PANCREAS IN T1D	504,261.
VANDERBILT UNIVERSITY MEDICAL CENTER OFFICE OF SPONSORED PROGRAMS NASHVILLE, TN 37203	N/A	PC	PANCREATLAS DATABASE EXPANSION.	825,315.
VANDERBILT UNIVERSITY MEDICAL CENTER OFFICE OF SPONSORED PROGRAMS NASHVILLE, TN 37203	N/A	PC	ISOLATING ISLETS TO UNDERSTAND HYPOGLYCEMIA IN TYPE 1 DIABETES	200,000.
VANDERBILT UNIVERSITY MEDICAL CENTER OFFICE OF SPONSORED PROGRAMS NASHVILLE, TN 37203	N/A	PC	COMBINATORIAL SINGLE CELL STRATEGIES FOR CROHNS DISEASE GUT CELL ATLAS	676,092.
VANDERBILT UNIVERSITY MEDICAL CENTER OFFICE OF SPONSORED PROGRAMS NASHVILLE, TN 37203	N/A	PC	IDENTIFY SMALL MOLECULES ENHANCING GLUCAGON SECRETION UNDER HYPOGLYCEMIA	330,000.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
VANDERBILT UNIVERSITY MEDICAL CENTER OFFICE OF SPONSORED PROGRAMS NASHVILLE, TN 37203	N/A	PC	ADMINISTRATIVE CORE AND COLLABORATIVE DATA REPOSITORY FOR THE GCA	522,458.
VANDERBILT UNIVERSITY MEDICAL CENTER OFFICE OF SPONSORED PROGRAMS NASHVILLE, TN 37203	N/A	PC	COMBINATORIAL SINGLE CELL STRATEGIES FOR CROHNS DISEASE GUT CELL ATLAS	166,933.
VANDERBILT UNIVERSITY MEDICAL CENTER OFFICE OF SPONSORED PROGRAMS NASHVILLE, TN 37203	N/A	PC	COMBINATORIAL SINGLE CELL STRATEGIES FOR CROHNS DISEASE GUT CELL ATLAS	509,159.
VANDERBILT UNIVERSITY 2201 WEST END AVE NASHVILLE, TN 37235	N/A	PC	UNDERSTANDING CALCIUM SIGNALING IN ALPHA CELLS AND HOW THEY WORK IN T1D	231,831.
VAYU HEALTH 19 ALISO WAY PORTOLA VALLEY, CA 94028	N/A	PC	VAYU FEASIBILITY PILOT	591,068.
VETERANS MEMORIAL HOSPITAL 40 1ST STREET, SE WAUKON, IA 52172	N/A	GOV	ECARE PHARMACY AND EMERGENCY SERVICES AT VETERANS MEMORIAL HOSPITAL	299,175.
VILLAGES OF HOPE: AFRICA SOCIETY 2450 MILLTOWER COURT MISSISSAUGA, CANADA	N/A	PC	ZAMBIA DEVELOPMENT: FOOD PRODUCTION, WATER SUPPLY, EDUCATION FACILITIES	622,818.

Total from continuation sheets

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
VIVLI, INC. 14 STORY STREET, SUITE 406 CAMBRIDGE, MA 02138	N/A	PC	PUBLICLY SHARING THE DATA FROM EXERCISE AND T1D STUDIES	147,174.
VIVLI, INC. 14 STORY STREET, SUITE 406 CAMBRIDGE, MA 02138	N/A	PC	VIVLI TECHNICAL DEBT AMELIORATION	250,000.
WASHINGTON UNIVERSITY 660 S EUCLID AVE. ST LOUIS, MO 63110	N/A	PC	VACCINE SAFETY AND EFFICACY	800,222.
WASHINGTON UNIVERSITY 660 S EUCLID AVE. ST LOUIS, MO 63110	N/A	PC	MANIPULATING ALPHA CELL SIGNALING TO RESTORE NORMAL GLUCAGON SECRETORY	250,000.
WASHINGTON UNIVERSITY 660 S EUCLID AVE. ST LOUIS, MO 63110	N/A	PC	SUPPORT DRUG DISCOVERY/UNDERSTANDING AND PREVENTING HYPOGLYCEMIA IN T1D	300,000.
WASHOE BARTON MEDICAL CLINIC 1107 US HIGHWAY 395 N GARDNERVILLE, NV 89410	N/A	PC	ULTRASOUND EQUIPMENT FOR CARSON VALLEY MEDICAL CENTER	437,369.
WASHOE BARTON MEDICAL CLINIC 1107 US HIGHWAY 395 N GARDNERVILLE, NV 89410	N/A	PC	RADIOLOGY AND INTERVENTIONAL EQUIPMENT WITH CONSTRUCTION RELATED COSTS.	2,160,914.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
WATER4 INC 2405 NW 10TH STREET OKLAHOMA CITY, OK 73107	N/A	PC	SCALING THE NUMA MODEL TO DELIVER SAFE, SUSTAINABLE WATER	1,180,873.
WATERAID AMERICA, INC. 233 BROADWAY NEW YORK, NY 10279	N/A	PC	SYSTEM STRENGTHENING FOR SUSTAINABLE WASH SERVICES	900,001.
WATERAID AMERICA, INC. 233 BROADWAY NEW YORK, NY 10279	N/A	PC	CREATING A NEW REALITY FOR WASH IN HEALTHCARE FACILITIES IN ZAMBIA	2,839,148.
WHITE PINE COUNTY HOSPITAL DISTRICT 1500 AVENUE H ELY, NV 89301	N/A	GOV	INCREASED ULTRASOUND AVAILABILITY AND ABILITY FOR RURAL NORTHEAST NEVADA	265,831.
WHITE PINE COUNTY HOSPITAL DISTRICT 1500 AVENUE H ELY, NV 89301	N/A	GOV	RADIOLOGY EQUIPMENT FOR HOSPITAL	958,500.
WILDLIFE CONSERVATION SOCIETY 2300 SOUTHERN BOULEVARD BRONX, NY 10460	N/A	PC	GENERAL OPERATING SUPPORT FOR THE ELEPHANT CONSERVATION PROGRAM	10,000.
WNET FOR THE WLIW-21 PUBLIC BROADCASTING 825 EIGHTH AVENUE NEW YORK, NY 10019-7435	N/A	PC	GENERAL OPERATING SUPPORT	5,000.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
WYOMING DEPARTMENT OF HEALTH 6101 YELLOWSTONE RD. SUITE 400 CHEYENNE, WY 82009	N/A	GOV	WYOMING FIRST RESPONDER AED PROJECT	269,693.
WYOMING STATE PARKS AND CULTURAL RESOURCES 2301 CENTRAL AVENUE CHEYENNE, WY 82002	N/A	GOV	INTERPRETIVE CENTER AT FORT PHIL KEARNY STATE HISTORIC SITE	885,000.
YAD SARAH 124 HERZL BLVD. JERUSALEM, ISRAEL	N/A	PC	HOME HOSPITAL PROGRAM FOR SOUTHERN ISRAEL	1,376,648.
YALE UNIVERSITY OFFICE OF SPONSORED PROJECTS NEW HAVEN, CT 06520-8327	N/A	PC	GENERAL OPERATING SUPPORT FOR CLASS OF 1982 40TH REUNION	20,000.
YALE UNIVERSITY OFFICE OF SPONSORED PROJECTS NEW HAVEN, CT 06520-8327	N/A	PC	THERAPEUTIC TARGETS AT THE HOST MICROBIOTA INTERFACE FOR FIBROSIS	336,846.
YALE UNIVERSITY OFFICE OF SPONSORED PROJECTS NEW HAVEN, CT 06520-8327	N/A	PC	EXPOSOMICS FOR EARLY LIFE CROHNS DISEASE	405,488.
YALE UNIVERSITY OFFICE OF SPONSORED PROJECTS NEW HAVEN, CT 06520-8327	N/A	PC	THERAPEUTIC TARGETS AT THE HOST MICROBIOTA INTERFACE FOR FIBROSIS	156,907.

Total from continuation sheets

Part XIV Supplementary Information (continued)

3a Grants and Contributions Paid During the Year

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
YEHUDA ABARBANEL GOVERNMENT HOSPITAL 15 KEREN KAYEMET ST. BAT YAM, ISRAEL	N/A	GOV	MODERNIZATION OF ABARBANELS INFORMATION TECHNOLOGY AND SECURITY SYSTEMS	1,000,000.
YITZHAK SHAMIR MEDICAL CENTER BE'ER YA'AKOV TZRIFIN, ISRAEL	N/A	GOV	EXPANSION AND RENOVATION OF SHAMIR MEDICAL CENTER'S CANCER INSTITUTE	729,642.
YOUNG MEN'S CHRISTIAN ASSOCIATION RETIREMENT FUND 120 BROADWAY NEW YORK, NY 10271	N/A	SOI	GENERAL OPERATING SUPPORT	5,000.
YOUTH DEVELOPMENT ORGANIZATION INC 15 UNION STREET #563 LAWRENCE, MA 01840	N/A	PC	EDUCATION AND CHARACTER DEVELOPMENT FOR LOCAL YOUTH	14,516.
ZEFAT ACADEMIC COLLEGE 11 JERUSALEM STREET, POB 160 ZEFAT, ISRAEL	N/A	PC	EQUIPPING ZEFAT ACADEMIC COLLEGE'S INST. FOR ADV. HEALTH TRAINING & ED.	4,114,152.
ZIV MEDICAL CENTER, ZEFAT RAMBAM ST. ZEFAT, ISRAEL	N/A	GOV	PURCHASE OF TWO ECMO MACHINES FOR ZIV MEDICAL CENTER	151,611.
ZIV MEDICAL CENTER, ZEFAT RAMBAM ST. ZEFAT, ISRAEL	N/A	GOV	REINFORCE CRUCIAL SITES DURING EMERGENCIES: ORS, BLOOD BANK & PHARMACY	1,503,124.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
ALBERT EINSTEIN COLLEGE OF MEDICINE 1300 MORRIS PARK AVE BRONX, NY 10461-1975	N/A	PC	PRECLINICAL WORK TO ADVANCE D-PEPTIDES AS ANTIGEN-SPECIFIC IMMUNOTHERAPY	556,499.
ALBERT EINSTEIN COLLEGE OF MEDICINE 1300 MORRIS PARK AVE BRONX, NY 10461-1975	N/A	PC	SUPPLEMENTAL SUPPORT FOR T1DTECHCHW	168,556.
ALBERT EINSTEIN COLLEGE OF MEDICINE 1300 MORRIS PARK AVE BRONX, NY 10461-1975	N/A	PC	SUPPLEMENTAL SUPPORT FOR T1DTECHCHW	173,613.
ALIMENTIV INC. 100 DUNDAS STREET LONDON, CANADA	N/A	NC	STENOSIS THERAPY AND ANTI-FIBROTIC RESEARCH (STAR) CONSORTIUM	948,511.
ALIMENTIV INC. 100 DUNDAS STREET LONDON, CANADA	N/A	NC	DEVELOP AN INTESTINAL MUCOSAL AND IMAGING BIOMARKER FOR STRICTURING CD	267,835.
ALIMENTIV INC. 100 DUNDAS STREET LONDON, CANADA	N/A	NC	DEVELOP AN INTESTINAL MUCOSAL AND IMAGING BIOMARKER FOR STRICTURING CD	259,951.
ALYN HOSPITAL - REHABILITATION CENTER FOR CHILDREN AND YOUTH 84 SHMARYAHU LEVIN ST JERUSALEM, ISRAEL	N/A	PC	ALYN CENTER FOR INNOVATION IN PEDIATRIC REHABILITATION RESEARCH	717,219.
Total from continuation sheets				459,902,418.

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
ALYN HOSPITAL - REHABILITATION CENTER FOR CHILDREN AND YOUTH 84 SHMARYAHU LEVIN ST JERUSALEM, ISRAEL	N/A	PC	ALYN CENTER FOR INNOVATION IN PEDIATRIC REHABILITATION RESEARCH	694,034.
AMC MEDICAL RESEARCH BV MEIBERGDRREEF 9 AMSTERDAM, NETHERLANDS	N/A	PC	IDENTIFICATION OF BIOMARKERS FOR PERIANAL FISTULIZING DISEASE	50,570.
AMC MEDICAL RESEARCH BV MEIBERGDRREEF 9 AMSTERDAM, NETHERLANDS	N/A	PC	IDENTIFICATION OF BIOMARKERS FOR PERIANAL FISTULIZING DISEASE	610,817.
AMERICAN CAMPING ASSOCIATION INC 5000 STATE ROAD 67 NORTH MARTINSVILLE, IN 46151	N/A	PC	ACA PROFESSIONAL DEVELOPMENT 2022 - 2024	48,955.
AMERICAN CAMPING ASSOCIATION INC 5000 STATE ROAD 67 NORTH MARTINSVILLE, IN 46151	N/A	PC	ACA PROFESSIONAL DEVELOPMENT 2022 - 2024	51,040.
AMERICAN DIABETES ASSOCIATION, INC. 2451 CRYSTAL DRIVE, SUITE 900 ARLINGTON, VA 22202	N/A	PC	FOCUS ON FELLOWS, DIABETES IS PRIMARY, PROFESSIONAL MEMBERSHIP PROJECTS	300,000.
AMERICAN DIABETES ASSOCIATION, INC. 2451 CRYSTAL DRIVE, SUITE 900 ARLINGTON, VA 22202	N/A	PC	ADA MENTAL HEALTH EDUCATION PROGRAM 2022 - 2024	337,310.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
AMERICAN DIABETES ASSOCIATION, INC. 2451 CRYSTAL DRIVE, SUITE 900 ARLINGTON, VA 22202	N/A	PC	2022-2024 TYPE 1 DIABETES CAMP INITIATIVE	399,368.
AMERICAN DIABETES ASSOCIATION, INC. 2451 CRYSTAL DRIVE, SUITE 900 ARLINGTON, VA 22202	N/A	PC	ADA MENTAL HEALTH EDUCATION PROGRAM 2022 - 2024	278,350.
AMERICAN DIABETES ASSOCIATION, INC. 2451 CRYSTAL DRIVE, SUITE 900 ARLINGTON, VA 22202	N/A	PC	2022-2024 TYPE 1 DIABETES CAMP INITIATIVE	399,368.
AMERICAN GASTROENTEROLOGICAL ASSOCIATION INSTITUTE 4930 DEL RAY AVE BETHESDA, MD 20814	N/A	PC	SPECIALIZED IBD TRAINING FOR ADVANCE PRACTICE PROVIDERS	155,930.
AMERICAN HEART ASSOCIATION, INC. 7272 GREENVILLE AVENUE DALLAS, TX 75231	N/A	PC	MISSION: LIFELINE STROKE MT AND POST-ACUTE STROKE CARE QUALITY STANDARDS	1,654,728.
AMERICAN HEART ASSOCIATION, INC. 7272 GREENVILLE AVENUE DALLAS, TX 75231	N/A	PC	MISSION: LIFELINE STROKE MT AND POST-ACUTE STROKE CARE QUALITY STANDARDS	690,948.
AMERICARES FOUNDATION, INC. 88 HAMILTON AVE STAMFORD, CT 06840	N/A	PC	MATERNAL, NEWBORN, AND CHILD HEALTH INTERVENTIONS	752,688.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
AMERICARES FOUNDATION, INC. 88 HAMILTON AVE STAMFORD, CT 06840	N/A	PC	MATERNAL, NEWBORN, AND CHILD HEALTH INTERVENTIONS	749,599.
APHP, ST ANTOINE HOSPITAL 184 RUE DU FAUBOURG SAINT-ANTOINE PARIS, FRANCE	N/A	GOV	FECAL MICROBIOTA TRANSPLANTATION IN CROHNS DISEASE	474,464.
APHP, ST ANTOINE HOSPITAL 184 RUE DU FAUBOURG SAINT-ANTOINE PARIS, FRANCE	N/A	GOV	FECAL MICROBIOTA TRANSPLANTATION IN CROHNS DISEASE	474,464.
APHP, ST ANTOINE HOSPITAL 184 RUE DU FAUBOURG SAINT-ANTOINE PARIS, FRANCE	N/A	GOV	FECAL MICROBIOTA TRANSPLANTATION IN CROHNS DISEASE	367,129.
APHP, ST ANTOINE HOSPITAL 184 RUE DU FAUBOURG SAINT-ANTOINE PARIS, FRANCE	N/A	GOV	FECAL MICROBIOTA TRANSPLANTATION IN CROHNS DISEASE	421,681.
ASIAN HEALTH CARE FOUNDATION 6-3-661, SOMAJIGUDA HYDERABAD, INDIA	N/A	PC	ACCESS TO CROHNS DIAGNOSTICS IN INDIA FOR PATIENTS LIVING IN POVERTY	210,551.
ASSOCIATION OF DIABETES CARE & EDUCATION SPECIALISTS 125 SOUTH WACKER DRIVE, SUITE 600 CHICAGO, IL 60606	N/A	NC	EXPANSION OF DANATECH PLATFORM	413,127.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
ASSOCIATION OF DIABETES CARE & EDUCATION SPECIALISTS 125 SOUTH WACKER DRIVE, SUITE 600 CHICAGO, IL 60606	N/A	NC	EXPANSION OF DANATECH PLATFORM	831,327.
ASSOCIATION OF DIABETES CARE & EDUCATION SPECIALISTS 125 SOUTH WACKER DRIVE, SUITE 600 CHICAGO, IL 60606	N/A	NC	EXPANSION OF DANATECH PLATFORM	855,546.
ASSOCIATION SANTE DIABETE 17 AVENUE MALHERBE GRENOBLE, FRANCE	N/A	PC	DIABETES SUPPORT TO PEOPLE IN BURKINA FASO, MALI AND UNION OF COMOROS	272,362.
ASSOCIATION SANTE DIABETE 17 AVENUE MALHERBE GRENOBLE, FRANCE	N/A	PC	DIABETES SUPPORT TO PEOPLE IN BURKINA FASO, MALI AND UNION OF COMOROS	205,984.
AUSTRALASIAN GASTRO INTESTINAL RESEARCH FOUNDATION LEVEL 2 FITZROY, AUSTRALIA	N/A	PC	FECAL MICROBIOTA TRANSPLANTATION IN CROHNS DISEASE: THE MIRO STUDY	587,840.
AUSTRALASIAN GASTRO INTESTINAL RESEARCH FOUNDATION LEVEL 2 FITZROY, AUSTRALIA	N/A	PC	FECAL MICROBIOTA TRANSPLANTATION IN CROHNS DISEASE: THE MIRO STUDY	587,840.
AVERA MCKENNAN HOSPITAL AND UNIVERSITY HEALTH CENTER 1325 S. CLIFF AVENUE SIOUX FALLS, SD 57105	N/A	PC	AVERA BEHAVIORAL HEALTH CENTER EXPANSION	500,000.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
AVERA MCKENNAN HOSPITAL AND UNIVERSITY HEALTH CENTER 1325 S. CLIFF AVENUE SIOUX FALLS, SD 57105	N/A	PC	AVERA BEHAVIORAL HEALTH CENTER EXPANSION	1,500,000.
AVERA MCKENNAN HOSPITAL AND UNIVERSITY HEALTH CENTER 1325 S. CLIFF AVENUE SIOUX FALLS, SD 57105	N/A	PC	AVERA BEHAVIORAL HEALTH CENTER EXPANSION	1,000,000.
AVERA MCKENNAN HOSPITAL AND UNIVERSITY HEALTH CENTER 1325 S. CLIFF AVENUE SIOUX FALLS, SD 57105	N/A	PC	AVERA BEHAVIORAL HEALTH CENTER EXPANSION	1,500,000.
BALLAD RESEARCH INSTITUTE 10865 ROAD TO THE CURE SAN DIEGO, CA 92121	N/A	PC	CD127-HIGH T-CELL POPULATIONS AS BIOMARKERS	325,801.
BANNER HEALTH 801 EAST WILLIAMS AVE. FALLON, NV 89406	N/A	PC	BANNER CHURCHILL COMMUNITY HOSPITAL ULTRASOUND INITIATIVE	139,574.
BAYLOR COLLEGE OF MEDICINE OFFICE OF RESEARCH HOUSTON, TX 77030	N/A	PC	PILOT STUDY TO ADDRESS DIABETES HEALTH-RELATED QUALITY OF LIFE	500,180.
BAYLOR COLLEGE OF MEDICINE OFFICE OF RESEARCH HOUSTON, TX 77030	N/A	PC	EMR-BASED PREDICTIVE ANALYTICS FOR TARGETED PROACTIVE T1D CARE	532,841.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
BAYLOR COLLEGE OF MEDICINE OFFICE OF RESEARCH HOUSTON, TX 77030	N/A	PC	PILOT STUDY TO ADDRESS DIABETES HEALTH-RELATED QUALITY OF LIFE	524,854.
BAYLOR COLLEGE OF MEDICINE OFFICE OF RESEARCH HOUSTON, TX 77030	N/A	PC	EMR-BASED PREDICTIVE ANALYTICS FOR TARGETED & PROACTIVE T1D CARE	547,540.
BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON 1201 NINTH AVENUE SEATTLE, WA 98101-2795	N/A	PC	LINKING DISEASE MECHANISM AND CLINICAL TRIAL DESIGN IN T1D	661,927.
BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON 1201 NINTH AVENUE SEATTLE, WA 98101-2795	N/A	PC	LINKING DISEASE MECHANISM AND CLINICAL TRIAL DESIGN IN T1D	567,763.
BETH ISRAEL DEACONESS MEDICAL CENTER, INC. 330 BROOKLINE AVENUE BOSTON, MA 02215-5491	N/A	PC	PROACTIVE OPTIMIZATION OF INFLIXIMAB USING A PHARMACOKINETIC DASHBOARD	519,550.
BETH ISRAEL DEACONESS MEDICAL CENTER, INC. 330 BROOKLINE AVENUE BOSTON, MA 02215-5491	N/A	PC	PROACTIVE OPTIMIZATION OF INFLIXIMAB USING A PHARMACOKINETIC DASHBOARD	519,548.
BETH ISRAEL DEACONESS MEDICAL CENTER, INC. 330 BROOKLINE AVENUE BOSTON, MA 02215-5491	N/A	PC	PROACTIVE OPTIMIZATION OF INFLIXIMAB USING A PHARMACOKINETIC DASHBOARD	538,077.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
BETH ISRAEL DEACONESS MEDICAL CENTER, INC. 330 BROOKLINE AVENUE BOSTON, MA 02215-5491	N/A	PC	PROACTIVE OPTIMIZATION OF INFLIXIMAB USING A PHARMACOKINETIC DASHBOARD	538,077.
BEYOND TYPE 1 1001 LAUREL ST, STE B SAN CARLOS, CA 94070	N/A	PC	DIABETIC KETOACIDOSIS (DKA) CAMPAIGN PHASE 3	149,167.
BEYOND TYPE 1 1001 LAUREL ST, STE B SAN CARLOS, CA 94070	N/A	PC	DIABETIC KETOACIDOSIS (DKA) CAMPAIGN PHASE 3	149,166.
BILLINGS CLINIC FOUNDATION 2917 TENTH AVENUE NORTH BILLINGS, MT 59102	N/A	PC	MONTANA PSYCHIATRY RESIDENCY PROGRAM SUSTAINING SUPPORT	1,000,000.
BIPARTISAN POLICY CENTER, INC. 1225 I ST NW #1000 WASHINGTON, DC 20005	N/A	PC	STRENGTHENING HEALTH CARE DELIVERY AND SERVICES IN RURAL AMERICA	625,293.
BLUE CIRCLE HEALTH, INC. 1209 ORANGE STREET WILMINGTON, DE 19801	N/A	NC	CREATION OF BLUE CIRCLE HEALTH FOR UNDERSERVED COMMUNITIES WITH T1D	1,740,266.
BLUE CIRCLE HEALTH, INC. 1209 ORANGE STREET WILMINGTON, DE 19801	N/A	NC	CREATION OF BLUE CIRCLE HEALTH FOR UNDERSERVED COMMUNITIES WITH T1D	1,740,267.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
BLUE CIRCLE HEALTH, INC. THE CORPORATION TRUST CENTER, 1209 ORANGE STREET WILMINGTON, DE 19801	N/A	NC	CREATION OF BLUE CIRCLE HEALTH FOR UNDERSERVED COMMUNITIES WITH T1D	2,500,000.
BLUE CIRCLE HEALTH, INC. THE CORPORATION TRUST CENTER, 1209 ORANGE STREET WILMINGTON, DE 19801	N/A	NC	CREATION OF BLUE CIRCLE HEALTH FOR UNDERSERVED COMMUNITIES WITH T1D	3,500,000.
BLUE CIRCLE HEALTH, INC. THE CORPORATION TRUST CENTER, 1209 ORANGE STREET WILMINGTON, DE 19801	N/A	NC	CREATION OF BLUE CIRCLE HEALTH FOR UNDERSERVED COMMUNITIES WITH T1D	3,480,533.
BLUE CIRCLE HEALTH, INC. THE CORPORATION TRUST CENTER, 1209 ORANGE STREET WILMINGTON, DE 19801	N/A	NC	CREATION OF BLUE CIRCLE HEALTH FOR UNDERSERVED COMMUNITIES WITH T1D	3,480,533.
BLUE CIRCLE HEALTH, INC. THE CORPORATION TRUST CENTER, 1209 ORANGE STREET WILMINGTON, DE 19801	N/A	NC	CREATION OF BLUE CIRCLE HEALTH FOR UNDERSERVED COMMUNITIES WITH T1D	4,470,844.
BLUE CIRCLE HEALTH, INC. THE CORPORATION TRUST CENTER, 1209 ORANGE STREET WILMINGTON, DE 19801	N/A	NC	CREATION OF BLUE CIRCLE HEALTH FOR UNDERSERVED COMMUNITIES WITH T1D	4,470,844.
BLUE CIRCLE HEALTH, INC. THE CORPORATION TRUST CENTER, 1209 ORANGE STREET WILMINGTON, DE 19801	N/A	NC	CREATION OF BLUE CIRCLE HEALTH FOR UNDERSERVED COMMUNITIES WITH T1D	4,470,843.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
BOULDER CITY HOSPITAL INC 901 ADAMS BLVD BOULDER CITY, NV 89005	N/A	PC	BOULDER CITY HOSPITAL EQUIPMENT REVITALIZATION PROJECT	37,497.
BOULDER CITY HOSPITAL INC 901 ADAMS BLVD BOULDER CITY, NV 89005	N/A	PC	BOULDER CITY HOSPITAL EQUIPMENT REVITALIZATION PROJECT	34,997.
BRIDGES TO PROSPERITY, INC. 1031 33RD STREET DENVER, CO 80205	N/A	PC	ETHIOPIA ASSESSMENT OF BRIDGE INFRASTRUCTURE	142,110.
BRIDGES TO PROSPERITY, INC. 1031 33RD STREET DENVER, CO 80205	N/A	PC	TRANSFORMATIVE CONNECTIVITY IN RURAL ETHIOPIA	2,812,542.
BRIDGES TO PROSPERITY, INC. 1031 33RD STREET DENVER, CO 80205	N/A	PC	TRANSFORMATIVE CONNECTIVITY IN RURAL ETHIOPIA	2,648,126.
BRIDGES TO PROSPERITY, INC. 1031 33RD STREET DENVER, CO 80205	N/A	PC	ZAMBIA ASSESSMENT OF BRIDGE INFRASTRUCTURE	142,110.
BRIGHAM AND WOMEN'S HOSPITAL 75 FRANCIS STREET BOSTON, MA 02115	N/A	PC	GLOBAL PARTNERSHIP TO ACHIEVE UNIVERSAL ACCESS FOR T1D AND NCDS	1,829,719.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
BRIGHAM AND WOMEN'S HOSPITAL 75 FRANCIS STREET BOSTON, MA 02115	N/A	PC	PEN-PLUS EXPANSION	1,988,392.
BRIGHAM AND WOMEN'S HOSPITAL 75 FRANCIS STREET BOSTON, MA 02115	N/A	PC	INVESTIGATION OF ANTI-GM-CSF AUAB AS A DISEASE DETERMINANT IN CD	1,326,053.
BRIGHAM AND WOMEN'S HOSPITAL 75 FRANCIS STREET BOSTON, MA 02115	N/A	PC	GLOBAL PARTNERSHIP TO ACHIEVE UNIVERSAL ACCESS FOR T1D AND NCDS	1,308,107.
BRIGHAM AND WOMEN'S HOSPITAL 75 FRANCIS STREET BOSTON, MA 02115	N/A	PC	PEN-PLUS EXPANSION	1,914,468.
BRIGHAM AND WOMEN'S HOSPITAL 75 FRANCIS STREET BOSTON, MA 02115	N/A	PC	INVESTIGATION OF ANTI-GM-CSF AUAB AS A DISEASE DETERMINANT IN CD	562,221.
BRIGHAM AND WOMEN'S HOSPITAL 75 FRANCIS STREET BOSTON, MA 02115	N/A	PC	GLOBAL PARTNERSHIP TO ACHIEVE UNIVERSAL ACCESS FOR T1D AND NCDS	1,785,375.
BRIGHAM AND WOMEN'S HOSPITAL 75 FRANCIS STREET BOSTON, MA 02115	N/A	PC	PEN-PLUS EXPANSION	1,914,468.

Total from continuation sheets

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
BRIGHAM AND WOMEN'S HOSPITAL 75 FRANCIS STREET BOSTON, MA 02115	N/A	PC	INVESTIGATION OF ANTI-GM-CSF AUAB AS A DISEASE DETERMINANT IN CD	499,459.
BRIGHAM AND WOMEN'S HOSPITAL 75 FRANCIS STREET BOSTON, MA 02115	N/A	PC	PEN-PLUS EXPANSION	3,802,596.
BRIGHAM AND WOMEN'S HOSPITAL 75 FRANCIS STREET BOSTON, MA 02115	N/A	PC	PEN-PLUS EXPANSION	6,054,477.
BRIGHAM AND WOMEN'S HOSPITAL 75 FRANCIS STREET BOSTON, MA 02115	N/A	PC	PASSIVE WIRELESS MONITORING TO PREDICT AND TRACK CROHNS DISEASE	360,771.
CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST HILLS ROAD CAMBRIDGE, UNITED KINGDOM	N/A	GOV	UK IBD BIORESOURCE: TRANSLATING TODAY'S SCIENCE INTO CD TREATMENTS	561,004.
CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST HILLS ROAD CAMBRIDGE, UNITED KINGDOM	N/A	GOV	UK IBD BIORESOURCE: TRANSLATING TODAY'S SCIENCE INTO CD TREATMENTS	313,576.
CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST HILLS ROAD CAMBRIDGE, UNITED KINGDOM	N/A	GOV	UK IBD BIORESOURCE: TRANSLATING TODAY'S SCIENCE INTO CD TREATMENTS	313,576.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
CARE-FOR-RARE FOUNDATION DR. VON HAUNERSCHES KINDERSPITAL KLINIKUM DER UNIVERSITT MUNCHEN MUNICH, GERMANY	N/A	PC	VEOIBD FROM PRECISION MOLECULAR DIAGNOSES TO TARGETED THERAPIES - MUNICH	655,603.
CARE-FOR-RARE FOUNDATION KINDERSPITAL KLINIKUM DER MUNICH, GERMANY	N/A	PC	VEOIBD FROM PRECISION MOLECULAR DIAGNOSES TO TARGETED THERAPIES - MUNICH	721,252.
CATHOLIC RELIEF SERVICES-USCCB 228 W. LEXINGTON ST. BALTIMORE, MD 21201	N/A	PC	RURAL EMERGENCY HEALTH SERVICE AND TRANSPORT FOR SYSTEM DEVELOPMENT	1,344,542.
CATHOLIC RELIEF SERVICES-USCCB 228 W. LEXINGTON ST. BALTIMORE, MD 21201	N/A	PC	MAYI MWANA PROJECT: HELPING ZAMBIAN MOTHERS & NEWBORNS SURVIVE & THRIVE	1,100,098.
CATHOLIC RELIEF SERVICES-USCCB 228 W. LEXINGTON ST. BALTIMORE, MD 21201	N/A	PC	INTEGRATED COMMUNITY WATER, SANITATION AND HYGIENE IMPROVEMENT IN GHANA	1,556,214.
CATHOLIC RELIEF SERVICES-USCCB 228 W. LEXINGTON ST. BALTIMORE, MD 21201	N/A	PC	BOUSSOUMA AND ZIGA, BURKINA FASO IMPROVED WASH INFRASTRUCTURE & SERVICES	749,145.
CEDARS-SINAI MEDICAL CENTER 8700 BEVERLY BLVD LOS ANGELES, CA 90048	N/A	PC	INTEGRATING GENOMIC AND IMAGING DATA WITH SCRNASEQ TO UNDERSTAND CD	268,151.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
CEDARS-SINAI MEDICAL CENTER 8700 BEVERLY BLVD LOS ANGELES, CA 90048	N/A	PC	PREHABILITATION PROGRAM FOR PATIENTS WITH IBD UNDERGOING ABD SURGERY	204,837.
CEDARS-SINAI MEDICAL CENTER 8700 BEVERLY BLVD LOS ANGELES, CA 90048	N/A	PC	INTEGRATING GENOMIC AND IMAGING DATA WITH SCRNAMEQ TO UNDERSTAND CD	231,849.
CEDARS-SINAI MEDICAL CENTER 8700 BEVERLY BLVD LOS ANGELES, CA 90048	N/A	PC	PREHABILITATION PROGRAM FOR PATIENTS WITH IBD UNDERGOING ABD SURGERY	216,002.
CEDARS-SINAI MEDICAL CENTER 8700 BEVERLY BLVD LOS ANGELES, CA 90048	N/A	PC	LONG-TERM RESPONSE TO SARS-COV-2 VACCINATION IN A DIVERSE IBD POPULATION	522,999.
CEDARS-SINAI MEDICAL CENTER 8700 BEVERLY BLVD LOS ANGELES, CA 90048	N/A	PC	VEOIBD PRECISION MOLECULAR DIAGNOSES TO TARGETED THERAPIES CEDARS-SINAI	115,500.
CEDARS-SINAI MEDICAL CENTER 8700 BEVERLY BLVD LOS ANGELES, CA 90048	N/A	PC	PREHABILITATION PROGRAM FOR PATIENTS WITH IBD UNDERGOING ABD SURGERY	200,041.
CEDARS-SINAI MEDICAL CENTER 8700 BEVERLY BLVD LOS ANGELES, CA 90048	N/A	PC	LONG-TERM RESPONSE TO SARS-COV-2 VACCINATION IN A DIVERSE IBD POPULATION	364,763.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
CEDARS-SINAI MEDICAL CENTER 8700 BEVERLY BLVD LOS ANGELES, CA 90048	N/A	PC	PREHABILITATION PROGRAM FOR PATIENTS WITH IBD UNDERGOING ABD SURGERY	202,791.
CEDARS-SINAI MEDICAL CENTER 8700 BEVERLY BLVD LOS ANGELES, CA 90048	N/A	PC	VEOIBD PRECISION MOLECULAR DIAGNOSES TO TARGETED THERAPIES CEDARS-SINAI	115,500.
CEDARS-SINAI MEDICAL CENTER 8700 BEVERLY BLVD LOS ANGELES, CA 90048	N/A	PC	PREHABILITATION PROGRAM FOR PATIENTS WITH IBD UNDERGOING ABD SURGERY	219,514.
CEDARS-SINAI MEDICAL CENTER 8700 BEVERLY BLVD LOS ANGELES, CA 90048	N/A	PC	PREHABILITATION PROGRAM FOR PATIENTS WITH IBD UNDERGOING ABD SURGERY	211,815.
CENTER FOR EXCELLENCE IN HEALTH CARE JOURNALISM 10 NEFF HALL COLUMBIA, MO 65211	N/A	SOII	TRAINING AND DEVELOPMENT OF HEALTH CARE JOURNALISTS AND HEALTH REPORTING	219,995.
CENTRAL MONTANA MEDICAL FACILITIES, INC. 408 WENDELL AVE. LEWISTOWN, MT 59457	N/A	PC	CANCER CENTER AT CENTRAL MONTANA MEDICAL CENTER	3,469,965.
CENTRAL MONTANA MEDICAL FACILITIES, INC. 408 WENDELL AVE. LEWISTOWN, MT 59457	N/A	PC	CANCER CENTER AT CENTRAL MONTANA MEDICAL CENTER	690,035.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
CENTRE HOSPITALIER REGIONAL DE NANCY 29 AVENUE MAL DE LATRE DE TASSIGNY NANCY, FRANCE	N/A	GOV	PREVENTION OF EXTRA-INTESTINAL MANIFESTATIONS/ COMORBIDITIES IN CD CARE	98,364.
CENTRE HOSPITALIER REGIONAL DE NANCY 29 AVENUE MAL DE LATRE DE TASSIGNY NANCY, FRANCE	N/A	GOV	PREVENTION OF EXTRA-INTESTINAL MANIFESTATIONS/ COMORBIDITIES IN CD CARE	89,352.
CENTRE HOSPITALIER REGIONAL DE NANCY 29 AVENUE MAL DE LATRE DE TASSIGNY NANCY, FRANCE	N/A	GOV	PREVENTION OF EXTRA-INTESTINAL MANIFESTATIONS/ COMORBIDITIES IN CD CARE	95,277.
CENTRE HOSPITALIER REGIONAL DE NANCY 29 AVENUE MAL DE LATRE DE TASSIGNY NANCY, FRANCE	N/A	GOV	PREVENTION OF EXTRA-INTESTINAL MANIFESTATIONS/ COMORBIDITIES IN CD CARE	103,796.
CENTRE HOSPITALIER REGIONAL DE NANCY 29 AVENUE MAL DE LATRE DE TASSIGNY NANCY, FRANCE	N/A	GOV	PREVENTION OF EXTRA-INTESTINAL MANIFESTATIONS/ COMORBIDITIES IN CD CARE	153,102.
CHASE COUNTY COMMUNITY HOSPITAL 600 WEST 12TH STREET IMPERIAL, NE 69033	N/A	GOV	EEMERGENCY AT CHASE COUNTY COMMUNITY HOSPITAL	29,056.
CHASE COUNTY COMMUNITY HOSPITAL 600 WEST 12TH STREET IMPERIAL, NE 69033	N/A	GOV	EEMERGENCY AT CHASE COUNTY COMMUNITY HOSPITAL	12,656.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
CHILDREN'S HOSPITAL CORPORATION ATTN: RESEARCH FINANCE BOSTON, MA 02241-4413	N/A	PC	MOLECULAR + SPATIAL SINGLE-CELL REMODELING IN PEDIATRIC CROHNS DISEASE	374,591.
CHILDREN'S HOSPITAL CORPORATION ATTN: RESEARCH FINANCE BOSTON, MA 02241-4413	N/A	PC	MOLECULAR + SPATIAL SINGLE-CELL REMODELING IN PEDIATRIC CROHNS DISEASE	374,591.
CHILDREN'S HOSPITAL CORPORATION ATTN: RESEARCH FINANCE BOSTON, MA 02241-4413	N/A	PC	DEVELOPMENT OF NOVEL GLUCOSE RESPONSIVE GLUCAGON (GRG) DELIVERY SYSTEM	1,153,809.
CHILDREN'S HOSPITAL CORPORATION ATTN: RESEARCH FINANCE BOSTON, MA 02241-4413	N/A	PC	MOLECULAR + SPATIAL SINGLE-CELL REMODELING IN PEDIATRIC CROHNS DISEASE	374,591.
CHILDREN'S HOSPITAL CORPORATION ATTN: RESEARCH FINANCE BOSTON, MA 02241-4413	N/A	PC	NOVEL GLUCOSE BINDERS FOR THE DEVELOPMENT OF GLUCOSE RESPONSIVE INSULINS	666,216.
CHILDREN'S HOSPITAL CORPORATION ATTN: RESEARCH FINANCE BOSTON, MA 02241-4413	N/A	PC	VEOIBD PRECISION MOLECULAR DIAGNOSES TO TARGETED THERAPIES- BOSTON	1,249,403.
CHILDREN'S HOSPITAL CORPORATION ATTN: RESEARCH FINANCE BOSTON, MA 02241-4413	N/A	PC	MOLECULAR SPATIAL SINGLE-CELL REMODELING IN PEDIATRIC CROHNS DISEASE	374,591.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
CHILDREN'S HOSPITAL CORPORATION ATTN: RESEARCH FINANCE BOSTON, MA 02241-4413	N/A	PC	DEVELOPMENT OF NOVEL GLUCOSE RESPONSIVE GLUCAGON (GRG) DELIVERY SYSTEM	1,173,337.
CHILDREN'S HOSPITAL CORPORATION ATTN: RESEARCH FINANCE BOSTON, MA 02241-4413	N/A	PC	VEOIBD PRECISION MOLECULAR DIAGNOSES TO TARGETED THERAPIES- BOSTON	1,226,580.
CHILDREN'S HOSPITAL CORPORATION ATTN: RESEARCH FINANCE BOSTON, MA 02241-4413	N/A	PC	NOVEL GLUCOSE BINDERS FOR THE DEVELOPMENT OF GLUCOSE RESPONSIVE INSULINS	665,654.
CHILDREN'S HOSPITAL LOS ANGELES SABAN RESEARCH INSTITUTE LOS ANGELES, CA 90027	N/A	PC	BEYOND COYOT1: EXPANSION OF PATIENT-CENTERED VIRTUAL CARE	679,025.
CHILDREN'S HOSPITAL LOS ANGELES SABAN RESEARCH INSTITUTE LOS ANGELES, CA 90027	N/A	PC	BEYOND COYOT1: EXPANSION OF PATIENT-CENTERED VIRTUAL CARE	684,686.
CHILDREN'S HOSPITAL MEDICAL CENTER 3333 BURNET AVENUE CINCINNATI, OH 45229	N/A	PC	PRECISION CROHNS DISEASE MANAGEMENT UTILIZING PREDICTIVE PROTEIN PANELS	235,507.
CHILDREN'S HOSPITAL MEDICAL CENTER 3333 BURNET AVENUE CINCINNATI, OH 45229	N/A	PC	BIOMARKERS OF INTESTINAL FIBROSIS IN SMALL BOWEL CROHNS DISEASE	282,554.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
CHILDREN'S HOSPITAL MEDICAL CENTER 3333 BURNET AVENUE CINCINNATI, OH 45229	N/A	PC	DELIVERY SYSTEM REDESIGN TO IMPROVE CARE FOR LOW-INCOME YOUTH WITH T1D	1,009,535.
CHILDREN'S HOSPITAL MEDICAL CENTER 3333 BURNET AVENUE CINCINNATI, OH 45229	N/A	PC	DEVELOP A PROGNOSTIC AI MODEL FOR FORECASTING CD PATIENT OUTCOMES	1,421,241.
CHILDREN'S HOSPITAL MEDICAL CENTER 3333 BURNET AVENUE CINCINNATI, OH 45229	N/A	PC	DEVELOP A PROGNOSTIC AI MODEL FOR FORECASTING CD PATIENT OUTCOMES	1,093,319.
CHILDREN'S HOSPITAL MEDICAL CENTER 3333 BURNET AVENUE CINCINNATI, OH 45229	N/A	PC	DELIVERY SYSTEM REDESIGN TO IMPROVE CARE FOR LOW-INCOME YOUTH WITH T1D	725,157.
CHILDREN'S HOSPITAL OF PHILADELPHIA 2716 SOUTH STREET PHILADELPHIA, PA 19146-2305	N/A	PC	CROHNS DISEASE EPITHELIAL STEM CELL ATLAS: PEDIATRIC TO ADULT CONTINUUM	272,676.
CHILDREN'S HUNGER FUND 13931 BALBOA BLVD SYLMAR, CA 91342	N/A	PC	FOOD SUPPORT IN ETHIOPIA AND ZAMBIA	151,800.
CHILDREN'S MERCY HOSPITAL 2401 GILLHAM ROAD KANSAS CITY, MO 64108	N/A	PC	TYPE 1 DIABETES RAPID LEARNING LAB	2,966,873.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
CHILDREN'S MERCY HOSPITAL 2401 GILLHAM ROAD KANSAS CITY, MO 64108	N/A	PC	TYPE 1 DIABETES RAPID LEARNING LAB	1,399,624.
CITIZENS HOUSING AND PLANNING COUNCIL OF NEW YORK, INC. 42 BROADWAY STE 2010 NEW YORK, NY 10004	N/A	PC	EDUCATION FOR NYC POLICYMAKERS ON HOUSING INITIATIVES TO IMPROVE HEALTH	200,000.
CITY PARKS FOUNDATION 830 FIFTH AVENUE NEW YORK, NY 10065	N/A	PC	NYC GREEN RELIEF & RECOVERY FUND	300,000.
CITY PARKS FOUNDATION 830 FIFTH AVENUE NEW YORK, NY 10065	N/A	PC	CATALYST: GROWING INTENSIVE PARK ENGAGEMENT IN VULNERABLE COMMUNITIES	491,131.
CLALIT HEALTH SERVICES 101 ARLOZOROV STREET TEL AVIV, ISRAEL	N/A	PC	YOSEFTAL HOSPITAL ADDITION	2,058,214.
CLALIT HEALTH SERVICES 101 ARLOZOROV STREET TEL AVIV, ISRAEL	N/A	PC	YOSEFTAL HOSPITAL ADDITION	3,847,500.
CLALIT HEALTH SERVICES 101 ARLOZOROV STREET TEL AVIV, ISRAEL	N/A	PC	COVID-19 VACCINE RESPONSES IN PATIENTS WITH IBD	177,281.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
CLALIT HEALTH SERVICES 101 ARLOZOROV STREET TEL AVIV, ISRAEL	N/A	PC	THE IBDMED NUTRITIONAL EDUCATION PROGRAM FOR CD CONTROL & PREVENTION	242,153.
CLALIT HEALTH SERVICES 101 ARLOZOROV STREET TEL AVIV, ISRAEL	N/A	PC	CLINICAL TRIAL TO EVALUATE A NOVEL MDI-BGM DECISION SUPPORT SYSTEM	926,084.
CLALIT HEALTH SERVICES 101 ARLOZOROV STREET TEL AVIV, ISRAEL	N/A	PC	CLINICAL TRIAL TO EVALUATE A NOVEL MDI-BGM DECISION SUPPORT SYSTEM	926,084.
CLALIT HEALTH SERVICES 101 ARLOZOROV STREET TEL AVIV, ISRAEL	N/A	PC	THE IBDMED NUTRITIONAL EDUCATION PROGRAM FOR CD CONTROL & PREVENTION	243,216.
CLALIT HEALTH SERVICES 101 ARLOZOROV STREET TEL AVIV, ISRAEL	N/A	PC	THE IBDMED NUTRITIONAL EDUCATION PROGRAM FOR CD CONTROL PREVENTION	243,216.
CLINTON HEALTH ACCESS INITIATIVE INC 383 DORCHESTER AVENUE, SUITE 400 BOSTON, MA 02127	N/A	PC	MARKET SHAPING TO IMPROVE ACCESS TO DIABETES CARE	1,132,215.
CLINTON HEALTH ACCESS INITIATIVE INC 383 DORCHESTER AVENUE, SUITE 400 BOSTON, MA 02127	N/A	PC	MARKET SHAPING TO IMPROVE ACCESS TO DIABETES CARE	1,372,583.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
COLUMBIA UNIVERSITY 615 WEST 131ST STREET NEW YORK, NY 10027-3922	N/A	PC	NOVEL SPATIALLY RESOLVED GENOMIC PROFILING OF CROHNS DISEASE TISSUE	210,228.
COLUMBIA UNIVERSITY 615 WEST 131ST STREET NEW YORK, NY 10027-3922	N/A	PC	COMBINATORIAL PERTURBATION OF CELLULAR NETWORK IN CROHNS DISEASE	210,638.
COLUMBIA UNIVERSITY 615 WEST 131ST STREET NEW YORK, NY 10027-3922	N/A	PC	COMBINATORIAL PERTURBATION OF CELLULAR NETWORK IN CROHNS DISEASE	351,258.
COLUMBIA UNIVERSITY 615 WEST 131ST STREET NEW YORK, NY 10027-3922	N/A	PC	COMBINATORIAL PERTURBATION OF CELLULAR NETWORK IN CROHNS DISEASE	334,798.
COLUMBIA UNIVERSITY 615 WEST 131ST STREET NEW YORK, NY 10027-3922	N/A	PC	COMBINATORIAL PERTURBATION OF CELLULAR NETWORK IN CROHNS DISEASE	429,646.
COLUMBIA UNIVERSITY 615 WEST 131ST STREET NEW YORK, NY 10027-3922	N/A	PC	COMBINATORIAL PERTURBATION OF CELLULAR NETWORK IN CROHNS DISEASE	413,263.
COMMUNITY MEMORIAL HOSPITAL DISTRICT 2731 HEALTHCARE DRIVE SYRACUSE, NE 68446	N/A	GOV	ECARE EMERGENCY AT SYRACUSE AREA HEALTH	13,320.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
CONSORCI INSTITUT D'INVESTIGACIONES BIOMEDICAS AUGUST ROSSELL 149 BARCELONA, SPAIN	N/A	GOV	EARLY DETECTION OF PERIANAL FISTULIZING DISEASE	261,948.
CONSORCI INSTITUT D'INVESTIGACIONES BIOMEDICAS AUGUST ROSSELL 149 BARCELONA, SPAIN	N/A	GOV	EARLY DETECTION OF PERIANAL FISTULIZING DISEASE	177,122.
COUNCIL ON FOUNDATIONS, INC. 1255 23RD ST NW WASHINGTON, DC 20037	N/A	PC	GENERAL OPERATING SUPPORT	34,000.
CROHN'S & COLITIS FOUNDATION, INC. 733 THIRD AVENUE, SUITE 510 NEW YORK, NY 10017	N/A	PC	SYSTEMATIZING IMPROVEMENT INTERVENTIONS OF URGENT CARE MANAGEMENT IN CD	570,831.
CROHN'S & COLITIS FOUNDATION, INC. 733 THIRD AVENUE, SUITE 510 NEW YORK, NY 10017	N/A	PC	SUPPORT JUNIOR SCIENTISTS TO ESTABLISH CAREERS IN IBD RESEARCH.	1,067,400.
CROHN'S & COLITIS FOUNDATION, INC. 733 THIRD AVENUE, SUITE 510 NEW YORK, NY 10017	N/A	PC	SYSTEMATIZING IMPROVEMENT INTERVENTIONS OF URGENT CARE MANAGEMENT IN CD	570,830.
CROHN'S & COLITIS FOUNDATION, INC. 733 THIRD AVENUE, SUITE 510 NEW YORK, NY 10017	N/A	PC	SYSTEMATIZING IMPROVEMENT INTERVENTIONS OF URGENT CARE MANAGEMENT IN CD	588,266.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
CROHN'S & COLITIS FOUNDATION, INC. 733 THIRD AVENUE, SUITE 510 NEW YORK, NY 10017	N/A	PC	SUPPORT JUNIOR SCIENTISTS TO ESTABLISH CAREERS IN IBD RESEARCH.	1,067,400.
CROHN'S & COLITIS FOUNDATION, INC. 733 THIRD AVENUE, SUITE 510 NEW YORK, NY 10017	N/A	PC	SYSTEMATIZING IMPROVEMENT INTERVENTIONS OF URGENT CARE MANAGEMENT IN CD	588,266.
CROHN'S AND COLITIS CANADA 60 ST CLAIR AVE EAST, SUITE 600 TORONTO, CANADA	N/A	PC	RCT TO IMPROVE TRANSITION OF PATIENTS W CD FROM PEDIATRIC TO ADULT CARE	255,521.
CROHN'S AND COLITIS CANADA 60 ST CLAIR AVE EAST, SUITE 600 TORONTO, CANADA	N/A	PC	IMPLEMENTATION OF A TELEMEDICINE NETWORK FOR CROHNS DISEASE PATIENTS	275,688.
CROHN'S AND COLITIS CANADA 60 ST CLAIR AVE EAST, SUITE 600 TORONTO, CANADA	N/A	PC	RCT TO IMPROVE TRANSITION OF PATIENTS W CD FROM PEDIATRIC TO ADULT CARE	253,783.
CROHN'S AND COLITIS CANADA 60 ST CLAIR AVE EAST, SUITE 600 TORONTO, CANADA	N/A	PC	IMPLEMENTATION OF A TELEMEDICINE NETWORK FOR CROHNS DISEASE PATIENTS	275,588.
CROHN'S AND COLITIS CANADA 60 ST CLAIR AVE EAST, SUITE 600 TORONTO, CANADA	N/A	PC	RCT TO IMPROVE TRANSITION OF PATIENTS W CD FROM PEDIATRIC TO ADULT CARE	284,646.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
CROHN'S AND COLITIS CANADA 60 ST CLAIR AVE EAST, SUITE 600 TORONTO, CANADA	N/A	PC	IMPLEMENTATION OF A TELEMEDICINE NETWORK FOR CROHNS DISEASE PATIENTS	286,838.
CROHN'S AND COLITIS CANADA 60 ST CLAIR AVE EAST, SUITE 600 TORONTO, CANADA	N/A	PC	RCT TO IMPROVE TRANSITION OF PATIENTS W CD FROM PEDIATRIC TO ADULT CARE	297,612.
CROHN'S AND COLITIS CANADA 60 ST CLAIR AVE EAST, SUITE 600 TORONTO, CANADA	N/A	PC	IMPLEMENTATION OF A TELEMEDICINE NETWORK FOR CROHNS DISEASE PATIENTS	374,912.
CROHN'S AND COLITIS UK 1 BISHOPS SQUARE HATFIELD, UNITED KINGDOM	N/A	PC	2021 2022 OPERATING SUPPORT FOR CROHNS AND COLITIS UK	75,900.
CROHN'S AND COLITIS UK 1 BISHOPS SQUARE HATFIELD, UNITED KINGDOM	N/A	PC	2021 2022 OPERATING SUPPORT FOR CROHNS AND COLITIS UK	75,900.
CROHN'S AND COLITIS UK 1 BISHOPS SQUARE HATFIELD, UNITED KINGDOM	N/A	PC	2021 2022 OPERATING SUPPORT FOR CROHNS AND COLITIS UK	75,900.
CROHN'S COLITIS CURE 1 O'CONNELL STREET SYDNEY, AUSTRALIA	N/A	PC	DEVELOPMENT OF CCCARE-P, A PEDIATRIC CD EMR TO DRIVE CONSISTENCY IN CARE	68,358.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
CROHN'S COLITIS CURE 1 O'CONNELL STREET SYDNEY, AUSTRALIA	N/A	PC	DEVELOPMENT OF CCCARE-P, A PEDIATRIC CD EMR TO DRIVE CONSISTENCY IN CARE	99,842.
CROHN'S COLITIS CURE 1 O'CONNELL STREET SYDNEY, AUSTRALIA	N/A	PC	DEVELOPMENT OF CCCARE-P, A PEDIATRIC CD EMR TO DRIVE CONSISTENCY IN CARE	90,467.
CROHN'S COLITIS CURE 1 O'CONNELL STREET SYDNEY, AUSTRALIA	N/A	PC	DEVELOPMENT OF CCCARE-P, A PEDIATRIC CD EMR TO DRIVE CONSISTENCY IN CARE	66,267.
DARTMOUTH- HITCHCOCK CLINIC ONE MEDICAL CENTER DRIVE LEBANON, NH 03756	N/A	PC	CAPACITY BUILDING FOR VIRTUAL IBD TELEMEDICINE NETWORK PROGRAM	197,461.
DE LA SALLE SOLIDARIETAINTERNAZIONALE ONLUS VIA AUREALIA, 476 ROME, ITALY	N/A	PC	ETHIOPIAN CATHOLIC UNIVERSITY DIAGNOSTIC LABORATORY	191,462.
DE LA SALLE SOLIDARIETAINTERNAZIONALE ONLUS VIA AUREALIA, 476 ROME, ITALY	N/A	PC	ETHIOPIAN CATHOLIC UNIVERSITY DIAGNOSTIC LABORATORY	94,780.
DUKE UNIVERSITY C/O OFFICE OF RESEARCH SUPPORT DURHAM, NC 27705-4677	N/A	PC	UTILIZATION OF INTERACTION BETWEEN AMINO ACIDS GIP IN PANCREATIC CELLS	275,000.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
DUNDY COUNTY HOSPITAL 1313 N CHEYENNE ST BENKELMAN, NE 69021	N/A	GOV	TELE-EMERGENCY SERVICES AT DUNDY COUNTY HOSPITAL	29,310.
DUNDY COUNTY HOSPITAL 1313 N CHEYENNE ST BENKELMAN, NE 69021	N/A	GOV	TELE-EMERGENCY SERVICES AT DUNDY COUNTY HOSPITAL	11,725.
DUNDY COUNTY HOSPITAL 1313 N CHEYENNE ST BENKELMAN, NE 69021	N/A	GOV	TELE-EMERGENCY SERVICES AT DUNDY COUNTY HOSPITAL	121,593.
ENGINEERING MINISTRIES INTERNATIONAL USA 7025 CAMPUS DRIVE COLORADO SPRINGS, CO 80920	N/A	PC	ALASKA WASH PROJECT	7,020,410.
FLORESTA USA INCORPORATED 4747 MORENA BLVD. STE 100 SAN DIEGO, CA 92117	N/A	PC	SCALING AT THE WATERSHED LEVEL TO EQUIP RURAL FAMILIES	516,231.
FOR INSPIRATION AND RECOGNITION OF SCIENCE TECHNOLOGY 200 BEDFORD STREET MANCHESTER, UNITED KINGDOM	N/A	PC	INSPIRE YOUNG PEOPLE TO BE SCIENCE AND TECHNOLOGY LEADERS	200,000.
FRANCISCAN CARE SERVICES INC 430 N MONITOR ST WEST POINT, NE 68788	N/A	PC	TELE-EMERGENCY SERVICES AT FRANCISCAN HEALTHCARE	42,729.

Total from continuation sheets

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
FRANCISCAN CARE SERVICES INC 430 N MONITOR ST WEST POINT, NE 68788	N/A	PC	TELE-EMERGENCY SERVICES AT FRANCISCAN HEALTHCARE	17,093.
FRIENDS OF THE ISRAEL DEFENSE FORCES 60 EAST 42 STREET NEW YORK, NY 10165	N/A	PC	THE UNIFORM TO UNIVERSITY SCHOLARSHIP PROGRAM	334,400.
FRIENDS OF THE ISRAEL DEFENSE FORCES 60 EAST 42 STREET NEW YORK, NY 10165	N/A	PC	THE UNIFORM TO UNIVERSITY SCHOLARSHIP PROGRAM	334,400.
FUND FOR PUBLIC HEALTH IN NEW YORK, INC. 22 CORTLANDT STREET, SUITE 802 NEW YORK, NY 10007	N/A	PC	NYC VACCINE EQUITY PARTNER ENGAGEMENT PROJECT	150,467.
GALILEE MEDICAL CENTER GALILEE MEDICAL CENTER NAHARIYA, ISRAEL	N/A	GOV	RENOVATION OF TWO FLOORS OF THE INTERNAL MEDICINE BUILDING	2,200,000.
GALILEE MEDICAL CENTER GALILEE MEDICAL CENTER NAHARIYA, ISRAEL	N/A	GOV	RENOVATION OF TWO FLOORS OF THE INTERNAL MEDICINE BUILDING	2,200,000.
GEORGIA TECH RESEARCH CORPORATION 505 10TH STREET, NW ATLANTA, GA 30332-0420	N/A	SOIII FI	TRACKING AND INTERPRETATION OF SINGLE-CELL CHARACTERISTICS IN CD PATIENTS	480,848.

Total from continuation sheets

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
GEORGIA TECH RESEARCH CORPORATION 505 10TH STREET, NW ATLANTA, GA 30332-0420	N/A	SOIII FI	TRACKING INTERPRETATION OF SINGLE-CELL CHARACTERISTICS IN CD PATIENTS	480,848.
GEORGIA TECH RESEARCH CORPORATION 505 10TH STREET, NW ATLANTA, GA 30332-0420	N/A	SOIII FI	TRACKING INTERPRETATION OF SINGLE-CELL CHARACTERISTICS IN CD PATIENTS	485,617.
GEORGIA TECH RESEARCH CORPORATION 505 10TH STREET, NW ATLANTA, GA 30332-0420	N/A	SOIII FI	TRACKING & INTERPRETATION OF SINGLE-CELL CHARACTERISTICS IN CD PATIENTS	485,616.
GIRLS WITH GUTS 6024 RIDGE AVENUE PHILADELPHIA, PA 19128	N/A	PC	2021 2022 OPERATING SUPPORT TO GIRLS WITH GUTS.	11,100.
GIRLS WITH GUTS 6024 RIDGE AVENUE PHILADELPHIA, PA 19128	N/A	PC	2021 2022 OPERATING SUPPORT TO GIRLS WITH GUTS.	11,100.
GLOBAL SOLIDARITY FUND 425 LEXINGTON AVE. NEW YORK, NY 10017	N/A	PC	JOB CREATION IN ETHIOPIA	1,508,200.
GLOBAL SOLIDARITY FUND 425 LEXINGTON AVE. NEW YORK, NY 10017	N/A	PC	JOB CREATION IN ETHIOPIA	1,508,200.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO 27 KING'S COLLEGE CIRCLE TORONTO, CANADA	N/A	PC	GLUCOSE RESPONSIVE GLUCAGON MICRONEEDLE PATCH - HYPOGLYCEMIA PREVENTION	185,460.
GRANTMAKERS IN HEALTH 1100 CT AVENUE NW WASHINGTON, DC 20036	N/A	PC	GRANTMAKERS IN HEALTH EFFECTIVE PHILANTHROPY FUND	119,803.
GUARDIAN ORG FOUNDATION 900 17TH STREET NW, SUITE 250 WASHINGTON, DC 20006	N/A	PC	AN INDEPENDENT JOURNALISM SERIES ON NON-COMMUNICABLE DISEASES	625,000.
HANNOVERSCHE KINDERHEILANSTALT JANUSZ-KORCZAK-ALLEE 12 HANNOVER, GERMANY	N/A	PC	FR1DA IN NORTH GERMANY: PRE-SYMPOMATIC TYPE 1 DIABETES TESTING IN KIDS	267,694.
HEBREW UNIVERSITY OF JERUSALEM OFFICE OF THE PRESIDENT JERUSALEM, ISRAEL	N/A	PC	METHYLATION PATTERNS OF CELL-FREE DNA AS A NOVEL BIOMARKER IN CROHNS	671,024.
HEBREW UNIVERSITY OF JERUSALEM OFFICE OF THE PRESIDENT JERUSALEM, ISRAEL	N/A	PC	METHYLATION PATTERNS OF CELL-FREE DNA AS A NOVEL BIOMARKER IN CROHNS	362,703.
HELEN KELLER INTERNATIONAL ONE DAG HAMMARSKJOLD PLAZA NEW YORK, NY 10017	N/A	PC	A CONTINUED PATH TO RESILIENCE AND EMPOWERMENT	1,652,490.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
HELEN KELLER INTERNATIONAL ONE DAG HAMMARSKJOLD PLAZA NEW YORK, NY 10017	N/A	PC	A CONTINUED PATH TO RESILIENCE AND EMPOWERMENT	1,941,293.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) HELMHOLTZ ZENTRUM MUNCHEN (GMBH), NEUHERBERG, GERMANY	N/A	PC	IDENTIFICATION OF INFANTS WITH HIGH RISK OF T1D - PRIMARY PREVENTION	1,431,241.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) HELMHOLTZ ZENTRUM MUNCHEN (GMBH), NEUHERBERG, GERMANY	N/A	PC	GPPAD COORDINATION CENTER CONTINUATION	668,906.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) HELMHOLTZ ZENTRUM MUNCHEN (GMBH), NEUHERBERG, GERMANY	N/A	PC	GPPAD-04 STUDY: SUPPLEMENT W/ B. INFANTIS TO MITIGATE T1D AUTOIMMUNITY	1,277,602.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) HELMHOLTZ ZENTRUM MUNCHEN (GMBH), NEUHERBERG, GERMANY	N/A	PC	THE GPPAD-03 STUDY: THE PRIMARY ORAL INSULIN TRIAL	2,350,161.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) HELMHOLTZ ZENTRUM MUNCHEN (GMBH), NEUHERBERG, GERMANY	N/A	PC	CONTINUATION OF THE GPPAD-02-STUDY	2,428,367.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) HELMHOLTZ ZENTRUM MUNCHEN (GMBH), NEUHERBERG, GERMANY	N/A	PC	FR1DA ORAL INSULIN INTERVENTION TRIAL AMENDMENT	460,108.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) HELMHOLTZ ZENTRUM MUNCHEN (GMBH), NEUHERBERG, GERMANY	N/A	PC	GPPAD-04 STUDY: SUPPLEMENT W/ B. INFANTIS TO MITIGATE T1D AUTOIMMUNITY	1,277,602.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) HELMHOLTZ ZENTRUM MUNCHEN (GMBH), NEUHERBERG, GERMANY	N/A	PC	CONTINUATION OF THE GPPAD-02-STUDY	2,451,335.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) HELMHOLTZ ZENTRUM MUNCHEN (GMBH), NEUHERBERG, GERMANY	N/A	PC	THE GPPAD-03 STUDY: THE PRIMARY ORAL INSULIN TRIAL	2,622,774.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) HELMHOLTZ ZENTRUM MUNCHEN (GMBH), NEUHERBERG, GERMANY	N/A	PC	GPPAD COORDINATION CENTER CONTINUATION	847,748.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) HELMHOLTZ ZENTRUM MUNCHEN (GMBH), NEUHERBERG, GERMANY	N/A	PC	GPPAD DRIED BLOOD SPOT OMICS TO PREDICT HEALTH OUTCOMES IN CHILDREN	80,432.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) HELMHOLTZ ZENTRUM MUNCHEN (GMBH), NEUHERBERG, GERMANY	N/A	PC	GPPAD COORDINATION CENTER CONTINUATION	847,748.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) HELMHOLTZ ZENTRUM MUNCHEN (GMBH), NEUHERBERG, GERMANY	N/A	PC	GPPAD-04 STUDY: SUPPLEMENT W/ B. INFANTIS TO MITIGATE T1D AUTOIMMUNITY	1,454,620.

Total from continuation sheets

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) HELMHOLTZ ZENTRUM MUNCHEN (GMBH), NEUHERBERG, GERMANY	N/A	PC	CONTINUATION OF THE GPPAD-02-STUDY	2,451,335.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) HELMHOLTZ ZENTRUM MUNCHEN (GMBH), NEUHERBERG, GERMANY	N/A	PC	THE GPPAD-03 STUDY: THE PRIMARY ORAL INSULIN TRIAL	2,622,773.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) HELMHOLTZ ZENTRUM MUNCHEN (GMBH), NEUHERBERG, GERMANY	N/A	PC	GPPAD-04 STUDY: SUPPLEMENT W/ B. INFANTIS TO MITIGATE T1D AUTOIMMUNITY	1,454,619.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) HELMHOLTZ ZENTRUM MUNCHEN (GMBH), NEUHERBERG, GERMANY	N/A	PC	CONTINUATION OF THE GPPAD-02-STUDY	2,440,023.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) HELMHOLTZ ZENTRUM MUNCHEN (GMBH), NEUHERBERG, GERMANY	N/A	PC	THE GPPAD-03 STUDY: THE PRIMARY ORAL INSULIN TRIAL	3,074,101.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) HELMHOLTZ ZENTRUM MUNCHEN (GMBH), NEUHERBERG, GERMANY	N/A	PC	GPPAD COORDINATION CENTER CONTINUATION	870,315.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) HELMHOLTZ ZENTRUM MUNCHEN (GMBH), NEUHERBERG, GERMANY	N/A	PC	GPPAD DRIED BLOOD SPOT OMICS TO PREDICT HEALTH OUTCOMES IN CHILDREN	82,445.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) HELMHOLTZ ZENTRUM MUNCHEN (GMBH), NEUHERBERG, GERMANY	N/A	PC	GPPAD COORDINATION CENTER CONTINUATION	870,314.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) HELMHOLTZ ZENTRUM MUNCHEN (GMBH), NEUHERBERG, GERMANY	N/A	PC	GPPAD-04 STUDY: SUPPLEMENT W/ B. INFANTIS TO MITIGATE T1D AUTOIMMUNITY	1,339,873.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) HELMHOLTZ ZENTRUM MUNCHEN (GMBH), NEUHERBERG, GERMANY	N/A	PC	THE GPPAD-03 STUDY: THE PRIMARY ORAL INSULIN TRIAL	3,074,100.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) HELMHOLTZ ZENTRUM MUNCHEN (GMBH), NEUHERBERG, GERMANY	N/A	PC	GPPAD-04 STUDY: SUPPLEMENT W/ B. INFANTIS TO MITIGATE T1D AUTOIMMUNITY	1,339,873.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) HELMHOLTZ ZENTRUM MUNCHEN (GMBH), NEUHERBERG, GERMANY	N/A	PC	GPPAD COORDINATION CENTER CONTINUATION	830,769.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) HELMHOLTZ ZENTRUM MUNCHEN (GMBH), NEUHERBERG, GERMANY	N/A	PC	GPPAD-04 STUDY: SUPPLEMENT W/ B. INFANTIS TO MITIGATE T1D AUTOIMMUNITY	1,482,901.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) HELMHOLTZ ZENTRUM MUNCHEN (GMBH), NEUHERBERG, GERMANY	N/A	PC	GPPAD COORDINATION CENTER CONTINUATION	830,769.

Total from continuation sheets

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) HELMHOLTZ ZENTRUM MUNCHEN (GMBH), NEUHERBERG, GERMANY	N/A	PC	GPPAD-04 STUDY: SUPPLEMENT W/ B. INFANTIS TO MITIGATE T1D AUTOIMMUNITY	1,482,900.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) HELMHOLTZ ZENTRUM MUNCHEN (GMBH), NEUHERBERG, GERMANY	N/A	PC	GPPAD-04 STUDY: SUPPLEMENT W/ B. INFANTIS TO MITIGATE T1D AUTOIMMUNITY	1,410,856.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) HELMHOLTZ ZENTRUM MUNCHEN (GMBH), NEUHERBERG, GERMANY	N/A	PC	GPPAD-04 STUDY: SUPPLEMENT W/ B. INFANTIS TO MITIGATE T1D AUTOIMMUNITY	1,410,856.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) HELMHOLTZ ZENTRUM MUNCHEN (GMBH), NEUHERBERG, GERMANY	N/A	PC	GPPAD-04 STUDY: SUPPLEMENT W/ B. INFANTIS TO MITIGATE T1D AUTOIMMUNITY	1,301,918.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) HELMHOLTZ ZENTRUM MUNCHEN (GMBH), NEUHERBERG, GERMANY	N/A	PC	GPPAD-04 STUDY: SUPPLEMENT W/ B. INFANTIS TO MITIGATE T1D AUTOIMMUNITY	1,301,917.
HELMHOLTZ ZENTRUM MUNCHEN (GMBH) HELMHOLTZ ZENTRUM MUNCHEN (GMBH), NEUHERBERG, GERMANY	N/A	PC	GPPAD-04 STUDY: SUPPLEMENT W/ B. INFANTIS TO MITIGATE T1D AUTOIMMUNITY	522,291.
HENRY J. KAISER FAMILY FOUNDATION 185 BERRY STREET NO 2000 SAN FRANCISCO, CA 94107	N/A	PC	KHN RURAL HEALTH DESK	1,239,878.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
HENRY J. KAISER FAMILY FOUNDATION 185 BERRY STREET NO 2000 SAN FRANCISCO, CA 94107	N/A	PC	KHN RURAL HEALTH DESK	1,275,901.
HERLEV OG GENTOFTE HOSPITAL HERLEV AND GENTOFTE HOSPITAL HERLEV, DENMARK	N/A	GOV	TARGETING GIP/GLP-2 RECEPTORS TO PREVENT HYPOGLYCEMIA IN T1D	394,362.
HERLEV OG GENTOFTE HOSPITAL HERLEV AND GENTOFTE HOSPITAL HERLEV, DENMARK	N/A	GOV	UTILIZATION OF INTERACTION BETWEEN AMINO ACIDS GIP IN PANCREATIC CELLS	275,000.
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI 1 GUSTAVE L. LEVY PL NEW YORK CITY, NY 10029	N/A	PC	MODULATING EARLY LIFE MICROBIOME THROUGH DIETARY INTERVENTION IN CROHNS	409,388.
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI 1 GUSTAVE L. LEVY PL NEW YORK CITY, NY 10029	N/A	PC	NEXT PHASE OF STEM CELL TRANSPLANT FOR REFRACTORY CROHNS DISEASE	415,688.
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI 1 GUSTAVE L. LEVY PL NEW YORK CITY, NY 10029	N/A	PC	NEXT PHASE OF STEM CELL TRANSPLANT FOR REFRACTORY CROHNS DISEASE	415,688.
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI 1 GUSTAVE L. LEVY PL NEW YORK CITY, NY 10029	N/A	PC	VEOIBD: PRECISION DIAGNOSES TO TARGETED THERAPIES: MOUNT SINAI STUDIES	220,000.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI 1 GUSTAVE L. LEVY PL NEW YORK CITY, NY 10029	N/A	PC	NEXT PHASE OF STEM CELL TRANSPLANT FOR REFRACTORY CROHNS DISEASE	404,688.
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI 1 GUSTAVE L. LEVY PL NEW YORK CITY, NY 10029	N/A	PC	NEXT PHASE OF STEM CELL TRANSPLANT FOR REFRACTORY CROHNS DISEASE	305,349.
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI 1 GUSTAVE L. LEVY PL NEW YORK CITY, NY 10029	N/A	PC	VEOIBD: PRECISION DIAGNOSES TO TARGETED THERAPIES: MOUNT SINAI STUDIES	220,000.
ICHUD HATZALAH ISRAEL 1221 (R.A.) 78 YIRMIYAHU ST. JERUSALEM, ISRAEL	N/A	PC	UNITED HATZALAH HUMANITARIAN MISSION FOR UKRAINE	739,000.
IDA COUNTY IOWA COMMUNITY HOSPITAL 701 EAST SECOND STREET IDA GROVE, IA 51445	N/A	PC	ECARE PHARMACY AT HORN MEMORIAL HOSPITAL	9,677.
IDEO.ORG 444 SPEAR STREET SAN FRANCISCO, CA 94105	N/A	PC	HUMAN-CENTERED DESIGN STUDY OF T1D IN MEDICALLY UNDERSERVED COMMUNITIES.	227,950.
IDEO.ORG 444 SPEAR STREET SAN FRANCISCO, CA 94105	N/A	PC	HUMAN-CENTERED DESIGN STUDY OF T1D IN MEDICALLY UNDERSERVED COMMUNITIES.	200,000.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
INSTITUT INTEGRATED BIOBANK OF LUXEMBOURG 1, RUE LOUIS RECH DUDELANGE, LUXEMBOURG	N/A	GOV	GPPAD BIOBANK - SINT1A	81,892.
INSTITUT INTEGRATED BIOBANK OF LUXEMBOURG 1, RUE LOUIS RECH DUDELANGE, LUXEMBOURG	N/A	GOV	BIOBANKING FOR THE PRIMARY ORAL INSULIN TRIAL	82,380.
INSTITUT INTEGRATED BIOBANK OF LUXEMBOURG 1, RUE LOUIS RECH DUDELANGE, LUXEMBOURG	N/A	GOV	GPPAD BIOBANK - SINT1A	87,446.
INSTITUT INTEGRATED BIOBANK OF LUXEMBOURG 1, RUE LOUIS RECH DUDELANGE, LUXEMBOURG	N/A	GOV	BIOBANKING FOR THE PRIMARY ORAL INSULIN TRIAL	90,190.
INSTITUT INTEGRATED BIOBANK OF LUXEMBOURG 1, RUE LOUIS RECH DUDELANGE, LUXEMBOURG	N/A	GOV	BIOBANKING FOR THE PRIMARY ORAL INSULIN TRIAL	148,458.
INSTITUT INTEGRATED BIOBANK OF LUXEMBOURG 1, RUE LOUIS RECH DUDELANGE, LUXEMBOURG	N/A	GOV	GPPAD BIOBANK - SINT1A	92,999.
INSTITUT INTEGRATED BIOBANK OF LUXEMBOURG 1, RUE LOUIS RECH DUDELANGE, LUXEMBOURG	N/A	GOV	GPPAD BIOBANK - SINT1A	98,553.

Total from continuation sheets

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
INSTITUT INTEGRATED BIOBANK OF LUXEMBOURG 1, RUE LOUIS RECH DUDELANGE, LUXEMBOURG	N/A	GOV	GPPAD BIOBANK - SINT1A	94,105.
INSTITUT INTEGRATED BIOBANK OF LUXEMBOURG 1, RUE LOUIS RECH DUDELANGE, LUXEMBOURG	N/A	GOV	GPPAD BIOBANK - SINT1A	99,659.
INSTITUT INTEGRATED BIOBANK OF LUXEMBOURG 1, RUE LOUIS RECH DUDELANGE, LUXEMBOURG	N/A	GOV	GPPAD BIOBANK - SINT1A	97,317.
INSTITUT NATIONALE DE LA SANTE ET DE LA RECHERCHE MEDICALE 86, RUE REGNAULT PARIS, FRANCE	N/A	GOV	BENIGN ISLET AUTOIMMUNITY TO T1D: CD8+ T-CELL BIOMARKERS OF PROGRESSION	164,338.
INSULIN FOR LIFE USA, INC. 2555 SW 76TH STREET GAINESVILLE, FL 32608	N/A	PC	INSULIN FOR LIFE USA STRENGTHENING ORGANIZATIONAL CAPACITY	320,933.
INSULIN FOR LIFE USA, INC. 2555 SW 76TH STREET GAINESVILLE, FL 32608	N/A	PC	INSULIN FOR LIFE USA STRENGTHENING ORGANIZATIONAL CAPACITY	341,606.
INTERNATIONAL BOWEL ULTRASOUND GROUP E.V. HARKORTSTR. 1 MUNSTER, GERMANY	N/A	NC	POINT-OF-CARE INTESTINAL ULTRASOUND TRAINING IN THE UNITED STATES	172,967.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
INTERNATIONAL BOWEL ULTRASOUND GROUP E.V. HARKORTSTR. 1 MUNSTER, GERMANY	N/A	NC	THE DEVELOPMENT OF A DISEASE ACTIVITY INDEX FOR INTESTINAL ULTRASOUND	779,377.
INTERNATIONAL BOWEL ULTRASOUND GROUP E.V. HARKORTSTR. 1 MUNSTER, GERMANY	N/A	NC	THE DEVELOPMENT OF A DISEASE ACTIVITY INDEX FOR INTESTINAL ULTRASOUND	718,578.
INTERNATIONAL BOWEL ULTRASOUND GROUP E.V. HARKORTSTR. 1 MUNSTER, GERMANY	N/A	NC	THE DEVELOPMENT OF A DISEASE ACTIVITY INDEX FOR INTESTINAL ULTRASOUND	375,221.
IOWA DEPARTMENT OF PUBLIC HEALTH 321 EAST 12TH DES MOINES, IA 50319	N/A	GOV	IOWA FIRST RESPONDER AED INITIATIVE	186,944.
IOWA DEPARTMENT OF PUBLIC HEALTH 321 EAST 12TH DES MOINES, IA 50319	N/A	GOV	IOWA FIRST RESPONDER AED INITIATIVE	58,968.
ISRAEL ANTIQUITIES AUTHORITY 27 SULTAN SULEIMAN STREET JERUSALEM, ISRAEL	N/A	GOV	JAY & JEANIE SCHOTTENSTEIN NATIONAL CAMPUS FOR THE ARCHAEOLOGY OF ISRAEL	400,000.
JAEB CENTER FOR HEALTH RESEARCH FOUNDATION, INC. 15310 AMBERLY DRIVE, SUITE 350 TAMPA, FL 33647	N/A	PC	EXERCISE IN DIABETES INITIATIVE: LARGE ADULT STUDY	159,838.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
JAEB CENTER FOR HEALTH RESEARCH FOUNDATION, INC. 15310 AMBERLY DRIVE, SUITE 350 TAMPA, FL 33647	N/A	PC	VIRTUAL DIABETES SPECIALTY CLINIC STUDY EVALUATING REMOTE INITIATION CGM	724,198.
JAEB CENTER FOR HEALTH RESEARCH FOUNDATION, INC. 15310 AMBERLY DRIVE, SUITE 350 TAMPA, FL 33647	N/A	PC	EXERCISE IN DIABETES INITIATIVE: PEDIATRIC STUDY	400,000.
JAEB CENTER FOR HEALTH RESEARCH FOUNDATION, INC. 15310 AMBERLY DRIVE, SUITE 350 TAMPA, FL 33647	N/A	PC	CGM MONITORING OF MATERNAL DYSGLYCEMIA	425,771.
JAEB CENTER FOR HEALTH RESEARCH FOUNDATION, INC. 15310 AMBERLY DRIVE, SUITE 350 TAMPA, FL 33647	N/A	PC	EXERCISE IN DIABETES INITIATIVE: PEDIATRIC STUDY	625,000.
JAEB CENTER FOR HEALTH RESEARCH FOUNDATION, INC. 15310 AMBERLY DRIVE, SUITE 350 TAMPA, FL 33647	N/A	PC	EXERCISE IN DIABETES INITIATIVE: PEDIATRIC STUDY	283,542.
JAEB CENTER FOR HEALTH RESEARCH FOUNDATION, INC. 15310 AMBERLY DRIVE, SUITE 350 TAMPA, FL 33647	N/A	PC	EVALUATION OF THE RELATIONSHIP OF GLUCOSE METRICS VIA CGM W DIABETES RETINOPATHY	286,747.
JAEB CENTER FOR HEALTH RESEARCH FOUNDATION, INC. 15310 AMBERLY DRIVE, SUITE 350 TAMPA, FL 33647	N/A	PC	EVALUATION OF THE RELATIONSHIP OF GLUCOSE METRICS VIA CGM W DIABETES RETINOPATHY	384,845.

Total from continuation sheets

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
JAEB CENTER FOR HEALTH RESEARCH FOUNDATION, INC. 15310 AMBERLY DRIVE, SUITE 350 TAMPA, FL 33647	N/A	PC	EVALUATION OF THE RELATIONSHIP OF GLUCOSE METRICS VIA CGM W DIABETES RETINOPATHY	387,943.
JAEB CENTER FOR HEALTH RESEARCH FOUNDATION, INC. 15310 AMBERLY DRIVE, SUITE 350 TAMPA, FL 33647	N/A	PC	EVALUATION OF THE RELATIONSHIP OF GLUCOSE METRICS VIA CGM W DIABETES RETINOPATHY	331,671.
JAEB CENTER FOR HEALTH RESEARCH FOUNDATION, INC. 15310 AMBERLY DRIVE, SUITE 350 TAMPA, FL 33647	N/A	PC	EVALUATION OF THE RELATIONSHIP OF GLUCOSE METRICS VIA CGM W DIABETES RETINOPATHY	162,082.
JDRF AUSTRALIA 80-84 CHANDOS STREET SYDNEY, AUSTRALIA	N/A	PC	ENDIA EARLY TO MID-CAREER SCIENCE ACCELERATOR AWARDS 2021	232,577.
JDRF INTERNATIONAL 200 VESEY STREET NEW YORK, NY 10281	N/A	PC	HELMSLEY AND JDRF CO-FUNDED WORKSHOPS	150,000.
JDRF INTERNATIONAL 200 VESEY STREET NEW YORK, NY 10281	N/A	PC	JDRF GLOBAL DIABETES ACCESS INITIATIVE	999,800.
JDRF INTERNATIONAL 200 VESEY STREET NEW YORK, NY 10281	N/A	PC	HCP T1D EDUCATION PROGRAM (STATE OF AFFAIRS AND PEAK)	99,699.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
JDRF INTERNATIONAL 200 VESEY STREET NEW YORK, NY 10281	N/A	PC	JDRF TRAINING PROGRAMS	750,000.
JDRF INTERNATIONAL 200 VESEY STREET NEW YORK, NY 10281	N/A	PC	HELMSLEY AND JDRF CO-FUNDED WORKSHOPS	150,000.
JERUSALEM COLLEGE OF TECHNOLOGY 21 HAVAAD HALEUMI ST. JERUSALEM, ISRAEL	N/A	PC	HELMSLEY FACULTY OF LIFE AND HEALTH SCIENCES BUILDING	5,465,000.
JOSLIN DIABETES CENTER, INC. ONE JOSLIN PLACE BOSTON, MA 02215	N/A	PC	AN INTEGRATED CARE MODEL FOR OLDER ADULTS WITH INSULIN-TREATED DIABETES	941,354.
JOSLIN DIABETES CENTER, INC. ONE JOSLIN PLACE BOSTON, MA 02215	N/A	PC	AN INTEGRATED CARE MODEL FOR OLDER ADULTS WITH INSULIN-TREATED DIABETES	857,270.
JUVENILE DIABETES RESEARCH FOUNDATION CANADA 235 YORKLAND BLVD., SUITE 600 TORONTO, CANADA	N/A	PC	JDRF CANADA PSYCHOSOCIAL HEALTH INITIATIVE	36,000.
JUVENILE DIABETES RESEARCH FOUNDATION CANADA 235 YORKLAND BLVD., SUITE 600 TORONTO, CANADA	N/A	PC	JDRF CANADA PSYCHOSOCIAL HEALTH INITIATIVE	19,000.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
KATHOLIEKE UNIVERSITEIT LEUVEN WAAISTRAAT 6 BOX 5105 LEUVEN, BELGIUM	N/A	PC	AN ENTEROCHROMAFFIN CELL AND MACROPHAGE ATLAS OF THE HUMAN GUT	530,354.
KATHOLIEKE UNIVERSITEIT LEUVEN WAAISTRAAT 6 BOX 5105 LEUVEN, BELGIUM	N/A	PC	COMBINATION THERAPY OF DIET WITH BIOLOGICALS FOR CD	656,542.
KATHOLIEKE UNIVERSITEIT LEUVEN WAAISTRAAT 6 BOX 5105 LEUVEN, BELGIUM	N/A	PC	AN ENTEROCHROMAFFIN CELL AND MACROPHAGE ATLAS OF THE HUMAN GUT	246,663.
KATHOLIEKE UNIVERSITEIT LEUVEN WAAISTRAAT 6 BOX 5105 LEUVEN, BELGIUM	N/A	PC	SUPPORT FOR INNODIA HARVEST ACTIVITIES AT ACADEMIC CONSORTIUM MEMBERS.	807,155.
KATHOLIEKE UNIVERSITEIT LEUVEN WAAISTRAAT 6 BOX 5105 LEUVEN, BELGIUM	N/A	PC	COMBINATION THERAPY OF DIET WITH BIOLOGICALS FOR CD	408,046.
KATHOLIEKE UNIVERSITEIT LEUVEN WAAISTRAAT 6 BOX 5105 LEUVEN, BELGIUM	N/A	PC	AN ENTEROCHROMAFFIN CELL AND MACROPHAGE ATLAS OF THE HUMAN GUT	246,662.
KATHOLIEKE UNIVERSITEIT LEUVEN WAAISTRAAT 6 BOX 5105 LEUVEN, BELGIUM	N/A	PC	COMBINATION THERAPY OF DIET WITH BIOLOGICALS FOR CD	362,770.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
KING'S COLLEGE LONDON 150 STAMFORD STREET LONDON, UNITED KINGDOM	N/A	PC	EVALUATE THE BIOLOGICAL, SOCIAL AND ECONOMIC IMPACT OF HYPOGLYCEMIA	307,779.
KING'S COLLEGE LONDON 150 STAMFORD STREET LONDON, UNITED KINGDOM	N/A	PC	T CELL RECEPTOR SEQUENCING IN T1D - BIOMARKER & TECHNOLOGY DEVELOPMENT	115,097.
KING'S COLLEGE LONDON 150 STAMFORD STREET LONDON, UNITED KINGDOM	N/A	PC	MULTIPEPTIDE PROOF-OF-CONCEPT STUDY: STAGE III	1,074,992.
KING'S COLLEGE LONDON 150 STAMFORD STREET LONDON, UNITED KINGDOM	N/A	PC	IDENTIFYING THE ROLE OF FOOD ADDITIVE EMULSIFIERS IN CROHNS DISEASE	288,101.
KING'S COLLEGE LONDON 150 STAMFORD STREET LONDON, UNITED KINGDOM	N/A	PC	MULTIPEPTIDE PROOF-OF-CONCEPT STUDY: STAGE III	1,142,151.
KING'S COLLEGE LONDON 150 STAMFORD STREET LONDON, UNITED KINGDOM	N/A	PC	IDENTIFYING THE ROLE OF FOOD ADDITIVE EMULSIFIERS IN CROHNS DISEASE	195,494.
KING'S COLLEGE LONDON 150 STAMFORD STREET LONDON, UNITED KINGDOM	N/A	PC	MULTIPEPTIDE PROOF-OF-CONCEPT STUDY: STAGE III	1,325,562.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
KING'S COLLEGE LONDON 150 STAMFORD STREET LONDON, UNITED KINGDOM	N/A	PC	MULTIPEPTIDE PROOF-OF-CONCEPT STUDY: STAGE III	1,296,483.
KING'S COLLEGE LONDON 150 STAMFORD STREET LONDON, UNITED KINGDOM	N/A	PC	MULTIPEPTIDE PROOF-OF-CONCEPT STUDY: STAGE III	369,984.
KING'S COLLEGE LONDON 150 STAMFORD STREET LONDON, UNITED KINGDOM	N/A	PC	MULTIPEPTIDE PROOF-OF-CONCEPT STUDY: STAGE III	778,535.
KING'S COLLEGE LONDON 150 STAMFORD STREET LONDON, UNITED KINGDOM	N/A	PC	MULTIPEPTIDE PROOF-OF-CONCEPT STUDY: STAGE III	1,079,926.
KITTSON MEMORIAL HOSPITAL ASSOCIATION 1010 SOUTH BIRCH AVENUE HALLOCK, MN 56728	N/A	PC	EEMERGENCY AT KITTSON HEALTHCARE	11,729.
KLINIKUM DER LUDWIG-MAXIMILIANS-UNIVERSITT FEODOR-LYNEN-STRABE 17 MUCHEN, GERMANY	N/A	GOV	FMT FOR MAINTENANCE OF REMISSION AFTER EEN TREATMENT IN CROHNS DISEASE	600,891.
KLINIKUM DER LUDWIG-MAXIMILIANS-UNIVERSITT FEODOR-LYNEN-STRABE 17 MUNCHEN, GERMANY	N/A	GOV	FMT FOR MAINTENANCE OF REMISSION AFTER EEN TREATMENT IN CROHNS DISEASE	644,601.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
KLINIKUM DER LUDWIG-MAXIMILIANS-UNIVERSITÄT FEODOR-LYNEN-STRABE 17 MUNICH, GERMANY	N/A	GOV	FMT FOR MAINTENANCE OF REMISSION AFTER EEN TREATMENT IN CROHNS DISEASE	606,581.
KLINIKUM DER UNIVERSITÄT MÜNCHEN FEODOR-LYNEN-STRABE 17 MÜNCHEN, GERMANY	N/A	GOV	FMT FOR MAINTENANCE OF REMISSION AFTER EEN TREATMENT IN CROHNS DISEASE	659,714.
KLINIKUM DER UNIVERSITÄT MÜNCHEN FEODOR-LYNEN-STRABE 17 MÜNCHEN, GERMANY	N/A	GOV	FMT FOR MAINTENANCE OF REMISSION AFTER EEN TREATMENT IN CROHNS DISEASE	649,424.
LAKES REGIONAL HEALTHCARE HIGHWAY 71 SOUTH SPIRIT LAKE, IA 51360	N/A	GOV	ECARE PHARMACY AT LAKES REGIONAL HEALTHCARE	10,856.
LINCOLN COUNTY HOSPITAL DISTRICT 700 NORTH SPRING STREET CALIENTE, NV 89008	N/A	GOV	GROVER C. DILS MEDICAL CENTER ULTRASOUND PROJECT	36,064.
LIVING WATER INTERNATIONAL 4001 GREENBRIAR DRIVE STAFFORD, CT 77477	N/A	PC	INTEGRATED WASH PROGRAM IN CHIPATA DISTRICT, ZAMBIA	1,369,113.
LUCAS COUNTY HEALTH CENTER 1200 NORTH 7TH STREET CHARITON, IA 50049	N/A	PC	AVERA ECARE EMERGENCY VIRTUAL HEALTH AT LUCAS COUNTY HEALTH CENTER	45,334.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
LUCAS COUNTY HEALTH CENTER 1200 NORTH 7TH STREET CHARITON, IA 50049	N/A	PC	AVERA ECARE EMERGENCY VIRTUAL HEALTH AT LUCAS COUNTY HEALTH CENTER	17,970.
MACCABI HEALTHCARE SERVICES 27 HAMERED ST TEL AVIV, ISRAEL	N/A	PC	MOBILE MAMMOGRAPHY UNIT	31,500.
MACCABI HEALTHCARE SERVICES 27 HAMERED ST TEL AVIV, ISRAEL	N/A	PC	MOBILE MAMMOGRAPHY UNIT	31,500.
MADISON COUNTY MEMORIAL HOSPITAL 300 W. HUTCHINGS STREET WINTERSET, IA 50273	N/A	GOV	IMPLEMENTATION OF EEMERGENCY AT MADISON COUNTY HEALTH CARE SYSTEM	37,965.
MADISON COUNTY MEMORIAL HOSPITAL 300 W. HUTCHINGS STREET WINTERSET, IA 50273	N/A	GOV	IMPLEMENTATION OF EEMERGENCY AT MADISON COUNTY HEALTH CARE SYSTEM	15,187.
MAINEHEALTH 22 BRAMHALL STREET PORTLAND, ME 04102	N/A	PC	TRANSFORMING RURAL DIABETES CARE IN MAINE	848,894.
MAINEHEALTH 22 BRAMHALL STREET PORTLAND, ME 04102	N/A	PC	TRANSFORMING RURAL DIABETES CARE IN MAINE	596,795.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
MASSACHUSETTS GENERAL HOSPITAL 55 FRUIT STREET BOSTON, MA 02114-2696	N/A	PC	DEVELOP A DEVICE TO IMPROVE ROUTINE DISEASE MONITORING FOR CD.	843,986.
MASSACHUSETTS GENERAL HOSPITAL 55 FRUIT STREET BOSTON, MA 02114-2696	N/A	PC	CROHNS DISEASE IN SOUTH ASIANS: DEFINING DISEASE BIOLOGY FOR PREVENTION	350,278.
MASSACHUSETTS GENERAL HOSPITAL 55 FRUIT STREET BOSTON, MA 02114-2696	N/A	PC	CROHNS DISEASE IN SOUTH ASIANS: DEFINING DISEASE BIOLOGY FOR PREVENTION	352,645.
MASSACHUSETTS GENERAL HOSPITAL 55 FRUIT STREET BOSTON, MA 02114-2696	N/A	PC	DEVELOP A DEVICE TO IMPROVE ROUTINE DISEASE MONITORING FOR CD.	752,326.
MASSACHUSETTS GENERAL HOSPITAL 55 FRUIT STREET BOSTON, MA 02114-2696	N/A	PC	CROHNS DISEASE IN SOUTH ASIANS: DEFINING DISEASE BIOLOGY FOR PREVENTION	353,249.
MAYO CLINIC 200 FIRST STREET SW ROCHESTER, MN 55905	N/A	PC	OFF-SITE REMOTE CONTROL ROBOTIC PERCUTANEOUS CORONARY INTERVENTIONS	385,906.
MAYO CLINIC 200 FIRST STREET SW ROCHESTER, MN 55905	N/A	PC	STENOSIS THERAPY AND ANTI-FIBROTIC RESEARCH CONSORTIUM	103,827.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
MAYO CLINIC 200 FIRST STREET SW ROCHESTER, MN 55905	N/A	PC	DEVELOP AN INTESTINAL MUCOSAL AND IMAGING BIOMARKER FOR STRICTURING CD	334,407.
MAYO CLINIC 200 FIRST STREET SW ROCHESTER, MN 55905	N/A	PC	DEVELOP AN INTESTINAL MUCOSAL AND IMAGING BIOMARKER FOR STRICTURING CD	151,705.
MCGILL UNIVERSITY JAMES ADMINISTRATION BUILDING MONTREAL, CANADA	N/A	PC	THE HUMAN CELL ATLAS: ETHICS AND DATA GOVERNANCE	189,596.
MEDSTAR HEALTH INC 3007 TILDEN STREET NW WASHINGTON, DC 20008	N/A	SOIII FI	2022 SUPPORT FOR THE 'MASTERING CLINICAL CHALLENGES IN IBD' SYMPOSIUM	35,000.
MEEKER MEMORIAL HOSPITAL 612 S SIBLEY AVE LITCHFIELD, MN 55355	N/A	GOV	EPHARMACY AT MEEKER MEMORIAL HOSPITAL	12,269.
MI STATE UNIVERSITY HANNAH ADMINISTRATION BUILDING EAST LANSING, MI 48824-2601	N/A	PC	A C-PEPTIDE COMPLEX FOR IMPROVED GLUCOSE METABOLISM IN PEOPLE WITH T1D	382,594.
MONROE COUNTY HOSPITAL 6580 165TH STREET ALBIA, IA 52531	N/A	GOV	EPHARMACY AT MONROE COUNTY HOSPITAL & CLINICS	17,577.

Total from continuation sheets

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
MONROE COUNTY HOSPITAL 6580 165TH STREET ALBIA, IA 52531	N/A	GOV	EPHARMACY AT MONROE COUNTY HOSPITAL CLINICS	7,031.
MONUMENT HEALTH NETWORK, INC. 2140 JUNCTION AVE. STURGIS, SD 57785	N/A	PC	EEMERGENCY AT MONUMENT HEALTH STURGIS HOSPITAL	41,418.
MONUMENT HEALTH NETWORK, INC. 2140 JUNCTION AVE. STURGIS, SD 57785	N/A	PC	EEMERGENCY AT MONUMENT HEALTH STURGIS HOSPITAL	16,568.
NATIONAL ACADEMY OF SCIENCES 500 5TH STREET NW WASHINGTON, DC 20001	N/A	PC	STRENGTHENING MINORITY SERVING INSTITUTIONS	150,000.
NATIONAL COMMITTEE FOR QUALITY ASSURANCE 1100 13TH ST NW WASHINGTON, DC 20005	N/A	PC	TRANSFORM HEALTHCARE THROUGH MEASUREMENT, TRANSPARENCY, & ACCOUNTABILITY	836,732.
NATIONAL COMMITTEE FOR QUALITY ASSURANCE 1100 13TH ST NW WASHINGTON, DC 20005	N/A	PC	TRANSFORM HEALTHCARE THROUGH MEASUREMENT, TRANSPARENCY, ACCOUNTABILITY	621,487.
NATIONAL COMMITTEE FOR QUALITY ASSURANCE 1100 13TH ST NW WASHINGTON, DC 20005	N/A	PC	TRANSFORM HEALTHCARE THROUGH MEASUREMENT, TRANSPARENCY, & ACCOUNTABILITY	753,478.

Total from continuation sheets

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
NATIONAL PARK FOUNDATION 1500 K ST. NW WASHINGTON, DC 20005	N/A	PC	BADLANDS NATIONAL PARK CEDAR PASS VISITOR CENTER	1,500,000.
NATIONAL PARK FOUNDATION 1500 K ST. NW WASHINGTON, DC 20005	N/A	PC	LITTLE BIGHORN BATTLEFIELD NATIONAL MONUMENT VISITOR CENTER	1,400,000.
NATIONAL PARK FOUNDATION 1500 K ST. NW WASHINGTON, DC 20005	N/A	PC	BERING LAND BRIDGE VISITOR CENTER	2,449,328.
NATIONAL PARK FOUNDATION 1500 K ST. NW WASHINGTON, DC 20005	N/A	PC	LITTLE BIGHORN BATTLEFIELD NATIONAL MONUMENT VISITOR CENTER	1,750,000.
NATIONAL PARK FOUNDATION 1500 K ST. NW WASHINGTON, DC 20005	N/A	PC	BADLANDS NATIONAL PARK CEDAR PASS VISITOR CENTER	750,000.
NATIONAL PARK FOUNDATION 1500 K ST. NW WASHINGTON, DC 20005	N/A	PC	BERING LAND BRIDGE VISITOR CENTER	1,163,270.
NEBRASKA DEPARTMENT OF HEALTH & HUMAN SERVICES 301 CENTENNIAL MALL SOUTH LINCOLN, NE 68508	N/A	GOV	NEBRASKA FIRST RESPONDER AED PROJECT	545,083.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
NEBRASKA DEPARTMENT OF HEALTH & HUMAN SERVICES 301 CENTENNIAL MALL SOUTH LINCOLN, NE 68508	N/A	GOV	NEBRASKA FIRST RESPONDER AED PROJECT	309,887.
NEVADA COMMUNITY FOUNDATION, INC. 1980 FESTIVAL PLAZA DRIVE LAS VEGAS, NV 89135	N/A	PC	RURAL NEVADA ULTRASOUND CARE INITIATIVE	1,035,951.
NEVADA DEPARTMENT OF HEALTH AND HUMAN SERVICES 4150 TECHNOLOGY WAY CARSON CITY, NV 89706	N/A	GOV	NEVADA VIRTUAL CRISIS CARE	1,333,324.
NEVADA DEPARTMENT OF HEALTH AND HUMAN SERVICES 4150 TECHNOLOGY WAY CARSON CITY, NV 89706	N/A	GOV	NEVADA VIRTUAL CRISIS CARE	1,230,038.
NEVADA DEPARTMENT OF HEALTH AND HUMAN SERVICES 4150 TECHNOLOGY WAY CARSON CITY, NV 89706	N/A	GOV	NEVADA VIRTUAL CRISIS CARE	1,239,092.
NEW DESTINY HOUSING CORPORATION 12 W. 37TH STREET, 7TH FLOOR NEW YORK, NY 10018	N/A	PC	AFTERCARE INTERVENTION TO IMPROVE HOUSING & HEALTH STABILITY	215,030.
NEW VENTURE FUND 1201 CT AVE NW, SUITE 300 WASHINGTON, DC 20036	N/A	PC	TYPE 1 DIABETES CAMPS PROJECT (2022 - 2024)	1,435,500.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
NEW VENTURE FUND 1201 CT AVE NW, SUITE 300 WASHINGTON, DC 20036	N/A	PC	TYPE 1 DIABETES CAMPS PROJECT (2022 - 2024)	1,468,813.
NEW YORK CITY HEALTH AND HOSPITALS CORPORATION 125 WORTH STREET NEW YORK, NY 10013	N/A	PC	EXPRESSCARE TELE-BEHAVIORAL SERV. & STRATEGIES (NYC HIGH NEEDS PATIENTS)	1,457,500.
NEW YORK CITY HEALTH AND HOSPITALS CORPORATION 125 WORTH STREET NEW YORK, NY 10013	N/A	PC	EXPRESSCARE TELE-BEHAVIORAL SERV. & STRATEGIES (NYC HIGH NEEDS PATIENTS)	825,000.
NEW YORK UNIVERSITY 665 BROADWAY NEW YORK, NY 10012	N/A	PC	IDENTIFYING ENVIRONMENTAL CONTRIBUTORS TO CROHNS DISEASE	1,046,686.
NEW YORK UNIVERSITY 665 BROADWAY NEW YORK, NY 10012	N/A	PC	EVALUATION OF INTERVENTIONS FOR COLLABORATIVE FOR HOMELESS HEALTHCARE	205,596.
NEW YORK UNIVERSITY 665 BROADWAY NEW YORK, NY 10012	N/A	PC	ANALYSIS OF MEDICAID DATA TO IMPROVE CARE FOR HOMELESS PATIENTS	101,043.
NEW YORK UNIVERSITY 665 BROADWAY NEW YORK, NY 10012	N/A	PC	ANALYSIS OF MEDICAID DATA TO IMPROVE CARE FOR HOMELESS PATIENTS	100,123.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
NORTH DAKOTA DEPARTMENT OF HEALTH 600 E BOULEVARD AVENUE BISMARCK, ND 58505-0200	N/A	GOV	NORTH DAKOTA LAW ENFORCEMENT AED PROJECT	173,689.
NORTHERN WESTCHESTER HOSPITAL ASSOCIATION 400 EAST MAIN STREET MOUNT KISCO, NY 10549	N/A	PC	MATERNAL CHILD HEALTH UNIT FACILITIES RENOVATION	200,000.
OREGON HEALTH & SCIENCE UNIVERSITY 3181 SW SAM JACKSON PARK RD. PORTLAND, OR 97239-3098	N/A	GOV	TO EXPAND THE NICH PROGRAM IN THE CALIFORNIA BAY AREA	654,234.
PALO ALTO VETERANS INSTITUTE FOR RESEARCH 3801 MIRANDA AVENUE PALO ALTO, CA 94304-0038	N/A	PC	CELL ATLAS OF INTESTINAL LYMPHOID TISSUES AND CHANGES IN CROHNS DISEASE	500,825.
PALO ALTO VETERANS INSTITUTE FOR RESEARCH 3801 MIRANDA AVENUE PALO ALTO, CA 94304-0038	N/A	PC	CELL ATLAS OF INTESTINAL LYMPHOID TISSUES AND CHANGES IN CROHNS DISEASE	499,175.
PANORAMA GLOBAL 2101 FOURTH AVENUE, SUITE 2100 SEATTLE, WA 98121	N/A	PC	TYPE 1 DIABETES GLOBAL ACCESS MICRO-GRANT FUND	999,473.
PANORAMA GLOBAL 2101 FOURTH AVENUE, SUITE 2100 SEATTLE, WA 98121	N/A	PC	TYPE 1 DIABETES GLOBAL ACCESS MICRO-GRANT FUND	1,167,087.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
PARKER INSTITUTE FOR CANCER IMMUNOTHERAPY 1 LETTERMAN DRIVE SAN FRANCISCO, CA 94129	N/A	PC	STUDYING AUTOIMMUNE DIABETES FOLLOWING CERTAIN CANCER IMMUNOTHERAPIES.	358,140.
PATH 2201 WESTLAKE AVENUE SEATTLE, WA 98121	N/A	PC	THE DIABETES CAREPAK PROJECT: ENABLING HIGH-QUALITY DIABETES SELF-CARE	2,004,478.
PATH 2201 WESTLAKE AVENUE SEATTLE, WA 98121	N/A	PC	THE DIABETES CAREPAK PROJECT: ENABLING HIGH-QUALITY DIABETES SELF-CARE	1,838,580.
PAWNEE COUNTY MEMORIAL HOSPITAL 600 I STREET PAWNEE CITY, NE 68420	N/A	GOV	ECARE PHARMACY AT PAWNEE COUNTY MEMORIAL HOSPITAL	17,845.
PAWNEE COUNTY MEMORIAL HOSPITAL 600 I STREET PAWNEE CITY, NE 68420	N/A	GOV	ECARE PHARMACY AT PAWNEE COUNTY MEMORIAL HOSPITAL	7,139.
PHILIP HEALTH SERVICES, INC. 503 W. PINE STREET PHILIP, SD 57567	N/A	PC	IMPLEMENTATION OF AVERA EEMERGENCY AT PHILIP HEALTH SERVICES	12,317.
PROJECT NYAME NSA, LTD. 33 WILLETS LANE MANHASSET, NY 11030	N/A	PC	PROJECT NYAME NSA ZAMBIA EXPANSION	241,600.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
PROVIDENCE MEDICAL CENTER 1200 PROVIDENCE ROAD WAYNE, NE 68787	N/A	PC	EPHARMACY AT PROVIDENCE MEDICAL CENTER	8,457.
PUBLIC HEALTH SOLUTIONS 40 WORTH STREET, 5TH FLOOR NEW YORK, NY 10013	N/A	PC	NEW YORK CITY FUND FOR YOUTH AND FAMILY HOMELESSNESS	262,335.
PULITZER CENTER ON CRISIS REPORTING 1779 MASSACHUSETTS AVE NW WASHINGTON, DC 20036	N/A	PC	BUILDING RESILIENCE THROUGH JOURNALISM AND EDUCATION	302,170.
PULITZER CENTER ON CRISIS REPORTING 1779 MASSACHUSETTS AVE NW WASHINGTON, DC 20036	N/A	PC	BUILDING RESILIENCE THROUGH JOURNALISM AND EDUCATION	310,123.
REGENTS OF THE UNIVERSITY OF MI 3003 SOUTH STATE STREET ANN ARBOR, MI 48109	N/A	PC	USE NLP FOR EXTRACTION OF CD RELEVANT DATA FROM CLINICAL RECORDS.	385,780.
REGENTS OF THE UNIVERSITY OF MI 3003 SOUTH STATE STREET ANN ARBOR, MI 48109	N/A	PC	HEALTH ECONOMIC ANALYSIS OF AUTOMATED INSULIN DELIVERY SYSTEMS	454,441.
REGENTS OF THE UNIVERSITY OF MI 3003 SOUTH STATE STREET ANN ARBOR, MI 48109	N/A	PC	USE NLP FOR EXTRACTION OF CD RELEVANT DATA FROM CLINICAL RECORDS.	369,880.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
REGENTS OF THE UNIVERSITY OF MI 3003 SOUTH STATE STREET ANN ARBOR, MI 48109	N/A	PC	HEALTH ECONOMIC ANALYSIS OF AUTOMATED INSULIN DELIVERY SYSTEMS	408,267.
REGENTS OF THE UNIVERSITY OF MINNESOTA 401 EAST RIVER ROAD MINNEAPOLIS, MN 55455	N/A	GOV	REDEFINING THE FUTURE OF EMERGENCY MEDICINE	5,026,234.
REGENTS OF THE UNIVERSITY OF MINNESOTA 401 EAST RIVER ROAD MINNEAPOLIS, MN 55455	N/A	GOV	PHASE 2: ENGINEERING ANTIGEN-SPECIFIC REGULATORY T CELLS FOR T1D	250,000.
REGENTS OF THE UNIVERSITY OF MINNESOTA 401 EAST RIVER ROAD MINNEAPOLIS, MN 55455	N/A	GOV	PRECLINICAL DEVELOPMENT OF A MONOCLONAL ANTIBODY TO SERPINB13	308,267.
REGENTS OF THE UNIVERSITY OF MINNESOTA 401 EAST RIVER ROAD MINNEAPOLIS, MN 55455	N/A	GOV	MINNESOTA FIRST RESPONDER AED PROJECT	4,885,390.
REGENTS OF THE UNIVERSITY OF MINNESOTA 401 EAST RIVER ROAD MINNEAPOLIS, MN 55455	N/A	GOV	MINNESOTA FIRST RESPONDER AED PROJECT	1,296,918.
RENOWN HEALTH FOUNDATION 245 E. LIBERTY ST RENO, NV 89501	N/A	PC	SIMULATION LAB AND INNOVATION CENTER	3,099,867.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
SAFE WATER NETWORK 122 EAST 42ND STREET NEW YORK, NY 10168	N/A	PC	SCALING AFFORDABLE SAFELY MANAGED WATER SUPPLY	1,595,750.
SAFE WATER NETWORK 122 EAST 42ND STREET NEW YORK, NY 10168	N/A	PC	SCALING AFFORDABLE SAFELY MANAGED WATER SUPPLY	1,552,050.
SAGE BIONETWORKS 2901 THIRD AVE SEATTLE, WA 98121-3014	N/A	PC	EXTENSION OF VEOIBD DATA COORDINATION	73,424.
SAGE BIONETWORKS 2901 THIRD AVE SEATTLE, WA 98121-3014	N/A	PC	EXTENSION OF VEOIBD DATA COORDINATION	75,165.
SANFORD RESEARCH 2301 E 60TH STREET N SIOUX FALL, SD 57104-0569	N/A	PC	SANFORD PLEDGE: PHASES 1 AND 2	212,565.
SCHWARTZ/REISMAN SCIENCE EDUCATION CENTER, REHOVOT HERZL ST. 234 REHOVOT, ISRAEL	N/A	PC	THE HELMSLEY CAMPUS FOR SCIENCE EDUCATION IN NETIVOT	1,982,305.
SEATTLE CHILDREN'S HOSPITAL PO BOX 5731, M/S: S-200 SEATTLE, WA 98145-5005	N/A	PC	DEVELOPMENT OF ANTIGEN-SPECIFIC ETREG THERAPY IN T1D - STAGE 3 STUDIES	1,224,949.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
SHAARE ZEDEK MEDICAL CENTER 12 SHMUEL BAIT STREET JERUSALEM, ISRAEL	N/A	PC	PREVENTION OF INFLAMMATORY BOWEL DISEASES IN PERSONS AT RISK	355,916.
SHAARE ZEDEK MEDICAL CENTER 12 SHMUEL BAIT STREET JERUSALEM, ISRAEL	N/A	PC	"TASTY & HEALTHY" DIET: A RANDOMIZED CONTROLLED TRIAL FOR INDUCING AND MAINTAINING REMISSION IN CROHN'S DISEASE.	527,468.
SHAARE ZEDEK MEDICAL CENTER 12 SHMUEL BAIT STREET JERUSALEM, ISRAEL	N/A	PC	THE HELMSLEY CANCER CENTER AT SHAARE ZEDEK MEDICAL CENTER JERUSALEM	5,226,272.
SHENANDOAH MEDICAL CENTER 300 PERSHING AVE SHENANDOAH, IA 51601	N/A	PC	SHENANDOAH MEDICAL CENTER / AVERA EEMERGENCY IMPLEMENTATION PROJECT	15,320.
SIMULATION IN MOTION MONTANA, INC. C/O MONTANA MEDICAL ASSOCIATION HELENA, MT 59601	N/A	PC	CAPACITY BUILDING TOWARD A SUSTAINABLE SIMULATION IN MOTION MONTANA	108,298.
SIOUX VALLEY MEMORIAL HOSPITAL ASSOCIATION 300 SIOUX VALLEY DRIVE CHEROKEE, IA 51012	N/A	PC	ECARE EMERGENCY AT CHEROKEE REGIONAL MEDICAL CENTER	13,877.
SNV NETHERLANDS DEVELOPMENT ORGANISATION PARKSTRAAT 83 DEN HAAG, NETHERLANDS	N/A	PC	HEALTHY FUTURE FOR ALL IMPROVING WATER, SANITATION, HYGIENE & NUTRITION	1,207,754.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
SNV NETHERLANDS DEVELOPMENT ORGANISATION PARKSTRAAT 83 DEN HAAG, NETHERLANDS	N/A	PC	HEALTHY FUTURE FOR ALL IMPROVING WATER, SANITATION, HYGIENE & NUTRITION	962,857.
SOS CHILDREN'S VILLAGES-USA, INC. 1620 I STREET, NW, SUITE 220 WASHINGTON, DC 20006	N/A	PC	EDUCARE 4.0: DEBRE TABOR AND GONDAR CITY, ETHIOPIA	1,386,577.
SOUTH LINCOLN HOSPITAL DISTRICT 711 ONYX ST KEMMERER, WY 83101	N/A	GOV	TELE-EMERGENCY SERVICE AT SOUTH LINCOLN MEDICAL CENTER	26,976.
SOUTH LINCOLN HOSPITAL DISTRICT 711 ONYX ST KEMMERER, WY 83101	N/A	GOV	TELE-EMERGENCY SERVICE AT SOUTH LINCOLN MEDICAL CENTER	10,791.
SOUTH LINCOLN HOSPITAL DISTRICT 711 ONYX ST KEMMERER, WY 83101	N/A	GOV	TELE-EMERGENCY SERVICE AT SOUTH LINCOLN MEDICAL CENTER	151,487.
SOUTHCENTRAL FOUNDATION 4501 DIPLOMACY DR ANCHORAGE, AK 99508	N/A	PC	FWWI NU'IJU TRANSFORMATIONAL LIVING COMMUNITY PROGRAM	903,283.
SOUTHCENTRAL FOUNDATION 4501 DIPLOMACY DR ANCHORAGE, AK 99508	N/A	PC	FWWI NU'IJU TRANSFORMATIONAL LIVING COMMUNITY PROGRAM	818,171.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
STANFORD UNIVERSITY 443 VIA ORTEGA STANFORD, CA 94305	N/A	PC	DIABETESWISE-PRO: INCREASING DIABETES DEVICE UPTAKE IN PEOPLE DIABETES	817,475.
STANFORD UNIVERSITY 443 VIA ORTEGA STANFORD, CA 94305	N/A	PC	INVESTIGATING THE ROLE OF THE HUMAN EXPOSOME IN CROHNS DISEASE	690,953.
STANFORD UNIVERSITY 443 VIA ORTEGA STANFORD, CA 94305	N/A	PC	EXERCISE EDUCATION AT NEW ONSET OF T1D	339,811.
STANFORD UNIVERSITY 443 VIA ORTEGA STANFORD, CA 94305	N/A	PC	EXPANSION & EVALUATION OF ECHO FOR PEOPLE WITH DIABETES ON IIT	330,000.
STANFORD UNIVERSITY 443 VIA ORTEGA STANFORD, CA 94305	N/A	PC	MICROBIOME-BASED THERAPEUTICS FOR CROHNS DISEASE	1,009,155.
STANFORD UNIVERSITY 443 VIA ORTEGA STANFORD, CA 94305	N/A	PC	INVESTIGATING THE ROLE OF THE HUMAN EXPOSOME IN CROHNS DISEASE	836,979.
STANFORD UNIVERSITY 443 VIA ORTEGA STANFORD, CA 94305	N/A	PC	DEVELOPMENT OF A CONTINUOUS MULTIANALYTE SENSOR FOR T1D	1,374,460.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
STANFORD UNIVERSITY 443 VIA ORTEGA STANFORD, CA 94305	N/A	PC	DEVELOPMENT OF A CONTINUOUS MULTIANALYTE SENSOR FOR T1D	1,374,444.
STANFORD UNIVERSITY 443 VIA ORTEGA STANFORD, CA 94305	N/A	PC	EXPANSION & EVALUATION OF ECHO FOR PEOPLE WITH DIABETES ON IIT	1,296,812.
STICHTING ACCESS TO MEDICINE FOUNDATION NARITAWEG 227 AMSTERDAM, NETHERLANDS	N/A	PC	EXPANDING ACCESS TO T1D CARE	750,000.
STICHTING ACCESS TO MEDICINE FOUNDATION NARITAWEG 227 AMSTERDAM, NETHERLANDS	N/A	PC	EXPANDING ACCESS TO T1D CARE	875,000.
STICHTING HEALTH ACTION INTERNATIONAL OVERTOOM 60/II AMSTERDAM, NETHERLANDS	N/A	PC	ADDRESSING THE CHALLENGE AND CONSTRAINTS OF INSULIN SOURCES AND SUPPLY	1,287,681.
STICHTING HEALTH ACTION INTERNATIONAL OVERTOOM 60/II AMSTERDAM, NETHERLANDS	N/A	PC	ADDRESSING THE CHALLENGE AND CONSTRAINTS OF INSULIN SOURCES AND SUPPLY	1,245,075.
STIFTELSEN FORSKNING AVSEENDE INFLAMMATORISKA TARM SJUKDOM DEPT. OF GASTROENTEROLOGY, OREBRO, SWEDEN	N/A	PC	HELMSLEY IOIBD CLINICAL EXPERIENCE EXCHANGE TO FOSTER INV CAREERS IN IBD	132,000.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
STIFTELSEN UTBILDNING AVSEENDE INFLAMMATORISKA TARMSJUKDOM DEPT. OF GASTROENTEROLOGY, OREBRO, SWEDEN	N/A	PC	HELMSLEY IOIBD CLINICAL EXPERIENCE EXCHANGE TO FOSTER INV CAREERS IN IBD	132,000.
STIFTELSENFORSKNING AVSEENDE INFLAMMATORISKA TARMSJUKDOM DEPT. OF GASTROENTEROLOGY, OREBRO, SWEDEN	N/A	PC	HELMSLEY IOIBD CLINICAL EXPERIENCE EXCHANGE TO FOSTER INV CAREERS IN IBD	132,000.
SYNERGOS INSTITUTE, INC. 3 EAST 54TH STREET NEW YORK, NY 10022	N/A	PC	IMPROVING LIVES AND LIVELIHOODS OF SMALLHOLDER FARMERS	1,063,518.
T1D EXCHANGE, INC 11 AVENUE DE LAFAYETTE BOSTON, MA 02111	N/A	PC	DATA APPROACH TO IMPROVE QUALITY AND OUTCOMES FOR INDIVIDUALS WITH T1D	261,908.
TECHNISCHE UNIVERSITT DRESDEN HELMHOLTZSTR. 10 DRESDEN, GERMANY	N/A	GOV	SUPPORT SCREENING FOR ISLET AUTOANTIBODIES IN CHILDREN.	52,102.
TECHNISCHE UNIVERSITT DRESDEN HELMHOLTZSTR. 10 DRESDEN, GERMANY	N/A	GOV	GENOMIC INFLUENCE OF MATERNAL T1D - UNDERSTANDING PROTECTION AGAINST T1D	210,829.
TECHNISCHE UNIVERSITT DRESDEN HELMHOLTZSTR. 10 DRESDEN, GERMANY	N/A	GOV	SUPPORT SCREENING FOR ISLET AUTOANTIBODIES IN CHILDREN.	60,079.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
THE ASPEN INSTITUTE INC. 2300 N STREET WASHINGTON, DC 20037	N/A	PC	THE ASPEN INSTITUTE IS AN EDUCATIONAL AND POLICY STUDIES ORGANIZATION	996,251.
THE ASPEN INSTITUTE INC. 2300 N STREET WASHINGTON, DC 20037	N/A	PC	THE ASPEN INSTITUTE IS AN EDUCATIONAL AND POLICY STUDIES ORGANIZATION	998,081.
THE BARUCH PADEH MEDICAL CENTER, PORIYA THE BARUCH PADEH MEDICAL CENTER, PORIYA TIBERIAS, ISRAEL	N/A	GOV	THE HELMSLEY REHABILITATION CENTER OF THE NORTH	4,453,113.
THE BARUCH PADEH MEDICAL CENTER, PORIYA THE BARUCH PADEH MEDICAL CENTER, PORIYA TIBERIAS, ISRAEL	N/A	GOV	THE HELMSLEY REHABILITATION CENTER OF THE NORTH	5,431,730.
THE BROAD INSTITUTE, INC. 415 MAIN STREET CAMBRIDGE, MA 02142	N/A	PC	HUMAN COLON AND SMALL INTESTINE CELL ATLAS IN HEALTH AND CROHNS DISEASE	463,751.
THE BROAD INSTITUTE, INC. 415 MAIN STREET CAMBRIDGE, MA 02142	N/A	PC	NOVEL THERAPEUTIC APPROACHES FOR CROHNS DISEASE	1,500,000.
THE BROAD INSTITUTE, INC. 415 MAIN STREET CAMBRIDGE, MA 02142	N/A	PC	HUMAN COLON AND SMALL INTESTINE CELL ATLAS IN HEALTH AND CROHNS DISEASE	463,755.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
THE BROAD INSTITUTE, INC. 415 MAIN STREET CAMBRIDGE, MA 02142	N/A	PC	NOVEL THERAPEUTIC APPROACHES FOR CROHNS DISEASE	1,500,000.
THE BROAD INSTITUTE, INC. 415 MAIN STREET CAMBRIDGE, MA 02142	N/A	PC	NOVEL THERAPEUTIC APPROACHES FOR CROHNS DISEASE	1,500,000.
THE BROAD INSTITUTE, INC. 415 MAIN STREET CAMBRIDGE, MA 02142	N/A	PC	NOVEL THERAPEUTIC APPROACHES FOR CROHNS DISEASE	1,500,000.
THE CHINESE UNIVERSITY OF HONG KONG PI CH'IU BUILDING SHATIN, HONG KONG	N/A	PC	MATERNAL TRANSFER OF SPECIALIZED CELLS FOR TREATMENT OF BOWEL DISEASE	492,017.
THE CHINESE UNIVERSITY OF HONG KONG PI CH'IU BUILDING SHATIN, HONG KONG	N/A	PC	IBD GIVES-21: GLOBAL IBD VISUALIZATION OF EPIDEMIOLOGY STUDIES, 21ST CEN	430,508.
THE CHINESE UNIVERSITY OF HONG KONG PI CH'IU BUILDING SHATIN, HONG KONG	N/A	PC	IBD GIVES-21: GLOBAL IBD VISUALIZATION OF EPIDEMIOLOGY STUDIES, 21ST CEN	249,337.
THE CHINESE UNIVERSITY OF HONG KONG PI CH'IU BUILDING SHATIN, HONG KONG	N/A	PC	IBD GIVES-21: GLOBAL IBD VISUALIZATION OF EPIDEMIOLOGY STUDIES, 21ST CEN	251,789.

Total from continuation sheets

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
THE CITY OF HOPE 1500 E. DUARTE RD. DUARTE, CA 91010	N/A	PC	UNDERSTANDING GENETIC PROTECTION FROM T1D.	275,000.
THE CITY OF HOPE 1500 E. DUARTE RD. DUARTE, CA 91010	N/A	PC	UNDERSTANDING GENETIC PROTECTION FROM T1D.	275,000.
THE CLEVELAND CLINIC FOUNDATION 9500 EUCLID AVENUE CLEVELAND, OH 44195	N/A	PC	CROHNS FISTULIZING PROGRAM INVESTIGATOR INITIATED CLINICAL TRIALS	954,604.
THE CLEVELAND CLINIC FOUNDATION 9500 EUCLID AVENUE CLEVELAND, OH 44195	N/A	PC	CROHNS FISTULIZING PROGRAM INVESTIGATOR INITIATED CLINICAL TRIALS	1,335,936.
THE CLEVELAND CLINIC FOUNDATION 9500 EUCLID AVENUE CLEVELAND, OH 44195	N/A	PC	STENOSIS THERAPY AND ANTI-FIBROTIC RESEARCH CONSORTIUM	155,544.
THE CLEVELAND CLINIC FOUNDATION 9500 EUCLID AVENUE CLEVELAND, OH 44195	N/A	PC	DEVELOP IUS AND HISTOPATHOLOGY INDICES FOR MONITORING STRICTURING CD	348,000.
THE CLEVELAND CLINIC FOUNDATION 9500 EUCLID AVENUE CLEVELAND, OH 44195	N/A	PC	DEVELOP AN INTESTINAL MUCOSAL AND IMAGING BIOMARKER FOR STRICTURING CD	1,355,310.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
THE CLEVELAND CLINIC FOUNDATION 9500 EUCLID AVENUE CLEVELAND, OH 44195	N/A	PC	DEVELOP IUS AND HISTOPATHOLOGY INDICES FOR MONITORING STRICTURING CD	111,750.
THE CLEVELAND CLINIC FOUNDATION 9500 EUCLID AVENUE CLEVELAND, OH 44195	N/A	PC	DEVELOP AN INTESTINAL MUCOSAL AND IMAGING BIOMARKER FOR STRICTURING CD	1,321,210.
THE GOVERNORS OF THE UNIVERSITY OF CALGARY 2500 UNIVERSITY DRIVE NW CALGARY, CANADA	N/A	PC	THE CHANGING EPIDEMIOLOGY OF CROHNS IN THE WESTERN WORLD	186,777.
THE GOVERNORS OF THE UNIVERSITY OF CALGARY 2500 UNIVERSITY DRIVE NW CALGARY, CANADA	N/A	PC	VISUALIZATION OF COVID-19 VACCINE SEROLOGY IN CD	89,047.
THE GOVERNORS OF THE UNIVERSITY OF CALGARY 2500 UNIVERSITY DRIVE NW CALGARY, CANADA	N/A	PC	INTERLEUKIN-4 ACTIVATED MACROPHAGES FOR PERSONALIZED CELL IMMUNOTHERAPY	122,854.
THE GOVERNORS OF THE UNIVERSITY OF CALGARY 2500 UNIVERSITY DRIVE NW CALGARY, CANADA	N/A	PC	DEVELOP PROTEIN PANEL TO IDENTIFY FIBROSTENOTIC CD PATIENTS	419,010.
THE GOVERNORS OF THE UNIVERSITY OF CALGARY 2500 UNIVERSITY DRIVE NW CALGARY, CANADA	N/A	PC	THE CHANGING EPIDEMIOLOGY OF CROHNS IN THE WESTERN WORLD	191,883.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
THE GOVERNORS OF THE UNIVERSITY OF CALGARY 2500 UNIVERSITY DRIVE NW CALGARY, CANADA	N/A	PC	VISUALIZATION OF COVID-19 VACCINE SEROLOGY IN CD	89,047.
THE GOVERNORS OF THE UNIVERSITY OF CALGARY 2500 UNIVERSITY DRIVE NW CALGARY, CANADA	N/A	PC	INTERLEUKIN-4 ACTIVATED MACROPHAGES FOR PERSONALIZED CELL IMMUNOTHERAPY	126,154.
THE GOVERNORS OF THE UNIVERSITY OF CALGARY 2500 UNIVERSITY DRIVE NW CALGARY, CANADA	N/A	PC	THE CHANGING EPIDEMIOLOGY OF CROHNS IN THE WESTERN WORLD	121,036.
THE GOVERNORS OF THE UNIVERSITY OF CALGARY 2500 UNIVERSITY DRIVE NW CALGARY, CANADA	N/A	PC	VISUALIZATION OF COVID-19 VACCINE SEROLOGY IN CD	89,047.
THE GOVERNORS OF THE UNIVERSITY OF CALGARY 2500 UNIVERSITY DRIVE NW CALGARY, CANADA	N/A	PC	INTERLEUKIN-4 ACTIVATED MACROPHAGES FOR PERSONALIZED CELL IMMUNOTHERAPY	137,153.
THE GOVERNORS OF THE UNIVERSITY OF CALGARY 2500 UNIVERSITY DRIVE NW CALGARY, CANADA	N/A	PC	DEVELOP PROTEIN PANEL TO IDENTIFY FIBROSTENOTIC CD PATIENTS	247,654.
THE GOVERNORS OF THE UNIVERSITY OF CALGARY 2500 UNIVERSITY DRIVE NW CALGARY, CANADA	N/A	PC	INTERLEUKIN-4 ACTIVATED MACROPHAGES FOR PERSONALIZED CELL IMMUNOTHERAPY	127,077.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
THE GOVERNORS OF THE UNIVERSITY OF CALGARY 2500 UNIVERSITY DRIVE NW CALGARY, CANADA	N/A	PC	INTERLEUKIN-4 ACTIVATED MACROPHAGES FOR PERSONALIZED CELL IMMUNOTHERAPY	137,417.
THE GOVERNORS OF THE UNIVERSITY OF CALGARY 2500 UNIVERSITY DRIVE NW CALGARY, CANADA	N/A	PC	INTERLEUKIN-4 ACTIVATED MACROPHAGES FOR PERSONALIZED CELL IMMUNOTHERAPY	119,554.
THE HOSPITAL FOR SICK CHILDREN 555 UNIVERSITY AVE TORONTO, CANADA	N/A	PC	VEOIBD: PRECISION MOLECULAR DIAGNOSES TO TARGETED THERAPIES-TORONTO	548,276.
THE HOSPITAL FOR SICK CHILDREN 555 UNIVERSITY AVE TORONTO, CANADA	N/A	PC	VEOIBD: PRECISION MOLECULAR DIAGNOSES TO TARGETED THERAPIES-TORONTO	555,480.
THE LEGATUM INSTITUTE FOUNDATION 11 CHARLES STREET LONDON, UNITED KINGDOM	N/A	NC	PHASE TWO OF THE UNITED STATES PROSPERITY INDEX	50,000.
THE LEGATUM INSTITUTE FOUNDATION 11 CHARLES STREET LONDON, UNITED KINGDOM	N/A	NC	PHASE TWO OF THE UNITED STATES PROSPERITY INDEX	50,000.
THE MAX STERN ACADEMIC COLLEGE OF EMEK YEZREEL YEZREEL VALLEY YEZREEL VALLEY, ISRAEL	N/A	PC	OPP. FOR SUCCESS SCHOLARSHIPS FOR ETHIOPIAN ISRAELIS SEEKING NURSING DEG	220,000.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
THE MAX STERN ACADEMIC COLLEGE OF EMEK YEZREEL YEZREEL VALLEY YEZREEL VALLEY, ISRAEL	N/A	PC	OPP. FOR SUCCESS SCHOLARSHIPS FOR ETHIOPIAN ISRAELIS SEEKING NURSING DEG	220,000.
THE ONE LOVE FOUNDATION IN HONOR OF YEARDLEY LOVE, INC. 44 PONDFIELD ROAD, SUITE 12 BRONXVILLE, NY 10708	N/A	PC	BUILDING FOR THE FUTURE: SUPPORT FOR DIGITAL PROGRAMS AND OPERATIONS	1,023,100.
THE RECTOR AND VISITORS OF THE UNIVERSITY OF VIRGINIA OFFICE OF SPONSORED PROGRAMS CHARLOTTESVILLE, VA 22904-4195	N/A	PC	TYPE 1 DIABETES RISK PREDICTION: INTEGRATION OF PHYSIOLOGY WITH GENETICS	331,333.
THE RECTOR AND VISITORS OF THE UNIVERSITY OF VIRGINIA OFFICE OF SPONSORED PROGRAMS CHARLOTTESVILLE, VA 22904-4195	N/A	PC	TYPE 1 DIABETES RISK PREDICTION: INTEGRATION OF PHYSIOLOGY WITH GENETICS	202,177.
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA AT IRVINE 120 THEORY, SUITE 200 IRVINE, CA 92697-1050	N/A	PC	DEVELOPMENT OF A MULTI-ANALYTE SENSOR FOR PEOPLE WITH T1D	851,633.
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA AT IRVINE 120 THEORY, SUITE 200 IRVINE, CA 92697-1050	N/A	PC	DEVELOPMENT OF A MULTI-ANALYTE SENSOR FOR PEOPLE WITH T1D	837,543.
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA AT IRVINE 120 THEORY, SUITE 200 IRVINE, CA 92697-1050	N/A	PC	DEVELOPMENT OF A MULTI-ANALYTE SENSOR FOR PEOPLE WITH T1D	837,542.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
THE REGENTS OF THE UNIVERSITY OF COLORADO, DENVER BUILDING 500 AURORA, CO 80045	N/A	PC	FEASIBILITY EVAL OF AID IN PRIMARY CARE AND THROUGH TELEHEALTH	705,874.
THE REGENTS OF THE UNIVERSITY OF COLORADO, DENVER BUILDING 500 AURORA, CO 80045	N/A	PC	CGM IN PRIMARY CARE - REFER OR LEARN: IMPLEMENTATION AND EVALUATION	580,677.
THE REGENTS OF THE UNIVERSITY OF COLORADO, DENVER BUILDING 500 AURORA, CO 80045	N/A	PC	DEVELOPMENT OF A CONTINUOUS INSULIN-GLUCOSE SENSOR	155,376.
THE REGENTS OF THE UNIVERSITY OF COLORADO, DENVER BUILDING 500 AURORA, CO 80045	N/A	PC	ASK THE EXPERTS	543,207.
THE REGENTS OF THE UNIVERSITY OF COLORADO, DENVER BUILDING 500 AURORA, CO 80045	N/A	PC	SINGLE PERSISTENT ISLET AUTOANTIBODY PHENOTYPE: CUSTOMIZED RISK ANALYSIS	264,341.
THE REGENTS OF THE UNIVERSITY OF COLORADO, DENVER BUILDING 500 AURORA, CO 80045	N/A	PC	FAILED GENETIC PROTECTION: T1D IN THE PRESENCE OF DQB1*06:02	266,200.
THE REGENTS OF THE UNIVERSITY OF COLORADO, DENVER BUILDING 500 AURORA, CO 80045	N/A	PC	CGM IN PRIMARY CARE - REFER OR LEARN: IMPLEMENTATION AND EVALUATION	1,111,050.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
THE REGENTS OF THE UNIVERSITY OF COLORADO, DENVER BUILDING 500 AURORA, CO 80045	N/A	PC	COMPLEMENT SYSTEM IN INITIATION AND PROGRESSION OF ISLET AUTOIMMUNITY	223,818.
THE REGENTS OF THE UNIVERSITY OF COLORADO, DENVER BUILDING 500 AURORA, CO 80045	N/A	PC	EXPLORING THE GENOMIC MECHANISM BEHIND THE MATERNAL PROTECTION FROM T1D	202,073.
THE REGENTS OF THE UNIVERSITY OF COLORADO, DENVER BUILDING 500 AURORA, CO 80045	N/A	PC	SEEDS PATHWAY: EMPOWERMENT FOR DIABETES TECHNOLOGY EARLY DEVICE SUCCESS	905,046.
THE REGENTS OF THE UNIVERSITY OF COLORADO, DENVER BUILDING 500 AURORA, CO 80045	N/A	PC	ASK THE EXPERTS	575,810.
THE REGENTS OF THE UNIVERSITY OF COLORADO, DENVER BUILDING 500 AURORA, CO 80045	N/A	PC	FAILED GENETIC PROTECTION: T1D IN THE PRESENCE OF DQB1*06:02	266,200.
THE REGENTS OF THE UNIVERSITY OF COLORADO, DENVER BUILDING 500 AURORA, CO 80045	N/A	PC	CGM IN PRIMARY CARE - REFER OR LEARN: IMPLEMENTATION AND EVALUATION	1,008,526.
THE REGENTS OF THE UNIVERSITY OF COLORADO, DENVER BUILDING 500 AURORA, CO 80045	N/A	PC	EXPLORING THE GENOMIC MECHANISM BEHIND THE MATERNAL PROTECTION FROM T1D	178,454.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
THE REGENTS OF THE UNIVERSITY OF COLORADO, DENVER BUILDING 500 AURORA, CO 80045	N/A	PC	SEEDS PATHWAY: EMPOWERMENT FOR DIABETES TECHNOLOGY EARLY DEVICE SUCCESS	694,245.
THE REGENTS OF THE UNIVERSITY OF NEW MEXICO SPONSORED PROJECTS - PREAWARD ALBUQUERQUE, NM 87131-0001	N/A	GOV	THE ECHO INSTITUTE: REPLICATION OF THE ECHO MODEL	1,188,238.
THE SDEROT DEVELOPMENT FOUNDATION 6 BAR LEV STREET SDEROT, ISRAEL	N/A	PC	SDEROT MEDICAL CENTER	1,558,573.
THE SDEROT DEVELOPMENT FOUNDATION 6 BAR LEV STREET SDEROT, ISRAEL	N/A	PC	SDEROT RESILIENCE COMPLEX, RESILIENCE CENTER AND PARENTHOOD HOUSE	184,286.
THE SDEROT DEVELOPMENT FOUNDATION 6 BAR LEV STREET SDEROT, ISRAEL	N/A	PC	ESTABLISHING A WARM HOME COMPLEX FOR CHILDREN AT RISK IN SDEROT	2,421,222.
THE SDEROT DEVELOPMENT FOUNDATION 6 BAR LEV STREET SDEROT, ISRAEL	N/A	PC	SDEROT MEDICAL CENTER	614,379.
THE SONIA NABETA FOUNDATION, INC. P.O. BOX 2222 NEW YORK, NY 10008-2222	N/A	PC	PROJECT BODA	412,944.

Total from continuation sheets

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
THE TEL AVIV JAFFA ACADEMIC COLLEGE RABENU YERUHAM ST. 2, P.O.B 8401 TEL AVIV YAFFO, ISRAEL	N/A	PC	SCHOLARSHIP SUPPORT FOR ULTRA-ORTHODOX MEN PURSUING NURSING DEGREES	306,724.
THE TEL AVIV JAFFA ACADEMIC COLLEGE RABENU YERUHAM ST. 2, P.O.B 8401 TEL AVIV YAFFO, ISRAEL	N/A	PC	SCHOLARSHIP SUPPORT FOR ULTRA-ORTHODOX MEN PURSUING NURSING DEGREES	253,818.
THE UNITED NATIONS INSTITUTE FOR TRAINING AND RESEARCH UNITAR GENEVA, SWITZERLAND	N/A	PC	ACCELERATING ACCESS: TREATMENT FOR NCDS IN LOW /MIDDLE-INCOME COUNTRIES.	1,000,000.
THE UNIVERSITY OF ADELAIDE THE UNIVERSITY OF ADELAIDE ADELAIDE, AUSTRALIA	N/A	PC	ENVIRONMENTAL DETERMINANTS OF ISLET AUTOIMMUNITY (ENDIA) STUDY	794,339.
THE UNIVERSITY OF ADELAIDE THE UNIVERSITY OF ADELAIDE ADELAIDE, AUSTRALIA	N/A	PC	ENDIA EXPANDED SUPPORT	419,418.
THE UNIVERSITY OF CHICAGO 5801 SOUTH ELLIS AVENUE CHICAGO, IL 60637	N/A	PC	A CELL ATLAS OF THE ILEAL COLONIC CROHNS DISEASE	487,806.
THE UNIVERSITY OF CHICAGO 5801 SOUTH ELLIS AVENUE CHICAGO, IL 60637	N/A	PC	IMMUNO PHARMACOGENOMICS TO PREDICT RESPONSE TO BIOLOGICS IN CROHNS	305,353.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
THE UNIVERSITY OF EDINBURGH BHF CENTRE FOR CARDIOVASCULAR SCIENCES EDINBURGH, UNITED KINGDOM	N/A	PC	MITOCHONDRIAL DAMPS AS MECHANISTIC BIOMARKERS OF MUCOSAL INFLAMMATION	708,833.
THE UNIVERSITY OF EDINBURGH BHF CENTRE FOR CARDIOVASCULAR SCIENCES EDINBURGH, UNITED KINGDOM	N/A	PC	DISCERN ALPHA CELL DYSFUNCTION AND CORRECTING GLUCAGON SECRETION IN T1D	230,209.
THE UNIVERSITY OF EDINBURGH BHF CENTRE FOR CARDIOVASCULAR SCIENCES EDINBURGH, UNITED KINGDOM	N/A	PC	GCA - HUMAN GUT CELL ATLAS - NORMAL INTESTINE AND CROHNS DISEASE	444,247.
THE UNIVERSITY OF EDINBURGH BHF CENTRE FOR CARDIOVASCULAR SCIENCES EDINBURGH, UNITED KINGDOM	N/A	PC	GCA - HUMAN GUT CELL ATLAS - NORMAL INTESTINE AND CROHNS DISEASE	444,246.
THE UNIVERSITY OF EDINBURGH BHF CENTRE FOR CARDIOVASCULAR SCIENCES EDINBURGH, UNITED KINGDOM	N/A	PC	DISCERN ALPHA CELL DYSFUNCTION AND CORRECTING GLUCAGON SECRETION IN T1D	109,128.
THE UNIVERSITY OF EDINBURGH BHF CENTRE FOR CARDIOVASCULAR SCIENCES EDINBURGH, UNITED KINGDOM	N/A	PC	GCA - HUMAN GUT CELL ATLAS - NORMAL INTESTINE AND CROHNS DISEASE	553,832.
THE UNIVERSITY OF OXFORD UNIVERSITY OFFICES, WELLINGTON SQUARE OXFORD, UNITED KINGDOM	N/A	PC	PHARMACOLOGICAL MODULATION TO ADDRESS GLUCAGON SECRETION IN T1D	546,306.

Total from continuation sheets

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
THE UNIVERSITY OF OXFORD UNIVERSITY OFFICES, WELLINGTON SQUARE OXFORD, UNITED KINGDOM	N/A	PC	THE CELLULAR LANDSCAPE OF MONOGENIC INFLAMMATORY BOWEL DISEASE	244,860.
THE UNIVERSITY OF OXFORD UNIVERSITY OFFICES, WELLINGTON SQUARE OXFORD, UNITED KINGDOM	N/A	PC	THE CELLULAR LANDSCAPE OF MONOGENIC INFLAMMATORY BOWEL DISEASE	244,860.
THE UNIVERSITY OF QUEENSLAND CUMBRAE STEWART BUILDING #72 BRISBANE, AUSTRALIA	N/A	PC	LIPOSOMAL ANTIGEN-SPECIFIC IMMUNOTHERAPY OF RECENT-ONSET T1D	435,713.
THE UNIVERSITY OF WESTERN AUSTRALIA 35 STIRLING HIGHWAY CRAWLEY, AUSTRALIA	N/A	PC	CGM ASSESSMENTS OF ENDIA CHILDREN	166,923.
THE WEIZMANN INSTITUTE OF SCIENCE 234 HERZEL ST REHOVOT, ISRAEL	N/A	PC	PERSONALIZED NUTRITIONAL, MICROBIOME AND HOST PATTERNS IN CROHNS	1,720,206.
THE WEIZMANN INSTITUTE OF SCIENCE 234 HERZEL ST REHOVOT, ISRAEL	N/A	PC	THE QUANTUM MATERIALS DEVICES FABRICATION LAB	660,000.
THE WEIZMANN INSTITUTE OF SCIENCE 234 HERZEL ST REHOVOT, ISRAEL	N/A	PC	THE QUANTUM MATERIALS DEVICES FABRICATION LAB	1,750,000.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
TOWNSEND HEALTH SYSTEMS, INC. 110 NORTH OAK TOWNSEND, MT 59644	N/A	PC	TELE-PHARMACY AT BILLINGS CLINIC BROADWATER	35,128.
TOWNSEND HEALTH SYSTEMS, INC. 110 NORTH OAK TOWNSEND, MT 59644	N/A	PC	TELE-PHARMACY AT BILLINGS CLINIC BROADWATER	15,112.
TRUSTEES OF INDIANA UNIVERSITY 509 E 3RD ST. BLOOMINGTON, MI 47401-3654	N/A	GOV	MOLECULAR DESIGN AND TESTING OF GLUCOSE-RESPONSIVE THERAPIES	696,962.
TRUSTEES OF INDIANA UNIVERSITY 509 E 3RD ST. BLOOMINGTON, MI 47401-3654	N/A	GOV	COLLABORATIVE EFFORT TO VALIDATE MICRORNAS AS BIOMARKERS OF T1D	426,380.
TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA OFFICE OF RESEARCH SERVICES, PHILADELPHIA, PA 19104-6205	N/A	PC	ULTRA PROCESSED DIET, GUT MICROBIOME, AND XENOBIOTIC EXPOSURE IN CD	285,463.
TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA OFFICE OF RESEARCH SERVICES, PHILADELPHIA, PA 19104-6205	N/A	PC	ULTRA PROCESSED DIET, GUT MICROBIOME, AND XENOBIOTIC EXPOSURE IN CD	285,463.
TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA OFFICE OF RESEARCH SERVICES, PHILADELPHIA, PA 19104-6205	N/A	PC	ULTRA PROCESSED DIET, GUT MICROBIOME, AND XENOBIOTIC EXPOSURE IN CD	285,079.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA OFFICE OF RESEARCH SERVICES, PHILADELPHIA, PA 19104-6205	N/A	PC	ULTRA PROCESSED DIET, GUT MICROBIOME, AND XENOBIOTIC EXPOSURE IN CD	293,370.
UNITED NATIONS DEVELOPMENT PROGRAMME 1 UNITED NATIONS PLAZA NEW YORK, NY 10017	N/A	PC	UNITED NATIONS MULTILATERAL AGENCY	377,955.
UNITED NATIONS DEVELOPMENT PROGRAMME 1 UNITED NATIONS PLAZA NEW YORK, NY 10017	N/A	PC	UNITED NATIONS MULTILATERAL AGENCY	339,777.
UNITED STATES AFRICAN DEVELOPMENT FOUNDATION 1400 I STREET NW WASHINGTON, DC 20005	N/A	GOV	LIVELIHOOD IMPROVEMENT PROGRAM	1,779,762.
UNITED STATES AFRICAN DEVELOPMENT FOUNDATION 1400 I STREET NW WASHINGTON, DC 20005	N/A	GOV	LIVELIHOOD IMPROVEMENT PROGRAM	1,283,255.
UNITED STATES FUND FOR UNICEF 125 MAIDEN LANE NEW YORK, NY 10038	N/A	PC	ACCELERATING GLOBAL FOCUS ON NCDS AND PEN-PLUS COUNTRY PROGRAMS	784,421.
UNITED STATES FUND FOR UNICEF 125 MAIDEN LANE NEW YORK, NY 10038	N/A	PC	ACCELERATING GLOBAL FOCUS ON NCDS AND PEN-PLUS COUNTRY PROGRAMS	869,232.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
UNIVERSITAIR MEDISCH CENTRUM UTRECHT HEIDELBERGLAAN 100 UTRECHT, NETHERLANDS	N/A	GOV	EPITHELIAL BASED DIAGNOSTICS FOR TARGETED THERAPIES OF VEOIBD	173,250.
UNIVERSITAIR MEDISCH CENTRUM UTRECHT HEIDELBERGLAAN 100 UTRECHT, NETHERLANDS	N/A	GOV	EPITHELIAL BASED DIAGNOSTICS FOR TARGETED THERAPIES OF VEOIBD	173,250.
UNIVERSITE CATHOLIQUE DE LOUVAIN PLACE DE L'UNIVERSITE 1 LOUVAIN-LA-NEUVE, BELGIUM	N/A	PC	STUDY OF THE GLUCAGON RESPONSE TO HYPOGLYCEMIA IN CHILDREN WITH T1D	147,087.
UNIVERSITE CATHOLIQUE DE LOUVAIN PLACE DE L'UNIVERSITE 1 LOUVAIN-LA-NEUVE, BELGIUM	N/A	PC	STUDY OF THE GLUCAGON RESPONSE TO HYPOGLYCEMIA IN CHILDREN WITH T1D	62,567.
UNIVERSITE LIBRE DE BRUXELLES AVENUE FRANKLIN ROOSEVELT 50 BRUSSELS, BELGIUM	N/A	GOV	DEVELOP TOOLS FOR QUANTIFICATION OF HUMAN BETA CELL MASS.	213,582.
UNIVERSITE LIBRE DE BRUXELLES AVENUE FRANKLIN ROOSEVELT 50 BRUSSELS, BELGIUM	N/A	GOV	DEVELOP TOOLS FOR QUANTIFICATION OF HUMAN BETA CELL MASS.	213,602.
UNIVERSITE LIBRE DE BRUXELLES AVENUE FRANKLIN ROOSEVELT 50 BRUSSELS, BELGIUM	N/A	GOV	DEVELOP TOOLS FOR QUANTIFICATION OF HUMAN BETA CELL MASS.	295,566.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
UNIVERSITY AT BUFFALO PEDIATRIC ASSOCIATES P. C. 1001 MAIN STREET BUFFALO, NY 14203	N/A	PC	TELEHEALTH REIMBURSEMENT STUDY FOR UNDERSERVED T1D PEDIATRIC POPULATIONS	576,839.
UNIVERSITY AT BUFFALO PEDIATRIC ASSOCIATES P. C. 1001 MAIN STREET BUFFALO, NY 14203	N/A	PC	TELEHEALTH REIMBURSEMENT STUDY FOR UNDERSERVED T1D PEDIATRIC POPULATIONS	233,094.
UNIVERSITY OF BIRMINGHAM INSTITUTE OF IMMUNOLOGY BIRMINGHAM, UNITED KINGDOM	N/A	PC	DEFINING THE EFFICACY AND MECHANISMS OF PEPTIDE IMMUNOTHERAPY FOR T1D.	322,720.
UNIVERSITY OF CALIFORNIA, LOS ANGELES UCLA OFFICE OF CONTRACTS AND GRANTS LOS ANGELES, CA 90095-1406	N/A	PC	GLUCOSE RESPONSIVE GLUCAGON TO REDUCE HYPOGLYCEMIA IN PEOPLE WITH T1D	568,851.
UNIVERSITY OF CALIFORNIA, LOS ANGELES UCLA OFFICE OF CONTRACTS AND GRANTS LOS ANGELES, CA 90095-1406	N/A	PC	GLUCOSE RESPONSIVE GLUCAGON TO REDUCE HYPOGLYCEMIA IN PEOPLE WITH T1D	568,027.
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO 490 ILLINOIS STREET, FOURTH FLOOR SAN FRANCISCO, CA 94143	N/A	PC	ENGINEERING ISLET ANTIGEN-SPECIFIC TREGS FOR T1D	537,711.
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO 490 ILLINOIS STREET, FOURTH FLOOR SAN FRANCISCO, CA 94143	N/A	PC	ID ANALYSIS OF EXTREME FORMS OF T1D, ESTABLISHMENT OF PATIENT REGISTRY	433,333.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
UNIVERSITY OF CAMBRIDGE THE OLD SCHOOLS CAMBRIDGE, UNITED KINGDOM	N/A	PC	CLOSED LOOP INSULIN DELIVERY IN NEWLY DIAGNOSED YOUTH WITH T1D PART 2	496,568.
UNIVERSITY OF CAMBRIDGE THE OLD SCHOOLS CAMBRIDGE, UNITED KINGDOM	N/A	PC	CLOSED LOOP INSULIN DELIVERY IN NEWLY DIAGNOSED YOUTH WITH T1D PART 2	500,000.
UNIVERSITY OF CAMBRIDGE THE OLD SCHOOLS CAMBRIDGE, UNITED KINGDOM	N/A	PC	CLOSED LOOP INSULIN DELIVERY IN NEWLY DIAGNOSED YOUTH WITH T1D PART 2	353,223.
UNIVERSITY OF DUNDEE NETHERGATE DUNDEE, UNITED KINGDOM	N/A	PC	HYPO-RESOLVE - UNDERSTANDING ORGAN SPECIFIC CONSEQUENCES OF HYPOGLYCEMIA	133,804.
UNIVERSITY OF EXETER NORTHCOTE HOUSE, THE QUEEN'S DRIVE EXETER, UNITED KINGDOM	N/A	PC	STIMULATED GLUCAGON LEVELS BIOMARKER OF HYPOGLYCEMIA RISK IN T1D	323,139.
UNIVERSITY OF EXETER NORTHCOTE HOUSE, THE QUEEN'S DRIVE EXETER, UNITED KINGDOM	N/A	PC	STIMULATED GLUCAGON LEVELS BIOMARKER OF HYPOGLYCEMIA RISK IN T1D	268,565.
UNIVERSITY OF EXETER NORTHCOTE HOUSE, THE QUEEN'S DRIVE EXETER, UNITED KINGDOM	N/A	PC	UNDERSTANDING EXTREMELY EARLY-ONSET TYPE 1 DIABETES	566,086.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
UNIVERSITY OF EXETER NORTHCOTE HOUSE, THE QUEEN'S DRIVE EXETER, UNITED KINGDOM	N/A	PC	UNDERSTANDING EXTREMELY EARLY-ONSET TYPE 1 DIABETES	451,469.
UNIVERSITY OF FLORIDA 219 GRINTER HALL GAINESVILLE, FL 32611-5500	N/A	GOV	HUMAN ATLAS NEONATAL DEVELOPMENTAL EARLY LIFE PANCREAS/IMMUNITY CON'T	1,043,638.
UNIVERSITY OF FLORIDA 219 GRINTER HALL GAINESVILLE, FL 32611-5500	N/A	GOV	COLLABORATIVE T1D RESEARCH: NETWORK FOR PANCREATIC ORGAN DONORS WITH T1D	1,199,692.
UNIVERSITY OF IOWA DIVISION OF SPONSORED PROGRAMS IOWA CITY, IA 52442	N/A	GOV	SIMULATION IN MOTION IOWA (SIM-IA)	999,877.
UNIVERSITY OF IOWA DIVISION OF SPONSORED PROGRAMS IOWA CITY, IA 52442	N/A	GOV	SIMULATION IN MOTION IOWA (SIM-IA)	748,244.
UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL 55 LAKE AVENUE NORTH WORCESTER, MA 01655	N/A	GOV	DAIN: A CROHNS DISEASE MANAGEMENT STRATEGY TAILORED FOR PUERTO RICANS	311,133.
UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL 55 LAKE AVENUE NORTH WORCESTER, MA 01655	N/A	GOV	DAIN: A CROHNS DISEASE MANAGEMENT STRATEGY TAILORED FOR PUERTO RICANS	311,131.

Total from continuation sheets

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL 55 LAKE AVENUE NORTH WORCESTER, MA 01655	N/A	GOV	DAIN: A CROHNS DISEASE MANAGEMENT STRATEGY TAILORED FOR PUERTO RICANS	286,613.
UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL 55 LAKE AVENUE NORTH WORCESTER, MA 01655	N/A	GOV	DAIN: A CROHNS DISEASE MANAGEMENT STRATEGY TAILORED FOR PUERTO RICANS	286,614.
UNIVERSITY OF MELBOURNE LEVEL 4, ALAN GILBERT BUILDING VICTORIA, AUSTRALIA	N/A	PC	ANIMAL AND CLINICAL EVALUATION OF A NOVEL CONTINUOUS KETONE SENSOR	703,827.
UNIVERSITY OF MIAMI 1320 SOUTH DIXIE HIGHWAY, SUITE 650 CORAL GABLES, FL 33146	N/A	PC	THE GEORGE S. EISENBARTH NPOD AWARD FOR TEAM SCIENCE	326,055.
UNIVERSITY OF MIAMI 1320 SOUTH DIXIE HIGHWAY, SUITE 650 CORAL GABLES, FL 33146	N/A	PC	THE GEORGE S. EISENBARTH NPOD AWARD FOR TEAM SCIENCE	328,238.
UNIVERSITY OF NEBRASKA FOUNDATION 1010 LINCOLN MALL LINCOLN, NE 68501	N/A	PC	MOBILE RURAL HEALTHCARE PROVIDER TRAINING	582,072.
UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL 104 AIRPORT DRIVE, SUITE 2200, CB 1350 CHAPEL HILL, NC 27599-1350	N/A	PC	MONITORING COVID-19 VACCINE EFFECTIVENESS IN IBD PATIENTS	966,865.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL 104 AIRPORT DRIVE, SUITE 2200, CB 1350 CHAPEL HILL, NC 27599-1350	N/A	PC	IDENTIFYING MOLECULAR PROFILES PREDICTIVE OF POST-OPERATIVE CD OUTCOMES	585,750.
UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL 104 AIRPORT DRIVE, SUITE 2200, CB 1350 CHAPEL HILL, NC 27599-1350	N/A	PC	IDENTIFYING MOLECULAR PROFILES PREDICTIVE OF POST-OPERATIVE CD OUTCOMES	581,625.
UNIVERSITY OF NOTRE DAME DU LAC 940 GRACE HALL NOTRE DAME, IN 46556-5708	N/A	PC	DEVELOPMENT OF A NOVEL GLUCOSE-RESPONSIVE GLUCAGON DELIVERY SYSTEM	593,043.
UNIVERSITY OF NOTRE DAME DU LAC 940 GRACE HALL NOTRE DAME, IN 46556-5708	N/A	PC	GLUCOSE-BINDING MOTIFS FROM DYNAMIC COMBINATORIAL LANDSCAPES	503,082.
UNIVERSITY OF NOTRE DAME DU LAC 940 GRACE HALL NOTRE DAME, IN 46556-5708	N/A	PC	DEVELOPMENT OF A NOVEL GLUCOSE-RESPONSIVE GLUCAGON DELIVERY SYSTEM	652,642.
UNIVERSITY OF NOTRE DAME DU LAC 940 GRACE HALL NOTRE DAME, IN 46556-5708	N/A	PC	GLUCOSE-BINDING MOTIFS FROM DYNAMIC COMBINATORIAL LANDSCAPES	542,672.
UNIVERSITY OF OULU P.O. BOX 8000 OULU, FINLAND	N/A	PC	MATERNAL AND PATERNAL T1D - MECHANISMS FOR RECURRENCE RISK IN OFFSPRING	284,289.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
UNIVERSITY OF OULU P.O. BOX 8000 OULU, FINLAND	N/A	PC	MATERNAL AND PATERNAL T1D - MECHANISMS FOR RECURRENCE RISK IN OFFSPRING	263,104.
UNIVERSITY OF PITTSBURGH 3420 FORBES AVENUE PITTSBURGH, PA 15260	N/A	PC	RANDOMIZED CONTROLLED TRIAL: ANALOGUE VS HUMAN INSULIN	1,338,570.
UNIVERSITY OF PITTSBURGH 3420 FORBES AVENUE PITTSBURGH, PA 15260	N/A	PC	RANDOMIZED CONTROLLED TRIAL: ANALOGUE VS HUMAN INSULIN	998,931.
UNIVERSITY OF TOLEDO 3000 ARLINGTON AVENUE TOLEDO, OH 43614-2595	N/A	GOV	TYPE 1 DIABETES CAR TREG THERAPEUTIC APPROACH	110,480.
UNIVERSITY OF UTAH 201 S. PRESIDENTS CIRCLE SALT LAKE CITY, UT 84112	N/A	PC	ANTI-PHAGE ANTIBODIES: CROHNS DISEASE DIAGNOSIS AND TREATMENT RESPONSE	203,988.
UNIVERSITY OF ZURICH DEPARTMENT OF IMMUNOLOGY, UNIVERSITY OF ZURICH AND UNIVERSITY HOSPITAL ZURIC ZURICH, SWITZERLAND	N/A	GOV	GENERATE BISPECIFIC INTERLEUKIN-2 IMMUNOTHERAPY TO TREAT T1D MELLITUS	126,830.
UPPSALA UNIVERSITET BOX 256 UPPSALA, SWEDEN	N/A	GOV	ALPHA-CELL SIGNALING FOR GLUCAGON SECRETION	305,920.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
VANDERBILT UNIVERSITY MEDICAL CENTER OFFICE OF SPONSORED PROGRAMS NASHVILLE, TN 37203	N/A	PC	COMBINATORIAL SINGLE CELL STRATEGIES FOR CROHNS DISEASE GUT CELL ATLAS	656,092.
VANDERBILT UNIVERSITY MEDICAL CENTER OFFICE OF SPONSORED PROGRAMS NASHVILLE, TN 37203	N/A	PC	ADMINISTRATIVE CORE AND COLLABORATIVE DATA REPOSITORY FOR THE GCA	244,200.
VANDERBILT UNIVERSITY MEDICAL CENTER OFFICE OF SPONSORED PROGRAMS NASHVILLE, TN 37203	N/A	PC	COMBINATORIAL SINGLE CELL STRATEGIES FOR CROHNS DISEASE GUT CELL ATLAS	146,933.
VANDERBILT UNIVERSITY MEDICAL CENTER OFFICE OF SPONSORED PROGRAMS NASHVILLE, TN 37203	N/A	PC	IDENTIFY SMALL MOLECULES ENHANCING GLUCAGON SECRETION UNDER HYPOGLYCEMIA	330,000.
VANDERBILT UNIVERSITY MEDICAL CENTER OFFICE OF SPONSORED PROGRAMS NASHVILLE, TN 37203	N/A	PC	ISOLATING ISLETS TO UNDERSTAND HYPOGLYCEMIA IN TYPE 1 DIABETES	200,000.
VANDERBILT UNIVERSITY MEDICAL CENTER OFFICE OF SPONSORED PROGRAMS NASHVILLE, TN 37203	N/A	PC	ADMINISTRATIVE CORE AND COLLABORATIVE DATA REPOSITORY FOR THE GCA	244,200.
VANDERBILT UNIVERSITY MEDICAL CENTER OFFICE OF SPONSORED PROGRAMS NASHVILLE, TN 37203	N/A	PC	USE OF MRI OF THE PANCREAS IN T1D	373,041.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
VANDERBILT UNIVERSITY MEDICAL CENTER OFFICE OF SPONSORED PROGRAMS NASHVILLE, TN 37203	N/A	PC	PANCREATLAS DATABASE EXPANSION.	659,685.
VANDERBILT UNIVERSITY MEDICAL CENTER OFFICE OF SPONSORED PROGRAMS NASHVILLE, TN 37203	N/A	PC	ADMINISTRATIVE CORE AND COLLABORATIVE DATA REPOSITORY FOR THE GCA	248,256.
VANDERBILT UNIVERSITY MEDICAL CENTER OFFICE OF SPONSORED PROGRAMS NASHVILLE, TN 37203	N/A	PC	ISOLATING ISLETS TO UNDERSTAND HYPOGLYCEMIA IN TYPE 1 DIABETES	200,000.
VANDERBILT UNIVERSITY MEDICAL CENTER OFFICE OF SPONSORED PROGRAMS NASHVILLE, TN 37203	N/A	PC	ADMINISTRATIVE CORE AND COLLABORATIVE DATA REPOSITORY FOR THE GCA	248,256.
VAYU HEALTH 19 ALISO WAY PORTOLA VALLEY, CA 94028	N/A	PC	VAYU FEASIBILITY PILOT	146,667.
VAYU HEALTH 19 ALISO WAY PORTOLA VALLEY, CA 94028	N/A	PC	VAYU FEASIBILITY PILOT	591,068.
VAYU HEALTH 19 ALISO WAY PORTOLA VALLEY, CA 94028	N/A	PC	VAYU FEASIBILITY PILOT	146,667.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
VAYU HEALTH 19 ALISO WAY PORTOLA VALLEY, CA 94028	N/A	PC	VAYU FEASIBILITY PILOT	700,486.
VAYU HEALTH 19 ALISO WAY PORTOLA VALLEY, CA 94028	N/A	PC	VAYU FEASIBILITY PILOT	146,666.
VAYU HEALTH 19 ALISO WAY PORTOLA VALLEY, CA 94028	N/A	PC	VAYU FEASIBILITY PILOT	233,495.
VETERANS MEMORIAL HOSPITAL 40 1ST STREET, SE WAUKON, IA 52172	N/A	GOV	ECARE PHARMACY AND EMERGENCY SERVICES AT VETERANS MEMORIAL HOSPITAL	74,191.
VETERANS MEMORIAL HOSPITAL 40 1ST STREET, SE WAUKON, IA 52172	N/A	GOV	ECARE PHARMACY AND EMERGENCY SERVICES AT VETERANS MEMORIAL HOSPITAL	30,504.
VILLAGES OF HOPE: AFRICA SOCIETY 2450 MILLTOWER COURT MISSISSAUGA, CANADA	N/A	PC	ZAMBIA DEVELOPMENT: FOOD PRODUCTION, WATER SUPPLY, EDUCATION FACILITIES	502,010.
VIVLI, INC. 14 STORY STREET, SUITE 406 CAMBRIDGE, MA 02138	N/A	PC	PUBLICLY SHARING THE DATA FROM EXERCISE AND T1D STUDIES	72,174.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
VIVLI, INC. 14 STORY STREET, SUITE 406 CAMBRIDGE, MA 02138	N/A	PC	PUBLICLY SHARING THE DATA FROM EXERCISE AND T1D STUDIES	72,174.
WASHINGTON UNIVERSITY 660 S EUCLID AVE. ST LOUIS, MO 63110	N/A	PC	VACCINE SAFETY AND EFFICACY	656,480.
WASHOE BARTON MEDICAL CLINIC 1107 US HIGHWAY 395 N GARDNERVILLE, NV 89410	N/A	PC	RADIOLOGY AND INTERVENTIONAL EQUIPMENT WITH CONSTRUCTION RELATED COSTS.	1,465,248.
WATER4 INC 2405 NW 10TH STREET OKLAHOMA CITY, OK 73107	N/A	PC	SCALING THE NUMA MODEL TO DELIVER SAFE, SUSTAINABLE WATER	1,439,503.
WATER4 INC 2405 NW 10TH STREET OKLAHOMA CITY, OK 73107	N/A	PC	SCALING THE NUMA MODEL TO DELIVER SAFE, SUSTAINABLE WATER	1,673,164.
WATERAID AMERICA, INC. 233 BROADWAY NEW YORK, NY 10279	N/A	PC	CREATING A NEW REALITY FOR WASH IN HEALTHCARE FACILITIES IN ZAMBIA	2,166,773.
WYOMING DEPARTMENT OF HEALTH 6101 YELLOWSTONE RD. SUITE 400 CHEYENNE, WY 82009	N/A	GOV	WYOMING FIRST RESPONDER AED PROJECT	183,693.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
WYOMING STATE PARKS AND CULTURAL RESOURCES 2301 CENTRAL AVENUE CHEYENNE, WY 82002	N/A	GOV	INTERPRETIVE CENTER AT FORT PHIL KEARNY STATE HISTORIC SITE	30,000.
YALE UNIVERSITY OFFICE OF SPONSORED PROJECTS NEW HAVEN, CT 06520-8327	N/A	PC	EXPOSOMICS FOR EARLY LIFE CROHNS DISEASE	443,827.
YALE UNIVERSITY OFFICE OF SPONSORED PROJECTS NEW HAVEN, CT 06520-8327	N/A	PC	EXPOSOMICS FOR EARLY LIFE CROHNS DISEASE	298,606.
YEHUDA ABARBANEL GOVERNMENT HOSPITAL 15 KEREN KAYEMET ST. BAT YAM, ISRAEL	N/A	GOV	MODERNIZATION OF ABARBANELS INFORMATION TECHNOLOGY AND SECURITY SYSTEMS	454,960.
YITZHAK SHAMIR MEDICAL CENTER BE'ER YA'AKOV TZRIFIN, ISRAEL	N/A	GOV	EXPANSION AND RENOVATION OF SHAMIR MEDICAL CENTER'S CANCER INSTITUTE	6,082,143.
YITZHAK SHAMIR MEDICAL CENTER BE'ER YA'AKOV TZRIFIN, ISRAEL	N/A	GOV	EXPANSION AND RENOVATION OF SHAMIR MEDICAL CENTER'S CANCER INSTITUTE	1,978,286.
YOUTH DEVELOPMENT ORGANIZATION INC 15 UNION STREET #563 LAWRENCE, MA 01840	N/A	PC	CAPACITY BUILDING PROJECT SUPPORT 2022	200,000.
Total from continuation sheets				

Part XIV Supplementary Information (continued)

3b Grants and Contributions Approved for Future Payment

Recipient Name and address (home or business)	If recipient is an individual, show any relationship to any foundation manager or substantial contributor	Foundation status of recipient	Purpose of grant or contribution	Amount
YOUTH DEVELOPMENT ORGANIZATION INC 15 UNION STREET #563 LAWRENCE, MA 01840	N/A	PC	CAPACITY BUILDING PROJECT SUPPORT 2022	200,000.

Total from continuation sheets

Underpayment of Estimated Tax by Corporations

▶ Attach to the corporation's tax return.

▶ Go to www.irs.gov/Form2220 for instructions and the latest information.

Name **THE LEONA M. AND HARRY B. HELMSLEY
CHARITABLE TRUST**

Employer identification number
13-7184401

Note: Generally, the corporation is not required to file Form 2220 (see Part II below for exceptions) because the IRS will figure any penalty owed and bill the corporation. However, the corporation may still use Form 2220 to figure the penalty. If so, enter the amount from page 2, line 38, on the estimated tax penalty line of the corporation's income tax return, but **do not** attach Form 2220.

Part I Required Annual Payment

1	Total tax (see instructions)		1	14,577,769.
2a	Personal holding company tax (Schedule PH (Form 1120), line 26) included on line 1	2a		
2b	Look-back interest included on line 1 under section 460(b)(2) for completed long-term contracts or section 167(g) for depreciation under the income forecast method	2b		
2c	Credit for federal tax paid on fuels (see instructions)	2c		
2d	Total. Add lines 2a through 2c	2d		
3	Subtract line 2d from line 1. If the result is less than \$500, do not complete or file this form. The corporation does not owe the penalty	3		14,577,769.
4	Enter the tax shown on the corporation's 2020 income tax return. See instructions. Caution: If the tax is zero or the tax year was for less than 12 months, skip this line and enter the amount from line 3 on line 5	4		9,477,512.
5	Required annual payment. Enter the smaller of line 3 or line 4. If the corporation is required to skip line 4, enter the amount from line 3	5		9,477,512.

Part II Reasons for Filing - Check the boxes below that apply. If any boxes are checked, the corporation **must** file Form 2220 even if it does not owe a penalty. See instructions.

- 6 The corporation is using the adjusted seasonal installment method.
- 7 The corporation is using the annualized income installment method.
- 8 The corporation is a "large corporation" figuring its first required installment based on the prior year's tax.

Part III Figuring the Underpayment

	(a)	(b)	(c)	(d)	
9 Installment due dates. Enter in columns (a) through (d) the 15th day of the 4th (Form 990-PF filers: Use 5th month), 6th, 9th, and 12th months of the corporation's tax year	9	08/15/21	09/15/21	12/15/21	03/15/22
10 Required installments. If the box on line 6 and/or line 7 above is checked, enter the amounts from Sch A, line 38. If the box on line 8 (but not 6 or 7) is checked, see instructions for the amounts to enter. If none of these boxes are checked, enter 25% (0.25) of line 5 above in each column	10	2,369,378.	4,919,507.	3,644,442.	3,644,443.
11 Estimated tax paid or credited for each period. For column (a) only, enter the amount from line 11 on line 15. See instructions	11	8,960,988.	1,500,000.	1,000,000.	4,000,000.
Complete lines 12 through 18 of one column before going to the next column.					
12 Enter amount, if any, from line 18 of the preceding column	12		6,591,610.	3,172,103.	527,661.
13 Add lines 11 and 12	13		8,091,610.	4,172,103.	4,527,661.
14 Add amounts on lines 16 and 17 of the preceding column	14				
15 Subtract line 14 from line 13. If zero or less, enter -0-	15	8,960,988.	8,091,610.	4,172,103.	4,527,661.
16 If the amount on line 15 is zero, subtract line 13 from line 14. Otherwise, enter -0-	16		0.	0.	
17 Underpayment. If line 15 is less than or equal to line 10, subtract line 15 from line 10. Then go to line 12 of the next column. Otherwise, go to line 18	17				
18 Overpayment. If line 10 is less than line 15, subtract line 10 from line 15. Then go to line 12 of the next column	18	6,591,610.	3,172,103.	527,661.	

Go to Part IV on page 2 to figure the penalty. Do not go to Part IV if there are no entries on line 17 - no penalty is owed.

Part IV Figuring the Penalty

	(a)	(b)	(c)	(d)
19 Enter the date of payment or the 15th day of the 4th month after the close of the tax year, whichever is earlier. (C corporations with tax years ending June 30 and S corporations: Use 3rd month instead of 4th month. Form 990-PF and Form 990-T filers: Use 5th month instead of 4th month.) See instructions 19				
20 Number of days from due date of installment on line 9 to the date shown on line 19	20			
21 Number of days on line 20 after 4/15/2021 and before 7/1/2021	21			
22 Underpayment on line 17 x $\frac{\text{Number of days on line 21} \times 3\% (0.03)}{365}$...	22 \$	\$	\$	\$
23 Number of days on line 20 after 6/30/2021 and before 10/1/2021	23			
24 Underpayment on line 17 x $\frac{\text{Number of days on line 23} \times 3\% (0.03)}{365}$...	24 \$	\$	\$	\$
25 Number of days on line 20 after 9/30/2021 and before 1/1/2022	25			
26 Underpayment on line 17 x $\frac{\text{Number of days on line 25} \times 3\% (0.03)}{365}$...	26 \$	\$	\$	\$
27 Number of days on line 20 after 12/31/2021 and before 4/1/2022	27			
28 Underpayment on line 17 x $\frac{\text{Number of days on line 27} \times 3\% (0.03)}{365}$...	28 \$	\$	\$	\$
29 Number of days on line 20 after 3/31/2022 and before 7/1/2022	29			
30 Underpayment on line 17 x $\frac{\text{Number of days on line 29} \times \%}{365}$	30 \$	\$	\$	\$
31 Number of days on line 20 after 6/30/2022 and before 10/1/2022	31			
32 Underpayment on line 17 x $\frac{\text{Number of days on line 31} \times \%}{365}$	32 \$	\$	\$	\$
33 Number of days on line 20 after 9/30/2022 and before 1/1/2023	33			
34 Underpayment on line 17 x $\frac{\text{Number of days on line 33} \times \%}{365}$	34 \$	\$	\$	\$
35 Number of days on line 20 after 12/31/2022 and before 3/16/2023	35			
36 Underpayment on line 17 x $\frac{\text{Number of days on line 35} \times \%}{365}$	36 \$	\$	\$	\$
37 Add lines 22, 24, 26, 28, 30, 32, 34, and 36	37 \$	\$	\$	\$
38 Penalty. Add columns (a) through (d) of line 37. Enter the total here and on Form 1120, line 34; or the comparable line for other income tax returns	38 \$			0.

* Use the penalty interest rate for each calendar quarter, which the IRS will determine during the first month in the preceding quarter. These rates are published quarterly in an IRS News Release and in a revenue ruling in the Internal Revenue Bulletin. To obtain this information on the Internet, access the IRS website at www.irs.gov. You can also call 1-800-829-4933 to get interest rate information.

Schedule A Adjusted Seasonal Installment Method and Annualized Income Installment Method

See instructions.

Form 1120-S filers: For lines 1, 2, 3, and 21, "taxable income" refers to excess net passive income or the amount on which tax is imposed under section 1374(a), whichever applies.

Part I Adjusted Seasonal Installment Method

Caution: Use this method only if the base period percentage for any 6 consecutive months is at least 70%. See instructions.

Table with 5 columns: (a) First 3 months, (b) First 5 months, (c) First 8 months, (d) First 11 months. Rows include taxable income for various periods (1a-1c, 3a-3c), calculations (4-6), and tax amounts (7-19).

Part II Annualized Income Installment Method

		(a)	(b)	(c)	(d)
		First <u>2</u> months	First <u>3</u> months	First <u>6</u> months	First <u>9</u> months
20	Annualization periods (see instructions)				
21	Enter taxable income for each annualization period. See instructions for the treatment of extraordinary items	224,537,025.	317,179,717.	546,678,400.	827,156,244.
22	Annualization amounts (see instructions)	6.000000	4.000000	2.000000	1.333330
23a	Annualized taxable income. Multiply line 21 by line 22	1,347,222,150.	1,268,718,868.	1,093,356,800.	1,102,872,235.
23b	Extraordinary items (see instructions)				
23c	Add lines 23a and 23b	1,347,222,150.	1,268,718,868.	1,093,356,800.	1,102,872,235.
24	Figure the tax on the amount on line 23c using the instructions for Form 1120, Schedule J, line 2, or comparable line of corporation's return	18,726,388.	17,635,192.	15,197,660.	15,329,924.
25	Enter any alternative minimum tax (trusts only) for each payment period (see instructions)				
26	Enter any other taxes for each payment period. See instr.				
27	Total tax. Add lines 24 through 26	18,726,388.	17,635,192.	15,197,660.	15,329,924.
28	For each period, enter the same type of credits as allowed on Form 2220, lines 1 and 2c. See instructions				
29	Total tax after credits. Subtract line 28 from line 27. If zero or less, enter -0-	18,726,388.	17,635,192.	15,197,660.	15,329,924.
30	Applicable percentage	25%	50%	75%	100%
31	Multiply line 29 by line 30	4,681,597.	8,817,596.	11,398,245.	15,329,924.

Part III Required Installments

		1st installment	2nd installment	3rd installment	4th installment
		Note: Complete lines 32 through 38 of one column before completing the next column.			
32	If only Part I or Part II is completed, enter the amount in each column from line 19 or line 31. If both parts are completed, enter the smaller of the amounts in each column from line 19 or line 31	4,681,597.	8,817,596.	11,398,245.	15,329,924.
33	Add the amounts in all preceding columns of line 38. See instructions		2,369,378.	7,288,885.	10,933,327.
34	Adjusted seasonal or annualized income installments. Subtract line 33 from line 32. If zero or less, enter -0-	4,681,597.	6,448,218.	4,109,360.	4,396,597.
35	Enter 25% (0.25) of line 5 on page 1 of Form 2220 in each column. Note: "Large corporations," see the instructions for line 10 for the amounts to enter	2,369,378.	4,919,507.	3,644,442.	3,644,443.
36	Subtract line 38 of the preceding column from line 37 of the preceding column				
37	Add lines 35 and 36	2,369,378.	4,919,507.	3,644,442.	3,644,443.
38	Required installments. Enter the smaller of line 34 or line 37 here and on page 1 of Form 2220, line 10. See instructions	2,369,378.	4,919,507.	3,644,442.	3,644,443.

Form 2220 (2021)

** ANNUALIZED INCOME INSTALLMENT METHOD USING STANDARD OPTION

FORM 990-PF INTEREST ON SAVINGS AND TEMPORARY CASH INVESTMENTS STATEMENT 1

SOURCE	(A) REVENUE PER BOOKS	(B) NET INVESTMENT INCOME	(C) ADJUSTED NET INCOME
INTEREST FROM SAVINGS	17,174.	17,174.	
INTEREST ON STATE TAX REFUND	1.	1.	
TOTAL TO PART I, LINE 3	17,175.	17,175.	

FORM 990-PF DIVIDENDS AND INTEREST FROM SECURITIES STATEMENT 2

SOURCE	GROSS AMOUNT	CAPITAL GAINS DIVIDENDS	(A) REVENUE PER BOOKS	(B) NET INVEST- MENT INCOME	(C) ADJUSTED NET INCOME
DIVIDENDS AND INTEREST FROM SECURITIES	36,631,242.	0.	36,631,242.	129,538,579.	
TO PART I, LINE 4	36,631,242.	0.	36,631,242.	129,538,579.	

FORM 990-PF OTHER INCOME STATEMENT 3

DESCRIPTION	(A) REVENUE PER BOOKS	(B) NET INVEST- MENT INCOME	(C) ADJUSTED NET INCOME
FX TRANSACTION NET GAIN	1,538,224.	1,521,732.	
CLASS ACTION PROCEEDS, NET	26,593.	26,593.	
OTHER PARTNERSHIP INCOME	38,741,078.	44,425,949.	
SECTION 951(A) INCOME INCLUSION	0.	233,106,429.	
GRANT RECOVERIES	892,513.	0.	
OTHER TAXABLE INCOME	414.	414.	
TOTAL TO FORM 990-PF, PART I, LINE 11	41,198,822.	279,081,117.	

FORM 990-PF

LEGAL FEES

STATEMENT 4

DESCRIPTION	(A) EXPENSES PER BOOKS	(B) NET INVEST- MENT INCOME	(C) ADJUSTED NET INCOME	(D) CHARITABLE PURPOSES
HAROLD A MERIAM III (INVESTMENT RELATED)	34,176.	34,176.		0.
LOEB & LOEB LLP (GENERAL AND ADMINISTRATIVE)	114,796.	0.		105,257.
ROPES & GRAY LLP (INVESTMENT RELATED)	206,358.	206,358.		0.
PATTERSON BELKNAP WEBB & TYLER LLP (GENERAL & ADMINISTRATIVE)	62,644.	0.		35,011.
PROSKAUER ROSE LLP (GENERAL & ADMINISTRATIVE)	13,675.	0.		13,675.
OTHER LEGAL FEES	15,220.	0.		17,165.
TO FM 990-PF, PG 1, LN 16A	446,869.	240,534.		171,108.

FORM 990-PF

ACCOUNTING FEES

STATEMENT 5

DESCRIPTION	(A) EXPENSES PER BOOKS	(B) NET INVEST- MENT INCOME	(C) ADJUSTED NET INCOME	(D) CHARITABLE PURPOSES
DEMASCO, SENA & JAHELKA LLP (BOOKKEEPING)	30,862.	4,721.		24,654.
PKF O'CONNOR DAVIES, LLP (AUDIT & TAX)	494,690.	283,800.		168,025.
PRICEWATERHOUSECOOPERS ADVISORY LTD. (GRANTS ADMINISTRATION)	92,823.	0.		87,761.
UKG INC. (DBA ULTIMATE SOFTWARE GROUP)	99.	0.		99.
TO FORM 990-PF, PG 1, LN 16B	618,474.	288,521.		280,539.

FORM 990-PF

OTHER PROFESSIONAL FEES

STATEMENT 6

DESCRIPTION	(A) EXPENSES PER BOOKS	(B) NET INVEST- MENT INCOME	(C) ADJUSTED NET INCOME	(D) CHARITABLE PURPOSES
COLLER VI (INVESTMENT MANAGEMENT)	826,179.	826,179.		0.
COLLER VII (INVESTMENT MANAGEMENT)	514,686.	514,686.		0.
COLLER VIII (INVESTMENT MANAGEMENT)	260,342.	260,342.		0.

DF DENT & COMPANY, INC. (INVESTMENT MANAGEMENT)	896,140.	896,140.	0.
EDWARD GILLEN (PROGRAM CONSULTING)	125,020.	0.	125,020.
FIDUCIARY MANAGEMENT, INC. (INVESTMENT MANAGEMENT)	772,776.	772,776.	0.
GAVEA INVESTMENT FUND V B L.P.	538,219.	538,219.	0.
GENESIS ANALYTICS (PROGRAM CONSULTING)	135,605.	0.	85,605.
GLOBAL HEALTH STRATEGIES (PROGRAM CONSULTING)	423,023.	0.	512,839.
GLOBAL STRATEGY GROUP LLC (PUBLIC RELATIONS)	324,670.	0.	327,170.
IFP GLOBAL EQUITY LP (INVESTMENT MANAGEMENT)	1,516,006.	1,516,006.	0.
OTHER CONSULTING FEES - GENERAL MANAGEMENT	60,982.	4,086.	47,321.
OTHER CONSULTING FEES - GRANTS MANAGEMENT	111,105.	0.	107,745.
OTHER CONSULTING FEES - HUMAN RESOURCES	12,330.	4,000.	8,330.
OTHER CONSULTING FEES - INFORMATION TECHNOLOGY	44,545.	0.	38,985.
OTHER INVESTMENT MANAGEMENT & CONSULTING FEES	42,937.	42,937.	0.
OTHER PROGRAM RELATED CONSULTING FEES	508,285.	0.	513,251.
OTHER PUBLIC RELATIONS CONSULTING FEES	115,331.	0.	130,835.
OTHER RECRUITMENT FEES	50,838.	0.	73,947.
PRECISION ADVISORS, LLC DBA PRECISION FOR VALUE, LLC (PROGRAM CONSULTING)	178,684.	0.	188,381.
SCOTT KAHN (PROGRAM CONSULTING)	194,890.	0.	207,265.
SOLUTION SIMPLE (INFORMATION TECHNOLOGY)	246,425.	29,416.	210,297.
T. ROWE PRICE ASSOCIATES INC. (INVESTMENT MANAGEMENT)	694,426.	694,426.	0.
WILSHIRE ASSOCIATES INCORPORATED (INVESTMENT ADVISORY)	438,320.	438,320.	0.
TO FORM 990-PF, PG 1, LN 16C	9,031,764.	6,537,533.	2,576,991.

FORM 990-PF

TAXES

STATEMENT 7

DESCRIPTION	(A) EXPENSES PER BOOKS	(B) NET INVEST- MENT INCOME	(C) ADJUSTED NET INCOME	(D) CHARITABLE PURPOSES
STATE UNRELATED BUSINESS INCOME TAX	1,777,255.	0.		0.
FOREIGN TAXES WITHHELD	530,184.	3,095,765.		0.
FEDERAL EXCISE TAX	13,726,064.	0.		0.
TO FORM 990-PF, PG 1, LN 18	16,033,503.	3,095,765.		0.

FORM 990-PF

OTHER EXPENSES

STATEMENT 8

DESCRIPTION	(A) EXPENSES PER BOOKS	(B) NET INVEST- MENT INCOME	(C) ADJUSTED NET INCOME	(D) CHARITABLE PURPOSES
AMERICAN DEPOSITARY RECEIPT FEE	16,890.	16,890.		0.
CONSULTING REIMBURSEMENTS CUSTODY, BANK, & PERFORMANCE REPORTING FEES	19,042.	0.		19,391.
FILING FEES AND PENALTIES INFORMATION	830,104.	829,889.		215.
TECHNOLOGY/COMPUTERS	51,276.	0.		1,625.
INSURANCE	1,554,580.	241,219.		1,289,674.
OFFICE EXPENSES	336,673.	39,538.		319,924.
PORTFOLIO DEDUCTIONS	791,818.	300,793.		470,551.
TO FORM 990-PF, PG 1, LN 23	19,483,419.	51,341,400.		0.
	23,083,802.	52,769,729.		2,101,380.

FORM 990-PF

CORPORATE STOCK

STATEMENT 9

DESCRIPTION	BOOK VALUE	FAIR MARKET VALUE
ALPHABET INC, 2,862 SHRS	7,993,537.	7,993,537.
AMAZON.COM INC, 1,739 SHRS	5,669,053.	5,669,053.
AMERICAN TOWER CORP, 15,113 SHRS	3,796,688.	3,796,688.
ANSYS INC, 16,010 SHRS	5,085,577.	5,085,577.
BIO-TECHNE CORP, 12,546 SHRS	5,432,920.	5,432,920.
BLACKLINE INC, 33,880 SHRS	2,480,694.	2,480,694.
AZENTA INC, 10,673 SHRS	884,578.	884,578.
CBRE GROUP INC, 55,720 SHRS	5,099,494.	5,099,494.
CABLE ONE INC, 2,855 SHRS	4,180,405.	4,180,405.
CARMAX INC, 33,809 SHRS	3,261,892.	3,261,892.
COSTAR GROUP INC, 42,938 SHRS	2,860,100.	2,860,100.
CROWDSTRIKE HOLDINGS INC, 9,928 SHRS	2,254,450.	2,254,450.
DANAHER CORP, 22,680 SHRS	6,652,724.	6,652,724.
DOLLAR GENERAL CORP, 16,258 SHRS	3,619,519.	3,619,519.
ECOLAB INC, 20,601 SHRS	3,637,313.	3,637,313.
FASTENAL CO, 59,691 SHRS	3,545,645.	3,545,645.
GUIDEWIRE SOFTWARE INC, 23,015 SHRS	2,177,679.	2,177,679.
HEICO CORP, 45,587 SHRS	5,781,799.	5,781,799.
IDEXX LABORATORIES INC, 4,096 SHRS	2,240,758.	2,240,758.
ILLUMINA INC, 16,733 SHRS	5,846,510.	5,846,510.
INTUITIVE SURGICAL INC, 21,969 SHRS	6,627,608.	6,627,608.
MARKEL CORP, 3,399 SHRS	5,014,341.	5,014,341.
MASTERCARD INC, 19,236 SHRS	6,874,562.	6,874,562.
MOODY'S CORP, 6,951 SHRS	2,345,337.	2,345,337.
OKTA INC, 7,695 SHRS	1,161,637.	1,161,637.
QUALCOMM INC, 32,515 SHRS	4,968,942.	4,968,942.
S&P GLOBAL INC, 14,521 SHRS	5,956,224.	5,956,224.
SBA COMMUNICATIONS CORP, 9,184 SHRS	3,160,214.	3,160,214.
SHOPIFY INC, 1,604 SHRS	1,084,240.	1,084,240.
SPROUT SOCIAL INC, 8,650 SHRS	693,038.	693,038.
TELEFLEX INC, 11,542 SHRS	4,095,448.	4,095,448.
THERMO FISHER SCIENTIFIC INC, 11,560 SHRS	6,827,914.	6,827,914.
TRANSDIGM GROUP INC, 8,842 SHRS	5,760,917.	5,760,917.
TWILIO INC, 6,204 SHRS	1,022,481.	1,022,481.
VEEVA SYSTEMS INC, 12,632 SHRS	2,683,795.	2,683,795.
VERISK ANALYTICS INC, 18,395 SHRS	3,948,119.	3,948,119.
VISA INC, 39,464 SHRS	8,751,931.	8,751,931.
VULCAN MATERIALS CO, 20,911 SHRS	3,841,351.	3,841,351.
WASTE CONNECTIONS INC, 39,215 SHRS	5,478,336.	5,478,336.
WILLSCOT MOBILE MINI HOLDINGS, 43,251 SHRS	1,692,412.	1,692,412.
WORKIVA INC, 11,503 SHRS	1,357,354.	1,357,354.
ATLISSIAN CORP PLC, 3,724 SHRS	1,094,223.	1,094,223.
ALPHABET INC, 2,653 SHRS	7,378,922.	7,378,922.
AVERY DENNISON CORP, 5,781 SHRS	1,005,721.	1,005,721.
BERKSHIRE HATHAWAY INC, 30,799 SHRS	10,869,275.	10,869,275.
BOOKING HOLDINGS INC, 2,792 SHRS	6,556,872.	6,556,872.
CDW CORP/DE, 8,780 SHRS	1,570,654.	1,570,654.
CARLISLE COS INC, 12,678 SHRS	3,117,774.	3,117,774.
CARMAX INC, 33,476 SHRS	3,229,764.	3,229,764.
COMCAST CORP, 116,977 SHRS	5,476,863.	5,476,863.
DOLLAR GENERAL CORP, 37,840 SHRS	8,424,319.	8,424,319.
DOLLAR TREE INC, 44,089 SHRS	7,060,853.	7,060,853.

DOVER CORP, 27,994 SHRS	4,392,259.	4,392,259.
META PLATFORMS INC, 14,120 SHRS	3,139,723.	3,139,723.
FRESENIUS MEDICAL CARE AG & CO, 129,576 SHRS	4,364,120.	4,364,120.
JPMORGAN CHASE & CO, 37,415 SHRS	5,100,413.	5,100,413.
KONINKLIJKE PHILIPS NV, 145,657 SHRS	4,446,908.	4,446,908.
MASCO CORP, 150,820 SHRS	7,691,820.	7,691,820.
MICRON TECHNOLOGY INC, 84,147 SHRS	6,554,210.	6,554,210.
NORTHERN TRUST CORP, 45,944 SHRS	5,350,179.	5,350,179.
OMNICOM GROUP INC, 62,210 SHRS	5,280,385.	5,280,385.
PPG INDUSTRIES INC, 31,507 SHRS	4,129,622.	4,129,622.
PACCAR INC, 63,404 SHRS	5,583,990.	5,583,990.
PROGRESSIVE CORP/THE, 46,833 SHRS	5,338,494.	5,338,494.
QUEST DIAGNOSTICS INC, 33,976 SHRS	4,649,955.	4,649,955.
SAP SE, 31,806 SHRS	3,529,194.	3,529,194.
SCHLUMBERGER LTD, 100,410 SHRS	4,147,937.	4,147,937.
CHARLES SCHWAB CORP/THE, 81,139 SHRS	6,840,829.	6,840,829.
SMITH & NEPHEW PLC, 149,359 SHRS	4,764,552.	4,764,552.
SONY GROUP CORP, 66,468 SHRS	6,826,928.	6,826,928.
TJX COS INC/THE, 54,941 SHRS	3,328,326.	3,328,326.
UNILEVER PLC, 118,915 SHRS	5,418,957.	5,418,957.
UNITEDHEALTH GROUP INC, 12,444 SHRS	6,346,067.	6,346,067.
ARCH CAPITAL GROUP LTD, 81,943 SHRS	3,967,680.	3,967,680.
EATON CORP PLC, 21,836 SHRS	3,313,831.	3,313,831.
CHUBB LTD, 16,804 SHRS	3,594,376.	3,594,376.
UNILEVER PLC, 112,629 SHRS	5,131,091.	5,131,091.
NINTENDO CO LTD, 15,800 SHRS	8,027,897.	8,027,897.
TGS ASA, 64,852 SHRS	976,043.	976,043.
GLAXOSMITHKLINE PLC, 349,926 SHRS	7,589,146.	7,589,146.
RECKITT BENCKISER GROUP PLC, 105,210 SHRS	8,078,763.	8,078,763.
INFORMA PLC, 650,658 SHRS	5,155,554.	5,155,554.
NOVARTIS AG, 124,594 SHRS	11,000,557.	11,000,557.
NESTLE SA, 66,975 SHRS	8,748,052.	8,748,052.
CIE FINANCIERE RICHEMONT SA, 64,029 SHRS	8,210,184.	8,210,184.
ALCON INC, 40,429 SHRS	3,237,835.	3,237,835.
ALPHABET INC, 2,923 SHRS	8,129,886.	8,129,886.
BOOKING HOLDINGS INC, 2,867 SHRS	6,733,006.	6,733,006.
BRISTOL-MYERS SQUIBB CO, 175,887 SHRS	12,845,028.	12,845,028.
CORTEVA INC, 134,177 SHRS	7,712,494.	7,712,494.
EBAY INC, 136,662 SHRS	7,825,266.	7,825,266.
ELECTRONIC ARTS INC, 58,456 SHRS	7,395,269.	7,395,269.
FOX CORP, 243,582 SHRS	9,609,310.	9,609,310.
INTERCONTINENTAL EXCHANGE INC, 63,295 SHRS	8,362,535.	8,362,535.
JOHNSON & JOHNSON, 39,431 SHRS	6,988,356.	6,988,356.
MICROSOFT CORP, 20,632 SHRS	6,361,052.	6,361,052.
NEWS CORP, 369,723 SHRS	8,189,364.	8,189,364.
NEWS CORP, 163,588 SHRS	3,684,002.	3,684,002.
ORACLE CORP, 83,656 SHRS	6,920,861.	6,920,861.
S&P GLOBAL INC, 14,641 SHRS	6,005,445.	6,005,445.
SALESFORCE INC, 20,882 SHRS	4,433,666.	4,433,666.
TRANSUNION, 46,201 SHRS	4,774,411.	4,774,411.
WESTERN UNION CO/THE, 220,210 SHRS	4,126,735.	4,126,735.
ZILLOW GROUP INC, 21,460 SHRS	1,035,016.	1,035,016.
ZILLOW GROUP INC, 120,087 SHRS	5,919,088.	5,919,088.
AON PLC, 27,075 SHRS	8,816,432.	8,816,432.
ACCENTURE PLC, 56 SHRS	18,885.	18,885.
ACCENTURE PLC, 11,632 SHRS	3,922,659.	3,922,659.
CHINA RENAISSANCE HOLDINGS LTD, 127,556 SHRS	157,768.	157,768.
MEITUAN, 183,364 SHRS	3,643,210.	3,643,210.

JW CAYMAN THERAPEUTICS CO LTD, 7,143 SHRS	7,406.	7,406.
BRII BIOSCIENCES LTD, 80,115 SHRS	113,553.	113,553.
AFFIRM HOLDINGS INC, 90,830 SHRS	4,203,612.	4,203,612.
AIRBNB INC, 12,774 SHRS	2,194,062.	2,194,062.
BERKELEY LIGHTS INC, 2,018 SHRS	14,348.	14,348.
BILL.COM HOLDINGS INC, 6,110 SHRS	1,385,687.	1,385,687.
CROWDSTRIKE HOLDINGS INC, 5,806 SHRS	1,318,426.	1,318,426.
DADA NEXUS LTD, 16,164 SHRS	147,577.	147,577.
DIGITALOCEAN HOLDINGS INC, 79,471 SHRS	4,597,397.	4,597,397.
DOORDASH INC, 22,663 SHRS	2,655,877.	2,655,877.
META PLATFORMS INC, 10,000 SHRS	2,223,600.	2,223,600.
FUTU HOLDINGS LTD, 5,962 SHRS	194,123.	194,123.
GUARDANT HEALTH INC, 4,000 SHRS	264,960.	264,960.
LYFT INC, 17,155 SHRS	658,752.	658,752.
OSCAR HEALTH INC, 22,936 SHRS	228,672.	228,672.
PINDUODUO INC, 146,148 SHRS	5,861,996.	5,861,996.
ROBLOX CORP, 72,000 SHRS	3,329,280.	3,329,280.
SENTINELONE INC, 23,937 SHRS	927,319.	927,319.
SNOWFLAKE INC, 11,358 SHRS	2,602,459.	2,602,459.
SUMO LOGIC INC, 55,907 SHRS	652,435.	652,435.
TWILIO INC, 10,000 SHRS	1,648,100.	1,648,100.
UIPATH INC, 133,883 SHRS	2,890,534.	2,890,534.
UNITY SOFTWARE INC, 30,651 SHRS	3,040,886.	3,040,886.
ZOOM VIDEO COMMUNICATIONS INC, 11,000 SHRS	1,289,530.	1,289,530.
TOTAL TO FORM 990-PF, PART II, LINE 10B	591,948,988.	591,948,988.

FORM 990-PF

OTHER INVESTMENTS

STATEMENT 10

DESCRIPTION	VALUATION METHOD	BOOK VALUE	FAIR MARKET VALUE
JPM US LARGE CAP	FMV	125,183,266.	125,183,266.
SPDR TRUST SERIES I	FMV	124,358,622.	124,358,622.
JPM CORE BOND	FMV	1,255,541,161.	1,255,541,161.
JPM SHORT DURATION BOND	FMV	326,609,332.	326,609,332.
CHATHAM	FMV	108,419,200.	108,419,200.
CHATHAM CO INVEST	FMV	70,062,390.	70,062,390.
CHATHAM OFFSHORE	FMV	107,383,116.	107,383,116.
BRILLIANT PARTNERS	FMV	75,250,122.	75,250,122.
CAMBER	FMV	140,373,678.	140,373,678.
ORBIMED GENESIS FUND	FMV	17,968,765.	17,968,765.
JERICHO	FMV	187,120,249.	187,120,249.
SEQUOIA CAP GLOBAL	FMV	218,057,635.	218,057,635.
ACADIAN FRONTIER	FMV	104,404,213.	104,404,213.
HIGHCLERE INTL SC	FMV	151,927,907.	151,927,907.
HIGHCLERE INTL SMID	FMV	82,124,194.	82,124,194.
LA CAPITAL GLOBAL	FMV	111,532,600.	111,532,600.
LACM WORLD SMALL CAP	FMV	110,390,023.	110,390,023.
MARATHON GLOBAL	FMV	105,854,074.	105,854,074.
SILCHESTER INTL	FMV	141,761,870.	141,761,870.
BLACKROCK US DEBT	FMV	231,439,336.	231,439,336.
ACCEL GROWTH FUND IV	FMV	30,645,594.	30,645,594.
ACCEL GROWTH II	FMV	14,875,787.	14,875,787.
ACCEL GROWTH III	FMV	19,128,215.	19,128,215.

ACCEL GROWTH V	FMV	38,337,112.	38,337,112.
ACCEL GROWTH VI	FMV	11,625,605.	11,625,605.
ACCEL INDIA V	FMV	15,744,558.	15,744,558.
ACCEL INDIA VI	FMV	8,221,624.	8,221,624.
ACCEL INDIA VII	FMV	640,000.	640,000.
ACCEL LEADERS FUND	FMV	12,870,376.	12,870,376.
ACCEL LEADERS II	FMV	11,190,585.	11,190,585.
ACCEL LEADERS III	FMV	25,535,297.	25,535,297.
ACCEL XI	FMV	7,610,255.	7,610,255.
ACCEL XII	FMV	28,131,818.	28,131,818.
ACCEL XIII	FMV	19,705,081.	19,705,081.
ACCEL XIV	FMV	11,574,672.	11,574,672.
ACCEL XV	FMV	3,872,286.	3,872,286.
AH BIO FUND I	FMV	9,110,573.	9,110,573.
AH BIO FUND II	FMV	19,043,732.	19,043,732.
AH BIO III	FMV	14,243,936.	14,243,936.
AH BIO IV	FMV	1,046,617.	1,046,617.
AH CNK IV	FMV	2,000,000.	2,000,000.
AH CNK SEED I	FMV	1,250,000.	1,250,000.
AH FUND VII	FMV	11,938,432.	11,938,432.
AH FUND VIII	FMV	1,326,986.	1,326,986.
AH III	FMV	63,683,169.	63,683,169.
AH III PARALLEL	FMV	12,003,088.	12,003,088.
AH IV	FMV	50,068,896.	50,068,896.
AH IV PARALLEL	FMV	21,653,467.	21,653,467.
AH LSV FUND II	FMV	21,569,100.	21,569,100.
AH LSV FUND III	FMV	5,641,070.	5,641,070.
AH LSV I	FMV	22,356,136.	22,356,136.
AH V	FMV	55,628,188.	55,628,188.
AH V PARALLEL	FMV	31,505,964.	31,505,964.
AH VI	FMV	29,989,545.	29,989,545.
ANGELENO INV III	FMV	16,814,435.	16,814,435.
ARBORETUM III	FMV	6,292,132.	6,292,132.
ARBORETUM IV	FMV	38,759,884.	38,759,884.
ARBORETUM V	FMV	15,421,213.	15,421,213.
BAYVIEW	FMV	61,702,904.	61,702,904.
COLLER VI	FMV	7,988,854.	7,988,854.
COLLER VII	FMV	41,152,855.	41,152,855.
COLLER VIII	FMV	20,280,774.	20,280,774.
CRESTVIEW ELO	FMV	7,213,977.	7,213,977.
CRESTVIEW III	FMV	44,406,113.	44,406,113.
CRESTVIEW IV	FMV	21,758,970.	21,758,970.
EIG ENERGY FUND XVI	FMV	50,259,711.	50,259,711.
EIG ENERGY XV	FMV	8,117,949.	8,117,949.
EIG ENERGY XVII	FMV	11,222,263.	11,222,263.
EMERGENCE III	FMV	87,147,420.	87,147,420.
EMERGENCE IV	FMV	49,692,754.	49,692,754.
EMERGENCE OPP I	FMV	5,987,177.	5,987,177.
EMERGENCE V	FMV	35,174,100.	35,174,100.
EMERGENCE VI	FMV	2,347,654.	2,347,654.
EPIRIS II	FMV	20,029,076.	20,029,076.
FORTISSIMO	FMV	24,365,576.	24,365,576.
FORTISSIMO V	FMV	16,714,172.	16,714,172.
FRAZIER GTH BUYOUT X	FMV	4,187,317.	4,187,317.
FRAZIER IX	FMV	8,040,922.	8,040,922.
FRAZIER PUBLIC FUND	FMV	10,041,196.	10,041,196.
FRAZIER SUNMD CO INV	FMV	6,000,000.	6,000,000.
FRAZIER X	FMV	9,849,046.	9,849,046.

GAVEA IV	FMV	1,423,455.	1,423,455.
GAVEA V	FMV	8,901,233.	8,901,233.
GAVEA V PLUS	FMV	2,202,473.	2,202,473.
GENERL ATLANTIC 2013	FMV	96,361,826.	96,361,826.
GENERL ATLANTIC 2018	FMV	108,629,521.	108,629,521.
GSO CAP SOLUTION III	FMV	3,348,966.	3,348,966.
GSO CAPITAL SOLS II	FMV	3,475,632.	3,475,632.
GSO CAPITAL SOLUTION	FMV	417,946.	417,946.
HARBOUR ENERGY	FMV	244,087,504.	244,087,504.
HIG BAYSIDE III	FMV	3,904,650.	3,904,650.
HIG BIOVENTURE II	FMV	18,420,605.	18,420,605.
HIG BRAZIL	FMV	3,808,092.	3,808,092.
HIG BRAZIL LATAM B	FMV	20,121,078.	20,121,078.
HIG BRAZIL LATAM C	FMV	20,121,078.	20,121,078.
HIG CAPITAL V	FMV	17,693,596.	17,693,596.
HIG GROWTH B&E F II	FMV	30,934,699.	30,934,699.
HIG GROWTH III	FMV	3,936,960.	3,936,960.
HIG MID MARKET II	FMV	21,131,884.	21,131,884.
HIG MID MARKET III	FMV	5,892,715.	5,892,715.
IDG BREYER	FMV	3,622,962.	3,622,962.
IDG CHINA CAP III	FMV	33,453,637.	33,453,637.
IDG CHINA VTR IV	FMV	40,828,775.	40,828,775.
IDG CHINA VTR V	FMV	45,266,218.	45,266,218.
IDG-ACCEL CHINA CAP	FMV	19,941,265.	19,941,265.
IDG-ACCEL CHINA GWTH	FMV	17,001,054.	17,001,054.
IRON POINT IV	FMV	19,326,121.	19,326,121.
JPM PEG SECONDRY III	FMV	7,398,507.	7,398,507.
MHR AXIOM	FMV	130,163,165.	130,163,165.
MHR INST PARTNERS IV	FMV	53,702,525.	53,702,525.
NEWMARKET IIFC	FMV	28,151,533.	28,151,533.
ORBIMED ASIA III	FMV	46,543,663.	46,543,663.
ORBIMED ASIA IV	FMV	14,622,698.	14,622,698.
ORBIMED ISRAEL	FMV	8,495,791.	8,495,791.
ORBIMED ISRAEL II	FMV	19,994,911.	19,994,911.
ORBIMED PI VI	FMV	13,579,228.	13,579,228.
ORBIMED PI VII	FMV	25,075,044.	25,075,044.
ORBIMED PI VIII	FMV	13,269,232.	13,269,232.
ORBIMED ROYALTY II	FMV	2,700,553.	2,700,553.
PEP IV CORE	FMV	24,547.	24,547.
PEP IV SUPPL	FMV	6,620.	6,620.
PEP VI	FMV	10,582,867.	10,582,867.
PITANGO GROWTH	FMV	58,909,417.	58,909,417.
PITANGO GROWTH II	FMV	16,020,456.	16,020,456.
PITANGO HEALTHTECH I	FMV	8,483,389.	8,483,389.
PITANGO SPV	FMV	22,465,094.	22,465,094.
PITANGO VI, LP	FMV	32,581,826.	32,581,826.
PITANGO VTR VII	FMV	39,038,518.	39,038,518.
PITANGO VTR VIII	FMV	9,600,875.	9,600,875.
RIDGEWOOD III	FMV	47,262,943.	47,262,943.
RIDGEWOOD IV	FMV	20,839,295.	20,839,295.
S CAPITAL	FMV	28,861,155.	28,861,155.
S CAPITAL II	FMV	8,110,693.	8,110,693.
SEQUOIA CAPITAL FUND	FMV	14,513,399.	14,513,399.
SEQUOIA CH GWTH VI	FMV	17,764,152.	17,764,152.
SEQUOIA CH VTR VIII	FMV	4,007,521.	4,007,521.
SEQUOIA CHINA GR III	FMV	64,873,538.	64,873,538.
SEQUOIA CHINA GR IV	FMV	22,456,554.	22,456,554.
SEQUOIA CHINA GRTH V	FMV	31,877,099.	31,877,099.

SEQUOIA CHINA VE VII	FMV	6,961,358.	6,961,358.
SEQUOIA CHINA VTR IV	FMV	12,117,192.	12,117,192.
SEQUOIA CHINA VTR V	FMV	9,516,172.	9,516,172.
SEQUOIA CHINA VTR VI	FMV	8,435,406.	8,435,406.
SEQUOIA GBL GRTH III	FMV	126,509,054.	126,509,054.
SEQUOIA GG 3 CH ANX	FMV	8,055,631.	8,055,631.
SEQUOIA GLB GROWTH	FMV	58,737,501.	58,737,501.
SEQUOIA GLB GRWTH II	FMV	46,203,352.	46,203,352.
SEQUOIA IND GWTH III	FMV	10,112,804.	10,112,804.
SEQUOIA IND VTR VII	FMV	2,976,104.	2,976,104.
SEQUOIA INDIA V	FMV	16,011,246.	16,011,246.
SEQUOIA INDIA VI	FMV	12,021,946.	12,021,946.
SEQUOIA ISRAEL V	FMV	8,061,256.	8,061,256.
SEQUOIA SCOUT III	FMV	2,319,529.	2,319,529.
SEQUOIA SCOUT IV	FMV	383,454.	383,454.
SEQUOIA US GROWTH V	FMV	3,644,549.	3,644,549.
SEQUOIA US GRTH VIII	FMV	14,487,067.	14,487,067.
SEQUOIA US GRWTH VII	FMV	17,899,869.	17,899,869.
SEQUOIA US GWTH IX	FMV	8,210,652.	8,210,652.
SEQUOIA US GWTH VI	FMV	13,536,477.	13,536,477.
SEQUOIA US VENT XVI	FMV	7,127,542.	7,127,542.
SEQUOIA US VTR XIV	FMV	33,485,268.	33,485,268.
SEQUOIA US VTR XV	FMV	8,007,347.	8,007,347.
SEQUOIA US VTR XVII	FMV	2,734,071.	2,734,071.
SQUOIA GG 3 US IN AX	FMV	12,398,506.	12,398,506.
STARWOOD X	FMV	27,691,411.	27,691,411.
STARWOOD XI	FMV	46,862,402.	46,862,402.
STARWOOD XII	FMV	6,883,036.	6,883,036.
TAURUS RESOURCES II	FMV	32,766,833.	32,766,833.
WTI VLL IX	FMV	16,144,368.	16,144,368.
WTI VLL VII	FMV	11,404,600.	11,404,600.
WTI VLL VIII	FMV	21,471,065.	21,471,065.
WTI VLL X	FMV	1,869,752.	1,869,752.
YORK CO INVEST 1	FMV	1,745,106.	1,745,106.
YORK DISTRESSED III	FMV	50,404,072.	50,404,072.
YORK DISTRESSED IV	FMV	24,545,279.	24,545,279.
YORK EUROPEAN	FMV	2,094,171.	2,094,171.
YORK EUROPEAN II	FMV	35,947,200.	35,947,200.
TOTAL TO FORM 990-PF, PART II, LINE 13		7,406,511,362.	7,406,511,362.

FORM 990-PF DEPRECIATION OF ASSETS NOT HELD FOR INVESTMENT STATEMENT 11

DESCRIPTION	COST OR OTHER BASIS	ACCUMULATED DEPRECIATION	BOOK VALUE
FURNITURE, FIXTURES AND EQUIPMENT	2,533,661.	1,473,077.	1,060,584.
LEASEHOLD IMPROVEMENTS	6,857,003.	865,085.	5,991,918.
WORK IN PROGRESS	246,869.	0.	246,869.
TOTAL TO FM 990-PF, PART II, LN 14	9,637,533.	2,338,162.	7,299,371.

FORM 990-PF

OTHER ASSETS

STATEMENT 12

DESCRIPTION	BEGINNING OF YR BOOK VALUE	END OF YEAR BOOK VALUE	FAIR MARKET VALUE
ACCRUED INCOME RECEIVABLE	1,758,404.	1,399,923.	1,399,923.
DUE FROM BROKER	10,708,909.	107,058,082.	107,058,082.
RETIREMENT PLAN ASSET	1,725,098.	1,898,891.	1,898,891.
ADVANCES AND OTHER RECEIVABLES	13.	22,058.	22,058.
PREPAID FEDERAL EXCISE TAX	9,454,455.	2,228,391.	2,228,391.
PROGRAM RELATED INVESTMENTS	16,614,400.	20,909,674.	20,909,674.
TOTAL TO FORM 990-PF, PART II, LINE 15	40,261,279.	133,517,019.	133,517,019.

FORM 990-PF

OTHER LIABILITIES

STATEMENT 13

DESCRIPTION	BOY AMOUNT	EOY AMOUNT
DEFERRED FEDERAL EXCISE TAX	43,954,729.	37,437,887.
RETIREMENT PLAN LIABILITY	2,389,093.	2,509,260.
ACCRUED VACATION	934,558.	1,452,558.
DEFERRED RENT EXPENSE	586,204.	560,586.
REFUNDABLE DEPOSITS	317.	319.
GRANT REFUNDS PENDING MODIFICATION	1,103,455.	1,005,850.
TOTAL TO FORM 990-PF, PART II, LINE 22	48,968,356.	42,966,460.

FORM 990-PF

NAME OF FOREIGN COUNTRY IN WHICH
ORGANIZATION HAS FINANCIAL INTEREST

STATEMENT 14

NAME OF COUNTRY

AUSTRALIA
AUSTRIA
BAHRAIN
BANGLADESH
BELGIUM
BOTSWANA
BRAZIL
CANADA
CHILE
COLOMBIA
CROATIA
CYPRUS
CZECH REPUBLIC
DENMARK
EGYPT
FINLAND
FRANCE
GERMANY
GREECE
HONG KONG
HUNGARY
ICELAND
INDIA
INDONESIA
ISRAEL
ITALY
JAPAN
JORDAN
KAZAKHSTAN
KENYA
KUWAIT
LITHUANIA
MALAYSIA
MEXICO
MOROCCO
NETHERLANDS
NEW ZEALAND
NIGERIA
NORWAY
OMAN
PAKISTAN
PANAMA
PHILIPPINES
POLAND
PORTUGAL
QATAR
ROMANIA
RUSSIA
SINGAPORE
SLOVENIA
SOUTH AFRICA

KOREA (SOUTH)
 SPAIN
 SRI LANKA
 SWEDEN
 SWITZERLAND
 TAIWAN
 TANZANIA
 THAILAND
 TUNISIA
 UNITED ARAB EMIRATES
 UNITED KINGDOM
 VIETNAM
 ZAMBIA
 ZIMBABWE

FORM 990-PF

TRANSFERS TO CONTROLLED ENTITIES
 PART VI-A, LINE 11

STATEMENT 15

NAME OF CONTROLLED ENTITY

EMPLOYER ID NO

ACADIAN FRONTIER MARKETS EQUITY FUND

20-5852756

ADDRESS

260 FRANKLIN STREET
 BOSTON, MA 02110

DESCRIPTION OF TRANSFER

MANAGEMENT FEE

AMOUNT
 OF TRANSFER

1,204,747.

THE LEONA M. AND HARRY B. HELMSLEY CHARI

13-7184401

NAME OF CONTROLLED ENTITY

EMPLOYER ID NO

MHR LONGEVITY PARTNERS

98-1471155

ADDRESS

1345 AVENUE OF THE AMERICAS 42ND FLOOR
NEW YORK, NY 10105

DESCRIPTION OF TRANSFER

CONTRIBUTION OF CAPITAL

AMOUNT
OF TRANSFER

55,474,168.

NAME OF CONTROLLED ENTITY

EMPLOYER ID NO

PITANGO SPV

98-1492234

ADDRESS

BEIT ACKERSHTEIN - BLDG. B, 11 HAMENOFIM ST. 11TH FL.
HERZLIYA, ISRAEL

DESCRIPTION OF TRANSFER

CONTRIBUTION OF CAPITAL

AMOUNT
OF TRANSFER

1,065,000.

TOTAL AMOUNT OF TRANSFERS TO CONTROLLED ENTITIES

57,743,915.

NAME OF CONTROLLED ENTITY

EMPLOYER ID NO

ACADIAN FRONTIER MARKETS EQUITY FUND

20-5852756

ADDRESS

260 FRANKLIN STREET
BOSTON, MA 02110

DESCRIPTION OF TRANSFER

DISTRIBUTION FROM PARTNERSHIP

AMOUNT
OF TRANSFER

50,605,214.

NAME OF CONTROLLED ENTITY

EMPLOYER ID NO

CHATHAM CO-INVEST

85-0651355

ADDRESS

26 MAIN STREET, SUITE 204
CHATHAM, NJ 07928

DESCRIPTION OF TRANSFER

DISTRIBUTION FROM PARTNERSHIP

AMOUNT
OF TRANSFER

55,000,000.

THE LEONA M. AND HARRY B. HELMSLEY CHARI

13-7184401

NAME OF CONTROLLED ENTITY

EMPLOYER ID NO

LACM GLOBAL EQUITY FUND, LP

45-3646231

ADDRESS

11150 SANTA MONICA BLVD., STE. 200
LOS ANGELES, CA 90025

DESCRIPTION OF TRANSFER

DISTRIBUTION FROM PARTNERSHIP

AMOUNT
OF TRANSFER

47,000,000.

NAME OF CONTROLLED ENTITY

EMPLOYER ID NO

LACM WORLD SMALL CAP EQUITY FUND, L.P.

83-2888004

ADDRESS

11150 SANTA MONICA BLVD., STE. 200
LOS ANGELES, CA 90025

DESCRIPTION OF TRANSFER

DISTRIBUTION FROM PARTNERSHIP

AMOUNT
OF TRANSFER

49,000,000.

NAME OF CONTROLLED ENTITY

EMPLOYER ID NO

MARATHON-LONDON GLOBAL SELECT INVESTMENT TRUST

61-1915057

ADDRESS

ORION HOUSE, 5 UPPER ST. MARTIN'S LANE
LONDON, UNITED KINGDOM WC2H 9EA

DESCRIPTION OF TRANSFER

DISTRIBUTION FROM PARTNERSHIP

AMOUNT
OF TRANSFER

100,000,000.

THE LEONA M. AND HARRY B. HELMSLEY CHARI

13-7184401

NAME OF CONTROLLED ENTITY

EMPLOYER ID NO

MHR LONGEVITY PARTNERS

98-1471155

ADDRESS

1345 AVENUE OF THE AMERICAS 42ND FLOOR
NEW YORK, NY 10105

DESCRIPTION OF TRANSFER

DISTRIBUTION FROM PARTNERSHIP

AMOUNT
OF TRANSFER

5,148,696.

NAME OF CONTROLLED ENTITY

EMPLOYER ID NO

NEWMARKET INTERNATIONAL INFRASTRUCTURE FINANCE COMPANY
FEEDER, L.P.

98-1142649

ADDRESS

2929 ARCH STREET 17TH FLOOR
PHILADELPHIA, PA 19104

DESCRIPTION OF TRANSFER

DISTRIBUTION

AMOUNT
OF TRANSFER

8,372,125.

TOTAL AMOUNT OF TRANSFERS FROM CONTROLLED ENTITIES

315,126,035.

FORM 990-PF

SCHEDULE OF CONTROLLED ENTITIES
PART VI-A, LINE 11

STATEMENT 17

<u>NAME OF CONTROLLED ENTITY</u>	<u>EMPLOYER ID NO</u>
ACADIAN FRONTIER MARKETS EQUITY FUND	20-5852756
<u>ADDRESS</u>	EXCESS BUSINESS HOLDING [] YES [X] NO
260 FRANKLIN STREET BOSTON, MA 02110	

<u>NAME OF CONTROLLED ENTITY</u>	<u>EMPLOYER ID NO</u>
CHATHAM CO-INVEST	85-0651355
<u>ADDRESS</u>	EXCESS BUSINESS HOLDING [] YES [X] NO
26 MAIN STREET, SUITE 204 CHATHAM, NJ 07928	

<u>NAME OF CONTROLLED ENTITY</u>	<u>EMPLOYER ID NO</u>
ESTATE OF LEONA M. HELMSLEY	20-7535047
<u>ADDRESS</u>	EXCESS BUSINESS HOLDING [] YES [X] NO
230 PARK AVENUE, SUITE 659 NEW YORK, NY 10169	

<u>NAME OF CONTROLLED ENTITY</u>	<u>EMPLOYER ID NO</u>
HELMSLEY ENTERPRISES, INC.	13-2665914
<u>ADDRESS</u>	EXCESS BUSINESS HOLDING [] YES [X] NO
230 PARK AVENUE, SUITE 659 NEW YORK, NY 10169	

<u>NAME OF CONTROLLED ENTITY</u>	<u>EMPLOYER ID NO</u>
LACM GLOBAL EQUITY FUND, LP	45-3646231
<u>ADDRESS</u>	EXCESS BUSINESS HOLDING [] YES [X] NO
11150 SANTA MONICA BLVD., STE. 200 LOS ANGELES, CA 90025	

NAME OF CONTROLLED ENTITY

EMPLOYER ID NO

LACM WORLD SMALL CAP EQUITY FUND, L.P.

83-2888004

ADDRESS

EXCESS BUSINESS HOLDING [] YES [X] NO

11150 SANTA MONICA BLVD., STE. 200
LOS ANGELES, CA 90025

NAME OF CONTROLLED ENTITY

EMPLOYER ID NO

MARATHON-LONDON GLOBAL SELECT INVESTMENT TRUST

61-1915057

ADDRESS

EXCESS BUSINESS HOLDING [] YES [X] NO

ORION HOUSE, 5 UPPER ST. MARTIN'S LANE
LONDON, UNITED KINGDOM WC2H 9EA

NAME OF CONTROLLED ENTITY

EMPLOYER ID NO

MHR LONGEVITY PARTNERS

98-1471155

ADDRESS

EXCESS BUSINESS HOLDING [] YES [X] NO

1345 AVENUE OF THE AMERICAS 42ND FLOOR
NEW YORK, NY 10105

NAME OF CONTROLLED ENTITY

EMPLOYER ID NO

NEWMARKET INTERNATIONAL INFRASTRUCTURE FINANCE COMPANY
FEEDER, L.P.

98-1142649

ADDRESS

EXCESS BUSINESS HOLDING [] YES [X] NO

2929 ARCH STREET 17TH FLOOR
PHILADELPHIA, PA 19104

NAME OF CONTROLLED ENTITY

EMPLOYER ID NO

PITANGO SPV

98-1492234

ADDRESS

EXCESS BUSINESS HOLDING [] YES [X] NO

BEIT ACKERSHTEIN - BLDG. B, 11 HAMENOFIM ST. 11TH FL.
HERZLIYA, ISRAEL

FORM 990-PF

PART VII - LIST OF OFFICERS, DIRECTORS
TRUSTEES AND FOUNDATION MANAGERS

STATEMENT 18

NAME AND ADDRESS	TITLE AND AVRG HRS/WK	COMPEN- SATION	EMPLOYEE BEN PLAN CONTRIB	EXPENSE ACCOUNT
SANDOR FRANKEL C/O TRUST, 230 PARK AVENUE NEW YORK, NY 10169	TRUSTEE 25.00	125,000.	0.	0.
DAVID PANZIRER C/O TRUST, 230 PARK AVENUE NEW YORK, NY 10169	TRUSTEE 35.00	125,000.	0.	0.
WALTER PANZIRER C/O TRUST, 230 PARK AVENUE NEW YORK, NY 10169	TRUSTEE 32.00	125,000.	0.	0.
SARAH E. PAUL C/O TRUST, 230 PARK AVENUE NEW YORK, NY 10169	CEO & GENERAL COUNSEL (STMT 22) 40.00	703,476.	164,438.	0.
STEPHANIE A. CUSKLEY C/O TRUST, 230 PARK AVENUE NEW YORK, NY 10169	CHIEF EXECUTIVE OFFICER THRU 10/31/21 40.00	1,578,355.	128,388.	0.
ROSALIND M. HEWSENIAN C/O TRUST, 230 PARK AVENUE NEW YORK, NY 10169	CHIEF INVESTMENT OFFICER 40.00	1,671,096.	204,786.	0.
NICHOLAS J. SCHIAVO C/O TRUST, 230 PARK AVENUE NEW YORK, NY 10169	CHIEF FINANCIAL OFFICER 40.00	393,338.	117,317.	0.
TOTALS INCLUDED ON 990-PF, PAGE 6, PART VII		4,721,265.	614,929.	0.

GRANTEE'S NAME

A GLIMMER OF HOPE FOUNDATION

GRANTEE'S ADDRESS

3600 N CAPITAL OF TEXAS HWY, BLDG B, SUITE 330
AUSTIN, TX 78746

GRANT AMOUNT

7,923,870.

DATE OF GRANT

09/09/19

AMOUNT EXPENDED

4,400,291.

PURPOSE OF GRANT

INTEGRATED COMMUNITY DEVELOPMENT IN ODA BULTUM, ETHIOPIA

DATES OF REPORTS BY GRANTEE

1/2020, 7/2020, 1/2021, 3/2021, 7/2021, 1/2022, 7/2022

ANY DIVERSION BY GRANTEE

NONE

GRANTEE'S NAME

A GLIMMER OF HOPE FOUNDATION

GRANTEE'S ADDRESS

3600 N CAPITAL OF TEXAS HWY, BLDG B, SUITE 330
AUSTIN, TX 78746

<u>GRANT AMOUNT</u>	<u>DATE OF GRANT</u>	<u>AMOUNT EXPENDED</u>
5,000,000.	02/20/18	5,000,000.

PURPOSE OF GRANT

INTEGRATED COMMUNITY DEVELOPMENT IN AMHARA, ETHIOPIA

DATES OF REPORTS BY GRANTEE

1/2019, 1/2020, 2/2021, 1/2022

ANY DIVERSION BY GRANTEE

NONE

GRANTEE'S NAME

AKSTON BIOSCIENCES CORPORATION

GRANTEE'S ADDRESS

100 CUMMINGS CENTER, SUITE 454C
BEVERLY, MA 01915

<u>GRANT AMOUNT</u>	<u>DATE OF GRANT</u>	<u>AMOUNT EXPENDED</u>
6,194,000.	03/01/17	5,586,294.

PURPOSE OF GRANT

PRECLINICAL TRIAL OF INSULIN-FUSION TO END AUTOIMMUNITY & IMPROVE T1D

DATES OF REPORTS BY GRANTEE

10/2018, 1/2019, 4/2019, 8/2019, 10/2019, 3/2020, 10/2020, 2/2021, 6/2022

ANY DIVERSION BY GRANTEE

NONE

GRANTEE'S NAME

ALIMENTIV INC. (FKA ROBARTS)

GRANTEE'S ADDRESS

100 DUNDAS STREET
LONDON, ON, CANADA, N6A5B6

<u>GRANT AMOUNT</u>	<u>DATE OF GRANT</u>	<u>AMOUNT EXPENDED</u>
894,043.	02/10/22	0.

PURPOSE OF GRANT

DEVELOP AN INTESTINAL MUCOSAL AND IMAGING BIOMARKER FOR STRICTURING CD

DATES OF REPORTS BY GRANTEE

PENDING

ANY DIVERSION BY GRANTEE

NONE

GRANTEE'S NAME

ALIMENTIV INC. (FKA ROBARTS)

GRANTEE'S ADDRESS

100 DUNDAS STREET
LONDON, ON, CANADA, N6A5B6

<u>GRANT AMOUNT</u>	<u>DATE OF GRANT</u>	<u>AMOUNT EXPENDED</u>
3,390,428.	11/20/18	1,983,840.

PURPOSE OF GRANT

STENOSIS THERAPY AND ANTI-FIBROTIC RESEARCH (STAR) CONSORTIUM

DATES OF REPORTS BY GRANTEE

PRIOR + 12/2019, 1/2020, 6/2020, 12/2020, 1/2021, 6/2021, 12/2021, 6/2022

ANY DIVERSION BY GRANTEE

NONE

GRANTEE'S NAME

ASSOCIATION OF DIABETES CARE & EDUCATION SPECIALISTS

GRANTEE'S ADDRESS

125 S WACKER DRIVE, SUITE 600
CHICAGO, IL 60606

<u>GRANT AMOUNT</u>	<u>DATE OF GRANT</u>	<u>AMOUNT EXPENDED</u>
2,500,000.	11/20/21	195,070.

PURPOSE OF GRANT

EXPANSION OF THE DANATECH PLATFORM

DATES OF REPORTS BY GRANTEE

1/2022, 5/2022

ANY DIVERSION BY GRANTEE

NONE

GRANTEE'S NAME

ASSOCIATION OF DIABETES CARE & EDUCATION SPECIALISTS

GRANTEE'S ADDRESS

125 S WACKER DRIVE, SUITE 600
CHICAGO, IL 60606

<u>GRANT AMOUNT</u>	<u>DATE OF GRANT</u>	<u>AMOUNT EXPENDED</u>
2,679,637.	07/11/18	2,639,117.

PURPOSE OF GRANT

AADE TECHNOLOGY INSTITUTE: DANA - DIABETES ADVANCED NETWORK ACCESS

DATES OF REPORTS BY GRANTEE

2/2019, 8/2019, 1/2020, 8/2020, 1/2021, 6/2021, 1/2022

ANY DIVERSION BY GRANTEE

NONE

GRANTEE'S NAME

ASITY MADAGASCAR

GRANTEE'S ADDRESS

LOT IAB 39 TER C ANALAMHINTSY
ANTANANARIVO, MADAGASCAR, 101

<u>GRANT AMOUNT</u>	<u>DATE OF GRANT</u>	<u>AMOUNT EXPENDED</u>
284,790.	03/01/17	284,790.

PURPOSE OF GRANT

IMPLEMENT SUSTAINABLE MANAGEMENT STRATEGIES FOR WETLAND CONSERVATION

DATES OF REPORTS BY GRANTEE

2/2018, 2/2019, 5/2020, 9/2021

ANY DIVERSION BY GRANTEE

NONE

GRANTEE'S NAME

AUSTRALASIAN GASTRO INTESTINAL RESEARCH FOUNDATION LTD.

GRANTEE'S ADDRESS

LEVEL 2, 55 VICTORIA PARADE
FITZROY, AUSTRALIA, 3065

<u>GRANT AMOUNT</u>	<u>DATE OF GRANT</u>	<u>AMOUNT EXPENDED</u>
2,309,216.	07/23/20	742,482.

PURPOSE OF GRANT

FECAL MICROBIOTA TRANSPLANTATION IN CROHN'S DISEASE: THE MIRO STUDY

DATES OF REPORTS BY GRANTEE

2/2021, 8/2021, 2/2022, 7/2022, 8/2022

ANY DIVERSION BY GRANTEE

NONE

GRANTEE'S NAME

AUSTRALASIAN GASTRO INTESTINAL RESEARCH FOUNDATION LTD.

GRANTEE'S ADDRESS

LEVEL 2, 55 VICTORIA PARADE
FITZROY, AUSTRALIA, 3065

<u>GRANT AMOUNT</u>	<u>DATE OF GRANT</u>	<u>AMOUNT EXPENDED</u>
3,719,569.	02/15/17	3,719,569.

PURPOSE OF GRANT

THE ENIGMA STUDIES - EASTERN INFLAMMATORY BOWEL DISEASE GUT MICROBIOTA

DATES OF REPORTS BY GRANTEE

PRIOR + 11/2019, 1/2020, 4/2020, 10/2020, 11/2020, 3/2021, 9/2021, 3/2022

ANY DIVERSION BY GRANTEE

NONE

GRANTEE'S NAME

BIORASIS, INC.

GRANTEE'S ADDRESS

1392 STORRS RD U4213, ATL ROOM 106
STORRS, CT 06269

GRANT AMOUNT

3,016,000.

DATE OF GRANT

02/06/18

AMOUNT EXPENDED

1,648,500.

PURPOSE OF GRANT

EARLY FEASIBILITY STUDIES OF THE GLUCOWIZZARD IN CARE FOR T1D

DATES OF REPORTS BY GRANTEE

PRIOR + 9/2019, 2/2020, 5/2020, 8/2020, 11/2020, 2/2021, 7/2021, 5/2022

ANY DIVERSION BY GRANTEE

NONE

GRANTEE'S NAME

BLUE CIRCLE HEALTH, INC.

GRANTEE'S ADDRESS

THE CORPORATION TRUST CENTER, 1209 ORANGE STREET
WILMINGTON, DE 19801

<u>GRANT AMOUNT</u>	<u>DATE OF GRANT</u>	<u>AMOUNT EXPENDED</u>
45,430,130.	12/21/21	15,476,957.

PURPOSE OF GRANT

CREATION OF BLUE CIRCLE HEALTH FOR UNDERSERVED COMMUNITIES WITH T1D

DATES OF REPORTS BY GRANTEE

2/2022, 7/2022

ANY DIVERSION BY GRANTEE

NONE

GRANTEE'S NAME

CAPILLARY BIOMEDICAL, INC.

GRANTEE'S ADDRESS

2 WRIGLEY
IRVINE, CA 92617

<u>GRANT AMOUNT</u>	<u>DATE OF GRANT</u>	<u>AMOUNT EXPENDED</u>
1,500,000.	09/02/20	1,428,325.

PURPOSE OF GRANT

ADVANCED EXTENDED INFUSION SET TO IMPROVE CARE IN T1D

DATES OF REPORTS BY GRANTEE

10/2020, 3/2021, 4/2021, 10/2021, 1/2022, 5/2022, 6/2022

ANY DIVERSION BY GRANTEE

NONE

GRANTEE'S NAME

DIABETOMICS, INC.

GRANTEE'S ADDRESS

2345 NE OVERLOOK DRIVE, SUITE #140
HILLSBORO, OR 97006

<u>GRANT AMOUNT</u>	<u>DATE OF GRANT</u>	<u>AMOUNT EXPENDED</u>
4,031,900.	01/11/18	3,031,900.

PURPOSE OF GRANT

POINT-OF-CARE RAPID TESTS FOR T1D SCREENING AND INTERVENTION

DATES OF REPORTS BY GRANTEE

PRIOR +1/2020, 5/2020, 10/2020, 4/2021, 10/2021, 12/2021, 2/2022, 4/2022

ANY DIVERSION BY GRANTEE

NONE

GRANTEE'S NAME

DREAMED DIABETES LTD.

GRANTEE'S ADDRESS

5 MOTA GUR ST.
PETAH TIKVA, ISRAEL, 4952701

<u>GRANT AMOUNT</u>	<u>DATE OF GRANT</u>	<u>AMOUNT EXPENDED</u>
3,585,828.	02/01/16	3,546,253.

PURPOSE OF GRANT

MD-LOGIC PUMP GUIDE4U - ADVISORY SYSTEM TO IMPROVE CARE OF T1D

DATES OF REPORTS BY GRANTEE

10/2016, 1/2017, 7/2017, 9/2017, 2/2018, 6/2018, 9/2018, 12/2019

ANY DIVERSION BY GRANTEE

NONE

GRANTEE'S NAME

FEROX THERAPEUTICS

GRANTEE'S ADDRESS

111 TOWN SQUARE PLACE, SUITE 1203 PMB 1034
JERSEY CITY, NJ 07310

<u>GRANT AMOUNT</u>	<u>DATE OF GRANT</u>	<u>AMOUNT EXPENDED</u>
872,300.	11/20/18	872,300.

PURPOSE OF GRANT

INSULIN INDUCED HYPOGLYCEMIA PREVENTION PROGRAM

DATES OF REPORTS BY GRANTEE

7/2019, 10/2019, 1/2020, 4/2020, 7/2020, 12/2020, 1/2021, 4/2021, 7/2021

ANY DIVERSION BY GRANTEE

NONE

GRANTEE'S NAME

GRAND CANYON UNIVERSITY

GRANTEE'S ADDRESS

3300 WEST CAMELBACK ROAD
PHOENIX, AZ 85017

<u>GRANT AMOUNT</u>	<u>DATE OF GRANT</u>	<u>AMOUNT EXPENDED</u>
2,274,027.	06/26/19	1,410,426.

PURPOSE OF GRANT

DEVELOPMENT OF A CONTINUOUS INSULIN-GLUCOSE SENSOR

DATES OF REPORTS BY GRANTEE

6/2020, 7/2020, 7/2021, 4/2022

ANY DIVERSION BY GRANTEE

NONE

GRANTEE'S NAME

INTERNATIONAL BOWEL ULTRASOUND GROUP E.V.

GRANTEE'S ADDRESS

HARKORTSTR. 1
MUNSTER, GERMANY

<u>GRANT AMOUNT</u>	<u>DATE OF GRANT</u>	<u>AMOUNT EXPENDED</u>
172,967.	10/21/20	0.

PURPOSE OF GRANT

POINT-OF-CARE INTESTINAL ULTRASOUND TRAINING IN THE UNITED STATES

DATES OF REPORTS BY GRANTEE

PENDING

ANY DIVERSION BY GRANTEE

NONE

GRANTEE'S NAME

JDRF INTERNATIONAL

GRANTEE'S ADDRESS

200 VESEY STREET, 28TH FLOOR
NEW YORK, NY 10281

GRANT AMOUNT

8,200,000.

DATE OF GRANT

05/21/12

AMOUNT EXPENDED

8,200,000.

PURPOSE OF GRANT

ORTHOGONALLY REDUNDANT GLUCOSE SENSOR TO IMPROVE CARE OF T1D

DATES OF REPORTS BY GRANTEE

7/2015, 5/2016, 7/2016, 6/2017, 6/2019, 11/2019, 5/2020, 8/2020

ANY DIVERSION BY GRANTEE

NONE

GRANTEE'S NAME

NURU INTERNATIONAL

GRANTEE'S ADDRESS

2020 PENNSYLVANIA AVE NW
WASHINGTON, DC 20006

<u>GRANT AMOUNT</u>	<u>DATE OF GRANT</u>	<u>AMOUNT EXPENDED</u>
4,680,506.	11/25/13	4,680,506.

PURPOSE OF GRANT

CREATING A SELF-SUSTAINING, SCALING, AGRICULTURE-BASED DEVELOPMENT MODEL

DATES OF REPORTS BY GRANTEE

PRIOR + 12/2015, 1/2017, 2/2018, 1/2019, 1/2020, 6/2020, 1/2022

ANY DIVERSION BY GRANTEE

NONE

GRANTEE'S NAME

PACIFIC DIABETES TECHNOLOGIES

GRANTEE'S ADDRESS

12154 SW GARDEN PLACE
PORTLAND, OR 97223

<u>GRANT AMOUNT</u>	<u>DATE OF GRANT</u>	<u>AMOUNT EXPENDED</u>
2,867,072.	09/08/14	2,867,072.

PURPOSE OF GRANT

DUAL USE CATHETER FOR INSULIN DELIVERY & SENSING TO IMPROVE CARE OF T1D

DATES OF REPORTS BY GRANTEE

1/2015, 5/2015, 12/2015, 2/2016, 7/2016, 2/2017, 12/2017, 6/2018

ANY DIVERSION BY GRANTEE

NONE

GRANTEE'S NAME

PERCUSENSE, INC

GRANTEE'S ADDRESS

25134 RYE CANYON LOOP
VALENCIA, CA 91355

<u>GRANT AMOUNT</u>	<u>DATE OF GRANT</u>	<u>AMOUNT EXPENDED</u>
2,500,000.	09/02/20	641,203.

PURPOSE OF GRANT

DEVELOPMENT OF CONTINUOUS GLUCOSE AND KETONE METER FOR TREATMENT IN T1D

DATES OF REPORTS BY GRANTEE

7/2021, 8/2021, 5/2022

ANY DIVERSION BY GRANTEE

NONE

GRANTEE'S NAME

SOUTH DAKOTA BROADCASTERS ASSOCIATION

GRANTEE'S ADDRESS

106 WEST CAPITOL AVE
PIERRE, SD 57501

<u>GRANT AMOUNT</u>	<u>DATE OF GRANT</u>	<u>AMOUNT EXPENDED</u>
1,110,000.	12/03/20	1,100,000.

PURPOSE OF GRANT

COVID-19 PUBLIC AWARENESS AND BEHAVIOR

DATES OF REPORTS BY GRANTEE

5/2021, 1/2022

ANY DIVERSION BY GRANTEE

NONE

GRANTEE'S NAME

THETIS PHARMACEUTICALS, LLC

GRANTEE'S ADDRESS

54 DANBURY ROAD, SUITE 285
RIDGEFIELD, NJ 06877

<u>GRANT AMOUNT</u>	<u>DATE OF GRANT</u>	<u>AMOUNT EXPENDED</u>
4,166,030.	02/24/22	117,079.

PURPOSE OF GRANT

DEVELOPMENT OF A NOVEL RESOLVIN E1 THERAPY FOR TREATMENT OF CROHNS DISEASE

DATES OF REPORTS BY GRANTEE

5/2022, 8/2022

ANY DIVERSION BY GRANTEE

NONE

GRANTEE'S NAME

THE LEGATUM INSTITUTE FOUNDATION

GRANTEE'S ADDRESS

11 CHARLES STREET
LONDON, UNITED KINGDOM, W1J 5DW

<u>GRANT AMOUNT</u>	<u>DATE OF GRANT</u>	<u>AMOUNT EXPENDED</u>
150,000.	09/21/21	4,050.

PURPOSE OF GRANT

PHASE TWO OF US PROSPERITY INDEX: EXPANDING COUNTY-LEVEL INDEX TO INCLUDE WYOMING AND DEEPENING IMPACT

DATES OF REPORTS BY GRANTEE

1/2022

ANY DIVERSION BY GRANTEE

NONE

GRANTEE'S NAME

THE LEGATUM INSTITUTE FOUNDATION

GRANTEE'S ADDRESS

11 CHARLES STREET
LONDON, UNITED KINGDOM, W1J 5DW

<u>GRANT AMOUNT</u>	<u>DATE OF GRANT</u>	<u>AMOUNT EXPENDED</u>
1,013,551.	12/04/17	1,013,551.

PURPOSE OF GRANT

UNITED STATES PROSPERITY INDEX

DATES OF REPORTS BY GRANTEE

PRIOR +7/2019, 8/2019, 1/2020, 7/2020, 12/2020, 1/2021, 11/2021, 1/2022

ANY DIVERSION BY GRANTEE

NONE

GRANTEE'S NAME

ZUCARA THERAPEUTICS

GRANTEE'S ADDRESS

1300-661 UNIVERSITY AVENUE
TORONTO, ON, CANADA, M5G 0B7

<u>GRANT AMOUNT</u>	<u>DATE OF GRANT</u>	<u>AMOUNT EXPENDED</u>
3,900,000.	02/06/18	3,900,000.

PURPOSE OF GRANT

PRECLINICAL DEVELOPMENT OF ZT-01 TO PREVENT HYPOGLYCEMIA IN T1D

DATES OF REPORTS BY GRANTEE

PRIOR + 7/2020, 2/2021, 4/2021, 7/2021, 10/2021, 2/2022, 4/2022, 7/2022

ANY DIVERSION BY GRANTEE

NONE

ESTATE OF LEONA M. HELMSLEY
230 PARK AVENUE, SUITE 659
NEW YORK, NY 10169
EIN# 20-7535047

HELMSLEY ENTERPRISES, INC.
230 PARK AVENUE, SUITE 659
NEW YORK, NY 10169
EIN# 13-2665914

LACM GLOBAL EQUITY FUND, LP
11150 SANTA MONICA BLVD., STE. 200
LOS ANGELES, CA 90025
EIN# 45-3646231

LACM WORLD SMALL CAP EQUITY FUND, L.P.
11150 SANTA MONICA BLVD., STE. 200
LOS ANGELES, CA 90025
EIN# 83-2888004

MARATHON-LONDON GLOBAL SELECT
ORION HOUSE, 5 UPPER ST. MARTIN'S LANE
LONDON, UK WC2H 9EA
EIN# 61-1915057

MHR LONGEVITY PARTNERS
1345 AVENUE OF THE AMERICAS 42ND FLOOR
NEW YORK, NY 10105
EIN# 98-1471155

NEWMARKET INTERNATIONAL INFRASTRUCTURE FINANCE COMPANY FEEDER, L.P.
2929 ARCH STREET 17TH FLOOR
PHILADELPHIA, PA 19104
EIN# 98-1142649

PITANGO SPV
BEIT ACKERSHTEIN - BLDG. B, 11 HAMENOFIM ST. 11TH FL.
HERZLIYA, ISRAEL
EIN# 98-1492234

GENERAL EXPLANATION

STATEMENT 22

FORM/LINE IDENTIFIER

FORM 990-PF, PART VII, LINE 1:

EXPLANATION:

STEPHANIE A. CUSKLEY WAS CHIEF EXECUTIVE OFFICER FROM 4/1/21-10/31/21.

SARAH E. PAUL WAS GENERAL COUNSEL 4/1/21-10/31/21 AND FROM 11/1/21-3/31/22 CEO AND GENERAL COUNSEL.

GENERAL EXPLANATION

STATEMENT 23

FORM/LINE IDENTIFIER

FORM 990-PF, PART VII, LINE 1 AND 2, COLUMN (C), COMPENSATION:

EXPLANATION:

ALL REPORTED COMPENSATION AMOUNTS INCLUDE "SALARY, FEES, BONUSES AND SEVERANCE PAYMENTS RECEIVED BY EACH PERSON LISTED," AS WELL AS CURRENT YEAR PAYMENTS OF AMOUNTS REPORTED OR REPORTABLE AS DEFERRED COMPENSATION IN CURRENT OR PRIOR YEARS.